activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	119276	CHEMBL770790	Inhibition of ROKa, ROCK II at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	13.0	CHEMBL2973	Homo sapiens	Inhibition	%	13.0
	119276	CHEMBL770790	Inhibition of ROKa, ROCK II at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	13.0	CHEMBL2973	Homo sapiens	Inhibition	%	13.0
	133235	CHEMBL770790	Inhibition of ROKa, ROCK II at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	Inhibition	%	4.0
	138060	CHEMBL770790	Inhibition of ROKa, ROCK II at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccccc3)c(Br)cc12)C1CC1		CHEMBL259270	=	Inhibition	%	8.0	CHEMBL2973	Homo sapiens	Inhibition	%	8.0
	144078	CHEMBL770790	Inhibition of ROKa, ROCK II at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)ccc12)C1CC1		CHEMBL405145	=	Inhibition	%	41.0	CHEMBL2973	Homo sapiens	Inhibition	%	41.0
	177492	CHEMBL770787	Inhibition of ROCK-II	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ncc(C(F)(F)F)cc1Cl		CHEMBL111620	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
	178805	CHEMBL770787	Inhibition of ROCK-II	B	COCCCn1cc(C2=C(c3ccccc3O)C(=O)NC2=O)c2cccnc21		CHEMBL109944	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	182552	CHEMBL770787	Inhibition of ROCK-II	B	COc1ccccc1C1=C(c2cn(CCCNC(=O)OC(C)(C)C)c3ncccc23)C(=O)NC1=O		CHEMBL109981	=	Activity	%	78.0	CHEMBL2973	Homo sapiens	Activity	%	78.0
	616535	CHEMBL769159	Inhibition of Protein kinase ROCK2 at 100 nM	B	Cn1ccc2ccc3c4[nH]c5c(CCCN[C@H]6CC[C@H](O)CC6)cccc5c4c4c(c3c21)C(=O)NC4=O		CHEMBL307152	=	Control	%	90.0	CHEMBL2973	Homo sapiens	Control	%	90.0
	616574	CHEMBL769160	Inhibition of Protein kinase ROCK2 at 500 nM	B	Cn1ccc2ccc3c4[nH]c5c(CCCN[C@H]6CC[C@H](O)CC6)cccc5c4c4c(c3c21)C(=O)NC4=O		CHEMBL307152	=	Control	%	62.0	CHEMBL2973	Homo sapiens	Control	%	62.0
	995144	CHEMBL769162	Inhibition of Protein kinase ROCK2 (ROCKII)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	1900.0	CHEMBL2973	Homo sapiens	IC50	uM	1.9
	1012569	CHEMBL769162	Inhibition of Protein kinase ROCK2 (ROCKII)	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	700.0	CHEMBL2973	Homo sapiens	IC50	uM	0.7
	1034891	CHEMBL770789	Inhibition of ROKa, ROCK II at 10 uM	B	COc1ccc(C2=C(Nc3cccc(Cl)c3)C(=O)NC2=O)cc1		CHEMBL158208	=	Inhibition	%	-7.0	CHEMBL2973	Homo sapiens	Inhibition	%	-7.0
	1036286	CHEMBL770789	Inhibition of ROKa, ROCK II at 10 uM	B	O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(O)c(Cl)c1		CHEMBL322970	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	Inhibition	%	0.0
	1048352	CHEMBL770789	Inhibition of ROKa, ROCK II at 10 uM	B	COc1ccccc1C1=C(N2CCc3ccccc32)C(=O)NC1=O		CHEMBL160585	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	Inhibition	%	0.0
	1055598	CHEMBL770789	Inhibition of ROKa, ROCK II at 10 uM	B	O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160586	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	Inhibition	%	0.0
	1058284	CHEMBL770789	Inhibition of ROKa, ROCK II at 10 uM	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156379	=	Inhibition	%	11.0	CHEMBL2973	Homo sapiens	Inhibition	%	11.0
	1173971	CHEMBL769161	Inhibition of Protein kinase ROCK2	B	CCN(CC)C/C=C/c1nc(O)c2c(ccc3nc(Nc4c(Cl)cccc4Cl)n(C)c32)c1C		CHEMBL281957	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	uM	1.0
	1481538	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COc1cc2nc(-c3cccs3)c(-c3cccs3)nc2cc1OC		CHEMBL373367	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	Inhibition	%	2.0
	1481665	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	Oc1cc2nc(-c3cccs3)c(-c3cccs3)nc2cc1O	Outside typical range	CHEMBL190039	=	Inhibition	%	-18.0	CHEMBL2973	Homo sapiens	Inhibition	%	-18.0
	1481794	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	c1csc(-c2nc3cc4c(cc3nc2-c2cccs2)OCO4)c1		CHEMBL189940	=	Inhibition	%	31.0	CHEMBL2973	Homo sapiens	Inhibition	%	31.0
	1481815	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	c1csc(-c2nc3cc4c(cc3nc2-c2cccs2)OCCO4)c1		CHEMBL192489	=	Inhibition	%	41.0	CHEMBL2973	Homo sapiens	Inhibition	%	41.0
	1481936	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)C1COc2cc3nc(-c4cccs4)c(-c4cccs4)nc3cc2O1		CHEMBL193232	=	Inhibition	%	-1.0	CHEMBL2973	Homo sapiens	Inhibition	%	-1.0
	1482068	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	c1csc(-c2nc3cc4c(cc3nc2-c2cccs2)OCCCO4)c1		CHEMBL191410	=	Inhibition	%	32.0	CHEMBL2973	Homo sapiens	Inhibition	%	32.0
	1482714	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	c1csc(-c2nc3cc4ccccc4cc3nc2-c2cccs2)c1		CHEMBL364499	=	Inhibition	%	19.0	CHEMBL2973	Homo sapiens	Inhibition	%	19.0
	1482843	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COC(=O)Cc1csc(-c2nc3cc4ccccc4cc3nc2-c2cc(CC(=O)OC)cs2)c1		CHEMBL192974	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	Inhibition	%	4.0
	1482864	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COC(=O)CCc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CCC(=O)OC)s2)s1		CHEMBL190143	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	Inhibition	%	5.0
	1482995	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COC(=O)CCCc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CCCC(=O)OC)s2)s1		CHEMBL189104	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	Inhibition	%	5.0
	1483125	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)Cc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CC(=O)O)s2)s1		CHEMBL193162	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	Inhibition	%	5.0
	1483256	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)Cc1csc(-c2nc3cc4ccccc4cc3nc2-c2cc(CC(=O)O)cs2)c1		CHEMBL192909	=	Inhibition	%	18.0	CHEMBL2973	Homo sapiens	Inhibition	%	18.0
	1483277	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)CCc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CCC(=O)O)s2)s1		CHEMBL366201	=	Inhibition	%	18.0	CHEMBL2973	Homo sapiens	Inhibition	%	18.0
	1483393	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)CCCc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CCCC(=O)O)s2)s1		CHEMBL190057	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	Inhibition	%	0.0
	1483513	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)c1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(C(=O)O)s2)s1		CHEMBL366185	=	Inhibition	%	19.0	CHEMBL2973	Homo sapiens	Inhibition	%	19.0
	1483534	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)c1ccc2cc3nc(-c4cccs4)c(-c4cccs4)nc3cc2c1		CHEMBL426445	=	Inhibition	%	15.0	CHEMBL2973	Homo sapiens	Inhibition	%	15.0
	1485479	CHEMBL836157	In vitro percent inhibition of Protein kinase ROCK2 at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COc1cc2nc3nc(-c4cccs4)c(-c4cccs4)nc3nc2cc1OC		CHEMBL193172	=	Inhibition	%	-1.0	CHEMBL2973	Homo sapiens	Inhibition	%	-1.0
	1489868	CHEMBL832884	Inhibition of protein kinase ROCK2; Range is 5-10	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F		CHEMBL1788116	=	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
Not Active	1658710	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12		CHEMBL188678		Activity			CHEMBL2973	Homo sapiens	Activity		
	1665747	CHEMBL859138	Inhibition of ROCK2 at 10 uM	B	CN1C(=O)C(C(=O)Nc2nncs2)c2cc3occc3cc21		CHEMBL200906	=	Inhibition	%	20.0	CHEMBL2973	Homo sapiens	Inhibition	%	20.0
	1666386	CHEMBL865777	Inhibition of ROCK2 activity at 10 uM	B	Oc1cc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)ccc1Cl		CHEMBL373011	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	Inhibition	%	3.0
	1666387	CHEMBL865777	Inhibition of ROCK2 activity at 10 uM	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1		CHEMBL477989	=	Inhibition	%	26.0	CHEMBL2973	Homo sapiens	Inhibition	%	26.0
	1671507	CHEMBL870643	Inhibition of ROCK 2 at 10 uM	B	Cc1c(Nc2ccc(Br)cc2F)c(C(=O)NOCCO)cn(C)c1=O		CHEMBL199860	=	Inhibition	%	13.0	CHEMBL2973	Homo sapiens	Inhibition	%	13.0
	1671530	CHEMBL870643	Inhibition of ROCK 2 at 10 uM	B	CCONC(=O)c1cn(C)c(=O)c(F)c1Nc1ccc(Br)cc1F		CHEMBL201426	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	Inhibition	%	4.0
	1671566	CHEMBL870643	Inhibition of ROCK 2 at 10 uM	B	CONC(=O)c1cn(C)c(=O)c(C)c1Nc1ccc(Br)cc1F		CHEMBL426840	=	Inhibition	%	10.0	CHEMBL2973	Homo sapiens	Inhibition	%	10.0
	1671646	CHEMBL870643	Inhibition of ROCK 2 at 10 uM	B	CCONC(=O)c1cn(C)c(=O)c(C)c1Nc1ccc(Br)cc1F		CHEMBL203138	=	Inhibition	%	13.0	CHEMBL2973	Homo sapiens	Inhibition	%	13.0
	1715704	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCCC1		CHEMBL437885	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716102	CHEMBL870120	Inhibition of ROCK2	B	COCCN1CC(C(N)=O)(N(C)Cc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)C1		CHEMBL207815	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716103	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CN(C(C)C)C1		CHEMBL425601	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716104	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CN(C)C1		CHEMBL207718	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716105	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CCN(C(C)C)CC1		CHEMBL383246	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716106	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CCN(C)CC1		CHEMBL207130	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716107	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](CN(C)C)C(N)=O		CHEMBL380889	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716108	CHEMBL870120	Inhibition of ROCK2	B	COCC[C@@H](C(N)=O)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC		CHEMBL207445	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716109	CHEMBL870120	Inhibition of ROCK2	B	COC[C@@H](C(N)=O)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC		CHEMBL379905	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716110	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](CO)C(N)=O		CHEMBL208286	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716111	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(CCN(C)C)[C@@H](C)C(N)=O		CHEMBL376967	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716112	CHEMBL870120	Inhibition of ROCK2	B	COCCN(Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC)[C@@H](C)C(N)=O		CHEMBL382823	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716113	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C(C)C)[C@@H](C)C(N)=O		CHEMBL208048	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716114	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1CCNC1=O		CHEMBL378370	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716115	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@H](C)C(=O)N(C)C		CHEMBL380006	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716116	CHEMBL870120	Inhibition of ROCK2	B	CNC(=O)[C@@H](C)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC		CHEMBL211003	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716117	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](C)C(N)=O		CHEMBL207687	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716118	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@H](C)C(N)=O		CHEMBL208118	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716119	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)CC(N)=O		CHEMBL379601	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716120	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN[C@H](C)C(N)=O		CHEMBL380386	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716121	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CC(C(N)=O)C1		CHEMBL207037	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716122	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC1C(N)=O		CHEMBL207246	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716123	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1C(N)=O		CHEMBL207674	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716124	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCCC[C@@H]1C(N)=O		CHEMBL206783	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716125	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCN(C)CC1C(N)=O		CHEMBL204420	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716126	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@H]1CC(N)=O		CHEMBL377772	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716127	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CC[C@H](C(N)=O)C1		CHEMBL380454	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716128	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@@H]1C(=O)N(C)C		CHEMBL382822	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716129	CHEMBL870120	Inhibition of ROCK2	B	CNC(=O)[C@H]1CCCN1Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC		CHEMBL383760	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716130	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1C[C@H](OC)C[C@@H]1C(N)=O		CHEMBL207235	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716131	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@@H]1C(N)=O		CHEMBL208292	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716132	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@H]1C(N)=O		CHEMBL207584	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716133	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN1CCC[C@H]1C(N)=O		CHEMBL382638	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1716134	CHEMBL870120	Inhibition of ROCK2	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN1CCC[C@@H]1C(N)=O		CHEMBL206955	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1723382	CHEMBL862046	Inhibition of ROCK2	B	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	>	Ki	nM	7500.0	CHEMBL2973	Homo sapiens	Ki	nM	7500.0
	1723494	CHEMBL862046	Inhibition of ROCK2	B	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	>	Ki	nM	7500.0	CHEMBL2973	Homo sapiens	Ki	nM	7500.0
	1723549	CHEMBL862046	Inhibition of ROCK2	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	>	Ki	nM	7500.0	CHEMBL2973	Homo sapiens	Ki	nM	7500.0
	1723550	CHEMBL862046	Inhibition of ROCK2	B	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	>	Ki	nM	7500.0	CHEMBL2973	Homo sapiens	Ki	nM	7500.0
	1723551	CHEMBL862046	Inhibition of ROCK2	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	>	Ki	nM	7500.0	CHEMBL2973	Homo sapiens	Ki	nM	7500.0
	1723552	CHEMBL862046	Inhibition of ROCK2	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	>	Ki	nM	7500.0	CHEMBL2973	Homo sapiens	Ki	nM	7500.0
Not Determined	1728733	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccco3)ccc12		CHEMBL196964		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1728776	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc(F)cc3)ccc12		CHEMBL197439		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1728819	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccsc3)ccc12		CHEMBL196764		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1728862	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4c3oc3ccccc34)ccc12		CHEMBL196759		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1728905	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cc4ccccc4s3)ccc12		CHEMBL381025		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1728958	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4c3Sc3ccccc3S4)ccc12		CHEMBL199216		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729001	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)ccc12		CHEMBL436767		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729044	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4ccccc34)ccc12		CHEMBL199050		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729087	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(/C=C/c3ccc(Cl)cc3)ccc12		CHEMBL199051		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729130	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc4[nH]ccc4c3)ccc12		CHEMBL369969		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729173	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc4ncccc4c3)ccc12		CHEMBL198740		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729216	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4c3Oc3ccccc3S4)ccc12		CHEMBL197239		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729259	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	Nc1cc(C(=O)O)cc(-c2ccc3c(=O)cc(N4CCOCC4)oc3c2)c1		CHEMBL370108		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729302	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4c3sc3ccccc34)ccc12		CHEMBL198801		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729348	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=C1c2ccccc2C(=O)N1Cc1cccc(-c2ccc3c(=O)cc(N4CCOCC4)oc3c2)c1		CHEMBL197219		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729391	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=C1c2ccccc2C(=O)N1Cc1ccc(-c2ccc3c(=O)cc(N4CCOCC4)oc3c2)cc1		CHEMBL197227		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729434	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccs3)ccc12		CHEMBL371968		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729477	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc4ccccc4c3)ccc12		CHEMBL200299		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729520	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3csc4ccccc34)ccc12		CHEMBL199416		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729563	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc(OCc4ccccc4)cc3)ccc12		CHEMBL382501		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729621	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	Cc1ccc(-c2ccc3c(=O)cc(N4CCOCC4)oc3c2)c2ccccc12		CHEMBL200275		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Determined	1729664	CHEMBL860402	Inhibitory activity against ROCK-II at 10 uM	B	COC(=O)/C=C/c1ccccc1-c1ccc2c(=O)cc(N3CCOCC3)oc2c1		CHEMBL199424		Activity			CHEMBL2973	Homo sapiens	Activity		
	1734091	CHEMBL862831	Residual activity at human ROCK2 at 10 uM in presence of 10 uM ATP relative to control	B	O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1		CHEMBL379156	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
	1744378	CHEMBL866673	Inhibition of Rock2	B	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	>	Ki	nM	7500.0	CHEMBL2973	Homo sapiens	Ki	uM	7.5
	1751524	CHEMBL869149	Inhibition of ROCK2	B	CC(C)c1nnc2ccc(-c3ocnc3-c3ccc(F)cc3Cl)cn12		CHEMBL215652	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1751525	CHEMBL869149	Inhibition of ROCK2	B	CC(C)c1nnc2ccc(-c3ocnc3-c3cc(F)c(F)cc3F)cn12		CHEMBL213423	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1751526	CHEMBL869149	Inhibition of ROCK2	B	CCNc1nnc2ccc(-c3ocnc3-c3ccc(F)cc3)cn12		CHEMBL213451	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1751527	CHEMBL869149	Inhibition of ROCK2	B	CC(C)(C)c1nnc2ccc(-c3ocnc3-c3ccc(F)cc3F)cn12		CHEMBL212382	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1751528	CHEMBL869149	Inhibition of ROCK2	B	CC(C)(C)c1nnc2ccc(-c3ocnc3-c3cc(F)c(F)cc3F)cn12		CHEMBL212968	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1751529	CHEMBL869149	Inhibition of ROCK2	B	CC(C)c1nnc2ccc(-c3c[nH]nc3-c3cc(F)ccc3F)cn12		CHEMBL214198	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1751647	CHEMBL869149	Inhibition of ROCK2	B	CC(C)c1nnc2ccc(-c3ocnc3-c3ccccc3)cn12		CHEMBL379929	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	1769447	CHEMBL910948	Inhibition of ROCK2	B	C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2		CHEMBL215803	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	uM	1.0
	1790029	CHEMBL854697	Percentage activity of human ROCK-II in the presence of 10 uM of compound and 10 uM of ATP in comparison with control	B	O=C(NCc1ccc(S(=O)(=O)N2CCC(n3nnc4ccccc43)CC2)s1)c1ccc(Cl)cc1		CHEMBL383955	=	Activity	%	101.0	CHEMBL2973	Homo sapiens	Activity	%	101.0
	1790341	CHEMBL873778	Percent residual activity, relative to control, of ROCK-II at 1 uM concentration of inhibitor in presence of 20 uM ATP	B	N=C(N)NCCC[C@@H](NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)NC(=O)CCCCCNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL413460	=	Activity	%	0.0	CHEMBL2973	Homo sapiens	Activity	%	0.0
	1790395	CHEMBL873778	Percent residual activity, relative to control, of ROCK-II at 1 uM concentration of inhibitor in presence of 20 uM ATP	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL279185	=	Activity	%	0.0	CHEMBL2973	Homo sapiens	Activity	%	0.0
	1824609	CHEMBL915367	Inhibition of Rock2	B	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	>	Ki	nM	10000.0	CHEMBL2973	Homo sapiens	Ki	uM	10.0
	1824675	CHEMBL915367	Inhibition of Rock2	B	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	>	Ki	nM	10000.0	CHEMBL2973	Homo sapiens	Ki	uM	10.0
	1824759	CHEMBL915367	Inhibition of Rock2	B	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	>	Ki	nM	10000.0	CHEMBL2973	Homo sapiens	Ki	uM	10.0
	1837903	CHEMBL920466	Inhibition of ROCK2 at 10 uM relative to control	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL376505	=	Inhibition	%	69.0	CHEMBL2973	Homo sapiens	Inhibition	%	69.0
	1837942	CHEMBL920466	Inhibition of ROCK2 at 10 uM relative to control	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	Inhibition	%	91.0	CHEMBL2973	Homo sapiens	Inhibition	%	91.0
	1968073	CHEMBL896389	Inhibition of ROCK2 at 10 uM	B	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1cccs1)n2CCCN		CHEMBL233338	=	Inhibition	%	-1.0	CHEMBL2973	Homo sapiens	Inhibition	%	-1.0
	1981713	CHEMBL899234	Inhibition of ROCK2 assessed as residual activity at 0.01 uM	B	N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(N)=O		CHEMBL397521	=	Activity	%	41.0	CHEMBL2973	Homo sapiens	Activity	%	41.0
	1981714	CHEMBL899235	Inhibition of ROCK2 assessed as residual activity at 1 uM	B	N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(N)=O		CHEMBL397521	=	Activity	%	1.0	CHEMBL2973	Homo sapiens	Activity	%	1.0
	2025190	CHEMBL887018	Inhibition of human ROCK2 at 1 uM relative to control	B	CN(C)c1cc2cc(n1)CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2		CHEMBL247067	=	Inhibition	%	103.0	CHEMBL2973	Homo sapiens	Inhibition	%	103.0
	2025462	CHEMBL887018	Inhibition of human ROCK2 at 1 uM relative to control	B	CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CC2		CHEMBL1162963	=	Inhibition	%	110.0	CHEMBL2973	Homo sapiens	Inhibition	%	110.0
	2025463	CHEMBL887018	Inhibition of human ROCK2 at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1ccc(c(N3CCCC3)n1)CCCn1cc2c2ccccc21		CHEMBL396327	=	Inhibition	%	104.0	CHEMBL2973	Homo sapiens	Inhibition	%	104.0
	2025464	CHEMBL887018	Inhibition of human ROCK2 at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1cc(nc(N3CCCC3)c1)CCCn1cc2c2ccccc21		CHEMBL397771	=	Inhibition	%	107.0	CHEMBL2973	Homo sapiens	Inhibition	%	107.0
	2026169	CHEMBL887137	Inhibition of ROCK2	B	O=C([C@H](O)c1ccccc1Cl)N1CCN(c2ccc3[nH]ncc3c2)CC1		CHEMBL239772	=	IC50	nM	1200.0	CHEMBL2973	Homo sapiens	IC50	uM	1.2
	2026172	CHEMBL887137	Inhibition of ROCK2	B	NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1		CHEMBL239816	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	uM	0.013
	2026173	CHEMBL887137	Inhibition of ROCK2	B	NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1		CHEMBL392609	=	IC50	nM	150.0	CHEMBL2973	Homo sapiens	IC50	uM	0.15
	2026174	CHEMBL887137	Inhibition of ROCK2	B	N[C@@H](Cc1ccccc1)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1		CHEMBL240889	=	IC50	nM	470.0	CHEMBL2973	Homo sapiens	IC50	uM	0.47
	2026175	CHEMBL887137	Inhibition of ROCK2	B	N[C@H](C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccccc1		CHEMBL238763	=	IC50	nM	830.0	CHEMBL2973	Homo sapiens	IC50	uM	0.83
	2026176	CHEMBL887137	Inhibition of ROCK2	B	C[C@H](N)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1		CHEMBL238762	=	IC50	nM	6000.0	CHEMBL2973	Homo sapiens	IC50	uM	6.0
	2026177	CHEMBL887137	Inhibition of ROCK2	B	O=C(C(O)c1ccc(Br)cc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1		CHEMBL241271	=	IC50	nM	80.0	CHEMBL2973	Homo sapiens	IC50	uM	0.08
	2026178	CHEMBL887137	Inhibition of ROCK2	B	O=C([C@@H](O)c1cccc(Cl)c1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1		CHEMBL241270	=	IC50	nM	350.0	CHEMBL2973	Homo sapiens	IC50	uM	0.35
	2026179	CHEMBL887137	Inhibition of ROCK2	B	O=C([C@@H](O)c1ccccc1Cl)N1CCC(Nc2ccc3[nH]ncc3c2)CC1		CHEMBL392064	=	IC50	nM	1700.0	CHEMBL2973	Homo sapiens	IC50	uM	1.7
	2026180	CHEMBL887137	Inhibition of ROCK2	B	O=C([C@H](O)c1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1		CHEMBL241064	=	IC50	nM	770.0	CHEMBL2973	Homo sapiens	IC50	uM	0.77
	2026181	CHEMBL887137	Inhibition of ROCK2	B	NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1		CHEMBL240867	=	IC50	nM	90.0	CHEMBL2973	Homo sapiens	IC50	uM	0.09
	2026182	CHEMBL887137	Inhibition of ROCK2	B	C[C@@H](N)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1		CHEMBL397114	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	2026183	CHEMBL887137	Inhibition of ROCK2	B	N[C@H](Cc1ccccc1)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1		CHEMBL240646	=	IC50	nM	380.0	CHEMBL2973	Homo sapiens	IC50	uM	0.38
	2026184	CHEMBL887137	Inhibition of ROCK2	B	NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1		CHEMBL240645	=	IC50	nM	760.0	CHEMBL2973	Homo sapiens	IC50	uM	0.76
	2026185	CHEMBL887137	Inhibition of ROCK2	B	NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Cl)cc1		CHEMBL394438	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	uM	0.19
	2026186	CHEMBL887137	Inhibition of ROCK2	B	N[C@@H](C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccccc1		CHEMBL391189	=	IC50	nM	1300.0	CHEMBL2973	Homo sapiens	IC50	uM	1.3
	2026187	CHEMBL887137	Inhibition of ROCK2	B	O=C([C@@H]1Cc2ccccc2CN1)N1CCN(c2ccc3[nH]ncc3c2)CC1		CHEMBL442086	=	IC50	nM	5300.0	CHEMBL2973	Homo sapiens	IC50	uM	5.3
	2026188	CHEMBL887137	Inhibition of ROCK2	B	O=C(C(O)c1ccc(Br)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1		CHEMBL239150	=	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	uM	0.1
	2026189	CHEMBL887137	Inhibition of ROCK2	B	O=C([C@H](O)c1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1		CHEMBL239149	=	IC50	nM	800.0	CHEMBL2973	Homo sapiens	IC50	uM	0.8
	2026190	CHEMBL887137	Inhibition of ROCK2	B	CC(C)[C@@H](O)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1		CHEMBL238945	=	IC50	nM	3900.0	CHEMBL2973	Homo sapiens	IC50	uM	3.9
	2026191	CHEMBL887137	Inhibition of ROCK2	B	O=C(C(O)c1ccc(Cl)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1		CHEMBL394993	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	uM	0.19
	2026192	CHEMBL887137	Inhibition of ROCK2	B	O=C([C@H](O)c1cccc(Cl)c1)N1CCN(c2ccc3[nH]ncc3c2)CC1		CHEMBL238744	=	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	uM	1.0
	2026237	CHEMBL887137	Inhibition of ROCK2	B	C[C@H](O)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1		CHEMBL395942	=	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	2051672	CHEMBL941808	Inhibition of ROCK2	B	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	>	Ki	nM	7500.0	CHEMBL2973	Homo sapiens	Ki	uM	7.5
	2099526	CHEMBL948240	Inhibition of ROCK2 at 10 uM	B	CN(C)CCCOc1cc2c(cc1O)c1c3c(c(-c4ccccc4Cl)cc1n2C)C(=O)NC3=O		CHEMBL410261	=	Inhibition	%	63.0	CHEMBL2973	Homo sapiens	Inhibition	%	63.0
	2099626	CHEMBL948240	Inhibition of ROCK2 at 10 uM	B	Cn1c2cc(C(=O)NCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL272267	=	Inhibition	%	66.0	CHEMBL2973	Homo sapiens	Inhibition	%	66.0
	2099627	CHEMBL948240	Inhibition of ROCK2 at 10 uM	B	Cn1c2cc(SCCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL404335	=	Inhibition	%	53.0	CHEMBL2973	Homo sapiens	Inhibition	%	53.0
	2099628	CHEMBL948240	Inhibition of ROCK2 at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)c(OCCCN3CCOCC3)cc2n1CCO		CHEMBL271715	=	Inhibition	%	70.0	CHEMBL2973	Homo sapiens	Inhibition	%	70.0
	2099629	CHEMBL948240	Inhibition of ROCK2 at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)c(OCCCN3CCCC3)cc2n1CCO		CHEMBL270021	=	Inhibition	%	67.0	CHEMBL2973	Homo sapiens	Inhibition	%	67.0
	2099630	CHEMBL948240	Inhibition of ROCK2 at 10 uM	B	Cn1c2cc(OCCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL255427	=	Inhibition	%	42.0	CHEMBL2973	Homo sapiens	Inhibition	%	42.0
	2101327	CHEMBL949035	Inhibition of ROCK2 at 10 uM	B	CC(C)(C)CN1CCC(NC(=O)c2csc(NC(=O)c3ccc4cc5n(c4c3)C3(CCC3)CNC5=O)n2)CC1		CHEMBL257834	=	Inhibition	%	63.0	CHEMBL2973	Homo sapiens	Inhibition	%	63.0
	2132665	CHEMBL921289	Inhibition of Rock2	B	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL410659	>	IC50	nM	5000.0	CHEMBL2973	Homo sapiens	IC50	uM	5.0
	2136968	CHEMBL940170	Inhibition of ROCK2	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	270.0	CHEMBL2973	Homo sapiens	IC50	nM	270.0
	2137226	CHEMBL940170	Inhibition of ROCK2	B	NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL319467	=	IC50	nM	600.0	CHEMBL2973	Homo sapiens	IC50	nM	600.0
	2147375	CHEMBL922160	Activity of human ROCK2 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
Not Evaluated	2149604	CHEMBL931301	Inhibition of human ROCK2	B	NC(=O)c1c(NC(=O)C2CC2)sc2c1CCCC2		CHEMBL379367		Activity			CHEMBL2973	Homo sapiens	Activity		
	2153722	CHEMBL928289	Inhibition of Rock2 at 20 uM	B	CN(C)CCOc1ccc2c(-c3c(-c4ccccn4)nn4c3CCC4)ccnc2c1		CHEMBL409525	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	Inhibition	%	50.0
	2153757	CHEMBL928289	Inhibition of Rock2 at 20 uM	B	c1ccc(-c2nn3c(c2-c2ccnc4cc(OCCN5CCOCC5)ccc24)CCC3)nc1		CHEMBL260015	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	Inhibition	%	50.0
	2157692	CHEMBL932647	Inhibition of ROCK2 at 1 uM	B	NCC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL406863	>	Inhibition	%	60.0	CHEMBL2973	Homo sapiens	Inhibition	%	60.0
Not Active	2170343	CHEMBL927902	Activity at ROCK2 at 3 uM	B	COc1c(NC(=O)c2ccc(C)c(N3C=C(C(=O)NCC(C)(C)CN(C)C)NN3)c2)cc(C(C)(C)C)cc1NS(C)(=O)=O		CHEMBL254992		Activity			CHEMBL2973	Homo sapiens	Activity		
	2239723	CHEMBL996952	Inhibition of ROCK2 at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCc1nnn[nH]1		CHEMBL471329	=	Inhibition	%	112.0	CHEMBL2973	Homo sapiens	INH	%	112.0
	2239751	CHEMBL996952	Inhibition of ROCK2 at 10 uM	B	CS(=O)(=O)NC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL460940	=	Inhibition	%	58.0	CHEMBL2973	Homo sapiens	INH	%	58.0
	2239779	CHEMBL996952	Inhibition of ROCK2 at 10 uM	B	CN(C)CCNC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL462011	=	Inhibition	%	100.0	CHEMBL2973	Homo sapiens	INH	%	100.0
	2239807	CHEMBL996952	Inhibition of ROCK2 at 10 uM	B	CNCCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL508541	=	Inhibition	%	22.0	CHEMBL2973	Homo sapiens	INH	%	22.0
	2239835	CHEMBL996952	Inhibition of ROCK2 at 10 uM	B	CNCCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4)cc21)C(=O)NC3=O		CHEMBL455192	=	Inhibition	%	20.0	CHEMBL2973	Homo sapiens	INH	%	20.0
	2239863	CHEMBL996952	Inhibition of ROCK2 at 10 uM	B	O=C1NC(=O)c2c1c(-c1c(Cl)cccc1Cl)cc1c2c2cc(O)ccc2n1CCCO		CHEMBL471163	=	Inhibition	%	13.0	CHEMBL2973	Homo sapiens	INH	%	13.0
	2239890	CHEMBL996952	Inhibition of ROCK2 at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCO		CHEMBL411662	=	Inhibition	%	38.0	CHEMBL2973	Homo sapiens	INH	%	38.0
	2239918	CHEMBL996952	Inhibition of ROCK2 at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	=	Inhibition	%	29.0	CHEMBL2973	Homo sapiens	INH	%	29.0
	2248291	CHEMBL1012720	Inhibition of ROCK2 at 5 uM	B	O=C1NC(=O)/C(=C/c2cccc(C(F)(F)F)c2)S1		CHEMBL183906	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	INH	%	5.0
	2248292	CHEMBL1012720	Inhibition of ROCK2 at 5 uM	B	CCCOc1ccc(/C=C2\SC(=O)NC2=O)cc1		CHEMBL84558	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	INH	%	5.0
	2251002	CHEMBL1011047	Binding affinity to ROCK2 by fluorescence polarization assay	B	Cl.Cl.O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL1315166	=	Kd	nM	31.0	CHEMBL2973	Homo sapiens	Kd	nM	31.0
	2251006	CHEMBL1011047	Binding affinity to ROCK2 by fluorescence polarization assay	B	C[C@@H](NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(=O)NCCCCCC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O		CHEMBL498924	=	Kd	nM	187.0	CHEMBL2973	Homo sapiens	Kd	nM	187.0
	2251007	CHEMBL1011047	Binding affinity to ROCK2 by fluorescence polarization assay	B	C[C@@H](NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)NCCCCCC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O		CHEMBL505949	=	Kd	nM	119.0	CHEMBL2973	Homo sapiens	Kd	nM	119.0
	2251008	CHEMBL1011047	Binding affinity to ROCK2 by fluorescence polarization assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	<	Kd	nM	1.0	CHEMBL2973	Homo sapiens	Kd	nM	1.0
	2251009	CHEMBL1011047	Binding affinity to ROCK2 by fluorescence polarization assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL524516	<	Kd	nM	1.0	CHEMBL2973	Homo sapiens	Kd	nM	1.0
	2251010	CHEMBL1011047	Binding affinity to ROCK2 by fluorescence polarization assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL297394	=	Kd	nM	1.4	CHEMBL2973	Homo sapiens	Kd	nM	1.4
	2251011	CHEMBL1011047	Binding affinity to ROCK2 by fluorescence polarization assay	B	N=C(N)NCCC[C@@H](NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL501706	=	Kd	nM	89.7	CHEMBL2973	Homo sapiens	Kd	nM	89.7
	2251012	CHEMBL1011047	Binding affinity to ROCK2 by fluorescence polarization assay	B	NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O		CHEMBL495766	=	Kd	nM	4480.0	CHEMBL2973	Homo sapiens	Kd	nM	4480.0
	2251074	CHEMBL1011949	Inhibition of ROCK2 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	Inhibition	%	104.0	CHEMBL2973	Homo sapiens	INH	%	104.0
	2279737	CHEMBL958302	Inhibition of ROCK2 at 10 uM	B	CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1		CHEMBL493937	>	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
Not Active	2298912	CHEMBL1018058	Inhibition of human ROCK2 at 10 umol/L	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C(=O)N(C)C)cc1)c1ccccc1		CHEMBL525203		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Active	2298936	CHEMBL1018058	Inhibition of human ROCK2 at 10 umol/L	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN2CCCCC2)cc1)c1ccccc1		CHEMBL497049		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Active	2298937	CHEMBL1018058	Inhibition of human ROCK2 at 10 umol/L	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835		Activity			CHEMBL2973	Homo sapiens	Activity		
	2341427	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(N3CCN(C(=O)Cc4c[nH]c5ccccc45)CC3)ncn2)c1		CHEMBL524898	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2341468	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL501459	=	Inhibition	%	29.0	CHEMBL2973	Homo sapiens	INH	%	29.0
	2341509	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCCc3ccc(O)cc3)CC2)n1		CHEMBL501728	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2341550	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(NCCc1ccc(O)cc1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL499617	=	Inhibition	%	11.0	CHEMBL2973	Homo sapiens	INH	%	11.0
	2341591	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2cc(Nc3cccc(Br)c3)ncn2)CC1		CHEMBL501200	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2341632	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)N[C@@H](CO)c2ccccc2)n1		CHEMBL525070	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	2341673	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)NCCc2cccc(I)c2)n1		CHEMBL501463	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	2341714	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(NC1Cc2ccccc2C1)c1cccc(Nc2ccnc(N3CCN(c4ccccc4)CC3)n2)c1		CHEMBL499624	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	2341755	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)ncn2)c1		CHEMBL502826	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2341796	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3ccc(CC(=O)Nc4ccc5ncsc5c4)cc3)ncn2)c1		CHEMBL502827	=	Inhibition	%	22.0	CHEMBL2973	Homo sapiens	INH	%	22.0
	2341837	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COc1ccc(NC(=O)Cc2ccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)cc2)cn1		CHEMBL526914	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2341878	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)n2)c1		CHEMBL501471	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	INH	%	4.0
	2341919	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(NCc1cccnc1)c1cccc(-c2ccc(Nc3ccc4ncsc4c3)nn2)c1		CHEMBL501182	=	Inhibition	%	93.0	CHEMBL2973	Homo sapiens	INH	%	93.0
	2341960	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N4CCCC5CCCCC54)c3)ncn2)c1		CHEMBL499606	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2342001	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)nc(N)n2)c1		CHEMBL499865	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	2342042	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)n2)c1		CHEMBL499866	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	INH	%	5.0
	2342083	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(CN1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1)Nc1cc(F)ccc1F		CHEMBL520451	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2342124	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(NCc1ccncc1)c1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1		CHEMBL482513	=	Inhibition	%	13.0	CHEMBL2973	Homo sapiens	INH	%	13.0
	2342165	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2cc(Nc3cccc(C(=O)N(CC(C)O)CC(C)O)c3)ncn2)c1		CHEMBL483318	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	2342206	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)ncn2)c1		CHEMBL520971	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2342247	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)ncn2)c1		CHEMBL521469	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2342288	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	CC(=O)N1CCN(C(=O)c2cccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)c2)CC1		CHEMBL521478	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2342329	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccncc4)c3)ncn2)c1		CHEMBL483506	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2342370	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	CN(CCc1ccccn1)C(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL483507	=	Inhibition	%	7.0	CHEMBL2973	Homo sapiens	INH	%	7.0
	2342411	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)nc(N)n2)c1		CHEMBL520980	=	Inhibition	%	12.0	CHEMBL2973	Homo sapiens	INH	%	12.0
	2342452	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1cc(Nc2cccc(OC)c2)nc(N)n1		CHEMBL519962	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2342493	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCN3CCCCC3)nc(N)n2)c1		CHEMBL526526	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2342534	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(COc1ccccc1)N1CCN(c2nccc(Nc3ccc4ncsc4c3)n2)CC1		CHEMBL482488	=	Inhibition	%	7.0	CHEMBL2973	Homo sapiens	INH	%	7.0
	2342805	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(NC[C@@H]1CCCO1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL500661	=	Inhibition	%	19.0	CHEMBL2973	Homo sapiens	INH	%	19.0
	2342840	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Clc1ccc2sc(CN3CCN(c4ncnc5c4CN(Cc4ccccc4)CC5)CC3)cc2c1		CHEMBL483710	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343036	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccccc2)cc(N2CCC(C(=O)NCCc3ccccn3)CC2)n1		CHEMBL521002	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343037	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1ccc(CN2CCN(c3nccc(C(C#N)c4ccccn4)n3)CC2)cc1		CHEMBL521145	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343038	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	CN(CCc1ccccn1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL521479	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343039	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(CC(C)C)CC(C)C)c3)ncn2)c1		CHEMBL484707	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343040	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(C1CCN(c2nccc(Nc3ccccc3)n2)CC1)N1CC[C@@H](O)C1		CHEMBL484706	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343041	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL521000	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343042	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL519349	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	INH	%	3.0
	2343043	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)C1CCCN1c1cc(Nc2cccc(Br)c2)ncn1		CHEMBL484521	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343044	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	CN(C)c1ccc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c2ccccc12		CHEMBL520331	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343045	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1		CHEMBL446637	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343046	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCCCn3ccnc3)n2)c1		CHEMBL482722	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343047	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)C1CCN(c2cc(N3CCOCC3)nc(N)n2)CC1		CHEMBL519311	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343048	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCN(C(=O)c4c(C)noc4C)CC3)n2)c1		CHEMBL482721	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343049	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COC(=O)C(CO)NC(=O)[C@@H]1CCCN1c1nccc(Oc2cccc(C)c2)n1		CHEMBL519310	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343050	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCc3cccnc3)n2)c1		CHEMBL482717	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343051	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCc3ccc(O)cc3)nc(N)n2)c1		CHEMBL483518	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343052	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c(C)n1C		CHEMBL482710	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343053	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc3c2CN(C(=O)c2cc(C)n(C)c2C)CC3)c1		CHEMBL519146	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343054	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(N3CCN(CC(=O)Nc4nc(-c5ccccc5)cs4)CC3)ncn2)c1		CHEMBL519534	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343055	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCN(CC(=O)Nc4cccc5c4CCCC5)CC3)n2)c1		CHEMBL520512	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343056	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	COc1ccc(-c2noc(CN3CCN(c4cc(Nc5cccc(O)c5)ncn4)CC3)n2)cc1		CHEMBL483715	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343057	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	CC(=O)CCCCC(=O)N1CCN(c2nccc(Oc3cccc(C)c3)n2)CC1		CHEMBL484713	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2343058	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc(C(=O)NCCc3ccncc3)cc2)cc(N2CCOCC2)n1		CHEMBL485524	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	2343059	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(CN2CCN(c3cc(N(C)c4cccc(C)c4)ncn3)CC2)c1		CHEMBL446087	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	2343060	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	CN(CCCn1ccnc1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL519658	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	2343061	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2ncnc3c2CN(C(=O)c2ccc(N(C)C)c4ccccc24)CC3)c1		CHEMBL484324	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	2343062	CHEMBL953388	Inhibition of ROCK2 at 10 uM by HTRF assay relative to control	B	Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCc3cccs3)CC2)n1		CHEMBL482910	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	2356956	CHEMBL958253	Inhibition of ROCK2 at 1 uM relative to control	B	Cc1ccn(-c2cccc(C(F)(F)F)c2)c(=O)c1-c1ccc2nc(N)ncc2c1		CHEMBL504805	>	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	2357006	CHEMBL958253	Inhibition of ROCK2 at 1 uM relative to control	B	Cc1ccn(-c2ccc(-c3ncco3)cc2)c(=O)c1-c1ccc2nc(N)ncc2c1		CHEMBL525893	>	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	2451262	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	CCC(Nc1cc(-c2[nH]c(SC)nc2-c2ccc(F)cc2)ccn1)c1ccccc1		CHEMBL494666	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2452066	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Inhibition	%	22.0	CHEMBL2973	Homo sapiens	INH	%	22.0
	2452067	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2452068	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Inhibition	%	23.0	CHEMBL2973	Homo sapiens	INH	%	23.0
	2452069	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	COCCn1c(SC)nc(-c2ccc(F)cc2)c1-c1ccnc(NC2CCCCC2)c1		CHEMBL481943	=	Inhibition	%	7.0	CHEMBL2973	Homo sapiens	INH	%	7.0
	2452070	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCC3CCCO3)c2)[nH]1		CHEMBL480952	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2452071	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)CCCC(C)C)c2)[nH]1		CHEMBL518964	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2452072	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCCc3cccs3)c2)[nH]1		CHEMBL519617	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2452073	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)CCc3ccccc3)c2)[nH]1		CHEMBL493669	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2452074	CHEMBL1013133	Inhibition of human ROCK2 at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC3CCc4ccccc43)c2)[nH]1		CHEMBL494871	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	2469921	CHEMBL1031376	Inhibition of ROCK2	B	O=C(Nc1nc(-c2ccncc2)cs1)C1COc2ccccc2O1		CHEMBL510515	=	IC50	nM	7.2	CHEMBL2973	Homo sapiens	IC50	uM	0.0072
	2469922	CHEMBL1031376	Inhibition of ROCK2	B	O=C(Nc1ccc(-c2ccncc2)cc1)C1COc2ccccc2O1		CHEMBL485213	=	IC50	nM	46.0	CHEMBL2973	Homo sapiens	IC50	uM	0.046
	2469923	CHEMBL1031376	Inhibition of ROCK2	B	O=C(Nc1ccc(-c2c[nH]cn2)cc1)C1COc2ccccc2O1		CHEMBL485214	=	IC50	nM	1.5	CHEMBL2973	Homo sapiens	IC50	uM	0.0015
	2469924	CHEMBL1031376	Inhibition of ROCK2	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL485215	=	IC50	nM	3.3	CHEMBL2973	Homo sapiens	IC50	uM	0.0033
	2469925	CHEMBL1031376	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	=	IC50	nM	3.2	CHEMBL2973	Homo sapiens	IC50	uM	0.0032
	2470001	CHEMBL1031376	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1N		CHEMBL485567	=	IC50	nM	920.0	CHEMBL2973	Homo sapiens	IC50	nM	920.0
	2470002	CHEMBL1031376	Inhibition of ROCK2	B	CC(=O)Nc1ccc(-c2cn[nH]c2)cc1OCCN(C)C		CHEMBL485568	=	IC50	nM	760.0	CHEMBL2973	Homo sapiens	IC50	nM	760.0
	2470343	CHEMBL995022	Inhibition of ROCK2 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL2973	Homo sapiens	INH	%	10.0
	2486606	CHEMBL994973	Inhibition of Rock2	B	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	>	Ki	nM	7500.0	CHEMBL2973	Homo sapiens	Ki	uM	7.5
	2505229	CHEMBL942694	Inhibition of ROCK2	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccccc2O1		CHEMBL519123	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2505230	CHEMBL942694	Inhibition of ROCK2	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccccc2C1		CHEMBL455658	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2505232	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(NC(=O)C2COc3ccccc3C2)ccc1-c1cn[nH]c1		CHEMBL480585	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	2505233	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2C1		CHEMBL480586	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	2505234	CHEMBL942694	Inhibition of ROCK2	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1F)C1COc2ccccc2C1		CHEMBL519101	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	2505235	CHEMBL942694	Inhibition of ROCK2	B	O=C(Nc1cc(F)c(-c2cn[nH]c2)c(F)c1)C1COc2ccccc2C1		CHEMBL480746	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	2505236	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)C1COc2ccccc2C1		CHEMBL481731	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	2505237	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(NC(=O)C2COc3ccccc3C2)c(F)cc1-c1cn[nH]c1		CHEMBL514172	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
	2505238	CHEMBL942694	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2C1		CHEMBL474425	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	2505239	CHEMBL942694	Inhibition of ROCK2	B	CN(C)CCOc1cc(NC(=O)C2COc3ccccc3C2)ccc1-c1cn[nH]c1		CHEMBL474426	=	IC50	nM	640.0	CHEMBL2973	Homo sapiens	IC50	nM	640.0
	2505240	CHEMBL942694	Inhibition of ROCK2	B	COc1cccc2c1OCC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)C2		CHEMBL474593	=	IC50	nM	285.0	CHEMBL2973	Homo sapiens	IC50	nM	285.0
	2505241	CHEMBL942694	Inhibition of ROCK2	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL475601	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	2505242	CHEMBL942694	Inhibition of ROCK2	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccc(F)cc2C1		CHEMBL475612	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	2505243	CHEMBL942694	Inhibition of ROCK2	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccc(Cl)cc2C1		CHEMBL475613	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	2505244	CHEMBL942694	Inhibition of ROCK2	B	Cc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL482309	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	2505245	CHEMBL942694	Inhibition of ROCK2	B	O=C(O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL442574	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
	2505246	CHEMBL942694	Inhibition of ROCK2	B	COC(=O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL481684	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	2505247	CHEMBL942694	Inhibition of ROCK2	B	CN(C)C(=O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL482310	=	IC50	nM	86.0	CHEMBL2973	Homo sapiens	IC50	nM	86.0
	2505248	CHEMBL942694	Inhibition of ROCK2	B	CN(C)CCNC(=O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL481685	<	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2505249	CHEMBL942694	Inhibition of ROCK2	B	CN(C)CCN(C)C(=O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL481509	=	IC50	nM	93.0	CHEMBL2973	Homo sapiens	IC50	nM	93.0
	2505250	CHEMBL942694	Inhibition of ROCK2	B	CN1CCN(C(=O)c2ccc3c(c2)CC(C(=O)Nc2ccc(-c4cn[nH]c4)cc2)CO3)CC1		CHEMBL482163	=	IC50	nM	78.0	CHEMBL2973	Homo sapiens	IC50	nM	78.0
	2505251	CHEMBL942694	Inhibition of ROCK2	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)c(OC)c1)CO2		CHEMBL519304	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	2505252	CHEMBL942694	Inhibition of ROCK2	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OC)CO2		CHEMBL482351	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	2505253	CHEMBL942694	Inhibition of ROCK2	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2		CHEMBL482336	<	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2505254	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(NC(=O)C2COc3ccc(F)cc3C2)ccc1-c1cn[nH]c1		CHEMBL482337	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	2505255	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(F)cc2C1		CHEMBL520103	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	2505256	CHEMBL942694	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(F)cc2C1		CHEMBL481545	<	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2505257	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(NC(=O)C2COc3ccc(Cl)cc3C2)ccc1-c1cn[nH]c1		CHEMBL482363	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2505258	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(Cl)cc2C1		CHEMBL519959	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	2505259	CHEMBL942694	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(Cl)cc2C1		CHEMBL481553	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	2505260	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(NC(=O)C2COc3ccc(C)cc3C2)ccc1-c1cn[nH]c1		CHEMBL481889	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	2505261	CHEMBL942694	Inhibition of ROCK2	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(C)cc2C1		CHEMBL519269	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	2505262	CHEMBL942694	Inhibition of ROCK2	B	Cc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2		CHEMBL481735	<	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2505327	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccccc2C1		CHEMBL455658	=	IC50	nM	25.0	CHEMBL2973	Homo sapiens	IC50	nM	25.0
	2505328	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(NC(=O)C2COc3ccccc3C2)ccc1-c1cn[nH]c1		CHEMBL480585	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	2505329	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2C1		CHEMBL480586	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2505330	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1F)C1COc2ccccc2C1		CHEMBL519101	=	IC50	nM	80.0	CHEMBL2973	Homo sapiens	IC50	nM	80.0
	2505331	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(Nc1cc(F)c(-c2cn[nH]c2)c(F)c1)C1COc2ccccc2C1		CHEMBL480746	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	nM	15.0
	2505332	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)C1COc2ccccc2C1		CHEMBL481731	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2505333	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(NC(=O)C2COc3ccccc3C2)c(F)cc1-c1cn[nH]c1		CHEMBL514172	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	2505334	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2C1		CHEMBL474425	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
Not Determined	2505335	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(NC(=O)C2COc3ccccc3C2)ccc1-c1cn[nH]c1		CHEMBL474426		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	2505336	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cccc2c1OCC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)C2		CHEMBL474593		IC50			CHEMBL2973	Homo sapiens	IC50		
	2505337	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL475601	=	IC50	nM	38.0	CHEMBL2973	Homo sapiens	IC50	nM	38.0
	2505338	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccc(F)cc2C1		CHEMBL475612	=	IC50	nM	71.0	CHEMBL2973	Homo sapiens	IC50	nM	71.0
	2505339	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccc(Cl)cc2C1		CHEMBL475613	=	IC50	nM	3487.0	CHEMBL2973	Homo sapiens	IC50	nM	3487.0
	2505340	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Cc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL482309	=	IC50	nM	4000.0	CHEMBL2973	Homo sapiens	IC50	nM	4000.0
	2505341	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL442574	=	IC50	nM	751.0	CHEMBL2973	Homo sapiens	IC50	nM	751.0
	2505342	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COC(=O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL481684	=	IC50	nM	22.0	CHEMBL2973	Homo sapiens	IC50	nM	22.0
	2505343	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)C(=O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL482310	=	IC50	nM	500.0	CHEMBL2973	Homo sapiens	IC50	nM	500.0
	2505344	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCNC(=O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL481685	=	IC50	nM	47.0	CHEMBL2973	Homo sapiens	IC50	nM	47.0
	2505345	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCN(C)C(=O)c1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1)CO2		CHEMBL481509	=	IC50	nM	1500.0	CHEMBL2973	Homo sapiens	IC50	nM	1500.0
Not Determined	2505346	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN1CCN(C(=O)c2ccc3c(c2)CC(C(=O)Nc2ccc(-c4cn[nH]c4)cc2)CO3)CC1		CHEMBL482163		IC50			CHEMBL2973	Homo sapiens	IC50		
	2505347	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)c(OC)c1)CO2		CHEMBL519304	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2505348	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OC)CO2		CHEMBL482351	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2505349	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2		CHEMBL482336	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2505350	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(NC(=O)C2COc3ccc(F)cc3C2)ccc1-c1cn[nH]c1		CHEMBL482337	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2505351	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(F)cc2C1		CHEMBL520103	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2505352	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(F)cc2C1		CHEMBL481545	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2505353	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(NC(=O)C2COc3ccc(Cl)cc3C2)ccc1-c1cn[nH]c1		CHEMBL482363	=	IC50	nM	38.0	CHEMBL2973	Homo sapiens	IC50	nM	38.0
	2505354	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(Cl)cc2C1		CHEMBL519959	=	IC50	nM	66.0	CHEMBL2973	Homo sapiens	IC50	nM	66.0
	2505355	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(Cl)cc2C1		CHEMBL481553	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2505356	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(NC(=O)C2COc3ccc(C)cc3C2)ccc1-c1cn[nH]c1		CHEMBL481889	=	IC50	nM	52.0	CHEMBL2973	Homo sapiens	IC50	nM	52.0
	2505357	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(C)cc2C1		CHEMBL519269	=	IC50	nM	35.0	CHEMBL2973	Homo sapiens	IC50	nM	35.0
	2505358	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Cc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2		CHEMBL481735	=	IC50	nM	16.0	CHEMBL2973	Homo sapiens	IC50	nM	16.0
	2505386	CHEMBL942698	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccccc2O1		CHEMBL519123	=	IC50	nM	72.0	CHEMBL2973	Homo sapiens	IC50	nM	72.0
	2506977	CHEMBL942628	Inhibition of Rock2 at 10 uM	B	COc1cc(O)ccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1		CHEMBL474619	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	2506978	CHEMBL942628	Inhibition of Rock2 at 10 uM	B	CN1CCN(c2cccc3nc(-c4n[nH]c5cc(-c6ccc(N)cc6)ccc45)[nH]c23)CC1		CHEMBL480391	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
Not Active	2527090	CHEMBL984166	Inhibition of ROCK2 at => 3 ug/mL	B	COc1c(NC(=O)Nc2ccc(-c3ccc(CN4CCOCC4)nc3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O		CHEMBL451523		Activity			CHEMBL2973	Homo sapiens	Activity		
	2586314	CHEMBL1009210	Inhibition of ROCK2	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccccc2C1		CHEMBL455658	<	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2586315	CHEMBL1009210	Inhibition of ROCK2	B	c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3o1)CO2		CHEMBL509011	=	IC50	nM	21.0	CHEMBL2973	Homo sapiens	IC50	nM	21.0
	2586316	CHEMBL1009210	Inhibition of ROCK2	B	c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3[nH]1)CO2		CHEMBL455659	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	nM	27.0
	2586317	CHEMBL1009210	Inhibition of ROCK2	B	Cc1[nH]ncc1-c1ccc2nc(C3COc4ccccc4C3)[nH]c2c1		CHEMBL453635	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	2586318	CHEMBL1009210	Inhibition of ROCK2	B	Cc1[nH]ncc1-c1ccc2nc(C3COc4ccccc4C3)oc2c1		CHEMBL508975	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	2586319	CHEMBL1009210	Inhibition of ROCK2	B	c1ccc2c(c1)CC(c1nc3ccc(-c4ccncc4)cc3[nH]1)CO2		CHEMBL452734	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2586320	CHEMBL1009210	Inhibition of ROCK2	B	Nc1nccc(-c2ccc3nc(C4COc5ccccc5C4)[nH]c3c2)n1		CHEMBL454654	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	2586321	CHEMBL1009210	Inhibition of ROCK2	B	Nc1nccc(-c2ccc3nc(C4COc5ccccc5C4)oc3c2)n1		CHEMBL454624	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	nM	27.0
	2586322	CHEMBL1009210	Inhibition of ROCK2	B	COc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3[nH]1)CO2		CHEMBL454638	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2586323	CHEMBL1009210	Inhibition of ROCK2	B	COc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3o1)CO2		CHEMBL461338	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	2586324	CHEMBL1009210	Inhibition of ROCK2	B	CC(C)Oc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3[nH]1)CO2		CHEMBL461339	=	IC50	nM	296.0	CHEMBL2973	Homo sapiens	IC50	nM	296.0
	2586325	CHEMBL1009210	Inhibition of ROCK2	B	CC(C)Oc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3o1)CO2		CHEMBL517891	=	IC50	nM	294.0	CHEMBL2973	Homo sapiens	IC50	nM	294.0
	2586326	CHEMBL1009210	Inhibition of ROCK2	B	Nc1nccc(-c2ccc3nc(C4COc5ccc(F)cc5C4)[nH]c3c2)n1		CHEMBL518825	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2586327	CHEMBL1009210	Inhibition of ROCK2	B	Nc1nccc(-c2ccc3nc(C4COc5ccc(F)cc5C4)oc3c2)n1		CHEMBL517561	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	nM	15.0
	2586328	CHEMBL1009210	Inhibition of ROCK2	B	Cc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3o1)CO2		CHEMBL462193	=	IC50	nM	78.0	CHEMBL2973	Homo sapiens	IC50	nM	78.0
	2586329	CHEMBL1009210	Inhibition of ROCK2	B	COC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3[nH]1)CO2		CHEMBL462194	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2586330	CHEMBL1009210	Inhibition of ROCK2	B	COC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3o1)CO2		CHEMBL518665	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	nM	24.0
	2586331	CHEMBL1009210	Inhibition of ROCK2	B	Nc1nccc(-c2ccc3nc(C4COc5ccc(C(=O)NC6CC6)cc5C4)[nH]c3c2)n1		CHEMBL454639	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	2586332	CHEMBL1009210	Inhibition of ROCK2	B	Nc1nccc(-c2ccc3nc(C4COc5ccc(C(=O)NCc6ccccc6)cc5C4)[nH]c3c2)n1		CHEMBL455446	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	2586333	CHEMBL1009210	Inhibition of ROCK2	B	COc1ccc2c(c1)CC(c1nc3c(F)cc(-c4ccnc(N)n4)cc3[nH]1)CO2		CHEMBL452598	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	2586354	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)C1COc2ccccc2C1		CHEMBL455658	=	IC50	nM	25.0	CHEMBL2973	Homo sapiens	IC50	nM	25.0
	2586355	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3o1)CO2		CHEMBL509011	=	IC50	nM	330.0	CHEMBL2973	Homo sapiens	IC50	nM	330.0
	2586356	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3[nH]1)CO2		CHEMBL455659	=	IC50	nM	86.0	CHEMBL2973	Homo sapiens	IC50	nM	86.0
Not Determined	2586357	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Cc1[nH]ncc1-c1ccc2nc(C3COc4ccccc4C3)[nH]c2c1		CHEMBL453635		IC50			CHEMBL2973	Homo sapiens	IC50		
	2586358	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Cc1[nH]ncc1-c1ccc2nc(C3COc4ccccc4C3)oc2c1		CHEMBL508975	=	IC50	nM	533.0	CHEMBL2973	Homo sapiens	IC50	nM	533.0
	2586359	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	c1ccc2c(c1)CC(c1nc3ccc(-c4ccncc4)cc3[nH]1)CO2		CHEMBL452734	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2586360	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Nc1nccc(-c2ccc3nc(C4COc5ccccc5C4)[nH]c3c2)n1		CHEMBL454654	=	IC50	nM	66.0	CHEMBL2973	Homo sapiens	IC50	nM	66.0
Not Determined	2586361	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Nc1nccc(-c2ccc3nc(C4COc5ccccc5C4)oc3c2)n1		CHEMBL454624		IC50			CHEMBL2973	Homo sapiens	IC50		
	2586362	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3[nH]1)CO2		CHEMBL454638	=	IC50	nM	99.0	CHEMBL2973	Homo sapiens	IC50	nM	99.0
	2586363	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3o1)CO2		CHEMBL461338	=	IC50	nM	46.0	CHEMBL2973	Homo sapiens	IC50	nM	46.0
Not Determined	2586364	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CC(C)Oc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3[nH]1)CO2		CHEMBL461339		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	2586365	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CC(C)Oc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3o1)CO2		CHEMBL517891		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	2586366	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Nc1nccc(-c2ccc3nc(C4COc5ccc(F)cc5C4)[nH]c3c2)n1		CHEMBL518825		IC50			CHEMBL2973	Homo sapiens	IC50		
	2586367	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Nc1nccc(-c2ccc3nc(C4COc5ccc(F)cc5C4)oc3c2)n1		CHEMBL517561	=	IC50	nM	28.0	CHEMBL2973	Homo sapiens	IC50	nM	28.0
Not Determined	2586368	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Cc1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3o1)CO2		CHEMBL462193		IC50			CHEMBL2973	Homo sapiens	IC50		
	2586369	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3[nH]1)CO2		CHEMBL462194	=	IC50	nM	271.0	CHEMBL2973	Homo sapiens	IC50	nM	271.0
Not Determined	2586370	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4ccnc(N)n4)cc3o1)CO2		CHEMBL518665		IC50			CHEMBL2973	Homo sapiens	IC50		
	2586371	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Nc1nccc(-c2ccc3nc(C4COc5ccc(C(=O)NC6CC6)cc5C4)[nH]c3c2)n1		CHEMBL454639	=	IC50	nM	212.0	CHEMBL2973	Homo sapiens	IC50	nM	212.0
	2586372	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Nc1nccc(-c2ccc3nc(C4COc5ccc(C(=O)NCc6ccccc6)cc5C4)[nH]c3c2)n1		CHEMBL455446	=	IC50	nM	23.0	CHEMBL2973	Homo sapiens	IC50	nM	23.0
	2586373	CHEMBL1009212	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)CC(c1nc3c(F)cc(-c4ccnc(N)n4)cc3[nH]1)CO2		CHEMBL452598	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	2595779	CHEMBL1019777	Inhibition of ROCK2	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	IC50	nM	3400.0	CHEMBL2973	Homo sapiens	IC50	nM	3400.0
	2596913	CHEMBL1017916	Inhibition of ROCK2 assessed as enzyme activity relative to control	B	C[C@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL457871	=	Activity	%	4.0	CHEMBL2973	Homo sapiens	Activity	%	4.0
	2596917	CHEMBL1017916	Inhibition of ROCK2 assessed as enzyme activity relative to control	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	Activity	%	2.4	CHEMBL2973	Homo sapiens	Activity	%	2.4
	2613318	CHEMBL1016952	Inhibition of ROCK2	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	IC50	nM	3400.0	CHEMBL2973	Homo sapiens	IC50	nM	3400.0
	2635884	CHEMBL1003314	Inhibition of ROCK2 at 1 uM relative to control	B	CSc1cc(Oc2ccnc3[nH]c(=O)[nH]c23)ccc1NC(=O)Nc1cccc(C(F)(F)F)c1		CHEMBL496009	=	Residual_activity	%	75.0	CHEMBL2973	Homo sapiens	Residual_activity	%	75.0
	2635952	CHEMBL1003314	Inhibition of ROCK2 at 1 uM relative to control	B	O=C(Nc1cc(C(F)(F)F)ccc1F)Nc1ccc(Oc2ccnc3[nH]c(=O)[nH]c23)c2ccccc12		CHEMBL498112	=	Residual_activity	%	75.0	CHEMBL2973	Homo sapiens	Residual_activity	%	75.0
	2636020	CHEMBL1003314	Inhibition of ROCK2 at 1 uM relative to control	B	CC(C)(C)c1cccc(NC(=O)Nc2ccc(Oc3ccnc4[nH]c(=O)[nH]c34)c3ccccc23)c1		CHEMBL496073	=	Residual_activity	%	75.0	CHEMBL2973	Homo sapiens	Residual_activity	%	75.0
	2721710	CHEMBL1055112	Inhibition of ROCK-2 at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	2891662	CHEMBL1063670	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Activity	%	53.0	CHEMBL2973	Homo sapiens	Activity	%	53.0
	2891663	CHEMBL1063670	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Activity	%	94.0	CHEMBL2973	Homo sapiens	Activity	%	94.0
	2891664	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	=	Activity	%	86.0	CHEMBL2973	Homo sapiens	Activity	%	86.0
	2891665	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	=	Activity	%	82.0	CHEMBL2973	Homo sapiens	Activity	%	82.0
	2891666	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Activity	%	83.0	CHEMBL2973	Homo sapiens	Activity	%	83.0
	2891667	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	56.0	CHEMBL2973	Homo sapiens	Activity	%	56.0
	2891668	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Activity	%	105.0	CHEMBL2973	Homo sapiens	Activity	%	105.0
	2891669	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	=	Activity	%	80.0	CHEMBL2973	Homo sapiens	Activity	%	80.0
	2891670	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
Antagonist	2891671	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Activity	%	32.0	CHEMBL2973	Homo sapiens	Activity	%	32.0
	2891672	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	CC(=O)c1c(O)c(C)c(O)c(Cc2c(O)c3c(c(C(=O)/C=C/c4ccccc4)c2O)OC(C)(C)C=C3)c1O		CHEMBL34241	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
Antagonist	2891673	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	C[C@H]1CNCCN1S(=O)(=O)c1cccc2cnccc12		CHEMBL1233654	=	Activity	%	16.0	CHEMBL2973	Homo sapiens	Activity	%	16.0
	2891674	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(O)c(Cl)c1		CHEMBL322970	=	Activity	%	79.0	CHEMBL2973	Homo sapiens	Activity	%	79.0
Antagonist	2891675	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	CNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL148333	=	Activity	%	13.0	CHEMBL2973	Homo sapiens	Activity	%	13.0
Antagonist	2891676	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Activity	%	5.0	CHEMBL2973	Homo sapiens	Activity	%	5.0
Antagonist	2891677	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Activity	%	7.0	CHEMBL2973	Homo sapiens	Activity	%	7.0
	2891678	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1sc(-c2ccsc2)cc1N		CHEMBL193093	=	Activity	%	59.0	CHEMBL2973	Homo sapiens	Activity	%	59.0
Antagonist	2891679	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21		CHEMBL264406	=	Activity	%	30.0	CHEMBL2973	Homo sapiens	Activity	%	30.0
	2891680	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Activity	%	77.0	CHEMBL2973	Homo sapiens	Activity	%	77.0
	2891681	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc(O)cc1		CHEMBL186526	=	Activity	%	96.0	CHEMBL2973	Homo sapiens	Activity	%	96.0
	2891682	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Activity	%	71.0	CHEMBL2973	Homo sapiens	Activity	%	71.0
	2891683	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1OC(C)=O		CHEMBL240954	=	Activity	%	109.0	CHEMBL2973	Homo sapiens	Activity	%	109.0
	2891684	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	O=C(Nc1cc(Cl)cc2c1[nH]c1cnccc12)c1cccnc1		CHEMBL79004	=	Activity	%	69.0	CHEMBL2973	Homo sapiens	Activity	%	69.0
	2891685	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	O=C(NOC[C@@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl.O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL540501	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	2891686	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(\N)Sc1ccccc1N		CHEMBL34704	=	Activity	%	81.0	CHEMBL2973	Homo sapiens	Activity	%	81.0
	2891687	CHEMBL1063774	Percentage ROCK2 activity remaining in the presence of 10uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	92.0	CHEMBL2973	Homo sapiens	Activity	%	92.0
	2891688	CHEMBL1062024	Percentage ROCK2 activity remaining in the presence of 25uM inhibitor	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349	=	Activity	%	78.0	CHEMBL2973	Homo sapiens	Activity	%	78.0
	2891689	CHEMBL1062024	Percentage ROCK2 activity remaining in the presence of 25uM inhibitor	B	NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12		CHEMBL489157	=	Activity	%	65.0	CHEMBL2973	Homo sapiens	Activity	%	65.0
	2891690	CHEMBL1063775	Percentage ROCK2 activity remaining in the presence of 2uM inhibitor	B	Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21		CHEMBL102714	=	Activity	%	101.0	CHEMBL2973	Homo sapiens	Activity	%	101.0
	2891691	CHEMBL1060218	Percentage ROCK2 activity remaining in the presence of 3uM inhibitor	B	Cc1ccc(-c2c(C(=O)CF)n(CCCO)c3ncnc(N)c23)cc1		CHEMBL515414	=	Activity	%	86.0	CHEMBL2973	Homo sapiens	Activity	%	86.0
	2891692	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Activity	%	79.0	CHEMBL2973	Homo sapiens	Activity	%	79.0
	2891693	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	=	Activity	%	79.0	CHEMBL2973	Homo sapiens	Activity	%	79.0
	2891694	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Activity	%	76.0	CHEMBL2973	Homo sapiens	Activity	%	76.0
	2891695	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	78.0	CHEMBL2973	Homo sapiens	Activity	%	78.0
	2891696	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Activity	%	86.0	CHEMBL2973	Homo sapiens	Activity	%	86.0
	2891697	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	=	Activity	%	68.0	CHEMBL2973	Homo sapiens	Activity	%	68.0
	2891698	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Activity	%	97.0	CHEMBL2973	Homo sapiens	Activity	%	97.0
	2891699	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Activity	%	73.0	CHEMBL2973	Homo sapiens	Activity	%	73.0
	2891700	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Activity	%	84.0	CHEMBL2973	Homo sapiens	Activity	%	84.0
	2891701	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O		CHEMBL428496	=	Activity	%	99.0	CHEMBL2973	Homo sapiens	Activity	%	99.0
	2891702	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
	2891703	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Activity	%	87.0	CHEMBL2973	Homo sapiens	Activity	%	87.0
Antagonist	2891704	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Activity	%	42.0	CHEMBL2973	Homo sapiens	Activity	%	42.0
	2891705	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CC(=O)O.O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL265470	=	Activity	%	99.0	CHEMBL2973	Homo sapiens	Activity	%	99.0
	2891706	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Activity	%	92.0	CHEMBL2973	Homo sapiens	Activity	%	92.0
	2891707	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Activity	%	80.0	CHEMBL2973	Homo sapiens	Activity	%	80.0
	2891708	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	COc1ccc2c(c1)[nH]c1c(C)nccc12		CHEMBL269538	=	Activity	%	80.0	CHEMBL2973	Homo sapiens	Activity	%	80.0
	2891709	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CC1=NCCc2c1[nH]c1cc(O)ccc21		CHEMBL129177	=	Activity	%	91.0	CHEMBL2973	Homo sapiens	Activity	%	91.0
	2891710	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Cc1nccc2c1[nH]c1ccccc12		CHEMBL12014	=	Activity	%	104.0	CHEMBL2973	Homo sapiens	Activity	%	104.0
	2891711	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	COc1ccc2c3c([nH]c2c1)C(C)=NCC3		CHEMBL340807	=	Activity	%	79.0	CHEMBL2973	Homo sapiens	Activity	%	79.0
	2891712	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Oc1c(Br)cc(C=C2c3cc(I)ccc3NC2O)cc1Br		CHEMBL1794051	=	Activity	%	66.0	CHEMBL2973	Homo sapiens	Activity	%	66.0
Antagonist	2891713	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL148333	=	Activity	%	6.0	CHEMBL2973	Homo sapiens	Activity	%	6.0
Antagonist	2891714	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	Activity	%	3.0	CHEMBL2973	Homo sapiens	Activity	%	3.0
	2891715	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Activity	%	67.0	CHEMBL2973	Homo sapiens	Activity	%	67.0
	2891716	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21		CHEMBL264406	=	Activity	%	86.0	CHEMBL2973	Homo sapiens	Activity	%	86.0
	2891717	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
	2891718	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Activity	%	84.0	CHEMBL2973	Homo sapiens	Activity	%	84.0
	2891719	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Activity	%	103.0	CHEMBL2973	Homo sapiens	Activity	%	103.0
	2891720	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Activity	%	64.0	CHEMBL2973	Homo sapiens	Activity	%	64.0
	2891721	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	CCCCCCOC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608532	=	Activity	%	73.0	CHEMBL2973	Homo sapiens	Activity	%	73.0
	2891722	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Activity	%	84.0	CHEMBL2973	Homo sapiens	Activity	%	84.0
	2891723	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	105.0	CHEMBL2973	Homo sapiens	Activity	%	105.0
	2891724	CHEMBL1063671	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	B	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	=	Activity	%	81.0	CHEMBL2973	Homo sapiens	Activity	%	81.0
	2892013	CHEMBL1063670	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	B	CC(C)CCN1c2nc(Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)C1C		CHEMBL573107	=	Activity	%	84.0	CHEMBL2973	Homo sapiens	Activity	%	84.0
Antagonist	2892014	CHEMBL1063670	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	28.0	CHEMBL2973	Homo sapiens	Activity	%	28.0
Antagonist	2892015	CHEMBL1063670	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Activity	%	8.0	CHEMBL2973	Homo sapiens	Activity	%	8.0
	2892016	CHEMBL1063670	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Activity	%	93.0	CHEMBL2973	Homo sapiens	Activity	%	93.0
	2892017	CHEMBL1063670	Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor	B	Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL6291	=	Activity	%	88.0	CHEMBL2973	Homo sapiens	Activity	%	88.0
	2897189	CHEMBL1062037	Percent residual ROCK-II activity in the presence of 10uM inhibitor	B	O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12		CHEMBL92361	=	Activity	%	94.0	CHEMBL2973	Homo sapiens	Activity	%	94.0
	2897190	CHEMBL1062037	Percent residual ROCK-II activity in the presence of 10uM inhibitor	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28	=	Activity	%	88.0	CHEMBL2973	Homo sapiens	Activity	%	88.0
	2897191	CHEMBL1062037	Percent residual ROCK-II activity in the presence of 10uM inhibitor	B	Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL289277	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
	2908268	CHEMBL1063773	Percentage ROCK2 activity remaining in the presence of 0.01uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
Antagonist	2908269	CHEMBL1063773	Percentage ROCK2 activity remaining in the presence of 0.01uM inhibitor	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Activity	%	48.0	CHEMBL2973	Homo sapiens	Activity	%	48.0
	2908270	CHEMBL1063773	Percentage ROCK2 activity remaining in the presence of 0.01uM inhibitor	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Activity	%	86.0	CHEMBL2973	Homo sapiens	Activity	%	86.0
	2921982	CHEMBL1052950	Inhibition of ROCK2 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	2924737	CHEMBL1056857	Inhibition of ROCK2 assessed as residual enzyme activity at 10 uM relative to untreated control	B	c1ccc2c(c1)[nH]c1c3cc[nH]c3ccc21		CHEMBL567173	=	Activity	%	89.0	CHEMBL2973	Homo sapiens	Activity	%	89.0
	2924738	CHEMBL1056857	Inhibition of ROCK2 assessed as residual enzyme activity at 10 uM relative to untreated control	B	c1ccc2c(c1)[nH]c1c2ccc2cc[nH]c21		CHEMBL584980	=	Activity	%	86.0	CHEMBL2973	Homo sapiens	Activity	%	86.0
	2924739	CHEMBL1056857	Inhibition of ROCK2 assessed as residual enzyme activity at 10 uM relative to untreated control	B	O=Cc1c[nH]c2ccc3c4ccccc4[nH]c3c12		CHEMBL575754	=	Activity	%	86.0	CHEMBL2973	Homo sapiens	Activity	%	86.0
	2924740	CHEMBL1056857	Inhibition of ROCK2 assessed as residual enzyme activity at 10 uM relative to untreated control	B	O=Cc1c[nH]c2c1ccc1c3ccccc3[nH]c12		CHEMBL583972	=	Activity	%	25.0	CHEMBL2973	Homo sapiens	Activity	%	25.0
	2926205	CHEMBL1049419	Inhibition of ROCK2 assessed as remaining enzyme activity at 3 uM relative to DMSO	B	COc1ccccc1-n1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL574236	=	Activity	%	94.0	CHEMBL2973	Homo sapiens	Activity	%	94.0
	2926720	CHEMBL1052149	Inhibition of recombinant ROCK2 at 20 uM by [gamma-33P]ATP based assay	B	CC(Oc1nc(-c2ccc(C(=O)NCC3CCCNC3)cc2)cnc1N)c1c(Cl)cccc1Cl.Cl		CHEMBL567391	=	Inhibition	%	42.0	CHEMBL2973	Homo sapiens	INH	%	42.0
	2926728	CHEMBL1052149	Inhibition of recombinant ROCK2 at 20 uM by [gamma-33P]ATP based assay	B	Cl.Nc1ncc(-c2ccc(C(=O)NCC3CCNC3)cc2)nc1Oc1ccc2cc[nH]c2c1		CHEMBL573177	=	Inhibition	%	98.0	CHEMBL2973	Homo sapiens	INH	%	98.0
	2926736	CHEMBL1052149	Inhibition of recombinant ROCK2 at 20 uM by [gamma-33P]ATP based assay	B	Cl.Nc1ncc(-c2ccc(C(=O)N[C@@H]3CCNC3)cc2)nc1Oc1ccc2cc[nH]c2c1		CHEMBL572910	=	Inhibition	%	37.0	CHEMBL2973	Homo sapiens	INH	%	37.0
	2926744	CHEMBL1052149	Inhibition of recombinant ROCK2 at 20 uM by [gamma-33P]ATP based assay	B	Cl.Nc1ncc(-c2ccc(C(=O)NC3CCNCC3)cc2)nc1Oc1ccc2cc[nH]c2c1		CHEMBL566083	=	Inhibition	%	99.0	CHEMBL2973	Homo sapiens	INH	%	99.0
	2926752	CHEMBL1052149	Inhibition of recombinant ROCK2 at 20 uM by [gamma-33P]ATP based assay	B	Cl.Nc1ncc(-c2ccc(C(=O)NCC3CCCNC3)cc2)nc1Oc1ccc2cc[nH]c2c1		CHEMBL567174	=	Inhibition	%	98.0	CHEMBL2973	Homo sapiens	INH	%	98.0
	2926760	CHEMBL1052149	Inhibition of recombinant ROCK2 at 20 uM by [gamma-33P]ATP based assay	B	Cl.Nc1ncc(-c2ccc(C(=O)NCC3CCCN3)cc2)nc1Oc1ccc2cc[nH]c2c1		CHEMBL575565	=	Inhibition	%	97.0	CHEMBL2973	Homo sapiens	INH	%	97.0
	2926768	CHEMBL1052149	Inhibition of recombinant ROCK2 at 20 uM by [gamma-33P]ATP based assay	B	Cl.Nc1ncc(-c2ccc(C(=O)NCC3CCNCC3)cc2)nc1Oc1ccc2cc[nH]c2c1		CHEMBL575566	=	Inhibition	%	98.0	CHEMBL2973	Homo sapiens	INH	%	98.0
	2928391	CHEMBL1057683	Inhibition of ROCK2 assessed as remaining enzyme activity at 1 uM relative to DMSO	B	COc1ccccc1-n1c(-c2cc(O)ccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL566515	=	Activity	%	77.0	CHEMBL2973	Homo sapiens	Activity	%	77.0
	2938446	CHEMBL1041419	Inhibition of ROCK 2 at 2 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	57.0	CHEMBL2973	Homo sapiens	INH	%	57.0
Not Active	2938602	CHEMBL1040615	Inhibition of ROCK2 at 10 uM	B	O=C1OC(/C=C/c2ccccc2)=N/C1=C\c1cccnc1		CHEMBL565286		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	2939393	CHEMBL1036969	Inhibition of human ROCK2	B	Cc1c[nH]c2ncnc(N3CCN(/C(=N/C#N)Nc4cccc(Br)c4)[C@@H](C)C3)c12		CHEMBL570126	=	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	nM	2700.0
	2939394	CHEMBL1036969	Inhibition of human ROCK2	B	Cc1c[nH]c2ncnc(N3CCN(/C(=N/C#N)Nc4ccc(F)c(Br)c4)[C@@H](C)C3)c12		CHEMBL565452	=	IC50	nM	2200.0	CHEMBL2973	Homo sapiens	IC50	nM	2200.0
	2939395	CHEMBL1036969	Inhibition of human ROCK2	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)Nc4ccc(F)c(Br)c4)[C@@H](C)C3)c12		CHEMBL570820	=	IC50	nM	280.0	CHEMBL2973	Homo sapiens	IC50	nM	280.0
	2939396	CHEMBL1036969	Inhibition of human ROCK2	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)Nc4cccc(OC(=O)N(C)C)c4)[C@@H](C)C3)c12		CHEMBL570116	=	IC50	nM	1100.0	CHEMBL2973	Homo sapiens	IC50	nM	1100.0
	2993579	CHEMBL1040954	Inhibition of human recombinant ROCK2	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	2998997	CHEMBL1041969	Inhibition of ROCK2 assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 20 uM ATP	B	CC(C)c1onc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL220227	=	Activity	%	76.0	CHEMBL2973	Homo sapiens	Activity	%	76.0
	2999787	CHEMBL1041969	Inhibition of ROCK2 assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 20 uM ATP	B	CC(C)c1noc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL375428	=	Activity	%	77.0	CHEMBL2973	Homo sapiens	Activity	%	77.0
	2999864	CHEMBL1048109	Inhibition of ROCK2 assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 20 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL569114	=	Activity	%	81.0	CHEMBL2973	Homo sapiens	Activity	%	81.0
	2999940	CHEMBL1048109	Inhibition of ROCK2 assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 20 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c([S+](C)[O-])nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL572006	=	Activity	%	88.0	CHEMBL2973	Homo sapiens	Activity	%	88.0
Not Active	3005080	CHEMBL1047309	Inhibition of ROCK-2 at 10 uM	B	CCCc1cc(N2CCC(N)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL578601		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Active	3005081	CHEMBL1047309	Inhibition of ROCK-2 at 10 uM	B	CCCc1cc(N2CCNCC2)nc2sc(C(N)=O)c(N)c12		CHEMBL568922		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Active	3005082	CHEMBL1047309	Inhibition of ROCK-2 at 10 uM	B	CCCc1cc(N2CCC(O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL576887		Activity			CHEMBL2973	Homo sapiens	Activity		
Not Active	3005083	CHEMBL1047309	Inhibition of ROCK-2 at 10 uM	B	CCCc1cc(N2CCCC(O)C2)nc2sc(C(N)=O)c(N)c12		CHEMBL576989		Activity			CHEMBL2973	Homo sapiens	Activity		
	3052468	CHEMBL1072506	Residual activity of ROCK2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	82.0	CHEMBL2973	Homo sapiens	Residual activity	%	82.0
	3052720	CHEMBL1043799	Residual activity of ROCK2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	93.0	CHEMBL2973	Homo sapiens	Residual activity	%	93.0
	3054029	CHEMBL1071359	Residual activity of ROCK2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	47.0	CHEMBL2973	Homo sapiens	Residual activity	%	47.0
	3055316	CHEMBL1072506	Residual activity of ROCK2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	98.0	CHEMBL2973	Homo sapiens	Residual activity	%	98.0
	3055568	CHEMBL1043799	Residual activity of ROCK2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	101.0	CHEMBL2973	Homo sapiens	Residual activity	%	101.0
	3056873	CHEMBL1071359	Residual activity of ROCK2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	54.0	CHEMBL2973	Homo sapiens	Residual activity	%	54.0
	3057125	CHEMBL1072506	Residual activity of ROCK2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	119.0	CHEMBL2973	Homo sapiens	Residual activity	%	119.0
	3058445	CHEMBL1043799	Residual activity of ROCK2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	93.0	CHEMBL2973	Homo sapiens	Residual activity	%	93.0
	3059729	CHEMBL1071359	Residual activity of ROCK2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	84.0	CHEMBL2973	Homo sapiens	Residual activity	%	84.0
	3066893	CHEMBL1066099	Inhibition of ROCK2 at 10 uM	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	3066983	CHEMBL1066099	Inhibition of ROCK2 at 10 uM	B	O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21		CHEMBL607196	=	Inhibition	%	52.0	CHEMBL2973	Homo sapiens	INH	%	52.0
	3084390	CHEMBL1072669	Inhibition of ROCK2	B	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	IC50	nM	440.0	CHEMBL2973	Homo sapiens	IC50	uM	0.44
	3091850	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	Nc1ncc(-c2ccncc2)nc1N1CCN(CCO)CC1		CHEMBL589655	=	IC50	nM	2500.0	CHEMBL2973	Homo sapiens	IC50	nM	2500.0
	3091852	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N)CC1		CHEMBL602706	=	IC50	nM	2500.0	CHEMBL2973	Homo sapiens	IC50	nM	2500.0
	3091854	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	Cc1cc(-c2cnc(N)c(N3CCCN(C)CC3)n2)ccn1		CHEMBL589656	>	IC50	nM	100000.0	CHEMBL2973	Homo sapiens	IC50	nM	100000.0
	3091856	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	Cc1cnccc1-c1cnc(N)c(N2CCCN(C)CC2)n1		CHEMBL601935	=	IC50	nM	58000.0	CHEMBL2973	Homo sapiens	IC50	nM	58000.0
	3091858	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccnc(N)c3)cnc2N)CC1		CHEMBL591271	=	IC50	nM	53000.0	CHEMBL2973	Homo sapiens	IC50	nM	53000.0
	3091860	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3cc[nH]n3)cnc2N)CC1		CHEMBL600849	=	IC50	nM	2900.0	CHEMBL2973	Homo sapiens	IC50	nM	2900.0
	3091862	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccnc4[nH]ccc34)cnc2N)CC1		CHEMBL591272	=	IC50	nM	530.0	CHEMBL2973	Homo sapiens	IC50	nM	530.0
	3091864	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3cccc4[nH]ncc34)cnc2N)CC1		CHEMBL600236	=	IC50	nM	2500.0	CHEMBL2973	Homo sapiens	IC50	nM	2500.0
	3091866	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccc4[nH]ncc4c3)cnc2N)CC1		CHEMBL590313	=	IC50	nM	950.0	CHEMBL2973	Homo sapiens	IC50	nM	950.0
	3091868	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccc4cn[nH]c4c3)cnc2N)CC1		CHEMBL589577	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3091870	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CNc1ncc(-c2ccncc2)nc1N1CCCN(C)CC1		CHEMBL589578	=	IC50	nM	2400.0	CHEMBL2973	Homo sapiens	IC50	nM	2400.0
	3091872	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N(C)C)CC1		CHEMBL601834	=	IC50	nM	1700.0	CHEMBL2973	Homo sapiens	IC50	nM	1700.0
	3091874	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CCN(CC)c1ncc(-c2ccncc2)nc1N1CCCN(C)CC1		CHEMBL589336	=	IC50	nM	6700.0	CHEMBL2973	Homo sapiens	IC50	nM	6700.0
	3091876	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccncc3)cnc2NCCO)CC1		CHEMBL589337	=	IC50	nM	3000.0	CHEMBL2973	Homo sapiens	IC50	nM	3000.0
	3091878	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	COCCNc1ncc(-c2ccncc2)nc1N1CCCN(C)CC1		CHEMBL590238	=	IC50	nM	52000.0	CHEMBL2973	Homo sapiens	IC50	nM	52000.0
	3091880	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	COCCN(C)c1ncc(-c2ccncc2)nc1N1CCCN(C)CC1		CHEMBL592701	=	IC50	nM	45000.0	CHEMBL2973	Homo sapiens	IC50	nM	45000.0
	3091882	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL592702	=	IC50	nM	330.0	CHEMBL2973	Homo sapiens	IC50	nM	330.0
	3091884	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N2CCCCC2)CC1		CHEMBL602753	=	IC50	nM	560.0	CHEMBL2973	Homo sapiens	IC50	nM	560.0
	3091886	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN1CCCN(c2nc(-c3ccncc3)cnc2N2CCOCC2)CC1		CHEMBL591754	=	IC50	nM	6300.0	CHEMBL2973	Homo sapiens	IC50	nM	6300.0
	3091888	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	c1cc(-c2cnc(N3CCCC3)c(N3CCCNCC3)n2)ccn1		CHEMBL591986	=	IC50	nM	39.0	CHEMBL2973	Homo sapiens	IC50	nM	39.0
	3091890	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	c1cc(-c2cnc(N3CCCC3)c(N3CCNCC3)n2)ccn1		CHEMBL591287	=	IC50	nM	62.0	CHEMBL2973	Homo sapiens	IC50	nM	62.0
	3091892	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	NC1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL602326	=	IC50	nM	62.0	CHEMBL2973	Homo sapiens	IC50	nM	62.0
	3091894	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CNC1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL591047	=	IC50	nM	250.0	CHEMBL2973	Homo sapiens	IC50	nM	250.0
	3091896	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	NCC1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL591285	=	IC50	nM	28.0	CHEMBL2973	Homo sapiens	IC50	nM	28.0
	3091898	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CNCC1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL602041	=	IC50	nM	49.0	CHEMBL2973	Homo sapiens	IC50	nM	49.0
	3091900	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	c1cc(-c2cnc(N3CCCC3)c(N3CCCNCC3)n2)c2cc[nH]c2n1		CHEMBL598963	=	IC50	nM	21.0	CHEMBL2973	Homo sapiens	IC50	nM	21.0
	3091902	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	c1cc(-c2cnc(N3CCCC3)c(N3CCNCC3)n2)c2cc[nH]c2n1		CHEMBL604934	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
	3091904	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	NC1CCN(c2nc(-c3ccnc4[nH]ccc34)cnc2N2CCCC2)CC1		CHEMBL599162	=	IC50	nM	89.0	CHEMBL2973	Homo sapiens	IC50	nM	89.0
	3091906	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	CN(C)c1ncc(-c2ccncc2)nc1N1CCN(CCO)CC1		CHEMBL611386	=	IC50	nM	300.0	CHEMBL2973	Homo sapiens	IC50	nM	300.0
	3091908	CHEMBL1074823	Inhibition of human recombinant ROCK2	B	OCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL599163	=	IC50	nM	78.0	CHEMBL2973	Homo sapiens	IC50	nM	78.0
	3127258	CHEMBL1074364	Inhibition of ROCK2 at 1 uM	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	Inhibition	%	96.0	CHEMBL2973	Homo sapiens	INH	%	96.0
	3127346	CHEMBL1074364	Inhibition of ROCK2 at 1 uM	B	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1		CHEMBL597211	=	Inhibition	%	30.0	CHEMBL2973	Homo sapiens	INH	%	30.0
	3127349	CHEMBL1074364	Inhibition of ROCK2 at 1 uM	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	Inhibition	%	82.0	CHEMBL2973	Homo sapiens	INH	%	82.0
	3130835	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3cccc(C(N)=O)c3)c2)cc1		CHEMBL603162	=	IC50	nM	290.0	CHEMBL2973	Homo sapiens	IC50	nM	290.0
	3130836	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3ccc(C(N)=O)c(Cl)c3)c2)cc1		CHEMBL591355	=	IC50	nM	180.0	CHEMBL2973	Homo sapiens	IC50	nM	180.0
	3130837	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3ccc(C(N)=O)cc3)c2)cc1		CHEMBL591116	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	3130838	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3ccc(C#N)c(Cl)c3)c2)cc1		CHEMBL591058	=	IC50	nM	45.0	CHEMBL2973	Homo sapiens	IC50	nM	45.0
	3130839	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc(CN)cc3)c2)cc1		CHEMBL590826	=	IC50	nM	210.0	CHEMBL2973	Homo sapiens	IC50	nM	210.0
	3130840	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3ccc(C#N)cc3)c2)cc1		CHEMBL590811	=	IC50	nM	160.0	CHEMBL2973	Homo sapiens	IC50	nM	160.0
	3130841	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1		CHEMBL590810	=	IC50	nM	48.0	CHEMBL2973	Homo sapiens	IC50	nM	48.0
	3130842	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)c3ccc(C#N)cc3)c2)cc1		CHEMBL589117	>	IC50	nM	6500.0	CHEMBL2973	Homo sapiens	IC50	nM	6500.0
	3130843	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)c3ccc(OC(F)(F)F)c(Cl)c3)c2)cc1		CHEMBL602437	=	IC50	nM	1300.0	CHEMBL2973	Homo sapiens	IC50	nM	1300.0
	3130844	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C(F)(F)F		CHEMBL589102	=	IC50	nM	350.0	CHEMBL2973	Homo sapiens	IC50	nM	350.0
	3130845	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl		CHEMBL592709	=	IC50	nM	230.0	CHEMBL2973	Homo sapiens	IC50	nM	230.0
	3130846	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C		CHEMBL604249	=	IC50	nM	660.0	CHEMBL2973	Homo sapiens	IC50	nM	660.0
	3130847	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)c3ccc(O)c(O)c3)c2)cc1		CHEMBL590072	>	IC50	nM	6400.0	CHEMBL2973	Homo sapiens	IC50	nM	6400.0
	3130848	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1		CHEMBL589827	>	IC50	nM	6500.0	CHEMBL2973	Homo sapiens	IC50	nM	6500.0
	3130849	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	COc1cccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)c1		CHEMBL590323	>	IC50	nM	7000.0	CHEMBL2973	Homo sapiens	IC50	nM	7000.0
	3130850	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC		CHEMBL599792	=	IC50	nM	230.0	CHEMBL2973	Homo sapiens	IC50	nM	230.0
	3130851	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC		CHEMBL597127	=	IC50	nM	140.0	CHEMBL2973	Homo sapiens	IC50	nM	140.0
	3130852	CHEMBL1066168	Inhibition of human ROCK2 by IMAP assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CCNC4)c2)cc1OC		CHEMBL597126	=	IC50	nM	320.0	CHEMBL2973	Homo sapiens	IC50	nM	320.0
	3131679	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	CCCNC(=O)c1cccc(CNC(=O)c2ccc(OC)c(OC)c2)c1		CHEMBL597321	=	IC50	nM	5000.0	CHEMBL2973	Homo sapiens	IC50	uM	5.0
	3131680	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)NCC3CCCO3)c2)cc1OC		CHEMBL597522	=	IC50	nM	1200.0	CHEMBL2973	Homo sapiens	IC50	uM	1.2
	3131681	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	N#Cc1cccc(NC(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)c1		CHEMBL597523	=	IC50	nM	5500.0	CHEMBL2973	Homo sapiens	IC50	uM	5.5
	3131682	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	N#Cc1cccc(NC(=O)NCc2cccc(C(=O)NCC3CCCO3)c2)c1		CHEMBL610775	=	IC50	nM	3500.0	CHEMBL2973	Homo sapiens	IC50	uM	3.5
	3131683	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Ki	nM	300.0	CHEMBL2973	Homo sapiens	Ki	nM	300.0
	3131684	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	260.0	CHEMBL2973	Homo sapiens	IC50	nM	260.0
	3131685	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	3131686	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1cccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)c1	Outside typical range	CHEMBL590323	>	IC50	nM	7000000.0	CHEMBL2973	Homo sapiens	IC50	uM	7000.0
	3131687	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(NC(=O)Nc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	Outside typical range	CHEMBL1163034	>	IC50	nM	7000000.0	CHEMBL2973	Homo sapiens	IC50	uM	7000.0
	3131688	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)c3ccc(O)c(O)c3)c2)cc1	Outside typical range	CHEMBL590072	>	IC50	nM	6000000.0	CHEMBL2973	Homo sapiens	IC50	uM	6000.0
	3131689	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(S(=O)(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	Outside typical range	CHEMBL603157	>	IC50	nM	6000000.0	CHEMBL2973	Homo sapiens	IC50	uM	6000.0
	3131690	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)Nc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	Outside typical range	CHEMBL592299	>	IC50	nM	6000000.0	CHEMBL2973	Homo sapiens	IC50	uM	6000.0
	3131691	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(CNC(=O)c2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	Outside typical range	CHEMBL592714	>	IC50	nM	6000000.0	CHEMBL2973	Homo sapiens	IC50	uM	6000.0
	3131692	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	Cc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1C	Outside typical range	CHEMBL610211	>	IC50	nM	7000000.0	CHEMBL2973	Homo sapiens	IC50	uM	7000.0
	3131693	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	O=C(NCCc1ccncc1)c1cccc(CNC(=O)c2ccc3c(c2)OCO3)c1	Outside typical range	CHEMBL597534	>	IC50	nM	7000000.0	CHEMBL2973	Homo sapiens	IC50	uM	7000.0
	3131694	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1cccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)c1	Outside typical range	CHEMBL591914	>	IC50	nM	7000000.0	CHEMBL2973	Homo sapiens	IC50	uM	7000.0
	3131695	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1	Outside typical range	CHEMBL596708	>	IC50	nM	7000000.0	CHEMBL2973	Homo sapiens	IC50	uM	7000.0
	3131696	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(CC(=O)Nc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	Outside typical range	CHEMBL592715	=	IC50	nM	3200000.0	CHEMBL2973	Homo sapiens	IC50	uM	3200.0
	3131697	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)c3ccc(C#N)cc3)c2)cc1	Outside typical range	CHEMBL589117	=	IC50	nM	1700000.0	CHEMBL2973	Homo sapiens	IC50	uM	1700.0
	3131698	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(NC(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	Outside typical range	CHEMBL602238	=	IC50	nM	1600000.0	CHEMBL2973	Homo sapiens	IC50	uM	1600.0
	3131699	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1	Outside typical range	CHEMBL589827	=	IC50	nM	1300000.0	CHEMBL2973	Homo sapiens	IC50	uM	1300.0
	3131700	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4cnccc4c3)c2)cc1OC	Outside typical range	CHEMBL597734	=	IC50	nM	685000.0	CHEMBL2973	Homo sapiens	IC50	uM	685.0
	3131701	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)c3ccc(OC(F)(F)F)c(Cl)c3)c2)cc1	Outside typical range	CHEMBL602437	=	IC50	nM	670000.0	CHEMBL2973	Homo sapiens	IC50	uM	670.0
	3131702	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C	Outside typical range	CHEMBL604249	=	IC50	nM	266000.0	CHEMBL2973	Homo sapiens	IC50	uM	266.0
	3131703	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3cccc(C(N)=O)c3)c2)cc1	Outside typical range	CHEMBL603162	=	IC50	nM	240000.0	CHEMBL2973	Homo sapiens	IC50	uM	240.0
	3131704	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C(F)(F)F	Outside typical range	CHEMBL589102	=	IC50	nM	160000.0	CHEMBL2973	Homo sapiens	IC50	uM	160.0
	3131705	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	N#Cc1ccc(NC(=O)NCc2cccc(NC(=O)CCC3CCCNC3)c2)cc1	Outside typical range	CHEMBL589844	=	IC50	nM	110000.0	CHEMBL2973	Homo sapiens	IC50	uM	110.0
	3131706	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCN(C)C3)c2)cc1OC	Outside typical range	CHEMBL604789	=	IC50	nM	102000.0	CHEMBL2973	Homo sapiens	IC50	uM	102.0
	3131707	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CCNC4)c2)cc1OC		CHEMBL597126	=	IC50	nM	100000.0	CHEMBL2973	Homo sapiens	IC50	uM	100.0
	3131708	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl		CHEMBL592709	=	IC50	nM	92.0	CHEMBL2973	Homo sapiens	IC50	nM	92.0
	3131709	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	N#Cc1cccc(NC(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)c1		CHEMBL589118	=	IC50	nM	89.0	CHEMBL2973	Homo sapiens	IC50	nM	89.0
	3131710	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc(CN)cc3)c2)cc1		CHEMBL590826	=	IC50	nM	70000.0	CHEMBL2973	Homo sapiens	IC50	uM	70.0
	3131711	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3ccc(C(N)=O)c(Cl)c3)c2)cc1		CHEMBL591355	=	IC50	nM	74000.0	CHEMBL2973	Homo sapiens	IC50	uM	74.0
	3131712	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3ccc(C#N)cc3)c2)cc1		CHEMBL590811	=	IC50	nM	65.0	CHEMBL2973	Homo sapiens	IC50	nM	65.0
	3131713	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1		CHEMBL589845	=	IC50	nM	65000.0	CHEMBL2973	Homo sapiens	IC50	uM	65.0
	3131714	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(NC(=O)Cc2cccc(NC(=O)CCC3CCCNC3)c2)cc1OC		CHEMBL605401	=	IC50	nM	37000.0	CHEMBL2973	Homo sapiens	IC50	uM	37.0
	3131715	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1		CHEMBL589359	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	3131716	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1		CHEMBL590810	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	3131717	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3ccc(C#N)c(Cl)c3)c2)cc1		CHEMBL591058	=	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	3131718	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	CN(C)Cc1ccc(NC(=O)c2cccc(CNC(=O)Nc3ccc(C(N)=O)cc3)c2)cc1		CHEMBL591116	=	IC50	nM	8000.0	CHEMBL2973	Homo sapiens	IC50	uM	8.0
	3131719	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	NC(=O)c1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1		CHEMBL600852	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	3131720	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC		CHEMBL598336	=	IC50	nM	2300.0	CHEMBL2973	Homo sapiens	IC50	nM	2300.0
	3131721	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CO)cc3)c2)cc1OC		CHEMBL605360	=	IC50	nM	870.0	CHEMBL2973	Homo sapiens	IC50	nM	870.0
	3131722	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(NC(=O)CCC3CCCNC3)c2)cc1OC		CHEMBL590322	=	IC50	nM	73.0	CHEMBL2973	Homo sapiens	IC50	nM	73.0
	3131723	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC		CHEMBL604085	=	IC50	nM	176.0	CHEMBL2973	Homo sapiens	IC50	nM	176.0
	3131724	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C		CHEMBL604249	=	IC50	nM	92.0	CHEMBL2973	Homo sapiens	IC50	nM	92.0
	3131725	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC		CHEMBL599792	=	IC50	nM	69.0	CHEMBL2973	Homo sapiens	IC50	nM	69.0
	3131726	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC		CHEMBL597127	=	IC50	nM	53.0	CHEMBL2973	Homo sapiens	IC50	nM	53.0
	3131727	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC		CHEMBL599791	=	IC50	nM	46.0	CHEMBL2973	Homo sapiens	IC50	nM	46.0
	3131728	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC		CHEMBL604087	=	IC50	nM	33.0	CHEMBL2973	Homo sapiens	IC50	nM	33.0
	3131729	CHEMBL1071707	Inhibition of human ROCK2 by homogenous luciferase assay	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	660.0	CHEMBL2973	Homo sapiens	IC50	nM	660.0
	3214036	CHEMBL1103231	Inhibition of ROCK2 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	INH	%	3.0
	3215498	CHEMBL1102485	Inhibition of ROCK2	B	Nc1nccc(-c2ccc3nc(C4COc5ccccc5C4)sc3c2)n1		CHEMBL1079782	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	3215499	CHEMBL1102485	Inhibition of ROCK2	B	c1ccc2c(c1)CC(c1nc3ccc(-c4ccncc4)cc3s1)CO2		CHEMBL1080135	=	IC50	nM	42.0	CHEMBL2973	Homo sapiens	IC50	nM	42.0
	3215500	CHEMBL1102485	Inhibition of ROCK2	B	Cc1cc(-c2ccc3nc(C4COc5ccccc5C4)sc3c2)ccn1		CHEMBL1080136	=	IC50	nM	1200.0	CHEMBL2973	Homo sapiens	IC50	nM	1200.0
	3215501	CHEMBL1102485	Inhibition of ROCK2	B	c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1080137	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	3215502	CHEMBL1102485	Inhibition of ROCK2	B	Cc1n[nH]cc1-c1ccc2nc(C3COc4ccccc4C3)sc2c1		CHEMBL1080138	=	IC50	nM	25.0	CHEMBL2973	Homo sapiens	IC50	nM	25.0
	3215503	CHEMBL1102485	Inhibition of ROCK2	B	Fc1cc2nc(C3COc4ccccc4C3)sc2cc1-c1cn[nH]c1		CHEMBL1081173	=	IC50	nM	47.0	CHEMBL2973	Homo sapiens	IC50	nM	47.0
	3215504	CHEMBL1102485	Inhibition of ROCK2	B	Fc1cc(-c2cn[nH]c2)cc2sc(C3COc4ccccc4C3)nc12		CHEMBL1081174	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	3215505	CHEMBL1102485	Inhibition of ROCK2	B	COc1cc(-c2cn[nH]c2)cc2sc(C3COc4ccccc4C3)nc12		CHEMBL1081349	=	IC50	nM	32.0	CHEMBL2973	Homo sapiens	IC50	nM	32.0
	3215506	CHEMBL1102485	Inhibition of ROCK2	B	c1ccc2c(c1)CC(c1nc3c(OCCN4CCOCC4)cc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1080264	=	IC50	nM	314.0	CHEMBL2973	Homo sapiens	IC50	nM	314.0
	3215507	CHEMBL1102485	Inhibition of ROCK2	B	c1ccc2c(c1)CC(c1nc3c(OCCC4CCOC4)cc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1080265	=	IC50	nM	500.0	CHEMBL2973	Homo sapiens	IC50	nM	500.0
	3215508	CHEMBL1102485	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)cc2sc(C3COc4ccccc4C3)nc12		CHEMBL1081899	=	IC50	nM	66.0	CHEMBL2973	Homo sapiens	IC50	nM	66.0
	3215509	CHEMBL1102485	Inhibition of ROCK2	B	CN(C)CCN(C)c1cc(-c2cn[nH]c2)cc2sc(C3COc4ccccc4C3)nc12		CHEMBL1081182	=	IC50	nM	51.0	CHEMBL2973	Homo sapiens	IC50	nM	51.0
	3215510	CHEMBL1102485	Inhibition of ROCK2	B	COc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1076298	=	IC50	nM	45.0	CHEMBL2973	Homo sapiens	IC50	nM	45.0
	3215511	CHEMBL1102485	Inhibition of ROCK2	B	Cc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1081183	=	IC50	nM	93.0	CHEMBL2973	Homo sapiens	IC50	nM	93.0
	3215512	CHEMBL1102485	Inhibition of ROCK2	B	Clc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1081184	=	IC50	nM	75.0	CHEMBL2973	Homo sapiens	IC50	nM	75.0
	3215513	CHEMBL1102485	Inhibition of ROCK2	B	Fc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1080635	=	IC50	nM	38.0	CHEMBL2973	Homo sapiens	IC50	nM	38.0
	3215514	CHEMBL1102485	Inhibition of ROCK2	B	COC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1079919	=	IC50	nM	59.0	CHEMBL2973	Homo sapiens	IC50	nM	59.0
	3215515	CHEMBL1102485	Inhibition of ROCK2	B	CN(C)CCNC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1079920	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	3215516	CHEMBL1102485	Inhibition of ROCK2	B	CN(C)CCCNC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1079921	=	IC50	nM	0.9	CHEMBL2973	Homo sapiens	IC50	nM	0.9
	3215517	CHEMBL1102485	Inhibition of ROCK2	B	O=C(NCc1ccccc1)c1nc2ccc(-c3cn[nH]c3)cc2s1		CHEMBL1080104	=	IC50	nM	53.0	CHEMBL2973	Homo sapiens	IC50	nM	53.0
	3215518	CHEMBL1102485	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2nc3ccc(-c4cn[nH]c4)cc3s2)c1		CHEMBL1081193	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	3215519	CHEMBL1102485	Inhibition of ROCK2	B	O=C(NCc1cccc(F)c1)c1nc2ccc(-c3cn[nH]c3)cc2s1		CHEMBL1081194	=	IC50	nM	72.0	CHEMBL2973	Homo sapiens	IC50	nM	72.0
	3215520	CHEMBL1102485	Inhibition of ROCK2	B	COc1cccc(CN(C)C(=O)c2nc3ccc(-c4cn[nH]c4)cc3s2)c1		CHEMBL1081195	=	IC50	nM	59.0	CHEMBL2973	Homo sapiens	IC50	nM	59.0
	3215521	CHEMBL1102485	Inhibition of ROCK2	B	CCN(Cc1cccc(OC)c1)C(=O)c1nc2ccc(-c3cn[nH]c3)cc2s1		CHEMBL1081196	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	IC50	nM	26.0
	3215522	CHEMBL1102485	Inhibition of ROCK2	B	COc1cccc(CN(C(=O)c2nc3ccc(-c4cn[nH]c4)cc3s2)C2CC2)c1		CHEMBL1080286	=	IC50	nM	94.0	CHEMBL2973	Homo sapiens	IC50	nM	94.0
	3215523	CHEMBL1102485	Inhibition of ROCK2	B	COCCN(Cc1cccc(OC)c1)C(=O)c1nc2ccc(-c3cn[nH]c3)cc2s1		CHEMBL1081001	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	3215524	CHEMBL1102485	Inhibition of ROCK2	B	COc1cccc(CN(CCN(C)C)C(=O)c2nc3ccc(-c4cn[nH]c4)cc3s2)c1		CHEMBL1080279	=	IC50	nM	0.4	CHEMBL2973	Homo sapiens	IC50	nM	0.4
	3215552	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Nc1nccc(-c2ccc3nc(C4COc5ccccc5C4)sc3c2)n1		CHEMBL1079782	=	IC50	nM	1500.0	CHEMBL2973	Homo sapiens	IC50	nM	1500.0
Not Determined	3215553	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	c1ccc2c(c1)CC(c1nc3ccc(-c4ccncc4)cc3s1)CO2		CHEMBL1080135		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3215554	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Cc1cc(-c2ccc3nc(C4COc5ccccc5C4)sc3c2)ccn1		CHEMBL1080136		IC50			CHEMBL2973	Homo sapiens	IC50		
	3215555	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1080137	=	IC50	nM	1550.0	CHEMBL2973	Homo sapiens	IC50	nM	1550.0
Not Determined	3215556	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Cc1n[nH]cc1-c1ccc2nc(C3COc4ccccc4C3)sc2c1		CHEMBL1080138		IC50			CHEMBL2973	Homo sapiens	IC50		
	3215557	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Fc1cc2nc(C3COc4ccccc4C3)sc2cc1-c1cn[nH]c1		CHEMBL1081173	>	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	nM	2700.0
	3215558	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Fc1cc(-c2cn[nH]c2)cc2sc(C3COc4ccccc4C3)nc12		CHEMBL1081174	>	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	nM	2700.0
	3215559	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cc(-c2cn[nH]c2)cc2sc(C3COc4ccccc4C3)nc12		CHEMBL1081349	=	IC50	nM	1241.0	CHEMBL2973	Homo sapiens	IC50	nM	1241.0
Not Determined	3215560	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	c1ccc2c(c1)CC(c1nc3c(OCCN4CCOCC4)cc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1080264		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3215561	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	c1ccc2c(c1)CC(c1nc3c(OCCC4CCOC4)cc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1080265		IC50			CHEMBL2973	Homo sapiens	IC50		
	3215562	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)cc2sc(C3COc4ccccc4C3)nc12		CHEMBL1081899	=	IC50	nM	365.0	CHEMBL2973	Homo sapiens	IC50	nM	365.0
	3215563	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCN(C)c1cc(-c2cn[nH]c2)cc2sc(C3COc4ccccc4C3)nc12		CHEMBL1081182	=	IC50	nM	365.0	CHEMBL2973	Homo sapiens	IC50	nM	365.0
	3215564	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1076298	>	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	nM	2700.0
Not Determined	3215565	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Cc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1081183		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3215566	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Clc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1081184		IC50			CHEMBL2973	Homo sapiens	IC50		
	3215567	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	Fc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1080635	=	IC50	nM	1485.0	CHEMBL2973	Homo sapiens	IC50	nM	1485.0
	3215568	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1079919	=	IC50	nM	1485.0	CHEMBL2973	Homo sapiens	IC50	nM	1485.0
	3215569	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCNC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1079920	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
	3215570	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCCNC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3s1)CO2		CHEMBL1079921	<	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
Not Determined	3215571	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(NCc1ccccc1)c1nc2ccc(-c3cn[nH]c3)cc2s1		CHEMBL1080104		IC50			CHEMBL2973	Homo sapiens	IC50		
	3215572	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cccc(CNC(=O)c2nc3ccc(-c4cn[nH]c4)cc3s2)c1		CHEMBL1081193	>	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	nM	2700.0
Not Determined	3215573	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	O=C(NCc1cccc(F)c1)c1nc2ccc(-c3cn[nH]c3)cc2s1		CHEMBL1081194		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3215574	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cccc(CN(C)C(=O)c2nc3ccc(-c4cn[nH]c4)cc3s2)c1		CHEMBL1081195		IC50			CHEMBL2973	Homo sapiens	IC50		
	3215575	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CCN(Cc1cccc(OC)c1)C(=O)c1nc2ccc(-c3cn[nH]c3)cc2s1		CHEMBL1081196	=	IC50	nM	455.0	CHEMBL2973	Homo sapiens	IC50	nM	455.0
Not Determined	3215576	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cccc(CN(C(=O)c2nc3ccc(-c4cn[nH]c4)cc3s2)C2CC2)c1		CHEMBL1080286		IC50			CHEMBL2973	Homo sapiens	IC50		
	3215577	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COCCN(Cc1cccc(OC)c1)C(=O)c1nc2ccc(-c3cn[nH]c3)cc2s1		CHEMBL1081001	=	IC50	nM	871.0	CHEMBL2973	Homo sapiens	IC50	nM	871.0
	3215578	CHEMBL1102487	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cccc(CN(CCN(C)C)C(=O)c2nc3ccc(-c4cn[nH]c4)cc3s2)c1		CHEMBL1080279	<	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	3219654	CHEMBL1110413	Displacement of ARC583 from ROCK2	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL297394	<	Kd	nM	3.0	CHEMBL2973	Homo sapiens	Kd	nM	3.0
	3219655	CHEMBL1110413	Displacement of ARC583 from ROCK2	B	CC(=O)NCCCCCC(=O)N[C@H](CCCCN)C(=O)NCCCCCC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O	Outside typical range	CHEMBL1077597	=	Kd	nM	123000.0	CHEMBL2973	Homo sapiens	Kd	nM	123000.0
	3219656	CHEMBL1110413	Displacement of ARC583 from ROCK2	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccccc1)C(N)=O		CHEMBL1077598	=	Kd	nM	8000.0	CHEMBL2973	Homo sapiens	Kd	nM	8000.0
	3219657	CHEMBL1110413	Displacement of ARC583 from ROCK2	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(C(N)=O)cc1)C(N)=O		CHEMBL1077599	=	Kd	nM	177.0	CHEMBL2973	Homo sapiens	Kd	nM	177.0
	3219658	CHEMBL1110413	Displacement of ARC583 from ROCK2	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)Nc1ccc(C(N)=O)cc1)C(N)=O		CHEMBL1077600	=	Kd	nM	6100.0	CHEMBL2973	Homo sapiens	Kd	nM	6100.0
	3219659	CHEMBL1110413	Displacement of ARC583 from ROCK2	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077369	<	Kd	nM	3.0	CHEMBL2973	Homo sapiens	Kd	nM	3.0
	3219660	CHEMBL1110413	Displacement of ARC583 from ROCK2	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1cccc(-c2ccncc2)c1)C(N)=O		CHEMBL1077370	=	Kd	nM	3.8	CHEMBL2973	Homo sapiens	Kd	nM	3.8
	3219661	CHEMBL1110413	Displacement of ARC583 from ROCK2	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1cccc(-c2ccnc(N)n2)c1)C(N)=O		CHEMBL1077371	=	Kd	nM	36.0	CHEMBL2973	Homo sapiens	Kd	nM	36.0
	3219662	CHEMBL1110413	Displacement of ARC583 from ROCK2	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1cn(-c2ncnc3[nH]cnc23)nn1)C(N)=O		CHEMBL1077372	=	Kd	nM	800.0	CHEMBL2973	Homo sapiens	Kd	nM	800.0
	3219706	CHEMBL1114120	Inhibition of ROCK2 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077375	=	Inhibition	%	106.0	CHEMBL2973	Homo sapiens	INH	%	106.0
	3224950	CHEMBL1101754	Inhibition of ROCK2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	3226329	CHEMBL1101754	Inhibition of ROCK2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	3240836	CHEMBL1109671	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	uM	1.0
	3260032	CHEMBL1105200	Inhibition of ROCK2 at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2nccc(Nc3cccc(Br)c3)c2c1		CHEMBL1089524	=	Activity	%	88.0	CHEMBL2973	Homo sapiens	Activity	%	88.0
	3261438	CHEMBL1105200	Inhibition of ROCK2 at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL1088901	=	Activity	%	95.0	CHEMBL2973	Homo sapiens	Activity	%	95.0
Not Active	3272512	CHEMBL1108318	Inhibition of ROCK2	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3272513	CHEMBL1108318	Inhibition of ROCK2	B	COc1ccccc1/C=C1/C(=O)Nc2ccccc21		CHEMBL444673		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3272514	CHEMBL1108318	Inhibition of ROCK2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1F		CHEMBL1088391		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3272515	CHEMBL1108318	Inhibition of ROCK2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1[N+](=O)[O-]		CHEMBL1088392		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3272516	CHEMBL1108318	Inhibition of ROCK2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1S(=O)(=O)O		CHEMBL1088529		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3272517	CHEMBL1108318	Inhibition of ROCK2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc2c(c1)OCO2		CHEMBL1086669		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3272518	CHEMBL1108318	Inhibition of ROCK2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1cc(F)cc(F)c1		CHEMBL1086670		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3272519	CHEMBL1108318	Inhibition of ROCK2	B	NC(=O)Cc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL1086795		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3272520	CHEMBL1108318	Inhibition of ROCK2	B	COc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1OC		CHEMBL1086796		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3272521	CHEMBL1108318	Inhibition of ROCK2	B	COc1cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc(OC)c1OC		CHEMBL383871		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	3272522	CHEMBL1108318	Inhibition of ROCK2	B	COc1cc(OC)c(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1		CHEMBL1086939	<	Inhibition	%	20.0	CHEMBL2973	Homo sapiens	INH	%	20.0
Not Active	3272523	CHEMBL1108318	Inhibition of ROCK2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	3306838	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1ccc2c(=O)[nH]cnc2c1		CHEMBL1086297	=	IC50	nM	2900.0	CHEMBL2973	Homo sapiens	IC50	nM	2900.0
	3306839	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1ccc2c(=O)[nH]ccc2c1		CHEMBL1086517	=	IC50	nM	1700.0	CHEMBL2973	Homo sapiens	IC50	nM	1700.0
	3306840	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1ccc2c(c1)CNNC2=O		CHEMBL1083117	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306841	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1ccc2c(c1)C(=O)NC2=O		CHEMBL1085343	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306842	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1ccc2[nH]nnc2c1		CHEMBL1085344	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306843	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1cccc2c(=O)[nH]cnc12		CHEMBL1085345	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306844	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1ccc2nc[nH]c(=O)c2c1		CHEMBL1085346	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306845	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1cccc2nc[nH]c(=O)c12		CHEMBL1084844	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306846	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1cccc2c(=O)[nH]ccc12		CHEMBL1084845	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306847	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1ccc2cc[nH]c(=O)c2c1		CHEMBL1084846	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306848	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1cccc2cc[nH]c(=O)c12		CHEMBL1083275	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306849	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Nc1ccc2c(=O)[nH]ccc2c1)OCc1ccccc1		CHEMBL1084052	=	IC50	nM	360.0	CHEMBL2973	Homo sapiens	IC50	nM	360.0
	3306850	CHEMBL1117927	Inhibition of ROCK2	B	O=C(NCc1ccccc1)Nc1ccc2c(=O)[nH]ccc2c1		CHEMBL1084053	=	IC50	nM	520.0	CHEMBL2973	Homo sapiens	IC50	nM	520.0
	3306851	CHEMBL1117927	Inhibition of ROCK2	B	O=c1[nH]ccc2cc(NS(=O)(=O)Cc3ccccc3)ccc12		CHEMBL1083116	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306852	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Cc1ccccc1)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1084890	=	IC50	nM	320.0	CHEMBL2973	Homo sapiens	IC50	nM	320.0
	3306853	CHEMBL1117927	Inhibition of ROCK2	B	CC(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1085137	=	IC50	nM	1300.0	CHEMBL2973	Homo sapiens	IC50	nM	1300.0
	3306854	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1085138	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	3306855	CHEMBL1117927	Inhibition of ROCK2	B	O=C(CCc1ccccc1)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1085139	=	IC50	nM	280.0	CHEMBL2973	Homo sapiens	IC50	nM	280.0
	3306856	CHEMBL1117927	Inhibition of ROCK2	B	O=C(CC1CCCCC1)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1085140	=	IC50	nM	430.0	CHEMBL2973	Homo sapiens	IC50	nM	430.0
	3306857	CHEMBL1117927	Inhibition of ROCK2	B	NC(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1085141	=	IC50	nM	57.0	CHEMBL2973	Homo sapiens	IC50	nM	57.0
	3306858	CHEMBL1117927	Inhibition of ROCK2	B	CNC(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1084892	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	3306859	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C(NC1CC1)c1ccccc1		CHEMBL1084106	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	nM	19.0
	3306860	CHEMBL1117927	Inhibition of ROCK2	B	CN(C)C(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1084107	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	IC50	nM	26.0
	3306861	CHEMBL1117927	Inhibition of ROCK2	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C(NCc1ccccc1)c1ccccc1		CHEMBL1084108	=	IC50	nM	5100.0	CHEMBL2973	Homo sapiens	IC50	nM	5100.0
	3306862	CHEMBL1117927	Inhibition of ROCK2	B	CC(NCc1ccccc1)C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1084381	=	IC50	nM	210.0	CHEMBL2973	Homo sapiens	IC50	nM	210.0
	3306863	CHEMBL1117927	Inhibition of ROCK2	B	O=C(CNCc1ccccc1)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1084900	=	IC50	nM	110.0	CHEMBL2973	Homo sapiens	IC50	nM	110.0
	3306864	CHEMBL1117927	Inhibition of ROCK2	B	N[C@@H](Cc1ccccc1)C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1083132	=	IC50	nM	48.0	CHEMBL2973	Homo sapiens	IC50	nM	48.0
	3306865	CHEMBL1117927	Inhibition of ROCK2	B	N[C@H](Cc1ccccc1)C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1083133	=	IC50	nM	160.0	CHEMBL2973	Homo sapiens	IC50	nM	160.0
	3306866	CHEMBL1117927	Inhibition of ROCK2	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	400.0	CHEMBL2973	Homo sapiens	IC50	nM	400.0
	3306867	CHEMBL1117927	Inhibition of ROCK2	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1.Cl.Cl		CHEMBL1605605	=	IC50	nM	61.0	CHEMBL2973	Homo sapiens	IC50	nM	61.0
Not Active	3306908	CHEMBL1117928	Inhibition of ROCK2 up to 10 uM	B	O=c1[nH]ccc2cc(NS(=O)(=O)Cc3ccccc3)ccc12		CHEMBL1083116		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	3306909	CHEMBL1117934	Inhibition of ROCK2 at 3 uM	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C(NC1CC1)c1ccccc1		CHEMBL1084106	=	Inhibition	%	0.55	CHEMBL2973	Homo sapiens	INH	%	0.55
Not Active	3307005	CHEMBL1117928	Inhibition of ROCK2 up to 10 uM	B	O=C(Cc1ccccc1)Nc1ccc2c(c1)CNNC2=O		CHEMBL1083117		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3307006	CHEMBL1117928	Inhibition of ROCK2 up to 10 uM	B	O=C(Cc1ccccc1)Nc1ccc2c(c1)C(=O)NC2=O		CHEMBL1085343		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	3307007	CHEMBL1117928	Inhibition of ROCK2 up to 10 uM	B	O=C(Cc1ccccc1)Nc1ccc2[nH]nnc2c1		CHEMBL1085344		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	3308766	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	NCC(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1083114	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	nM	120.0
	3308767	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	NC(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1cccc(Cl)c1		CHEMBL1083115	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	nM	15.0
	3308768	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	CNC(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1084892	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	3308771	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	CN1CCC(C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)CC1		CHEMBL1083113	=	IC50	nM	31.0	CHEMBL2973	Homo sapiens	IC50	nM	31.0
	3308774	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CCNCC1		CHEMBL1085082	=	IC50	nM	28.0	CHEMBL2973	Homo sapiens	IC50	nM	28.0
	3308777	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)[C@@H]1CCNC1		CHEMBL1085083	=	IC50	nM	67.0	CHEMBL2973	Homo sapiens	IC50	nM	67.0
	3308780	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)[C@@H]1CCCNC1		CHEMBL1085341	=	IC50	nM	47.0	CHEMBL2973	Homo sapiens	IC50	nM	47.0
	3308783	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1(c2ccccc2)CCNCC1		CHEMBL1085342	=	IC50	nM	230.0	CHEMBL2973	Homo sapiens	IC50	nM	230.0
	3308786	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1(c2ccccc2)CCNC1		CHEMBL1084323	=	IC50	nM	240.0	CHEMBL2973	Homo sapiens	IC50	nM	240.0
	3308789	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCCC1c1ccccc1		CHEMBL1084324	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	3308792	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1ccccc1		CHEMBL1084597	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	3308795	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1cccc(Br)c1		CHEMBL1083747	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	3308798	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	COc1cccc(C2CNCC2C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)c1		CHEMBL1083748	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	3308801	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	Cc1cccc(C2CNCC2C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)c1		CHEMBL1083749	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	3308804	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	CCc1cccc(C2CNCC2C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)c1		CHEMBL1084051	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	3308807	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	CC(C)c1cccc(C2CNCC2C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)c1		CHEMBL1085773	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	3308810	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	CC(C)(C)c1cccc(C2CNCC2C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)c1		CHEMBL1084554	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	3308813	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1cccc(OC(F)(F)F)c1		CHEMBL1084800	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	3308816	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1cccc(C(F)(F)F)c1		CHEMBL1083276	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	3308819	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1ccc(Cl)cc1Cl		CHEMBL1083799	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	3308822	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1ccccn1		CHEMBL1083800	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	3308825	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1cccnc1		CHEMBL1084104	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	3308828	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1ccncc1		CHEMBL1084105	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	IC50	nM	26.0
	3308831	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1ccc(F)cc1		CHEMBL1084110	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	3308834	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1ccc(Br)cc1		CHEMBL1084653	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	3308837	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CNCC1c1ccc(Cl)cc1		CHEMBL1082819	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	3308840	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)[C@H]1CNC[C@@H]1c1ccc(Cl)cc1		CHEMBL1082820	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	3308843	CHEMBL1120081	Inhibition of ROCK2 by luciferase based ATP detection assay	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)[C@@H]1CNC[C@H]1c1ccc(Cl)cc1		CHEMBL1082821	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	3332136	CHEMBL1166847	Inhibition of ROCK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	3333551	CHEMBL1166847	Inhibition of ROCK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	3334956	CHEMBL1166847	Inhibition of ROCK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	3336376	CHEMBL1166847	Inhibition of ROCK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	3341918	CHEMBL1166847	Inhibition of ROCK2 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	=	Inhibition	%	76.0	CHEMBL2973	Homo sapiens	INH	%	76.0
	3343365	CHEMBL1166847	Inhibition of ROCK2 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	3358792	CHEMBL1175320	Inhibition of ROCK2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	19.0	CHEMBL2973	Homo sapiens	INH	%	19.0
	3359234	CHEMBL1175320	Inhibition of ROCK2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	18.0	CHEMBL2973	Homo sapiens	INH	%	18.0
	3400038	CHEMBL1217235	Inhibition of human ROCK-2 at 10 uM	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL1214141	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	3406811	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCO)NC2		CHEMBL1215378	=	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	nM	2700.0
	3406812	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1NCCc2ccccc21		CHEMBL1215091	>	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	nM	2700.0
	3406817	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1SCCC(=O)N(C)C)NC2		CHEMBL1215452	=	IC50	nM	1786.0	CHEMBL2973	Homo sapiens	IC50	nM	1786.0
	3406821	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@H]1Cc2cc(F)ccc2CN1		CHEMBL1215094	=	IC50	nM	868.0	CHEMBL2973	Homo sapiens	IC50	nM	868.0
	3406822	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)CN[C@@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)C2		CHEMBL1212964	=	IC50	nM	850.0	CHEMBL2973	Homo sapiens	IC50	nM	850.0
	3406825	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1C(=O)CN(C)C		CHEMBL1215593	=	IC50	nM	775.0	CHEMBL2973	Homo sapiens	IC50	nM	775.0
	3406827	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	N[C@H](Cc1cccc(F)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL1215020	=	IC50	nM	713.0	CHEMBL2973	Homo sapiens	IC50	nM	713.0
	3406833	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1NCCc2ccccc21		CHEMBL1215091	=	IC50	nM	371.0	CHEMBL2973	Homo sapiens	IC50	nM	371.0
	3406837	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COCCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@H]1Cc2cc(OC)ccc2CN1		CHEMBL1215377	=	IC50	nM	339.0	CHEMBL2973	Homo sapiens	IC50	nM	339.0
	3406838	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1)NC2		CHEMBL1215303	=	IC50	nM	334.0	CHEMBL2973	Homo sapiens	IC50	nM	334.0
	3406840	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C(N)c1ccc(Cl)cc1		CHEMBL1215023	=	IC50	nM	310.0	CHEMBL2973	Homo sapiens	IC50	nM	310.0
	3406841	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@@H]1Cc2cc(F)ccc2CN1		CHEMBL1215168	=	IC50	nM	290.0	CHEMBL2973	Homo sapiens	IC50	nM	290.0
	3406843	CHEMBL1219161	Inhibition of ROCK2	B	COc1cccc2c1CNC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)C2		CHEMBL1215239	=	IC50	nM	261.0	CHEMBL2973	Homo sapiens	IC50	nM	261.0
	3406844	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1SCCN(C)C)NC2		CHEMBL1215379	=	IC50	nM	260.0	CHEMBL2973	Homo sapiens	IC50	nM	260.0
	3406845	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)c(F)c1OCCN(C)C)NC2		CHEMBL1215453	=	IC50	nM	250.0	CHEMBL2973	Homo sapiens	IC50	nM	250.0
	3406849	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN1CCCC1)NC2		CHEMBL1215305	=	IC50	nM	218.0	CHEMBL2973	Homo sapiens	IC50	nM	218.0
	3406851	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1c(F)cc(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215455	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	nM	190.0
	3406853	CHEMBL1219161	Inhibition of ROCK2	B	CCOc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215238	=	IC50	nM	156.0	CHEMBL2973	Homo sapiens	IC50	nM	156.0
	3406867	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@@H]1Cc2cc(Cl)ccc2CN1		CHEMBL1215170	=	IC50	nM	85.0	CHEMBL2973	Homo sapiens	IC50	nM	85.0
	3406873	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3c[nH]nc3C)cc1SCCN(C)C)NC2		CHEMBL1215380	=	IC50	nM	74.0	CHEMBL2973	Homo sapiens	IC50	nM	74.0
	3406878	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OC1CCN(C)CC1)NC2		CHEMBL1215306	=	IC50	nM	70.0	CHEMBL2973	Homo sapiens	IC50	nM	70.0
	3406884	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1C		CHEMBL1215525	=	IC50	nM	62.0	CHEMBL2973	Homo sapiens	IC50	nM	62.0
	3406888	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@H]1Cc2cc(F)ccc2CN1		CHEMBL1215094	=	IC50	nM	59.0	CHEMBL2973	Homo sapiens	IC50	nM	59.0
	3406893	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@H]1Cc2cc(Cl)ccc2CN1		CHEMBL1215169	=	IC50	nM	52.0	CHEMBL2973	Homo sapiens	IC50	nM	52.0
	3407931	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCC1CCN(C)CC1)NC2		CHEMBL1215304	=	IC50	nM	51.0	CHEMBL2973	Homo sapiens	IC50	nM	51.0
	3407932	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215171	=	IC50	nM	51.0	CHEMBL2973	Homo sapiens	IC50	nM	51.0
	3407938	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCO)NC2		CHEMBL1215378	=	IC50	nM	42.0	CHEMBL2973	Homo sapiens	IC50	nM	42.0
	3407940	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215237	=	IC50	nM	41.0	CHEMBL2973	Homo sapiens	IC50	nM	41.0
	3407945	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CCN1Cc2ccc(OC)cc2C[C@@H]1C(=O)Nc1cc(F)c(-c2cn[nH]c2)cc1OCCN(C)C		CHEMBL1215594	=	IC50	nM	32.0	CHEMBL2973	Homo sapiens	IC50	nM	32.0
	3407947	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@@H]1Cc2ccccc2CN1		CHEMBL1215093	=	IC50	nM	32.0	CHEMBL2973	Homo sapiens	IC50	nM	32.0
	3407948	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@H]1Cc2ccccc2CN1		CHEMBL1215092	=	IC50	nM	32.0	CHEMBL2973	Homo sapiens	IC50	nM	32.0
	3407951	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1CC1CC1		CHEMBL1215527	=	IC50	nM	29.0	CHEMBL2973	Homo sapiens	IC50	nM	29.0
	3407952	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)c(F)c1OCCN(C)C)NC2		CHEMBL1215453	=	IC50	nM	28.0	CHEMBL2973	Homo sapiens	IC50	nM	28.0
	3407955	CHEMBL1219161	Inhibition of ROCK2	B	COCCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@H]1Cc2cc(OC)ccc2CN1		CHEMBL1215377	=	IC50	nM	25.0	CHEMBL2973	Homo sapiens	IC50	nM	25.0
	3407956	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	NC(C(=O)Nc1ccc(-c2cn[nH]c2)cc1)c1ccc(Cl)cc1		CHEMBL1215022	=	IC50	nM	25.0	CHEMBL2973	Homo sapiens	IC50	nM	25.0
	3407959	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1c(F)cc(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215455	=	IC50	nM	23.0	CHEMBL2973	Homo sapiens	IC50	nM	23.0
	3407960	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@@H]1Cc2cc(Cl)ccc2CN1		CHEMBL1215170	=	IC50	nM	23.0	CHEMBL2973	Homo sapiens	IC50	nM	23.0
	3407964	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C(N)c1ccc(Cl)cc1		CHEMBL1215023	=	IC50	nM	22.0	CHEMBL2973	Homo sapiens	IC50	nM	22.0
	3407966	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1CC1CC1		CHEMBL1215527	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	3407967	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1C		CHEMBL1215525	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	3407970	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	NC(Cc1ccc(Cl)cc1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL1215021	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	3407972	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3c[nH]nc3C)cc1SCCN(C)C)NC2		CHEMBL1215380	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
	3407978	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1		CHEMBL1215524	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	nM	15.0
	3407979	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1SCCN(C)C)NC2		CHEMBL1215379	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	nM	15.0
	3407982	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1cc(F)c(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215454	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	3407985	CHEMBL1219161	Inhibition of ROCK2	B	N[C@H](Cc1cccc(F)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL1215020	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	3407987	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CCN1Cc2ccccc2C[C@@H]1C(=O)Nc1cc(F)c(-c2cn[nH]c2)cc1OCCN(C)C		CHEMBL1215526	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	3407990	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215237	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	3407992	CHEMBL1219161	Inhibition of ROCK2	B	CCN1Cc2ccc(OC)cc2C[C@@H]1C(=O)Nc1cc(F)c(-c2cn[nH]c2)cc1OCCN(C)C		CHEMBL1215594	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	3407995	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@H]1Cc2cc(Cl)ccc2CN1		CHEMBL1215169	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	3407996	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@@H]1Cc2ccccc2CN1		CHEMBL1215093	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	3407997	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@H]1Cc2ccccc2CN1		CHEMBL1215092	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	3407999	CHEMBL1219161	Inhibition of ROCK2	B	CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1		CHEMBL1215524	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	3408000	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN1CCCC1)NC2		CHEMBL1215305	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	3408004	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1SCCC(=O)N(C)C)NC2		CHEMBL1215452	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	3408009	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1cc(F)c(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215454	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	3408011	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OC1CCN(C)CC1)NC2		CHEMBL1215306	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	3408015	CHEMBL1219161	Inhibition of ROCK2	B	CCN1Cc2ccccc2C[C@@H]1C(=O)Nc1cc(F)c(-c2cn[nH]c2)cc1OCCN(C)C		CHEMBL1215526	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	3408016	CHEMBL1219161	Inhibition of ROCK2	B	NC(Cc1ccc(Cl)cc1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL1215021	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	3408020	CHEMBL1219161	Inhibition of ROCK2	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCC1CCN(C)CC1)NC2		CHEMBL1215304	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	3408021	CHEMBL1219161	Inhibition of ROCK2	B	NC(C(=O)Nc1ccc(-c2cn[nH]c2)cc1)c1ccc(Cl)cc1		CHEMBL1215022	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
Not Determined	3408061	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@@H]1Cc2cc(F)ccc2CN1		CHEMBL1215168		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3408063	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215171		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3408065	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CCOc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)NC2		CHEMBL1215238		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3408067	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)CN[C@@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)C2		CHEMBL1212964		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3408069	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1cccc2c1CNC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)C2		CHEMBL1215239		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3408071	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1)NC2		CHEMBL1215303		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	3408075	CHEMBL1219164	Inhibition of ROCK2 assessed as myosin light chain phosphorylation by cell-based assay	B	CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1C(=O)CN(C)C		CHEMBL1215593		IC50			CHEMBL2973	Homo sapiens	IC50		
	3411550	CHEMBL1228286	Inhibition of ROCK2	B	CN(C)C(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1084107	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	nM	19.0
	3411551	CHEMBL1228286	Inhibition of ROCK2	B	NC(C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)c1ccccc1		CHEMBL1085141	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	IC50	nM	26.0
	3411552	CHEMBL1228286	Inhibition of ROCK2	B	NCC(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1083114	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	nM	120.0
	3411553	CHEMBL1228286	Inhibition of ROCK2	B	CC(C)[C@H](N)C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1223498	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	3411554	CHEMBL1228286	Inhibition of ROCK2	B	CC(C)[C@@H](N)C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1223499	=	IC50	nM	240.0	CHEMBL2973	Homo sapiens	IC50	nM	240.0
	3411555	CHEMBL1228286	Inhibition of ROCK2	B	CC(C)C[C@H](N)C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1223500	=	IC50	nM	340.0	CHEMBL2973	Homo sapiens	IC50	nM	340.0
	3411556	CHEMBL1228286	Inhibition of ROCK2	B	CC(C)C[C@@H](N)C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1222413	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	nM	19.0
	3411557	CHEMBL1228286	Inhibition of ROCK2	B	CC(C)(C)C[C@H](N)C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1222414	=	IC50	nM	845.0	CHEMBL2973	Homo sapiens	IC50	nM	845.0
	3411558	CHEMBL1228286	Inhibition of ROCK2	B	CC(C)(C)C[C@@H](N)C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl		CHEMBL1222415	=	IC50	nM	110.0	CHEMBL2973	Homo sapiens	IC50	nM	110.0
	3411559	CHEMBL1228286	Inhibition of ROCK2	B	N[C@H](C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CCCCC1		CHEMBL1222416	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
	3411560	CHEMBL1228286	Inhibition of ROCK2	B	N[C@@H](C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CCCCC1		CHEMBL1222417	=	IC50	nM	400.0	CHEMBL2973	Homo sapiens	IC50	nM	400.0
	3411561	CHEMBL1228286	Inhibition of ROCK2	B	CC(C)N[C@H](C(=O)Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CCCCC1		CHEMBL1222418	=	IC50	nM	25.0	CHEMBL2973	Homo sapiens	IC50	nM	25.0
	3411562	CHEMBL1228286	Inhibition of ROCK2	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)[C@H]1CCCN1		CHEMBL1222482	=	IC50	nM	130.0	CHEMBL2973	Homo sapiens	IC50	nM	130.0
	3411563	CHEMBL1228286	Inhibition of ROCK2	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)[C@@H]1CCCN1		CHEMBL1222483	=	IC50	nM	35.0	CHEMBL2973	Homo sapiens	IC50	nM	35.0
	3411564	CHEMBL1228286	Inhibition of ROCK2	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)[C@H]1CCNC1		CHEMBL1222484	=	IC50	nM	180.0	CHEMBL2973	Homo sapiens	IC50	nM	180.0
	3411565	CHEMBL1228286	Inhibition of ROCK2	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)[C@@H]1CCNC1		CHEMBL1085083	=	IC50	nM	67.0	CHEMBL2973	Homo sapiens	IC50	nM	67.0
	3411566	CHEMBL1228286	Inhibition of ROCK2	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C1CCNCC1		CHEMBL1085082	=	IC50	nM	28.0	CHEMBL2973	Homo sapiens	IC50	nM	28.0
	3411567	CHEMBL1228286	Inhibition of ROCK2	B	CN1CCC(C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)CC1		CHEMBL1083113	=	IC50	nM	31.0	CHEMBL2973	Homo sapiens	IC50	nM	31.0
	3411568	CHEMBL1228286	Inhibition of ROCK2	B	N[C@H]1CC[C@H](C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)CC1		CHEMBL1222570	=	IC50	nM	330.0	CHEMBL2973	Homo sapiens	IC50	nM	330.0
	3411569	CHEMBL1228286	Inhibition of ROCK2	B	N[C@H]1CC[C@@H](C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)CC1		CHEMBL1222571	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	nM	15.0
	3411570	CHEMBL1228286	Inhibition of ROCK2	B	N[C@@H]1CC[C@H](C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)C1		CHEMBL1222572	=	IC50	nM	310.0	CHEMBL2973	Homo sapiens	IC50	nM	310.0
	3411571	CHEMBL1228286	Inhibition of ROCK2	B	N[C@H]1CC[C@@H](C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)C1		CHEMBL1222573	=	IC50	nM	7.3	CHEMBL2973	Homo sapiens	IC50	nM	7.3
	3411572	CHEMBL1228286	Inhibition of ROCK2	B	CN(C)[C@H]1CC[C@@H](C(=O)Nc2cc3cc[nH]c(=O)c3cc2Cl)CC1		CHEMBL1222574	=	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	3443513	CHEMBL1244279	Inhibition of ROCK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	INH	%	3.0
	3443730	CHEMBL1244279	Inhibition of ROCK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	21.0	CHEMBL2973	Homo sapiens	INH	%	21.0
	3444885	CHEMBL1244279	Inhibition of ROCK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	INH	%	4.0
	3445288	CHEMBL1244962	Binding affinity to ROCK2	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	71.0	CHEMBL2973	Homo sapiens	Kd	nM	71.0
	3445509	CHEMBL1244279	Inhibition of ROCK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	3445726	CHEMBL1244279	Inhibition of ROCK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	INH	%	3.0
	3445919	CHEMBL1244279	Inhibition of ROCK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	71.0	CHEMBL2973	Homo sapiens	INH	%	71.0
	3446109	CHEMBL1244279	Inhibition of ROCK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	9.0	CHEMBL2973	Homo sapiens	INH	%	9.0
	3448043	CHEMBL1249682	Inhibition of human ROCK-2 activity at 10 uM by radiometric assay	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	INH	%	4.0
	3448119	CHEMBL1249682	Inhibition of human ROCK-2 activity at 10 uM by radiometric assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Inhibition	%	8.0	CHEMBL2973	Homo sapiens	INH	%	8.0
	3448609	CHEMBL1244962	Binding affinity to ROCK2	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	uM	10.0
	3449039	CHEMBL1244962	Binding affinity to ROCK2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	2300.0	CHEMBL2973	Homo sapiens	Kd	nM	2300.0
	3449332	CHEMBL1244962	Binding affinity to ROCK2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	140.0	CHEMBL2973	Homo sapiens	Kd	nM	140.0
	3449836	CHEMBL1244962	Binding affinity to ROCK2	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	uM	10.0
	3450228	CHEMBL1244962	Binding affinity to ROCK2	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	uM	10.0
	3451137	CHEMBL1244962	Binding affinity to ROCK2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	uM	10.0
	3463346	CHEMBL1251679	Inhibition of ROCK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	100.0	CHEMBL2973	Homo sapiens	INH	%	100.0
	3463890	CHEMBL1251679	Inhibition of ROCK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	3464109	CHEMBL1251679	Inhibition of ROCK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	72.0	CHEMBL2973	Homo sapiens	INH	%	72.0
	3502343	CHEMBL1259606	Inhibition of ROCK2 at 1 uM	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)C4Cc5ccccc5C4)CC3)c12		CHEMBL1257283	>	Inhibition	%	90.0	CHEMBL2973	Homo sapiens	INH	%	90.0
	3521262	CHEMBL1272520	Inhibition of ROCK2	B	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc([C@@H](C)N3C[C@H](C)O[C@H](C)C3)ns2)n1		CHEMBL1270399	>	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	3525172	CHEMBL1274099	Inhibition of ROCK2 at 1 uM	B	CCN(C)C(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN2CCCCC2)cc1)c1ccccc1		CHEMBL496862	=	Inhibition	%	88.0	CHEMBL2973	Homo sapiens	INH	%	88.0
	3525202	CHEMBL1274099	Inhibition of ROCK2 at 1 uM	B	O=C1Nc2ccccc2/C1=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1		CHEMBL500435	=	Inhibition	%	54.0	CHEMBL2973	Homo sapiens	INH	%	54.0
	3525232	CHEMBL1274099	Inhibition of ROCK2 at 1 uM	B	CN(C)C(=O)c1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL1272078	=	Inhibition	%	79.0	CHEMBL2973	Homo sapiens	INH	%	79.0
	3525262	CHEMBL1274099	Inhibition of ROCK2 at 1 uM	B	CCNC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(CCN(C)C)S(C)(=O)=O)cc1)c1ccccc1		CHEMBL1272128	=	Inhibition	%	88.0	CHEMBL2973	Homo sapiens	INH	%	88.0
	3525292	CHEMBL1274099	Inhibition of ROCK2 at 1 uM	B	CCNC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL1272289	=	Inhibition	%	95.0	CHEMBL2973	Homo sapiens	INH	%	95.0
	3525322	CHEMBL1274099	Inhibition of ROCK2 at 1 uM	B	CCNCc1ccc(N/C(=C2\C(=O)Nc3cc(C(=O)N(C)CC)ccc32)c2ccccc2)cc1		CHEMBL1271471	=	Inhibition	%	80.0	CHEMBL2973	Homo sapiens	INH	%	80.0
	3603127	CHEMBL1291224	Inhibition of ROCK2 at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scnc1-c1cscn1		CHEMBL1288160	=	Inihibition	%	3.0	CHEMBL2973	Homo sapiens	Inihibition	%	3.0
	5120118	CHEMBL1648821	Inhibition of ROCK2 at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccccn2)nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644615	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	INH	%	5.0
	5120130	CHEMBL1648821	Inhibition of ROCK2 at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccncc2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644642	=	Inhibition	%	6.0	CHEMBL2973	Homo sapiens	INH	%	6.0
	5120148	CHEMBL1648821	Inhibition of ROCK2 at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCOC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644619	=	Inhibition	%	8.0	CHEMBL2973	Homo sapiens	INH	%	8.0
	5120151	CHEMBL1648821	Inhibition of ROCK2 at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(C2CCOCC2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644639	=	Inhibition	%	9.0	CHEMBL2973	Homo sapiens	INH	%	9.0
	5120159	CHEMBL1648821	Inhibition of ROCK2 at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644620	=	Inhibition	%	10.0	CHEMBL2973	Homo sapiens	INH	%	10.0
	5120185	CHEMBL1648821	Inhibition of ROCK2 at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644618	=	Inhibition	%	15.0	CHEMBL2973	Homo sapiens	INH	%	15.0
	5120331	CHEMBL1648703	Inhibition of human ROCK-2 at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	101.0	CHEMBL2973	Homo sapiens	INH	%	101.0
	5122890	CHEMBL1647667	Inhibition of ROCK-2 by Immobilized metal ion affinity-based fluorescence polarization assay	B	Nc1nccc2cc(CNCCc3ccccc3)ccc12		CHEMBL1643361	=	IC50	nM	1288.25	CHEMBL2973	Homo sapiens	pIC50		5.89
	5123944	CHEMBL1647803	Inhibition of ROCK2 at 10 uM	B	Nc1nccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1643368	>	Inhibition	%	80.0	CHEMBL2973	Homo sapiens	INH	%	80.0
	5123978	CHEMBL1647667	Inhibition of ROCK-2 by Immobilized metal ion affinity-based fluorescence polarization assay	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	1348.96	CHEMBL2973	Homo sapiens	pIC50		5.87
	5123987	CHEMBL1647667	Inhibition of ROCK-2 by Immobilized metal ion affinity-based fluorescence polarization assay	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	245.47	CHEMBL2973	Homo sapiens	pIC50		6.61
	5123996	CHEMBL1647667	Inhibition of ROCK-2 by Immobilized metal ion affinity-based fluorescence polarization assay	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	=	IC50	nM	575.44	CHEMBL2973	Homo sapiens	pIC50		6.24
	5132606	CHEMBL1648759	Inhibition of ROCK2 assessed as residual activity at 10 uM	B	CN(C)C/C=C/C(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641990	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	5133749	CHEMBL1648759	Inhibition of ROCK2 assessed as residual activity at 10 uM	B	CN(C)CCCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641989	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	5133922	CHEMBL1648759	Inhibition of ROCK2 assessed as residual activity at 10 uM	B	CN1CCN(CCC(=O)Nc2ccc3c(C#N)cnc(Nc4cccc(Br)c4)c3c2)CC1		CHEMBL1641992	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	5143850	CHEMBL1656185	Inhibition of ROCK2	B	CCN(Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1)C(C)(C)CO.Cl		CHEMBL1650533	>	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
	5143867	CHEMBL1656185	Inhibition of ROCK2	B	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(CN3CCC(F)(F)C3)ns2)n1.Cl		CHEMBL1650545	>	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
	5143884	CHEMBL1656185	Inhibition of ROCK2	B	Cl.[2H]C([2H])(c1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1)N1CCC(F)(F)C1		CHEMBL1650551	>	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
	5152494	CHEMBL1656539	Inhibition of ROCK2 by Caliper mobility shift assay	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O		CHEMBL2012519	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	5152519	CHEMBL1656539	Inhibition of ROCK2 by Caliper mobility shift assay	B	COc1cc(O)c2c(c1)CCC[C@H](O)CC(=O)/C=C\C[C@H](C)OC2=O		CHEMBL1651521	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	5191363	CHEMBL1664038	Inhibition of ROCK 2 at 1 uM	B	COc1cc2nc(-c3cc(F)ccc3O)nc(N[C@@H]3CNC[C@H]3C(C)(C)O)c2cc1OC		CHEMBL1236782	=	Inhibition	%	64.0	CHEMBL2973	Homo sapiens	INH	%	64.0
	5191364	CHEMBL1664038	Inhibition of ROCK 2 at 1 uM	B	CC(C)(O)[C@@H]1CNC[C@H]1Nc1nc(-c2cc(-c3cc[nH]n3)ccc2O)nc2ccccc12		CHEMBL1650131	=	Inhibition	%	84.0	CHEMBL2973	Homo sapiens	INH	%	84.0
	5197177	CHEMBL1670414	Inhibition of ROCK2 by IMAP assay	B	O=c1[nH]ccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1667967	=	IC50	nM	38.9	CHEMBL2973	Homo sapiens	pIC50		7.41
	5197191	CHEMBL1670414	Inhibition of ROCK2 by IMAP assay	B	c1ccc(CN2CCC[C@H](Oc3ccc4cnccc4c3)C2)cc1		CHEMBL1667965	=	IC50	nM	79.43	CHEMBL2973	Homo sapiens	pIC50		7.1
	5197220	CHEMBL1670414	Inhibition of ROCK2 by IMAP assay	B	Nc1nccc2c(S(=O)(=O)N3CCCNCC3)cccc12		CHEMBL1667963	=	IC50	nM	575.44	CHEMBL2973	Homo sapiens	pIC50		6.24
	5197227	CHEMBL1670414	Inhibition of ROCK2 by IMAP assay	B	Nc1nccc2cc(O[C@H]3CCCN(Cc4ccccc4)C3)ccc12		CHEMBL1643574	=	IC50	nM	91.2	CHEMBL2973	Homo sapiens	pIC50		7.04
	5197233	CHEMBL1670414	Inhibition of ROCK2 by IMAP assay	B	Nc1nccc2cc(O[C@H]3CCCNC3)ccc12		CHEMBL1643368	=	IC50	nM	1122.02	CHEMBL2973	Homo sapiens	pIC50		5.95
	5240206	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	CCCc1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1682335	=	Ki	nM	108.0	CHEMBL2973	Homo sapiens	Ki	uM	0.108
	5240207	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	COCc1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1682336	=	Ki	nM	635.0	CHEMBL2973	Homo sapiens	Ki	uM	0.635
	5240208	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	OCCCc1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1682337	=	Ki	nM	230.0	CHEMBL2973	Homo sapiens	Ki	uM	0.23
	5240209	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1cc2[nH]ncc2cc1-n1cc(C2CC2)nn1		CHEMBL1682338	=	Ki	nM	356.0	CHEMBL2973	Homo sapiens	Ki	uM	0.356
	5240210	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1cc2[nH]ncc2cc1-n1cc(C2CCCC2)nn1		CHEMBL1682339	=	Ki	nM	44.0	CHEMBL2973	Homo sapiens	Ki	uM	0.044
	5240211	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1cc2[nH]ncc2cc1-n1cc(CC2CCCCC2)nn1		CHEMBL1682340	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	Ki	uM	0.1
	5240212	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682341	=	Ki	nM	18.0	CHEMBL2973	Homo sapiens	Ki	uM	0.018
	5240213	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1ccc(CCc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682342	=	Ki	nM	19.0	CHEMBL2973	Homo sapiens	Ki	uM	0.019
	5240214	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1ccc(CCCc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682343	=	Ki	nM	62.0	CHEMBL2973	Homo sapiens	Ki	uM	0.062
	5240215	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1cc2[nH]ncc2cc1-c1c[nH]nn1		CHEMBL1682344	=	Ki	nM	209.0	CHEMBL2973	Homo sapiens	Ki	uM	0.209
	5240216	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682345	=	Ki	nM	97.0	CHEMBL2973	Homo sapiens	Ki	uM	0.097
	5240217	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1682346	=	Ki	nM	64.0	CHEMBL2973	Homo sapiens	Ki	uM	0.064
	5240218	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Clc1ccccc1Cn1cc(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1682347	=	Ki	nM	97.0	CHEMBL2973	Homo sapiens	Ki	uM	0.097
	5240219	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Clc1cccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1		CHEMBL1682348	=	Ki	nM	39.0	CHEMBL2973	Homo sapiens	Ki	uM	0.039
	5240220	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Clc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682349	=	Ki	nM	68.0	CHEMBL2973	Homo sapiens	Ki	uM	0.068
	5240221	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Fc1ccccc1Cn1cc(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1682350	=	Ki	nM	285.0	CHEMBL2973	Homo sapiens	Ki	uM	0.285
	5240222	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Fc1cccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1		CHEMBL1682351	=	Ki	nM	180.0	CHEMBL2973	Homo sapiens	Ki	uM	0.18
	5240223	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Fc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682352	=	Ki	nM	285.0	CHEMBL2973	Homo sapiens	Ki	uM	0.285
	5240224	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Cc1cccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1		CHEMBL1682353	=	Ki	nM	375.0	CHEMBL2973	Homo sapiens	Ki	uM	0.375
	5240225	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Clc1cccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1Cl		CHEMBL1682354	=	Ki	nM	15.0	CHEMBL2973	Homo sapiens	Ki	uM	0.015
	5240226	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Clc1ccc(Cl)c(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1		CHEMBL1682355	=	Ki	nM	18.0	CHEMBL2973	Homo sapiens	Ki	uM	0.018
	5240227	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Clc1cc(Cl)cc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c1		CHEMBL1682356	=	Ki	nM	41.0	CHEMBL2973	Homo sapiens	Ki	uM	0.041
	5240228	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1ccc(Cc2cc(-c3ccc4[nH]ncc4c3)on2)cc1		CHEMBL1682357	=	Ki	nM	28.0	CHEMBL2973	Homo sapiens	Ki	uM	0.028
	5240229	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	Nc1n[nH]c2ccc(-c3cc(Cc4ccccc4)no3)cc12		CHEMBL1682358	=	Ki	nM	16.0	CHEMBL2973	Homo sapiens	Ki	uM	0.016
	5240230	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	CCCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1682359	=	Ki	nM	113.0	CHEMBL2973	Homo sapiens	Ki	uM	0.113
	5240231	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	CNC(=O)c1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1681795	=	Ki	nM	402.0	CHEMBL2973	Homo sapiens	Ki	uM	0.402
	5240232	CHEMBL1685408	Inhibition of Rock2 after 1 hr using biotinylated longS peptide as substrate	B	c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1		CHEMBL1682360	=	Ki	nM	315.0	CHEMBL2973	Homo sapiens	Ki	uM	0.315
	5241402	CHEMBL1685436	Inhibition of Rock2	B	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	=	Ki	nM	226.0	CHEMBL2973	Homo sapiens	Ki	uM	0.226
	5241403	CHEMBL1685436	Inhibition of Rock2	B	c1ccc(-c2c(-c3ccc4[nH]ncc4c3)nc3ncccn23)cc1		CHEMBL1682541	=	Ki	nM	6.0	CHEMBL2973	Homo sapiens	Ki	uM	0.006
	5241404	CHEMBL1685436	Inhibition of Rock2	B	Cc1nc(-c2ccc3[nH]ncc3c2)cs1		CHEMBL1682542	=	Ki	nM	513.0	CHEMBL2973	Homo sapiens	Ki	uM	0.513
	5241405	CHEMBL1685436	Inhibition of Rock2	B	Nc1nc(-c2ccc3[nH]ncc3c2)cs1		CHEMBL1682543	=	Ki	nM	909.0	CHEMBL2973	Homo sapiens	Ki	uM	0.909
	5241406	CHEMBL1685436	Inhibition of Rock2	B	CCNc1nc(-c2ccc3[nH]ncc3c2)cs1		CHEMBL1682544	=	Ki	nM	888.0	CHEMBL2973	Homo sapiens	Ki	uM	0.888
	5241407	CHEMBL1685436	Inhibition of Rock2	B	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	=	Ki	nM	864.0	CHEMBL2973	Homo sapiens	Ki	uM	0.864
	5241408	CHEMBL1685436	Inhibition of Rock2	B	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	=	Ki	nM	136.0	CHEMBL2973	Homo sapiens	Ki	uM	0.136
	5241409	CHEMBL1685436	Inhibition of Rock2	B	c1ccc(CCNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682547	=	Ki	nM	364.0	CHEMBL2973	Homo sapiens	Ki	uM	0.364
	5241410	CHEMBL1685436	Inhibition of Rock2	B	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)c(-c3ccccc3)s2)cc1		CHEMBL1682548	=	Ki	nM	1413.0	CHEMBL2973	Homo sapiens	Ki	uM	1.413
	5241411	CHEMBL1685436	Inhibition of Rock2	B	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)c(-c3ccccc3)s2)cc1		CHEMBL1682549	=	Ki	nM	822.0	CHEMBL2973	Homo sapiens	Ki	uM	0.822
	5241412	CHEMBL1685436	Inhibition of Rock2	B	c1ccn2c(NC3CCCCC3)c(-c3ccc4[nH]ncc4c3)nc2c1		CHEMBL1682550	=	Ki	nM	2475.0	CHEMBL2973	Homo sapiens	Ki	uM	2.475
Not Determined	5241413	CHEMBL1685436	Inhibition of Rock2	B	c1cn2c(NC3CCCCC3)c(-c3ccc4[nH]ncc4c3)nc2cn1		CHEMBL1682551		Ki			CHEMBL2973	Homo sapiens	Ki		
	5241414	CHEMBL1685436	Inhibition of Rock2	B	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	=	Ki	nM	245.0	CHEMBL2973	Homo sapiens	Ki	uM	0.245
	5241415	CHEMBL1685436	Inhibition of Rock2	B	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	=	Ki	nM	65.0	CHEMBL2973	Homo sapiens	Ki	uM	0.065
	5241416	CHEMBL1685436	Inhibition of Rock2	B	CCCCNc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682554	=	Ki	nM	116.0	CHEMBL2973	Homo sapiens	Ki	uM	0.116
	5241417	CHEMBL1685436	Inhibition of Rock2	B	Clc1ccc(Nc2c(-c3ccc4[nH]ncc4c3)nc3ncccn23)cc1		CHEMBL1682555	=	Ki	nM	1565.0	CHEMBL2973	Homo sapiens	Ki	uM	1.565
	5241418	CHEMBL1685436	Inhibition of Rock2	B	c1cn2c(NC3CCCCC3)c(-c3ccc4[nH]ncc4c3)nc2s1		CHEMBL1682556	=	Ki	nM	622.0	CHEMBL2973	Homo sapiens	Ki	uM	0.622
	5241419	CHEMBL1685436	Inhibition of Rock2	B	CN(C)CCn1cnc(-c2ccc(F)cc2)c1-c1ccc2[nH]ncc2c1		CHEMBL1682557	>	Ki	nM	6000.0	CHEMBL2973	Homo sapiens	Ki	uM	6.0
	5241420	CHEMBL1685436	Inhibition of Rock2	B	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	>	Ki	nM	6000.0	CHEMBL2973	Homo sapiens	Ki	uM	6.0
	5241421	CHEMBL1685436	Inhibition of Rock2	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682559	>	Ki	nM	6000.0	CHEMBL2973	Homo sapiens	Ki	uM	6.0
	5241422	CHEMBL1685436	Inhibition of Rock2	B	Fc1ccc(-c2ncn(C3CCN(Cc4ccccc4)C3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682560	>	Ki	nM	6000.0	CHEMBL2973	Homo sapiens	Ki	uM	6.0
	5246422	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	O=c1[nH]c(C2=Cc3ccccc3OC2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL1684195	>	IC50	nM	5000.0	CHEMBL2973	Homo sapiens	IC50	nM	5000.0
	5246423	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	O=c1[nH]c(C2CCc3ccccc3O2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL1684196	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	5246424	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	O=c1[nH]c(C2COc3ccccc3C2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL1684197	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	5246425	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1cccc2c1CC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684198	=	IC50	nM	31.0	CHEMBL2973	Homo sapiens	IC50	nM	31.0
	5246426	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1cccc2c1OCC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)C2		CHEMBL1684199	=	IC50	nM	423.0	CHEMBL2973	Homo sapiens	IC50	nM	423.0
	5246427	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684200	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	5246428	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)C[C@H](c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684201	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	5246429	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)C[C@@H](c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684202	=	IC50	nM	87.0	CHEMBL2973	Homo sapiens	IC50	nM	87.0
	5246430	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	Cc1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684203	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	5246431	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	O=c1[nH]c(C2COc3ccc(F)cc3C2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL1684204	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	5246432	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	O=C(c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2)C1CC1		CHEMBL1684205	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	5246433	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	CN(C)CCNC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684206	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	5246434	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COCCNC(=O)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684207	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	5246435	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	O=C(NC1CC1)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684208	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	5246436	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	O=C(NCCc1ccccn1)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684209	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	5246437	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	O=C(NCCN1CCOCC1)c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684210	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	5246438	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccccc1OCc1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL1684211	=	IC50	nM	188.0	CHEMBL2973	Homo sapiens	IC50	nM	188.0
	5246439	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1cccc(OCc2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)c1		CHEMBL1684212	=	IC50	nM	33.0	CHEMBL2973	Homo sapiens	IC50	nM	33.0
	5246440	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	O=c1[nH]c(C2CC2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL1684213	=	IC50	nM	123.0	CHEMBL2973	Homo sapiens	IC50	nM	123.0
	5246441	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc(SCCN(C)C)c3cc(-c4cn[nH]c4)ccc3n1)CO2		CHEMBL1684214	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	5246442	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc(N(C)CCO)c3cc(-c4cn[nH]c4)ccc3n1)CO2		CHEMBL1684215	=	IC50	nM	22.0	CHEMBL2973	Homo sapiens	IC50	nM	22.0
	5246443	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc(N(C)CCN(C)C)c3cc(-c4cn[nH]c4)ccc3n1)CO2		CHEMBL1684216	=	IC50	nM	358.0	CHEMBL2973	Homo sapiens	IC50	nM	358.0
	5246444	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc(NCc3ccccn3)c3cc(-c4cn[nH]c4)ccc3n1)CO2		CHEMBL1684217	>	IC50	nM	5000.0	CHEMBL2973	Homo sapiens	IC50	nM	5000.0
	5246445	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	CN(C)CCSc1nc(C2COc3ccc(C(=O)NC4CC4)cc3C2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL1684218	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	5246446	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COCCNC(=O)c1ccc2c(c1)CC(c1nc(SCCN(C)C)c3cc(-c4cn[nH]c4)ccc3n1)CO2		CHEMBL1684219	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	5246447	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	CN(C)CCSc1nc(C2COc3ccc(C(=O)NCCN4CCOCC4)cc3C2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL1684220	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	5246448	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc3c(OC)cc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684221	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	5246449	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc3c(F)cc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684222	=	IC50	nM	104.0	CHEMBL2973	Homo sapiens	IC50	nM	104.0
	5246450	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc3c(N(C)CCN(C)C)cc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684223	=	IC50	nM	21.0	CHEMBL2973	Homo sapiens	IC50	nM	21.0
	5246451	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc3c(OCCN(C)C)cc(-c4cn[nH]c4)cc3c(=O)[nH]1)CO2		CHEMBL1684224	=	IC50	nM	16.0	CHEMBL2973	Homo sapiens	IC50	nM	16.0
	5246452	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c(C3COc4ccc(F)cc4C3)nc12		CHEMBL1684225	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	5246453	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c(C3COc4ccc(C)cc4C3)nc12		CHEMBL1684226	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	5246454	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1ccc2c(c1)CC(c1nc3c(OC)cc(-c4cn[nH]c4)cc3c(=O)[nH]1)CC2		CHEMBL1684227	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	5246455	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c(C3COc4ccccc4O3)nc12		CHEMBL1684228	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	5246456	CHEMBL1686688	Inhibition of ROCK2 by HTRF assay	B	COc1cccc(OCc2nc3c(OC)cc(-c4cn[nH]c4)cc3c(=O)[nH]2)c1		CHEMBL1684229	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	5249451	CHEMBL1686802	Inhibition of ROCK2 at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scc(Cl)c1-c1ncn[nH]1		CHEMBL1682017	=	Inhibition	%	9.0	CHEMBL2973	Homo sapiens	INH	%	9.0
	6167673	CHEMBL1769214	Inhibition of ROCK2	B	CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1		CHEMBL1765781	>	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	Ki	uM	1.0
	6169198	CHEMBL1768976	Inhibition of human ROCK2 assessed as residual activity at 10 uM	B	CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1		CHEMBL1765740	=	Activity	%	26.0	CHEMBL2973	Homo sapiens	Activity	%	26.0
	6221252	CHEMBL1787677	Inhibition of ROCK2 at 10 uM	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	25.0	CHEMBL2973	Homo sapiens	INH	%	25.0
	6262768	CHEMBL1798991	Inhibition of ROCK II	B	Cc1ccc(C(=O)NCCO)cc1-n1cnc(OCc2ccc(F)cc2F)c(Cl)c1=O		CHEMBL1738710	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	6267539	CHEMBL1799042	Inhibition of ROCK2 at 10 uM	B	O=c1c(Cl)c(OCc2ccc(F)cc2F)cc(CO)n1-c1c(F)cccc1F		CHEMBL1797211	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	6267540	CHEMBL1799042	Inhibition of ROCK2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cccc(C(N)=O)c1		CHEMBL1797224	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	6268172	CHEMBL1805364	Inhibition of Rock2	B	CSc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C)ns2)n1		CHEMBL1270795	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	6274420	CHEMBL1806017	Inhibition of ROCK 2 assessed as residual enzyme activity at 10 uM	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833	=	Activity	%	102.0	CHEMBL2973	Homo sapiens	Activity	%	102.0
	6340987	CHEMBL1827573	Activity of ROCK2 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	97.0	CHEMBL2973	Homo sapiens	Activity	%	97.0
	6352273	CHEMBL1826250	Inhibition of ROCK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Activity	%	51.0	CHEMBL2973	Homo sapiens	Activity	%	51.0
	6353480	CHEMBL1825792	Inhibition of ROCK2 at 10 uM	B	O=C(Cn1c(=O)ccc2cc(C(F)(F)F)ccc21)Nc1scc(Br)c1-c1ncn[nH]1		CHEMBL1822146	=	Inhibition	%	11.0	CHEMBL2973	Homo sapiens	INH	%	11.0
	6384634	CHEMBL1837775	Inhibition of human ROCK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1		CHEMBL1834114	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	6384635	CHEMBL1837775	Inhibition of human ROCK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1		CHEMBL1834318	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	6384636	CHEMBL1837775	Inhibition of human ROCK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834323	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	6384637	CHEMBL1837775	Inhibition of human ROCK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834324	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	6384638	CHEMBL1837775	Inhibition of human ROCK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2		CHEMBL1834330	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	6387473	CHEMBL1839923	Inhibition of recombinant ROCK2	B	CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O		CHEMBL1834657	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	7567367	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7567826	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	Kd	nM	420.0	CHEMBL2973	Homo sapiens	Kd	nM	420.0
	7568323	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7568755	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	660.0	CHEMBL2973	Homo sapiens	Kd	nM	660.0
	7569340	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7569830	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7570293	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	=	Kd	nM	8700.0	CHEMBL2973	Homo sapiens	Kd	nM	8700.0
	7570720	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	140.0	CHEMBL2973	Homo sapiens	Kd	nM	140.0
	7571331	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	3300.0	CHEMBL2973	Homo sapiens	Kd	nM	3300.0
	7571807	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	52.0	CHEMBL2973	Homo sapiens	Kd	nM	52.0
	7572270	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7572686	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	130.0	CHEMBL2973	Homo sapiens	Kd	nM	130.0
	7572855	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7573312	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7573788	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7574257	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	2300.0	CHEMBL2973	Homo sapiens	Kd	nM	2300.0
	7574665	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7574833	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7575294	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7575765	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7576230	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7576638	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	2200.0	CHEMBL2973	Homo sapiens	Kd	nM	2200.0
	7576807	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7577266	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	1800.0	CHEMBL2973	Homo sapiens	Kd	nM	1800.0
	7577744	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	250.0	CHEMBL2973	Homo sapiens	Kd	nM	250.0
	7578214	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7578815	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7579189	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7579639	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	1500.0	CHEMBL2973	Homo sapiens	Kd	nM	1500.0
	7580113	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7580543	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	=	Kd	nM	3600.0	CHEMBL2973	Homo sapiens	Kd	nM	3600.0
	7581173	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7581558	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7582003	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7582496	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7582896	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7583519	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Kd	nM	630.0	CHEMBL2973	Homo sapiens	Kd	nM	630.0
	7583916	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7584390	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7584852	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	560.0	CHEMBL2973	Homo sapiens	Kd	nM	560.0
	7585256	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7585849	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7586257	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7586261	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7586732	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7587186	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	=	Kd	nM	730.0	CHEMBL2973	Homo sapiens	Kd	nM	730.0
	7588240	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7588711	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7589162	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7589333	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7589757	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	71.0	CHEMBL2973	Homo sapiens	Kd	nM	71.0
	7590224	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7590698	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7591149	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7591306	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7591728	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	3100.0	CHEMBL2973	Homo sapiens	Kd	nM	3100.0
	7592200	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7592673	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7593126	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	360.0	CHEMBL2973	Homo sapiens	Kd	nM	360.0
	7593273	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	390.0	CHEMBL2973	Homo sapiens	Kd	nM	390.0
	7593708	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7594180	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	200.0	CHEMBL2973	Homo sapiens	Kd	nM	200.0
	7594653	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7595241	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7595685	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7596159	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7596635	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7597213	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7597666	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7598139	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7598167	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL2973	Homo sapiens	Kd	nM	10000.0
	7598609	CHEMBL1908666	Binding constant for ROCK2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	0.24	CHEMBL2973	Homo sapiens	Kd	nM	0.24
	7939957	CHEMBL1919626	Inhibition of human ROCK-2	B	[O-][n+]1ccc2c(-c3ccc(F)cc3Cl)ccnc2c1-c1c(Cl)cccc1Cl		CHEMBL1916359	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	7949078	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922026	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	7949079	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3n2CCCO)c1		CHEMBL1922027	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	nM	24.0
	7949080	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3n2CCN(C)C)c1		CHEMBL1922028	=	IC50	nM	310.0	CHEMBL2973	Homo sapiens	IC50	nM	310.0
	7949081	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922029	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	7949082	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3n2C)c1		CHEMBL1922030	=	IC50	nM	200.0	CHEMBL2973	Homo sapiens	IC50	nM	200.0
	7949083	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3n2CCN(C)C)c1		CHEMBL1922031	=	IC50	nM	2300.0	CHEMBL2973	Homo sapiens	IC50	nM	2300.0
	7949084	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(CCN2CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922032	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	7949085	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(CCCN(C)C)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922033	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	7949086	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1922034	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	7949087	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2C)c1		CHEMBL1922035	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949088	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2CC2CC2)c1		CHEMBL1922036	=	IC50	nM	150.0	CHEMBL2973	Homo sapiens	IC50	nM	150.0
	7949089	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2Cc2cccc(OC)c2)c1		CHEMBL1922037	=	IC50	nM	4400.0	CHEMBL2973	Homo sapiens	IC50	nM	4400.0
	7949090	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2CCN(C)C)c1		CHEMBL1922038	=	IC50	nM	43.0	CHEMBL2973	Homo sapiens	IC50	nM	43.0
	7949091	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2CCCO)c1		CHEMBL1922039	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	nM	24.0
	7949092	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(CC[N+]2(C)CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2C)c1		CHEMBL1922040	=	IC50	nM	1900.0	CHEMBL2973	Homo sapiens	IC50	nM	1900.0
	7949093	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(CCN2CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2C)c1		CHEMBL1922041	=	IC50	nM	220.0	CHEMBL2973	Homo sapiens	IC50	nM	220.0
	7949094	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1922042	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	7949095	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(C(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)C2CC2)c1		CHEMBL1922043	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	7949096	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(CCN2CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1922044	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	7949097	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922045	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949098	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(C)C(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922046	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	7949099	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922047	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949100	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(C)C(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922124	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949101	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cn(-c3ccccc3)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922125	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	7949102	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(CCCN(C)C)C(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922126	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949103	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(CCN(C)C)C(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922127	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949104	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cn(CCCO)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922128	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949105	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cn(CCN(C)C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922129	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949106	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(C)C(=O)c2cn(CCN(C)C)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922130	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	7949107	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(CCN(C)C)C(=O)c2cn(CCN3CCCC3)c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922131	=	IC50	nM	2800.0	CHEMBL2973	Homo sapiens	IC50	nM	2800.0
	7949108	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922132	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	7949109	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(C(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)C2CC2)c1		CHEMBL1922133	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	7949110	CHEMBL1924421	Inhibition of ROCK2	B	CCN(Cc1cccc(OC)c1)C(=O)c1c[nH]c2nc(-c3cn[nH]c3)ccc12		CHEMBL1922134	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	nM	19.0
	7949111	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CN(CCCN2CCN(C)CC2)C(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922135	=	IC50	nM	62.0	CHEMBL2973	Homo sapiens	IC50	nM	62.0
	7949112	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cn(C)c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922136	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949113	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2cn(CCN3CCCC3)c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922137	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	7949114	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN(C)C)c1		CHEMBL1922138	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	7949115	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN2CCOCC2)c1		CHEMBL1922139	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	7949116	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN2CCN(C)CC2)c1		CHEMBL1922140	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949117	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN2CCCNCC2)c1		CHEMBL1922141	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7949118	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2[nH]c3nc(-c4cn[nH]c4)ccc3c2CN2CCN(C)CC2)c1		CHEMBL1922142	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	7949119	CHEMBL1924421	Inhibition of ROCK2	B	COc1cccc(CNC(=O)c2[nH]c3nc(-c4cn[nH]c4)ccc3c2CN2CCOCC2)c1		CHEMBL1922143	=	IC50	nM	16.0	CHEMBL2973	Homo sapiens	IC50	nM	16.0
	7956369	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1922026	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	7956370	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3ccc(-c4ccncc4)cc3[nH]2)c1		CHEMBL1923052	=	IC50	nM	160.0	CHEMBL2973	Homo sapiens	IC50	nM	160.0
	7956371	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3ccc(-c4ccnc(N)n4)cc3[nH]2)c1		CHEMBL1923053	=	IC50	nM	36.0	CHEMBL2973	Homo sapiens	IC50	nM	36.0
	7956372	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3ccc(-c4ccnc(N)c4)cc3[nH]2)c1		CHEMBL1923161	=	IC50	nM	1200.0	CHEMBL2973	Homo sapiens	IC50	nM	1200.0
	7956373	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3cnc(-c4cn[nH]c4)cc3[nH]2)c1		CHEMBL1923162	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	nM	190.0
	7956374	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3cnc(-c4cn[nH]c4C)cc3[nH]2)c1		CHEMBL1923163	=	IC50	nM	530.0	CHEMBL2973	Homo sapiens	IC50	nM	530.0
	7956375	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3cnc(-c4ccncc4)cc3[nH]2)c1		CHEMBL1923164	=	IC50	nM	420.0	CHEMBL2973	Homo sapiens	IC50	nM	420.0
	7956376	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1922034	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	7956377	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4C)nc3[nH]2)c1		CHEMBL1923165	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	7956378	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2cc3ccc(-c4ccncc4)nc3[nH]2)c1		CHEMBL1923166	=	IC50	nM	220.0	CHEMBL2973	Homo sapiens	IC50	nM	220.0
	7956379	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922045	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7956380	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2c[nH]c3cc(-c4ccncc4)ccc23)c1		CHEMBL1923167	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	7956381	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)c1		CHEMBL1922132	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	7956382	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2c[nH]c3nc(-c4ccncc4)ccc23)c1		CHEMBL1923168	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	7956383	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1ccccc1CNC(=O)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923169	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	7956384	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1ccc(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)cc1		CHEMBL1923170	=	IC50	nM	750.0	CHEMBL2973	Homo sapiens	IC50	nM	750.0
	7956385	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	O=C(NCc1cccc(OC(F)(F)F)c1)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923171	=	IC50	nM	220.0	CHEMBL2973	Homo sapiens	IC50	nM	220.0
	7956386	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	O=C(NCc1ccc(F)c(F)c1)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923172	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	7956387	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc([C@@H](C)NC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1923173	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7956388	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc([C@H](C)NC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1923174	=	IC50	nM	130.0	CHEMBL2973	Homo sapiens	IC50	nM	130.0
	7956389	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	O=C(NCC1CCCCC1)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923175	=	IC50	nM	76.0	CHEMBL2973	Homo sapiens	IC50	nM	76.0
	7956390	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CCNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1923176	=	IC50	nM	170.0	CHEMBL2973	Homo sapiens	IC50	nM	170.0
	7956391	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	O=C(NCCc1cccs1)c1c[nH]c2cc(-c3cn[nH]c3)ccc12		CHEMBL1923177	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	7956392	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1ccc(OC)c(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1		CHEMBL1923178	=	IC50	nM	740.0	CHEMBL2973	Homo sapiens	IC50	nM	740.0
	7956393	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1ccccc1CNC(=O)c1cc2ccc(-c3cn[nH]c3)nc2[nH]1		CHEMBL1923179	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	7956394	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1ccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)cc1		CHEMBL1923180	=	IC50	nM	180.0	CHEMBL2973	Homo sapiens	IC50	nM	180.0
	7956395	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc([C@@H](C)NC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1923181	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	7956396	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc([C@H](C)NC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1		CHEMBL1923182	=	IC50	nM	290.0	CHEMBL2973	Homo sapiens	IC50	nM	290.0
	7956397	CHEMBL1925273	Inhibition of human 6-His-tagged ROCK2 expressed in Sf9 cells	B	COc1cccc(CNC(=O)c2nc3cc(-c4cc[nH]n4)ccc3s2)c1		CHEMBL1923183	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	7961149	CHEMBL1931556	Inhibition of ROCK-2	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL2973	Homo sapiens	IC50	uM	30.0
	7961150	CHEMBL1931556	Inhibition of ROCK-2	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	IC50	nM	30000.0	CHEMBL2973	Homo sapiens	IC50	uM	30.0
	7969791	CHEMBL1930363	Inhibition of ROCK2 assessed as residual activity at 10 uM using [33P-ATP] by radiometric filter binding assay	B	Cc1ccc(F)cc1-c1nc2[nH]nc(N)c2c2c1CCCC2		CHEMBL1927262	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
	7971380	CHEMBL1929902	Inhibition of ROCK2 at 10 uM	B	NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL1929247	=	Inhibition	%	-1.0	CHEMBL2973	Homo sapiens	INH	%	-1.0
	8010821	CHEMBL1941457	Inhibition of ROCK2 at 1 uM	B	CC(C)(C)NS(=O)(=O)c1ccc(-c2cc3c(N)ncc(C(=O)NCCN4CCOCC4)c3s2)cc1		CHEMBL1938659	=	Inhibition	%	20.0	CHEMBL2973	Homo sapiens	INH	%	20.0
	8013078	CHEMBL1947865	Inhibition of ROCK2 using ATP as substrate	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O		CHEMBL1945559	=	IC50	nM	220.0	CHEMBL2973	Homo sapiens	IC50	uM	0.22
	8047301	CHEMBL1960788	Inhibition of human ROCK2	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	8047302	CHEMBL1960788	Inhibition of human ROCK2	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21		CHEMBL1956071	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	8047364	CHEMBL1960788	Inhibition of human ROCK2	B	CCn1c(-c2nonc2N)nc2cnccc21		CHEMBL189657	<	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	8047365	CHEMBL1960788	Inhibition of human ROCK2	B	CCn1c(-c2nonc2N)nc2cncc(-c3ccc(CN)cc3)c21.Cl		CHEMBL1956072	<	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
Active	8047366	CHEMBL1960788	Inhibition of human ROCK2	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	8047367	CHEMBL1960788	Inhibition of human ROCK2	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	8061244	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-0.88	CHEMBL2973	Homo sapiens	Inhibition	%	-0.88
	8061421	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	1.36	CHEMBL2973	Homo sapiens	Inhibition	%	1.36
	8061645	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.42	CHEMBL2973	Homo sapiens	Inhibition	%	0.42
	8061752	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	3.27	CHEMBL2973	Homo sapiens	Inhibition	%	3.27
	8061943	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	2.47	CHEMBL2973	Homo sapiens	Inhibition	%	2.47
	8062167	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	8.3	CHEMBL2973	Homo sapiens	Inhibition	%	8.3
	8062283	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	19.98	CHEMBL2973	Homo sapiens	Inhibition	%	19.98
	8062669	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	3.63	CHEMBL2973	Homo sapiens	Inhibition	%	3.63
	8062767	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.99	CHEMBL2973	Homo sapiens	Inhibition	%	0.99
	8062991	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-1.58	CHEMBL2973	Homo sapiens	Inhibition	%	-1.58
	8063123	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.95	CHEMBL2973	Homo sapiens	Inhibition	%	0.95
	8063514	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	5.75	CHEMBL2973	Homo sapiens	Inhibition	%	5.75
	8063622	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.09	CHEMBL2973	Homo sapiens	Inhibition	%	2.09
	8064028	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	Inhibition	%	0.0
	8064143	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	67.45	CHEMBL2973	Homo sapiens	Inhibition	%	67.45
	8064367	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	85.54	CHEMBL2973	Homo sapiens	Inhibition	%	85.54
	8064577	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-0.74	CHEMBL2973	Homo sapiens	Inhibition	%	-0.74
	8064715	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-0.31	CHEMBL2973	Homo sapiens	Inhibition	%	-0.31
	8065105	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	1.6	CHEMBL2973	Homo sapiens	Inhibition	%	1.6
	8065221	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	3.61	CHEMBL2973	Homo sapiens	Inhibition	%	3.61
	8065445	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	3.44	CHEMBL2973	Homo sapiens	Inhibition	%	3.44
	8065620	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.32	CHEMBL2973	Homo sapiens	Inhibition	%	1.32
	8065959	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	86.02	CHEMBL2973	Homo sapiens	Inhibition	%	86.02
	8066169	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	1.91	CHEMBL2973	Homo sapiens	Inhibition	%	1.91
	8066305	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	2.22	CHEMBL2973	Homo sapiens	Inhibition	%	2.22
	8066529	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	2.33	CHEMBL2973	Homo sapiens	Inhibition	%	2.33
	8066695	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	3.71	CHEMBL2973	Homo sapiens	Inhibition	%	3.71
	8067043	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	6.83	CHEMBL2973	Homo sapiens	Inhibition	%	6.83
	8067218	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.37	CHEMBL2973	Homo sapiens	Inhibition	%	1.37
	8067563	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	5.66	CHEMBL2973	Homo sapiens	Inhibition	%	5.66
	8067773	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	16.99	CHEMBL2973	Homo sapiens	Inhibition	%	16.99
	8068132	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	15.03	CHEMBL2973	Homo sapiens	Inhibition	%	15.03
	8068296	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	Inhibition	%	2.0
	8068645	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.42	CHEMBL2973	Homo sapiens	Inhibition	%	0.42
	8068819	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	-0.72	CHEMBL2973	Homo sapiens	Inhibition	%	-0.72
	8069043	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	2.12	CHEMBL2973	Homo sapiens	Inhibition	%	2.12
	8069168	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	3.03	CHEMBL2973	Homo sapiens	Inhibition	%	3.03
	8069463	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	6.01	CHEMBL2973	Homo sapiens	Inhibition	%	6.01
	8069624	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	6.5	CHEMBL2973	Homo sapiens	Inhibition	%	6.5
	8069848	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	2.77	CHEMBL2973	Homo sapiens	Inhibition	%	2.77
	8069974	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	2.62	CHEMBL2973	Homo sapiens	Inhibition	%	2.62
	8070370	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	-0.11	CHEMBL2973	Homo sapiens	Inhibition	%	-0.11
	8070495	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.45	CHEMBL2973	Homo sapiens	Inhibition	%	0.45
	8070719	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	1.63	CHEMBL2973	Homo sapiens	Inhibition	%	1.63
	8070793	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	38.8	CHEMBL2973	Homo sapiens	Inhibition	%	38.8
	8071174	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	4.97	CHEMBL2973	Homo sapiens	Inhibition	%	4.97
	8071300	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.72	CHEMBL2973	Homo sapiens	Inhibition	%	0.72
	8071524	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-0.18	CHEMBL2973	Homo sapiens	Inhibition	%	-0.18
	8071697	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.99	CHEMBL2973	Homo sapiens	Inhibition	%	0.99
	8072046	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	0.66	CHEMBL2973	Homo sapiens	Inhibition	%	0.66
	8072136	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-1.5	CHEMBL2973	Homo sapiens	Inhibition	%	-1.5
	8072360	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.89	CHEMBL2973	Homo sapiens	Inhibition	%	-0.89
	8072517	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	8.68	CHEMBL2973	Homo sapiens	Inhibition	%	8.68
	8072866	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.35	CHEMBL2973	Homo sapiens	Inhibition	%	-0.35
	8073033	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	-0.88	CHEMBL2973	Homo sapiens	Inhibition	%	-0.88
	8073382	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.17	CHEMBL2973	Homo sapiens	Inhibition	%	1.17
	8073501	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-0.99	CHEMBL2973	Homo sapiens	Inhibition	%	-0.99
	8073725	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	2.52	CHEMBL2973	Homo sapiens	Inhibition	%	2.52
	8073958	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	0.14	CHEMBL2973	Homo sapiens	Inhibition	%	0.14
	8074110	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	17.2	CHEMBL2973	Homo sapiens	Inhibition	%	17.2
	8074464	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	1.56	CHEMBL2973	Homo sapiens	Inhibition	%	1.56
	8074621	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	-0.06	CHEMBL2973	Homo sapiens	Inhibition	%	-0.06
	8074845	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	0.19	CHEMBL2973	Homo sapiens	Inhibition	%	0.19
	8074972	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.02	CHEMBL2973	Homo sapiens	Inhibition	%	0.02
	8075307	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.06	CHEMBL2973	Homo sapiens	Inhibition	%	0.06
	8075544	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	1.51	CHEMBL2973	Homo sapiens	Inhibition	%	1.51
	8075685	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.95	CHEMBL2973	Homo sapiens	Inhibition	%	1.95
	8075909	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	4.98	CHEMBL2973	Homo sapiens	Inhibition	%	4.98
	8076051	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.01	CHEMBL2973	Homo sapiens	Inhibition	%	-0.01
	8076423	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.94	CHEMBL2973	Homo sapiens	Inhibition	%	0.94
	8076557	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.45	CHEMBL2973	Homo sapiens	Inhibition	%	0.45
	8076883	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-4.4	CHEMBL2973	Homo sapiens	Inhibition	%	-4.4
	8077130	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	11.47	CHEMBL2973	Homo sapiens	Inhibition	%	11.47
	8077482	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-0.03	CHEMBL2973	Homo sapiens	Inhibition	%	-0.03
	8077633	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.4	CHEMBL2973	Homo sapiens	Inhibition	%	-0.4
	8078000	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	-1.5	CHEMBL2973	Homo sapiens	Inhibition	%	-1.5
	8078139	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-1.97	CHEMBL2973	Homo sapiens	Inhibition	%	-1.97
	8078363	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	3.32	CHEMBL2973	Homo sapiens	Inhibition	%	3.32
	8078465	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-1.08	CHEMBL2973	Homo sapiens	Inhibition	%	-1.08
	8078715	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	59.44	CHEMBL2973	Homo sapiens	Inhibition	%	59.44
	8079055	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	3.81	CHEMBL2973	Homo sapiens	Inhibition	%	3.81
	8079213	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.36	CHEMBL2973	Homo sapiens	Inhibition	%	-0.36
	8079437	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	0.84	CHEMBL2973	Homo sapiens	Inhibition	%	0.84
	8079579	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.14	CHEMBL2973	Homo sapiens	Inhibition	%	0.14
	8079942	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	19.92	CHEMBL2973	Homo sapiens	Inhibition	%	19.92
	8080047	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-0.29	CHEMBL2973	Homo sapiens	Inhibition	%	-0.29
	8080271	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	-0.28	CHEMBL2973	Homo sapiens	Inhibition	%	-0.28
	8080299	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	6.15	CHEMBL2973	Homo sapiens	Inhibition	%	6.15
	8080523	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	43.85	CHEMBL2973	Homo sapiens	Inhibition	%	43.85
	8080638	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.37	CHEMBL2973	Homo sapiens	Inhibition	%	1.37
	8081026	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-3.31	CHEMBL2973	Homo sapiens	Inhibition	%	-3.31
	8081161	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.33	CHEMBL2973	Homo sapiens	Inhibition	%	0.33
	8081529	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	69.83	CHEMBL2973	Homo sapiens	Inhibition	%	69.83
	8081856	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	-2.05	CHEMBL2973	Homo sapiens	Inhibition	%	-2.05
	8082108	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	42.41	CHEMBL2973	Homo sapiens	Inhibition	%	42.41
	8082221	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.27	CHEMBL2973	Homo sapiens	Inhibition	%	1.27
	8082445	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.69	CHEMBL2973	Homo sapiens	Inhibition	%	0.69
	8082618	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-3.28	CHEMBL2973	Homo sapiens	Inhibition	%	-3.28
	8082741	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.03	CHEMBL2973	Homo sapiens	Inhibition	%	1.03
	8082965	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	-0.46	CHEMBL2973	Homo sapiens	Inhibition	%	-0.46
	8083121	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	5.67	CHEMBL2973	Homo sapiens	Inhibition	%	5.67
	8083444	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.82	CHEMBL2973	Homo sapiens	Inhibition	%	0.82
	8083698	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	83.39	CHEMBL2973	Homo sapiens	Inhibition	%	83.39
	8084032	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	5.69	CHEMBL2973	Homo sapiens	Inhibition	%	5.69
	8084217	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	15.9	CHEMBL2973	Homo sapiens	Inhibition	%	15.9
	8084559	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	2.57	CHEMBL2973	Homo sapiens	Inhibition	%	2.57
	8084720	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	25.39	CHEMBL2973	Homo sapiens	Inhibition	%	25.39
	8085042	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-0.9	CHEMBL2973	Homo sapiens	Inhibition	%	-0.9
	8085298	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-0.21	CHEMBL2973	Homo sapiens	Inhibition	%	-0.21
	8085630	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.82	CHEMBL2973	Homo sapiens	Inhibition	%	0.82
	8085819	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	60.28	CHEMBL2973	Homo sapiens	Inhibition	%	60.28
	8086158	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	3.89	CHEMBL2973	Homo sapiens	Inhibition	%	3.89
	8086320	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	3.65	CHEMBL2973	Homo sapiens	Inhibition	%	3.65
	8086544	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	7.61	CHEMBL2973	Homo sapiens	Inhibition	%	7.61
	8086643	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.14	CHEMBL2973	Homo sapiens	Inhibition	%	0.14
	8087078	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	1.93	CHEMBL2973	Homo sapiens	Inhibition	%	1.93
	8087236	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.63	CHEMBL2973	Homo sapiens	Inhibition	%	2.63
	8087574	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	4.07	CHEMBL2973	Homo sapiens	Inhibition	%	4.07
	8087712	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.16	CHEMBL2973	Homo sapiens	Inhibition	%	2.16
	8087936	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-0.24	CHEMBL2973	Homo sapiens	Inhibition	%	-0.24
	8088078	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	4.33	CHEMBL2973	Homo sapiens	Inhibition	%	4.33
	8088226	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.41	CHEMBL2973	Homo sapiens	Inhibition	%	0.41
	8088450	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.85	CHEMBL2973	Homo sapiens	Inhibition	%	1.85
	8088578	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	3.27	CHEMBL2973	Homo sapiens	Inhibition	%	3.27
	8088895	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	42.63	CHEMBL2973	Homo sapiens	Inhibition	%	42.63
	8089247	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	7.48	CHEMBL2973	Homo sapiens	Inhibition	%	7.48
	8089395	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	3.96	CHEMBL2973	Homo sapiens	Inhibition	%	3.96
	8089739	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	1.15	CHEMBL2973	Homo sapiens	Inhibition	%	1.15
	8089919	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.18	CHEMBL2973	Homo sapiens	Inhibition	%	0.18
	8090308	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	2.82	CHEMBL2973	Homo sapiens	Inhibition	%	2.82
	8090475	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	2.1	CHEMBL2973	Homo sapiens	Inhibition	%	2.1
	8090838	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	-0.23	CHEMBL2973	Homo sapiens	Inhibition	%	-0.23
	8091043	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	2.02	CHEMBL2973	Homo sapiens	Inhibition	%	2.02
	8091404	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	2.53	CHEMBL2973	Homo sapiens	Inhibition	%	2.53
	8091559	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	3.64	CHEMBL2973	Homo sapiens	Inhibition	%	3.64
	8091899	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	3.77	CHEMBL2973	Homo sapiens	Inhibition	%	3.77
	8092260	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	0.28	CHEMBL2973	Homo sapiens	Inhibition	%	0.28
	8092411	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	3.92	CHEMBL2973	Homo sapiens	Inhibition	%	3.92
	8092783	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.99	CHEMBL2973	Homo sapiens	Inhibition	%	0.99
	8092912	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	5.4	CHEMBL2973	Homo sapiens	Inhibition	%	5.4
	8093136	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	1.42	CHEMBL2973	Homo sapiens	Inhibition	%	1.42
	8093224	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	2.07	CHEMBL2973	Homo sapiens	Inhibition	%	2.07
	8093588	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	7.79	CHEMBL2973	Homo sapiens	Inhibition	%	7.79
	8093727	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	20.47	CHEMBL2973	Homo sapiens	Inhibition	%	20.47
	8093951	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	2.14	CHEMBL2973	Homo sapiens	Inhibition	%	2.14
	8094071	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	2.53	CHEMBL2973	Homo sapiens	Inhibition	%	2.53
	8094251	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.76	CHEMBL2973	Homo sapiens	Inhibition	%	0.76
	8094475	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.41	CHEMBL2973	Homo sapiens	Inhibition	%	1.41
	8094650	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	4.69	CHEMBL2973	Homo sapiens	Inhibition	%	4.69
	8094806	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.91	CHEMBL2973	Homo sapiens	Inhibition	%	0.91
	8095030	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.66	CHEMBL2973	Homo sapiens	Inhibition	%	1.66
	8095170	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	3.48	CHEMBL2973	Homo sapiens	Inhibition	%	3.48
	8095373	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	2.23	CHEMBL2973	Homo sapiens	Inhibition	%	2.23
	8095597	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.99	CHEMBL2973	Homo sapiens	Inhibition	%	0.99
	8095738	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	12.76	CHEMBL2973	Homo sapiens	Inhibition	%	12.76
	8095886	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	2.52	CHEMBL2973	Homo sapiens	Inhibition	%	2.52
	8096110	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	7.05	CHEMBL2973	Homo sapiens	Inhibition	%	7.05
	8096227	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.87	CHEMBL2973	Homo sapiens	Inhibition	%	3.87
	8096590	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.05	CHEMBL2973	Homo sapiens	Inhibition	%	0.05
	8096746	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	5.77	CHEMBL2973	Homo sapiens	Inhibition	%	5.77
	8096970	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	3.14	CHEMBL2973	Homo sapiens	Inhibition	%	3.14
	8097117	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	1.7	CHEMBL2973	Homo sapiens	Inhibition	%	1.7
	8097424	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	2.72	CHEMBL2973	Homo sapiens	Inhibition	%	2.72
	8097648	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	3.52	CHEMBL2973	Homo sapiens	Inhibition	%	3.52
	8097798	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	45.9	CHEMBL2973	Homo sapiens	Inhibition	%	45.9
	8098155	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	5.7	CHEMBL2973	Homo sapiens	Inhibition	%	5.7
	8098275	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.06	CHEMBL2973	Homo sapiens	Inhibition	%	-0.06
	8098499	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	0.84	CHEMBL2973	Homo sapiens	Inhibition	%	0.84
	8098679	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	1.39	CHEMBL2973	Homo sapiens	Inhibition	%	1.39
	8098864	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	29.15	CHEMBL2973	Homo sapiens	Inhibition	%	29.15
	8099232	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.35	CHEMBL2973	Homo sapiens	Inhibition	%	1.35
	8099374	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.87	CHEMBL2973	Homo sapiens	Inhibition	%	1.87
	8099792	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.79	CHEMBL2973	Homo sapiens	Inhibition	%	0.79
	8099939	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	3.08	CHEMBL2973	Homo sapiens	Inhibition	%	3.08
	8100309	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	16.29	CHEMBL2973	Homo sapiens	Inhibition	%	16.29
	8100425	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.72	CHEMBL2973	Homo sapiens	Inhibition	%	3.72
	8100649	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.81	CHEMBL2973	Homo sapiens	Inhibition	%	2.81
	8100789	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.91	CHEMBL2973	Homo sapiens	Inhibition	%	0.91
	8101173	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	6.03	CHEMBL2973	Homo sapiens	Inhibition	%	6.03
	8101315	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-0.74	CHEMBL2973	Homo sapiens	Inhibition	%	-0.74
	8101724	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	2.59	CHEMBL2973	Homo sapiens	Inhibition	%	2.59
	8101977	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	11.7	CHEMBL2973	Homo sapiens	Inhibition	%	11.7
	8102132	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	1.22	CHEMBL2973	Homo sapiens	Inhibition	%	1.22
	8102487	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	1.64	CHEMBL2973	Homo sapiens	Inhibition	%	1.64
	8102831	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	1.34	CHEMBL2973	Homo sapiens	Inhibition	%	1.34
	8103009	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.1	CHEMBL2973	Homo sapiens	Inhibition	%	0.1
	8103205	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	9.12	CHEMBL2973	Homo sapiens	Inhibition	%	9.12
	8103429	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	51.29	CHEMBL2973	Homo sapiens	Inhibition	%	51.29
	8103567	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	0.51	CHEMBL2973	Homo sapiens	Inhibition	%	0.51
	8103717	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.95	CHEMBL2973	Homo sapiens	Inhibition	%	2.95
	8103941	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.94	CHEMBL2973	Homo sapiens	Inhibition	%	2.94
	8104126	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	2.53	CHEMBL2973	Homo sapiens	Inhibition	%	2.53
	8104274	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	5.34	CHEMBL2973	Homo sapiens	Inhibition	%	5.34
	8104498	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	3.44	CHEMBL2973	Homo sapiens	Inhibition	%	3.44
	8104644	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	58.3	CHEMBL2973	Homo sapiens	Inhibition	%	58.3
	8104982	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	4.38	CHEMBL2973	Homo sapiens	Inhibition	%	4.38
	8105122	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.7	CHEMBL2973	Homo sapiens	Inhibition	%	0.7
	8105346	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.87	CHEMBL2973	Homo sapiens	Inhibition	%	0.87
	8105512	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	1.57	CHEMBL2973	Homo sapiens	Inhibition	%	1.57
	8105650	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	3.74	CHEMBL2973	Homo sapiens	Inhibition	%	3.74
	8105874	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	3.77	CHEMBL2973	Homo sapiens	Inhibition	%	3.77
	8105930	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.44	CHEMBL2973	Homo sapiens	Inhibition	%	0.44
	8106154	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.1	CHEMBL2973	Homo sapiens	Inhibition	%	0.1
	8106319	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.71	CHEMBL2973	Homo sapiens	Inhibition	%	1.71
	8106475	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	13.44	CHEMBL2973	Homo sapiens	Inhibition	%	13.44
	8106699	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	10.55	CHEMBL2973	Homo sapiens	Inhibition	%	10.55
	8106828	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	2.3	CHEMBL2973	Homo sapiens	Inhibition	%	2.3
	8107173	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	15.86	CHEMBL2973	Homo sapiens	Inhibition	%	15.86
	8107345	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.92	CHEMBL2973	Homo sapiens	Inhibition	%	0.92
	8107770	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	2.08	CHEMBL2973	Homo sapiens	Inhibition	%	2.08
	8107905	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	1.52	CHEMBL2973	Homo sapiens	Inhibition	%	1.52
	8108287	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	1.36	CHEMBL2973	Homo sapiens	Inhibition	%	1.36
	8108462	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	5.68	CHEMBL2973	Homo sapiens	Inhibition	%	5.68
	8108833	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	9.54	CHEMBL2973	Homo sapiens	Inhibition	%	9.54
	8108975	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.09	CHEMBL2973	Homo sapiens	Inhibition	%	1.09
	8109313	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	2.54	CHEMBL2973	Homo sapiens	Inhibition	%	2.54
	8109667	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.65	CHEMBL2973	Homo sapiens	Inhibition	%	-0.65
	8109838	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	5.08	CHEMBL2973	Homo sapiens	Inhibition	%	5.08
	8110194	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	-3.98	CHEMBL2973	Homo sapiens	Inhibition	%	-3.98
	8110473	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.31	CHEMBL2973	Homo sapiens	Inhibition	%	1.31
	8110639	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	3.88	CHEMBL2973	Homo sapiens	Inhibition	%	3.88
	8111021	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	53.67	CHEMBL2973	Homo sapiens	Inhibition	%	53.67
	8111144	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	5.32	CHEMBL2973	Homo sapiens	Inhibition	%	5.32
	8111368	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	8.2	CHEMBL2973	Homo sapiens	Inhibition	%	8.2
	8111495	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	-0.51	CHEMBL2973	Homo sapiens	Inhibition	%	-0.51
	8111661	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	1.05	CHEMBL2973	Homo sapiens	Inhibition	%	1.05
	8111885	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.95	CHEMBL2973	Homo sapiens	Inhibition	%	0.95
	8112090	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	3.95	CHEMBL2973	Homo sapiens	Inhibition	%	3.95
	8112227	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.57	CHEMBL2973	Homo sapiens	Inhibition	%	-0.57
	8112451	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-1.33	CHEMBL2973	Homo sapiens	Inhibition	%	-1.33
	8112619	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	2.98	CHEMBL2973	Homo sapiens	Inhibition	%	2.98
	8112791	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-1.1	CHEMBL2973	Homo sapiens	Inhibition	%	-1.1
	8113015	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.07	CHEMBL2973	Homo sapiens	Inhibition	%	0.07
	8113167	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	3.51	CHEMBL2973	Homo sapiens	Inhibition	%	3.51
	8113303	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	6.38	CHEMBL2973	Homo sapiens	Inhibition	%	6.38
	8113527	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	1.28	CHEMBL2973	Homo sapiens	Inhibition	%	1.28
	8113651	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	4.11	CHEMBL2973	Homo sapiens	Inhibition	%	4.11
	8113991	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.5	CHEMBL2973	Homo sapiens	Inhibition	%	-0.5
	8114167	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	2.07	CHEMBL2973	Homo sapiens	Inhibition	%	2.07
	8114523	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	3.35	CHEMBL2973	Homo sapiens	Inhibition	%	3.35
	8114799	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.7	CHEMBL2973	Homo sapiens	Inhibition	%	1.7
	8114965	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	7.01	CHEMBL2973	Homo sapiens	Inhibition	%	7.01
	8115189	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	39.97	CHEMBL2973	Homo sapiens	Inhibition	%	39.97
	8115354	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	3.13	CHEMBL2973	Homo sapiens	Inhibition	%	3.13
	8115698	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	2.45	CHEMBL2973	Homo sapiens	Inhibition	%	2.45
	8115831	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	10.04	CHEMBL2973	Homo sapiens	Inhibition	%	10.04
	8116214	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	10.29	CHEMBL2973	Homo sapiens	Inhibition	%	10.29
	8116417	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	4.86	CHEMBL2973	Homo sapiens	Inhibition	%	4.86
	8116775	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-1.58	CHEMBL2973	Homo sapiens	Inhibition	%	-1.58
	8116947	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	2.92	CHEMBL2973	Homo sapiens	Inhibition	%	2.92
	8117342	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	0.96	CHEMBL2973	Homo sapiens	Inhibition	%	0.96
	8117500	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	5.7	CHEMBL2973	Homo sapiens	Inhibition	%	5.7
	8117854	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	5.61	CHEMBL2973	Homo sapiens	Inhibition	%	5.61
	8117992	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	1.74	CHEMBL2973	Homo sapiens	Inhibition	%	1.74
	8118216	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	5.45	CHEMBL2973	Homo sapiens	Inhibition	%	5.45
	8118332	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	2.99	CHEMBL2973	Homo sapiens	Inhibition	%	2.99
	8118504	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	3.5	CHEMBL2973	Homo sapiens	Inhibition	%	3.5
	8118728	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	4.09	CHEMBL2973	Homo sapiens	Inhibition	%	4.09
	8118864	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	4.12	CHEMBL2973	Homo sapiens	Inhibition	%	4.12
	8119135	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	1.26	CHEMBL2973	Homo sapiens	Inhibition	%	1.26
	8119518	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	1.64	CHEMBL2973	Homo sapiens	Inhibition	%	1.64
	8119685	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	6.65	CHEMBL2973	Homo sapiens	Inhibition	%	6.65
	8120028	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	5.8	CHEMBL2973	Homo sapiens	Inhibition	%	5.8
	8120167	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.44	CHEMBL2973	Homo sapiens	Inhibition	%	0.44
	8120391	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.89	CHEMBL2973	Homo sapiens	Inhibition	%	1.89
	8120551	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-1.02	CHEMBL2973	Homo sapiens	Inhibition	%	-1.02
	8120752	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	22.58	CHEMBL2973	Homo sapiens	Inhibition	%	22.58
	8121104	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.82	CHEMBL2973	Homo sapiens	Inhibition	%	-0.82
	8121276	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.88	CHEMBL2973	Homo sapiens	Inhibition	%	1.88
	8121667	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	1.68	CHEMBL2973	Homo sapiens	Inhibition	%	1.68
	8121830	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	2.13	CHEMBL2973	Homo sapiens	Inhibition	%	2.13
	8122175	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	2.27	CHEMBL2973	Homo sapiens	Inhibition	%	2.27
	8122537	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	12.02	CHEMBL2973	Homo sapiens	Inhibition	%	12.02
	8122657	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	5.06	CHEMBL2973	Homo sapiens	Inhibition	%	5.06
	8123048	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	4.98	CHEMBL2973	Homo sapiens	Inhibition	%	4.98
	8123190	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	3.56	CHEMBL2973	Homo sapiens	Inhibition	%	3.56
	8123414	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	8.03	CHEMBL2973	Homo sapiens	Inhibition	%	8.03
	8123468	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	7.68	CHEMBL2973	Homo sapiens	Inhibition	%	7.68
	8123842	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	8.94	CHEMBL2973	Homo sapiens	Inhibition	%	8.94
	8124009	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	3.27	CHEMBL2973	Homo sapiens	Inhibition	%	3.27
	8124352	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	2.21	CHEMBL2973	Homo sapiens	Inhibition	%	2.21
	8124715	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	1.79	CHEMBL2973	Homo sapiens	Inhibition	%	1.79
	8124880	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-1.36	CHEMBL2973	Homo sapiens	Inhibition	%	-1.36
	8125081	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.09	CHEMBL2973	Homo sapiens	Inhibition	%	2.09
	8125305	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	3.7	CHEMBL2973	Homo sapiens	Inhibition	%	3.7
	8125435	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.06	CHEMBL2973	Homo sapiens	Inhibition	%	0.06
	8125603	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	2.51	CHEMBL2973	Homo sapiens	Inhibition	%	2.51
	8125827	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	1.53	CHEMBL2973	Homo sapiens	Inhibition	%	1.53
	8125991	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	0.68	CHEMBL2973	Homo sapiens	Inhibition	%	0.68
	8126155	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	3.77	CHEMBL2973	Homo sapiens	Inhibition	%	3.77
	8126379	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	2.02	CHEMBL2973	Homo sapiens	Inhibition	%	2.02
	8126494	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	27.82	CHEMBL2973	Homo sapiens	Inhibition	%	27.82
	8126854	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	47.46	CHEMBL2973	Homo sapiens	Inhibition	%	47.46
	8126976	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	2.53	CHEMBL2973	Homo sapiens	Inhibition	%	2.53
	8127200	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	3.69	CHEMBL2973	Homo sapiens	Inhibition	%	3.69
	8127367	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	3.63	CHEMBL2973	Homo sapiens	Inhibition	%	3.63
	8127733	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	11.11	CHEMBL2973	Homo sapiens	Inhibition	%	11.11
	8127797	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	0.99	CHEMBL2973	Homo sapiens	Inhibition	%	0.99
	8128021	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	-0.91	CHEMBL2973	Homo sapiens	Inhibition	%	-0.91
	8128173	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.81	CHEMBL2973	Homo sapiens	Inhibition	%	1.81
	8128340	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	6.91	CHEMBL2973	Homo sapiens	Inhibition	%	6.91
	8128564	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	3.13	CHEMBL2973	Homo sapiens	Inhibition	%	3.13
	8128683	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	15.38	CHEMBL2973	Homo sapiens	Inhibition	%	15.38
	8129044	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	0.12	CHEMBL2973	Homo sapiens	Inhibition	%	0.12
	8129215	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-2.12	CHEMBL2973	Homo sapiens	Inhibition	%	-2.12
	8129628	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	11.29	CHEMBL2973	Homo sapiens	Inhibition	%	11.29
	8129767	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.61	CHEMBL2973	Homo sapiens	Inhibition	%	0.61
	8130152	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.94	CHEMBL2973	Homo sapiens	Inhibition	%	0.94
	8130324	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.77	CHEMBL2973	Homo sapiens	Inhibition	%	-0.77
	8130708	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	13.71	CHEMBL2973	Homo sapiens	Inhibition	%	13.71
	8130824	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	3.03	CHEMBL2973	Homo sapiens	Inhibition	%	3.03
	8131048	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	3.45	CHEMBL2973	Homo sapiens	Inhibition	%	3.45
	8131187	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.92	CHEMBL2973	Homo sapiens	Inhibition	%	3.92
	8131531	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	2.81	CHEMBL2973	Homo sapiens	Inhibition	%	2.81
	8131698	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	3.95	CHEMBL2973	Homo sapiens	Inhibition	%	3.95
	8132063	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	46.85	CHEMBL2973	Homo sapiens	Inhibition	%	46.85
	8132349	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	0.89	CHEMBL2973	Homo sapiens	Inhibition	%	0.89
	8132496	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	3.8	CHEMBL2973	Homo sapiens	Inhibition	%	3.8
	8132888	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	6.36	CHEMBL2973	Homo sapiens	Inhibition	%	6.36
	8133009	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	2.04	CHEMBL2973	Homo sapiens	Inhibition	%	2.04
	8133233	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	2.71	CHEMBL2973	Homo sapiens	Inhibition	%	2.71
	8133371	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	1.58	CHEMBL2973	Homo sapiens	Inhibition	%	1.58
	8133543	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.39	CHEMBL2973	Homo sapiens	Inhibition	%	-0.39
	8133767	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-0.61	CHEMBL2973	Homo sapiens	Inhibition	%	-0.61
	8133947	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	52.0	CHEMBL2973	Homo sapiens	Inhibition	%	52.0
	8134095	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	0.73	CHEMBL2973	Homo sapiens	Inhibition	%	0.73
	8134319	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	1.85	CHEMBL2973	Homo sapiens	Inhibition	%	1.85
	8134479	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.78	CHEMBL2973	Homo sapiens	Inhibition	%	0.78
	8134663	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-0.88	CHEMBL2973	Homo sapiens	Inhibition	%	-0.88
	8134887	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	1.99	CHEMBL2973	Homo sapiens	Inhibition	%	1.99
	8135047	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	1.11	CHEMBL2973	Homo sapiens	Inhibition	%	1.11
	8135386	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	2.7	CHEMBL2973	Homo sapiens	Inhibition	%	2.7
	8135527	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	7.66	CHEMBL2973	Homo sapiens	Inhibition	%	7.66
	8135872	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	2.18	CHEMBL2973	Homo sapiens	Inhibition	%	2.18
	8136040	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	2.65	CHEMBL2973	Homo sapiens	Inhibition	%	2.65
	8136264	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	3.61	CHEMBL2973	Homo sapiens	Inhibition	%	3.61
	8136408	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	4.88	CHEMBL2973	Homo sapiens	Inhibition	%	4.88
	8136698	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-0.53	CHEMBL2973	Homo sapiens	Inhibition	%	-0.53
	8136833	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	71.21	CHEMBL2973	Homo sapiens	Inhibition	%	71.21
	8137057	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	89.92	CHEMBL2973	Homo sapiens	Inhibition	%	89.92
	8137220	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	4.97	CHEMBL2973	Homo sapiens	Inhibition	%	4.97
	8137564	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	1.01	CHEMBL2973	Homo sapiens	Inhibition	%	1.01
	8137712	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.93	CHEMBL2973	Homo sapiens	Inhibition	%	0.93
	8138102	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	0.55	CHEMBL2973	Homo sapiens	Inhibition	%	0.55
	8138281	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.87	CHEMBL2973	Homo sapiens	Inhibition	%	0.87
	8138653	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-1.71	CHEMBL2973	Homo sapiens	Inhibition	%	-1.71
	8138811	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	-1.14	CHEMBL2973	Homo sapiens	Inhibition	%	-1.14
	8139220	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.42	CHEMBL2973	Homo sapiens	Inhibition	%	2.42
	8139379	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	3.33	CHEMBL2973	Homo sapiens	Inhibition	%	3.33
	8139717	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	2.3	CHEMBL2973	Homo sapiens	Inhibition	%	2.3
	8139858	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	2.9	CHEMBL2973	Homo sapiens	Inhibition	%	2.9
	8140082	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	5.33	CHEMBL2973	Homo sapiens	Inhibition	%	5.33
	8140205	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.6	CHEMBL2973	Homo sapiens	Inhibition	%	2.6
	8140588	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.69	CHEMBL2973	Homo sapiens	Inhibition	%	1.69
	8140731	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	8.46	CHEMBL2973	Homo sapiens	Inhibition	%	8.46
	8141033	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.55	CHEMBL2973	Homo sapiens	Inhibition	%	0.55
	8141387	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	1.89	CHEMBL2973	Homo sapiens	Inhibition	%	1.89
	8141547	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	28.15	CHEMBL2973	Homo sapiens	Inhibition	%	28.15
	8141890	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	1.34	CHEMBL2973	Homo sapiens	Inhibition	%	1.34
	8142051	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-0.09	CHEMBL2973	Homo sapiens	Inhibition	%	-0.09
	8142275	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	1.51	CHEMBL2973	Homo sapiens	Inhibition	%	1.51
	8142443	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	1.51	CHEMBL2973	Homo sapiens	Inhibition	%	1.51
	8142619	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	1.92	CHEMBL2973	Homo sapiens	Inhibition	%	1.92
	8142843	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	-0.14	CHEMBL2973	Homo sapiens	Inhibition	%	-0.14
	8142992	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-1.76	CHEMBL2973	Homo sapiens	Inhibition	%	-1.76
	8143147	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.93	CHEMBL2973	Homo sapiens	Inhibition	%	1.93
	8143371	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.92	CHEMBL2973	Homo sapiens	Inhibition	%	1.92
	8143558	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	4.03	CHEMBL2973	Homo sapiens	Inhibition	%	4.03
	8143717	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.31	CHEMBL2973	Homo sapiens	Inhibition	%	3.31
	8143941	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.33	CHEMBL2973	Homo sapiens	Inhibition	%	3.33
	8144055	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	0.72	CHEMBL2973	Homo sapiens	Inhibition	%	0.72
	8144418	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	2.97	CHEMBL2973	Homo sapiens	Inhibition	%	2.97
	8144548	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	3.44	CHEMBL2973	Homo sapiens	Inhibition	%	3.44
	8144772	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	3.87	CHEMBL2973	Homo sapiens	Inhibition	%	3.87
	8144925	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	2.18	CHEMBL2973	Homo sapiens	Inhibition	%	2.18
	8145062	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	3.77	CHEMBL2973	Homo sapiens	Inhibition	%	3.77
	8145286	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	5.56	CHEMBL2973	Homo sapiens	Inhibition	%	5.56
	8145375	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	-1.46	CHEMBL2973	Homo sapiens	Inhibition	%	-1.46
	8145723	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	Inhibition	%	3.0
	8145884	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	3.46	CHEMBL2973	Homo sapiens	Inhibition	%	3.46
	8146108	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	9.15	CHEMBL2973	Homo sapiens	Inhibition	%	9.15
	8146228	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.53	CHEMBL2973	Homo sapiens	Inhibition	%	0.53
	8146612	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	3.13	CHEMBL2973	Homo sapiens	Inhibition	%	3.13
	8146779	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	12.04	CHEMBL2973	Homo sapiens	Inhibition	%	12.04
	8147172	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.92	CHEMBL2973	Homo sapiens	Inhibition	%	0.92
	8147314	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	1.21	CHEMBL2973	Homo sapiens	Inhibition	%	1.21
	8147691	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	2.74	CHEMBL2973	Homo sapiens	Inhibition	%	2.74
	8147878	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	1.52	CHEMBL2973	Homo sapiens	Inhibition	%	1.52
	8148260	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	4.11	CHEMBL2973	Homo sapiens	Inhibition	%	4.11
	8148374	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.26	CHEMBL2973	Homo sapiens	Inhibition	%	1.26
	8148598	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.12	CHEMBL2973	Homo sapiens	Inhibition	%	2.12
	8148737	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	3.48	CHEMBL2973	Homo sapiens	Inhibition	%	3.48
	8149099	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	4.42	CHEMBL2973	Homo sapiens	Inhibition	%	4.42
	8149258	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.1	CHEMBL2973	Homo sapiens	Inhibition	%	0.1
	8149616	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	80.59	CHEMBL2973	Homo sapiens	Inhibition	%	80.59
	8149714	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	1.43	CHEMBL2973	Homo sapiens	Inhibition	%	1.43
	8149938	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	3.24	CHEMBL2973	Homo sapiens	Inhibition	%	3.24
	8150063	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	4.21	CHEMBL2973	Homo sapiens	Inhibition	%	4.21
	8150447	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.98	CHEMBL2973	Homo sapiens	Inhibition	%	0.98
	8150567	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-0.19	CHEMBL2973	Homo sapiens	Inhibition	%	-0.19
	8150791	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.83	CHEMBL2973	Homo sapiens	Inhibition	%	0.83
	8150956	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	23.21	CHEMBL2973	Homo sapiens	Inhibition	%	23.21
	8151119	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	0.52	CHEMBL2973	Homo sapiens	Inhibition	%	0.52
	8151343	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	16.14	CHEMBL2973	Homo sapiens	Inhibition	%	16.14
	8151520	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	1.74	CHEMBL2973	Homo sapiens	Inhibition	%	1.74
	8151658	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	0.98	CHEMBL2973	Homo sapiens	Inhibition	%	0.98
	8151882	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	1.46	CHEMBL2973	Homo sapiens	Inhibition	%	1.46
	8152036	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.41	CHEMBL2973	Homo sapiens	Inhibition	%	1.41
	8152224	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	3.89	CHEMBL2973	Homo sapiens	Inhibition	%	3.89
	8152448	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	0.61	CHEMBL2973	Homo sapiens	Inhibition	%	0.61
	8152606	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	2.92	CHEMBL2973	Homo sapiens	Inhibition	%	2.92
	8152944	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	4.04	CHEMBL2973	Homo sapiens	Inhibition	%	4.04
	8153083	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.84	CHEMBL2973	Homo sapiens	Inhibition	%	1.84
	8153444	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	3.45	CHEMBL2973	Homo sapiens	Inhibition	%	3.45
	8153601	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.19	CHEMBL2973	Homo sapiens	Inhibition	%	0.19
	8153958	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	90.41	CHEMBL2973	Homo sapiens	Inhibition	%	90.41
	8154279	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	9.34	CHEMBL2973	Homo sapiens	Inhibition	%	9.34
	8154405	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	31.34	CHEMBL2973	Homo sapiens	Inhibition	%	31.34
	8154629	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	1.22	CHEMBL2973	Homo sapiens	Inhibition	%	1.22
	8154788	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	4.37	CHEMBL2973	Homo sapiens	Inhibition	%	4.37
	8155132	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-0.02	CHEMBL2973	Homo sapiens	Inhibition	%	-0.02
	8155308	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-1.57	CHEMBL2973	Homo sapiens	Inhibition	%	-1.57
	8155693	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	0.62	CHEMBL2973	Homo sapiens	Inhibition	%	0.62
	8155871	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.93	CHEMBL2973	Homo sapiens	Inhibition	%	2.93
	8156233	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	-0.05	CHEMBL2973	Homo sapiens	Inhibition	%	-0.05
	8156445	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	2.81	CHEMBL2973	Homo sapiens	Inhibition	%	2.81
	8156595	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	6.73	CHEMBL2973	Homo sapiens	Inhibition	%	6.73
	8156819	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	4.87	CHEMBL2973	Homo sapiens	Inhibition	%	4.87
	8156962	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	8.55	CHEMBL2973	Homo sapiens	Inhibition	%	8.55
	8157306	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	83.79	CHEMBL2973	Homo sapiens	Inhibition	%	83.79
	8157447	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	2.6	CHEMBL2973	Homo sapiens	Inhibition	%	2.6
	8157671	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	8.14	CHEMBL2973	Homo sapiens	Inhibition	%	8.14
	8157801	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	3.16	CHEMBL2973	Homo sapiens	Inhibition	%	3.16
	8157962	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-1.22	CHEMBL2973	Homo sapiens	Inhibition	%	-1.22
	8158186	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	0.43	CHEMBL2973	Homo sapiens	Inhibition	%	0.43
	8158436	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	74.94	CHEMBL2973	Homo sapiens	Inhibition	%	74.94
	8158594	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	7.89	CHEMBL2973	Homo sapiens	Inhibition	%	7.89
	8158987	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	2.28	CHEMBL2973	Homo sapiens	Inhibition	%	2.28
	8159122	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	4.15	CHEMBL2973	Homo sapiens	Inhibition	%	4.15
	8159466	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	11.21	CHEMBL2973	Homo sapiens	Inhibition	%	11.21
	8159821	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	27.17	CHEMBL2973	Homo sapiens	Inhibition	%	27.17
	8159962	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	5.37	CHEMBL2973	Homo sapiens	Inhibition	%	5.37
	8160323	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	3.55	CHEMBL2973	Homo sapiens	Inhibition	%	3.55
	8160473	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-1.47	CHEMBL2973	Homo sapiens	Inhibition	%	-1.47
	8160767	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	1.43	CHEMBL2973	Homo sapiens	Inhibition	%	1.43
	8161141	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	18.13	CHEMBL2973	Homo sapiens	Inhibition	%	18.13
	8161284	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	4.95	CHEMBL2973	Homo sapiens	Inhibition	%	4.95
	8161633	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	6.16	CHEMBL2973	Homo sapiens	Inhibition	%	6.16
	8161995	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	3.4	CHEMBL2973	Homo sapiens	Inhibition	%	3.4
	8162125	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	4.34	CHEMBL2973	Homo sapiens	Inhibition	%	4.34
	8162509	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	0.51	CHEMBL2973	Homo sapiens	Inhibition	%	0.51
	8162762	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	83.5	CHEMBL2973	Homo sapiens	Inhibition	%	83.5
	8162910	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	27.36	CHEMBL2973	Homo sapiens	Inhibition	%	27.36
	8163134	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	69.4	CHEMBL2973	Homo sapiens	Inhibition	%	69.4
	8163303	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.81	CHEMBL2973	Homo sapiens	Inhibition	%	1.81
	8163437	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	8.38	CHEMBL2973	Homo sapiens	Inhibition	%	8.38
	8163661	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	5.67	CHEMBL2973	Homo sapiens	Inhibition	%	5.67
	8163784	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	16.13	CHEMBL2973	Homo sapiens	Inhibition	%	16.13
	8164142	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	71.27	CHEMBL2973	Homo sapiens	Inhibition	%	71.27
	8164282	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.54	CHEMBL2973	Homo sapiens	Inhibition	%	1.54
	8164506	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.8	CHEMBL2973	Homo sapiens	Inhibition	%	1.8
	8164661	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	3.28	CHEMBL2973	Homo sapiens	Inhibition	%	3.28
	8164805	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-1.96	CHEMBL2973	Homo sapiens	Inhibition	%	-1.96
	8165029	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	0.25	CHEMBL2973	Homo sapiens	Inhibition	%	0.25
	8165099	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	3.75	CHEMBL2973	Homo sapiens	Inhibition	%	3.75
	8165323	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	8.67	CHEMBL2973	Homo sapiens	Inhibition	%	8.67
	8165464	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	3.01	CHEMBL2973	Homo sapiens	Inhibition	%	3.01
	8165607	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	19.14	CHEMBL2973	Homo sapiens	Inhibition	%	19.14
	8165831	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	20.31	CHEMBL2973	Homo sapiens	Inhibition	%	20.31
	8165957	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	3.66	CHEMBL2973	Homo sapiens	Inhibition	%	3.66
	8166319	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	8.75	CHEMBL2973	Homo sapiens	Inhibition	%	8.75
	8166449	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	3.56	CHEMBL2973	Homo sapiens	Inhibition	%	3.56
	8166673	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	6.34	CHEMBL2973	Homo sapiens	Inhibition	%	6.34
	8166774	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	12.08	CHEMBL2973	Homo sapiens	Inhibition	%	12.08
	8167086	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	89.97	CHEMBL2973	Homo sapiens	Inhibition	%	89.97
	8167451	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	29.24	CHEMBL2973	Homo sapiens	Inhibition	%	29.24
	8167615	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.22	CHEMBL2973	Homo sapiens	Inhibition	%	1.22
	8167972	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	19.0	CHEMBL2973	Homo sapiens	Inhibition	%	19.0
	8168096	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	64.1	CHEMBL2973	Homo sapiens	Inhibition	%	64.1
	8168320	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	74.54	CHEMBL2973	Homo sapiens	Inhibition	%	74.54
	8168461	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	3.55	CHEMBL2973	Homo sapiens	Inhibition	%	3.55
	8168821	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	0.53	CHEMBL2973	Homo sapiens	Inhibition	%	0.53
	8168985	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	12.38	CHEMBL2973	Homo sapiens	Inhibition	%	12.38
	8169351	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	-0.32	CHEMBL2973	Homo sapiens	Inhibition	%	-0.32
	8169655	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	Inhibition	%	3.0
	8169789	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	7.02	CHEMBL2973	Homo sapiens	Inhibition	%	7.02
	8170158	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	71.59	CHEMBL2973	Homo sapiens	Inhibition	%	71.59
	8170283	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	3.93	CHEMBL2973	Homo sapiens	Inhibition	%	3.93
	8170507	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.59	CHEMBL2973	Homo sapiens	Inhibition	%	1.59
	8170647	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	6.21	CHEMBL2973	Homo sapiens	Inhibition	%	6.21
	8171006	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	5.29	CHEMBL2973	Homo sapiens	Inhibition	%	5.29
	8171203	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	1.83	CHEMBL2973	Homo sapiens	Inhibition	%	1.83
	8171420	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	90.45	CHEMBL2973	Homo sapiens	Inhibition	%	90.45
	8171785	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	72.08	CHEMBL2973	Homo sapiens	Inhibition	%	72.08
	8171938	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	1.84	CHEMBL2973	Homo sapiens	Inhibition	%	1.84
	8172294	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	3.76	CHEMBL2973	Homo sapiens	Inhibition	%	3.76
	8172646	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	5.64	CHEMBL2973	Homo sapiens	Inhibition	%	5.64
	8172788	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	5.31	CHEMBL2973	Homo sapiens	Inhibition	%	5.31
	8173148	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	2.48	CHEMBL2973	Homo sapiens	Inhibition	%	2.48
	8173313	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	4.97	CHEMBL2973	Homo sapiens	Inhibition	%	4.97
	8173678	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	2.87	CHEMBL2973	Homo sapiens	Inhibition	%	2.87
	8173989	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	12.45	CHEMBL2973	Homo sapiens	Inhibition	%	12.45
	8174121	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	3.8	CHEMBL2973	Homo sapiens	Inhibition	%	3.8
	8174345	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	5.21	CHEMBL2973	Homo sapiens	Inhibition	%	5.21
	8174493	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	2.43	CHEMBL2973	Homo sapiens	Inhibition	%	2.43
	8174839	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	2.86	CHEMBL2973	Homo sapiens	Inhibition	%	2.86
	8174982	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	27.49	CHEMBL2973	Homo sapiens	Inhibition	%	27.49
	8175342	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	24.67	CHEMBL2973	Homo sapiens	Inhibition	%	24.67
	8175598	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	7.17	CHEMBL2973	Homo sapiens	Inhibition	%	7.17
	8175761	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.09	CHEMBL2973	Homo sapiens	Inhibition	%	2.09
	8175985	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	3.32	CHEMBL2973	Homo sapiens	Inhibition	%	3.32
	8176138	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	82.94	CHEMBL2973	Homo sapiens	Inhibition	%	82.94
	8176287	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	2.56	CHEMBL2973	Homo sapiens	Inhibition	%	2.56
	8176511	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	5.46	CHEMBL2973	Homo sapiens	Inhibition	%	5.46
	8176643	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	13.73	CHEMBL2973	Homo sapiens	Inhibition	%	13.73
	8176997	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	7.73	CHEMBL2973	Homo sapiens	Inhibition	%	7.73
	8177139	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	2.66	CHEMBL2973	Homo sapiens	Inhibition	%	2.66
	8177363	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	2.33	CHEMBL2973	Homo sapiens	Inhibition	%	2.33
	8177501	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	6.62	CHEMBL2973	Homo sapiens	Inhibition	%	6.62
	8177665	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	19.39	CHEMBL2973	Homo sapiens	Inhibition	%	19.39
	8177889	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	4.08	CHEMBL2973	Homo sapiens	Inhibition	%	4.08
	8178029	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	7.43	CHEMBL2973	Homo sapiens	Inhibition	%	7.43
	8178341	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	2.11	CHEMBL2973	Homo sapiens	Inhibition	%	2.11
	8178692	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	4.65	CHEMBL2973	Homo sapiens	Inhibition	%	4.65
	8178841	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.11	CHEMBL2973	Homo sapiens	Inhibition	%	1.11
	8179188	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.32	CHEMBL2973	Homo sapiens	Inhibition	%	0.32
	8179332	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	4.18	CHEMBL2973	Homo sapiens	Inhibition	%	4.18
	8179556	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	15.09	CHEMBL2973	Homo sapiens	Inhibition	%	15.09
	8179693	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	1.92	CHEMBL2973	Homo sapiens	Inhibition	%	1.92
	8179950	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	3.27	CHEMBL2973	Homo sapiens	Inhibition	%	3.27
	8180328	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	1.64	CHEMBL2973	Homo sapiens	Inhibition	%	1.64
	8180484	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	92.92	CHEMBL2973	Homo sapiens	Inhibition	%	92.92
	8180856	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	13.31	CHEMBL2973	Homo sapiens	Inhibition	%	13.31
	8180989	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	4.28	CHEMBL2973	Homo sapiens	Inhibition	%	4.28
	8181213	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	5.46	CHEMBL2973	Homo sapiens	Inhibition	%	5.46
	8181344	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	2.95	CHEMBL2973	Homo sapiens	Inhibition	%	2.95
	8181708	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	2.59	CHEMBL2973	Homo sapiens	Inhibition	%	2.59
	8181847	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	16.56	CHEMBL2973	Homo sapiens	Inhibition	%	16.56
	8182234	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	5.66	CHEMBL2973	Homo sapiens	Inhibition	%	5.66
	8182374	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.24	CHEMBL2973	Homo sapiens	Inhibition	%	1.24
	8182598	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	2.36	CHEMBL2973	Homo sapiens	Inhibition	%	2.36
	8182690	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	2.54	CHEMBL2973	Homo sapiens	Inhibition	%	2.54
	8183036	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	6.14	CHEMBL2973	Homo sapiens	Inhibition	%	6.14
	8183185	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.89	CHEMBL2973	Homo sapiens	Inhibition	%	0.89
	8183409	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	1.18	CHEMBL2973	Homo sapiens	Inhibition	%	1.18
	8183538	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	4.66	CHEMBL2973	Homo sapiens	Inhibition	%	4.66
	8183904	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	3.76	CHEMBL2973	Homo sapiens	Inhibition	%	3.76
	8184040	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	2.01	CHEMBL2973	Homo sapiens	Inhibition	%	2.01
	8184306	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	7.43	CHEMBL2973	Homo sapiens	Inhibition	%	7.43
	8184530	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.91	CHEMBL2973	Homo sapiens	Inhibition	%	3.91
	8184677	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	2.17	CHEMBL2973	Homo sapiens	Inhibition	%	2.17
	8184834	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	1.49	CHEMBL2973	Homo sapiens	Inhibition	%	1.49
	8185058	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	2.36	CHEMBL2973	Homo sapiens	Inhibition	%	2.36
	8185207	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	3.83	CHEMBL2973	Homo sapiens	Inhibition	%	3.83
	8185562	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	3.83	CHEMBL2973	Homo sapiens	Inhibition	%	3.83
	8185693	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	9.54	CHEMBL2973	Homo sapiens	Inhibition	%	9.54
	8186056	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	0.78	CHEMBL2973	Homo sapiens	Inhibition	%	0.78
	8186197	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	3.85	CHEMBL2973	Homo sapiens	Inhibition	%	3.85
	8186421	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	6.06	CHEMBL2973	Homo sapiens	Inhibition	%	6.06
	8186585	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	2.97	CHEMBL2973	Homo sapiens	Inhibition	%	2.97
	8186948	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	5.05	CHEMBL2973	Homo sapiens	Inhibition	%	5.05
	8187046	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	3.18	CHEMBL2973	Homo sapiens	Inhibition	%	3.18
	8187270	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	2.02	CHEMBL2973	Homo sapiens	Inhibition	%	2.02
	8187394	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	3.74	CHEMBL2973	Homo sapiens	Inhibition	%	3.74
	8187766	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.66	CHEMBL2973	Homo sapiens	Inhibition	%	1.66
	8187895	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	8.18	CHEMBL2973	Homo sapiens	Inhibition	%	8.18
	8188119	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	4.11	CHEMBL2973	Homo sapiens	Inhibition	%	4.11
	8188262	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	10.61	CHEMBL2973	Homo sapiens	Inhibition	%	10.61
	8188397	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	1.71	CHEMBL2973	Homo sapiens	Inhibition	%	1.71
	8188621	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	1.85	CHEMBL2973	Homo sapiens	Inhibition	%	1.85
	8188895	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	8.24	CHEMBL2973	Homo sapiens	Inhibition	%	8.24
	8189043	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	0.86	CHEMBL2973	Homo sapiens	Inhibition	%	0.86
	8189423	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	2.91	CHEMBL2973	Homo sapiens	Inhibition	%	2.91
	8189572	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	3.71	CHEMBL2973	Homo sapiens	Inhibition	%	3.71
	8189928	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	6.92	CHEMBL2973	Homo sapiens	Inhibition	%	6.92
	8190060	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	1.89	CHEMBL2973	Homo sapiens	Inhibition	%	1.89
	8190284	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	2.15	CHEMBL2973	Homo sapiens	Inhibition	%	2.15
	8190424	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	3.44	CHEMBL2973	Homo sapiens	Inhibition	%	3.44
	8190785	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	3.23	CHEMBL2973	Homo sapiens	Inhibition	%	3.23
	8190949	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	3.17	CHEMBL2973	Homo sapiens	Inhibition	%	3.17
	8191311	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	24.04	CHEMBL2973	Homo sapiens	Inhibition	%	24.04
	8191631	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	35.73	CHEMBL2973	Homo sapiens	Inhibition	%	35.73
	8191753	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	8.15	CHEMBL2973	Homo sapiens	Inhibition	%	8.15
	8191977	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	2.34	CHEMBL2973	Homo sapiens	Inhibition	%	2.34
	8192126	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	-0.13	CHEMBL2973	Homo sapiens	Inhibition	%	-0.13
	8192479	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	9.48	CHEMBL2973	Homo sapiens	Inhibition	%	9.48
	8192623	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	4.29	CHEMBL2973	Homo sapiens	Inhibition	%	4.29
	8192983	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	0.14	CHEMBL2973	Homo sapiens	Inhibition	%	0.14
	8193255	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.33	CHEMBL2973	Homo sapiens	Inhibition	%	2.33
	8193400	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	2.83	CHEMBL2973	Homo sapiens	Inhibition	%	2.83
	8193624	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	-0.16	CHEMBL2973	Homo sapiens	Inhibition	%	-0.16
	8193781	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	5.46	CHEMBL2973	Homo sapiens	Inhibition	%	5.46
	8193930	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	3.86	CHEMBL2973	Homo sapiens	Inhibition	%	3.86
	8194154	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	30.65	CHEMBL2973	Homo sapiens	Inhibition	%	30.65
	8194285	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	3.05	CHEMBL2973	Homo sapiens	Inhibition	%	3.05
	8194640	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	2.69	CHEMBL2973	Homo sapiens	Inhibition	%	2.69
	8194783	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	9.1	CHEMBL2973	Homo sapiens	Inhibition	%	9.1
	8195007	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	3.17	CHEMBL2973	Homo sapiens	Inhibition	%	3.17
	8195140	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	8.52	CHEMBL2973	Homo sapiens	Inhibition	%	8.52
	8195304	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	2.19	CHEMBL2973	Homo sapiens	Inhibition	%	2.19
	8195528	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	12.07	CHEMBL2973	Homo sapiens	Inhibition	%	12.07
	8195667	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	3.74	CHEMBL2973	Homo sapiens	Inhibition	%	3.74
	8195989	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	75.01	CHEMBL2973	Homo sapiens	Inhibition	%	75.01
	8196330	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	4.82	CHEMBL2973	Homo sapiens	Inhibition	%	4.82
	8196480	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	2.77	CHEMBL2973	Homo sapiens	Inhibition	%	2.77
	8196832	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	3.91	CHEMBL2973	Homo sapiens	Inhibition	%	3.91
	8196973	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	8.78	CHEMBL2973	Homo sapiens	Inhibition	%	8.78
	8197197	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	2.48	CHEMBL2973	Homo sapiens	Inhibition	%	2.48
	8197334	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	-0.36	CHEMBL2973	Homo sapiens	Inhibition	%	-0.36
	8197609	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	6.23	CHEMBL2973	Homo sapiens	Inhibition	%	6.23
	8197973	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	2.11	CHEMBL2973	Homo sapiens	Inhibition	%	2.11
	8198130	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	2.98	CHEMBL2973	Homo sapiens	Inhibition	%	2.98
	8198492	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	2.91	CHEMBL2973	Homo sapiens	Inhibition	%	2.91
	8198622	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	3.9	CHEMBL2973	Homo sapiens	Inhibition	%	3.9
	8198846	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	3.61	CHEMBL2973	Homo sapiens	Inhibition	%	3.61
	8198977	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.72	CHEMBL2973	Homo sapiens	Inhibition	%	1.72
	8199349	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	5.65	CHEMBL2973	Homo sapiens	Inhibition	%	5.65
	8199483	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	3.76	CHEMBL2973	Homo sapiens	Inhibition	%	3.76
	8199870	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	4.67	CHEMBL2973	Homo sapiens	Inhibition	%	4.67
	8200008	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	1.44	CHEMBL2973	Homo sapiens	Inhibition	%	1.44
	8200336	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	2.19	CHEMBL2973	Homo sapiens	Inhibition	%	2.19
	8200675	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	4.64	CHEMBL2973	Homo sapiens	Inhibition	%	4.64
	8200825	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	2.45	CHEMBL2973	Homo sapiens	Inhibition	%	2.45
	8201049	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	2.62	CHEMBL2973	Homo sapiens	Inhibition	%	2.62
	8201179	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	11.3	CHEMBL2973	Homo sapiens	Inhibition	%	11.3
	8201538	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	6.37	CHEMBL2973	Homo sapiens	Inhibition	%	6.37
	8201671	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.57	CHEMBL2973	Homo sapiens	Inhibition	%	-0.57
	8201950	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	3.57	CHEMBL2973	Homo sapiens	Inhibition	%	3.57
	8202314	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.52	CHEMBL2973	Homo sapiens	Inhibition	%	-0.52
	8202481	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	5.06	CHEMBL2973	Homo sapiens	Inhibition	%	5.06
	8202830	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	7.8	CHEMBL2973	Homo sapiens	Inhibition	%	7.8
	8203184	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	4.65	CHEMBL2973	Homo sapiens	Inhibition	%	4.65
	8203315	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	2.24	CHEMBL2973	Homo sapiens	Inhibition	%	2.24
	8203685	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	4.49	CHEMBL2973	Homo sapiens	Inhibition	%	4.49
	8203819	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	7.12	CHEMBL2973	Homo sapiens	Inhibition	%	7.12
	8204043	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	4.88	CHEMBL2973	Homo sapiens	Inhibition	%	4.88
	8204209	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	3.55	CHEMBL2973	Homo sapiens	Inhibition	%	3.55
	8204346	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.07	CHEMBL2973	Homo sapiens	Inhibition	%	2.07
	8204570	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	0.33	CHEMBL2973	Homo sapiens	Inhibition	%	0.33
	8204675	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	3.84	CHEMBL2973	Homo sapiens	Inhibition	%	3.84
	8205014	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	13.93	CHEMBL2973	Homo sapiens	Inhibition	%	13.93
	8205387	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	10.66	CHEMBL2973	Homo sapiens	Inhibition	%	10.66
	8205523	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	4.9	CHEMBL2973	Homo sapiens	Inhibition	%	4.9
	8205886	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	3.27	CHEMBL2973	Homo sapiens	Inhibition	%	3.27
	8206018	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.64	CHEMBL2973	Homo sapiens	Inhibition	%	-0.64
	8206242	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-0.91	CHEMBL2973	Homo sapiens	Inhibition	%	-0.91
	8206294	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	4.82	CHEMBL2973	Homo sapiens	Inhibition	%	4.82
	8206518	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	3.86	CHEMBL2973	Homo sapiens	Inhibition	%	3.86
	8206661	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	2.2	CHEMBL2973	Homo sapiens	Inhibition	%	2.2
	8206841	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	11.61	CHEMBL2973	Homo sapiens	Inhibition	%	11.61
	8207065	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	45.27	CHEMBL2973	Homo sapiens	Inhibition	%	45.27
	8207191	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	4.39	CHEMBL2973	Homo sapiens	Inhibition	%	4.39
	8207545	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	4.18	CHEMBL2973	Homo sapiens	Inhibition	%	4.18
	8207677	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	2.37	CHEMBL2973	Homo sapiens	Inhibition	%	2.37
	8207901	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.25	CHEMBL2973	Homo sapiens	Inhibition	%	2.25
	8208046	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	4.16	CHEMBL2973	Homo sapiens	Inhibition	%	4.16
	8208402	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	7.92	CHEMBL2973	Homo sapiens	Inhibition	%	7.92
	8208568	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	77.03	CHEMBL2973	Homo sapiens	Inhibition	%	77.03
	8208925	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	56.38	CHEMBL2973	Homo sapiens	Inhibition	%	56.38
	8209030	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.1	CHEMBL2973	Homo sapiens	Inhibition	%	1.1
	8209254	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	Inhibition	%	1.0
	8209370	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	2.83	CHEMBL2973	Homo sapiens	Inhibition	%	2.83
	8209744	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.8	CHEMBL2973	Homo sapiens	Inhibition	%	0.8
	8209880	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	23.12	CHEMBL2973	Homo sapiens	Inhibition	%	23.12
	8210104	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	4.45	CHEMBL2973	Homo sapiens	Inhibition	%	4.45
	8210245	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	5.25	CHEMBL2973	Homo sapiens	Inhibition	%	5.25
	8210605	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.3	CHEMBL2973	Homo sapiens	Inhibition	%	0.3
	8210864	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	5.72	CHEMBL2973	Homo sapiens	Inhibition	%	5.72
	8211008	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	1.69	CHEMBL2973	Homo sapiens	Inhibition	%	1.69
	8211402	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	2.86	CHEMBL2973	Homo sapiens	Inhibition	%	2.86
	8211525	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	7.84	CHEMBL2973	Homo sapiens	Inhibition	%	7.84
	8211749	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	4.24	CHEMBL2973	Homo sapiens	Inhibition	%	4.24
	8211878	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	6.43	CHEMBL2973	Homo sapiens	Inhibition	%	6.43
	8212234	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.26	CHEMBL2973	Homo sapiens	Inhibition	%	2.26
	8212375	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	7.81	CHEMBL2973	Homo sapiens	Inhibition	%	7.81
	8212732	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	3.74	CHEMBL2973	Homo sapiens	Inhibition	%	3.74
	8212902	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	84.2	CHEMBL2973	Homo sapiens	Inhibition	%	84.2
	8213126	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	4.32	CHEMBL2973	Homo sapiens	Inhibition	%	4.32
	8213255	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	80.97	CHEMBL2973	Homo sapiens	Inhibition	%	80.97
	8213583	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-1.68	CHEMBL2973	Homo sapiens	Inhibition	%	-1.68
	8213696	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	6.38	CHEMBL2973	Homo sapiens	Inhibition	%	6.38
	8213920	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	3.19	CHEMBL2973	Homo sapiens	Inhibition	%	3.19
	8214067	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.01	CHEMBL2973	Homo sapiens	Inhibition	%	1.01
	8214428	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	13.56	CHEMBL2973	Homo sapiens	Inhibition	%	13.56
	8214562	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	4.11	CHEMBL2973	Homo sapiens	Inhibition	%	4.11
	8214938	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-0.2	CHEMBL2973	Homo sapiens	Inhibition	%	-0.2
	8215189	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	4.99	CHEMBL2973	Homo sapiens	Inhibition	%	4.99
	8215342	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	1.32	CHEMBL2973	Homo sapiens	Inhibition	%	1.32
	8215566	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	3.52	CHEMBL2973	Homo sapiens	Inhibition	%	3.52
	8215730	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	5.23	CHEMBL2973	Homo sapiens	Inhibition	%	5.23
	8216073	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	8.05	CHEMBL2973	Homo sapiens	Inhibition	%	8.05
	8216192	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	2.8	CHEMBL2973	Homo sapiens	Inhibition	%	2.8
	8216552	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	2.95	CHEMBL2973	Homo sapiens	Inhibition	%	2.95
	8216690	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	9.75	CHEMBL2973	Homo sapiens	Inhibition	%	9.75
	8216914	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	54.32	CHEMBL2973	Homo sapiens	Inhibition	%	54.32
	8217048	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	6.19	CHEMBL2973	Homo sapiens	Inhibition	%	6.19
	8217446	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	4.11	CHEMBL2973	Homo sapiens	Inhibition	%	4.11
	8217577	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	5.73	CHEMBL2973	Homo sapiens	Inhibition	%	5.73
	8217902	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-2.33	CHEMBL2973	Homo sapiens	Inhibition	%	-2.33
	8218241	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	4.22	CHEMBL2973	Homo sapiens	Inhibition	%	4.22
	8218368	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	5.29	CHEMBL2973	Homo sapiens	Inhibition	%	5.29
	8218735	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	6.51	CHEMBL2973	Homo sapiens	Inhibition	%	6.51
	8218866	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	13.62	CHEMBL2973	Homo sapiens	Inhibition	%	13.62
	8219090	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.35	CHEMBL2973	Homo sapiens	Inhibition	%	3.35
	8219250	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-1.4	CHEMBL2973	Homo sapiens	Inhibition	%	-1.4
	8219500	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	5.24	CHEMBL2973	Homo sapiens	Inhibition	%	5.24
	8219885	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	1.94	CHEMBL2973	Homo sapiens	Inhibition	%	1.94
	8220054	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.8	CHEMBL2973	Homo sapiens	Inhibition	%	2.8
	8220407	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	3.95	CHEMBL2973	Homo sapiens	Inhibition	%	3.95
	8220521	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	4.98	CHEMBL2973	Homo sapiens	Inhibition	%	4.98
	8220745	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	72.35	CHEMBL2973	Homo sapiens	Inhibition	%	72.35
	8220883	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	3.95	CHEMBL2973	Homo sapiens	Inhibition	%	3.95
	8221243	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	77.87	CHEMBL2973	Homo sapiens	Inhibition	%	77.87
	8221376	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	2.05	CHEMBL2973	Homo sapiens	Inhibition	%	2.05
	8221600	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	5.77	CHEMBL2973	Homo sapiens	Inhibition	%	5.77
	8221765	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.51	CHEMBL2973	Homo sapiens	Inhibition	%	1.51
	8221896	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	6.61	CHEMBL2973	Homo sapiens	Inhibition	%	6.61
	8222120	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.53	CHEMBL2973	Homo sapiens	Inhibition	%	2.53
	8222218	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	1.98	CHEMBL2973	Homo sapiens	Inhibition	%	1.98
	8222576	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	4.4	CHEMBL2973	Homo sapiens	Inhibition	%	4.4
	8222694	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	9.45	CHEMBL2973	Homo sapiens	Inhibition	%	9.45
	8222918	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	70.33	CHEMBL2973	Homo sapiens	Inhibition	%	70.33
	8223062	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	41.83	CHEMBL2973	Homo sapiens	Inhibition	%	41.83
	8223415	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	8.83	CHEMBL2973	Homo sapiens	Inhibition	%	8.83
	8223576	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	1.54	CHEMBL2973	Homo sapiens	Inhibition	%	1.54
	8223826	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	10.51	CHEMBL2973	Homo sapiens	Inhibition	%	10.51
	8224050	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	12.3	CHEMBL2973	Homo sapiens	Inhibition	%	12.3
	8224212	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	5.19	CHEMBL2973	Homo sapiens	Inhibition	%	5.19
	8224382	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	5.16	CHEMBL2973	Homo sapiens	Inhibition	%	5.16
	8224606	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	1.39	CHEMBL2973	Homo sapiens	Inhibition	%	1.39
	8224741	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	5.99	CHEMBL2973	Homo sapiens	Inhibition	%	5.99
	8225079	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	85.84	CHEMBL2973	Homo sapiens	Inhibition	%	85.84
	8225213	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	3.43	CHEMBL2973	Homo sapiens	Inhibition	%	3.43
	8225437	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	4.85	CHEMBL2973	Homo sapiens	Inhibition	%	4.85
	8225575	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	5.54	CHEMBL2973	Homo sapiens	Inhibition	%	5.54
	8225934	CHEMBL1961926	GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	5.37	CHEMBL2973	Homo sapiens	Inhibition	%	5.37
	8226092	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.52	CHEMBL2973	Homo sapiens	Inhibition	%	1.52
	8226441	CHEMBL1961927	GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	4.22	CHEMBL2973	Homo sapiens	Inhibition	%	4.22
inactive	9574367	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574368	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
inactive	9574369	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	<	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9574370	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574371	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
inactive	9574372	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574373	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1		CHEMBL1999718	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574374	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccc(Cl)cc1		CHEMBL1987073	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9574375	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
inactive	9574376	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)CC(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1995712	<	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9574377	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574378	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2003657	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574379	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
inactive	9574380	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9574381	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1ccc(Nc2ncnc3[nH]cc(-c4ccccc4)c23)cc1		CHEMBL1975440	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
active	9574382	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCCNc1cc2cc(-c3ccncc3)ccc2cn1		CHEMBL1998435	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
active	9574383	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9574384	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)N(C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)C(C)C		CHEMBL2006156	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574385	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9574386	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
inactive	9574387	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	<	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
active	9574388	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	=	Ki	nM	12.59	CHEMBL2973	Homo sapiens	pKi		7.9
active	9574389	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
inactive	9574390	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	FC(F)(F)Oc1ccc(-c2ccc3[nH]cc(C4=CCNCC4)c3c2)cc1		CHEMBL1987982	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574391	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574392	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		CHEMBL1969102	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
active	9574393	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1682346	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
inactive	9574394	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574395	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)N1CCN(CCCOc2ccc3c(c2)-c2[nH]nc(-c4ccc(C#N)nc4)c2C3)CC1		CHEMBL2001998	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574396	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O		CHEMBL1994241	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574397	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574398	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574399	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9574400	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
active	9574401	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1		CHEMBL1981725	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
active	9574402	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
active	9574403	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]ncc34)cc2)c1		CHEMBL375284	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
active	9574404	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
active	9574405	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1980562	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
active	9574406	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
inactive	9574407	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574408	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1cc(-c2cccc(F)c2)[nH]c2c(-c3ccc(F)cc3)cnn12		CHEMBL2004156	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574409	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574410	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(CSc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL1968926	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9574411	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCNC(=O)c1n[nH]c(-c2cc(Cl)c(O)cc2O)c1-c1ccc(OC)cc1		CHEMBL365617	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
inactive	9574412	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(C(=O)NCc2ccncc2)cc(N)c1C#N		CHEMBL1984206	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574413	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL462120	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9574414	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C1CCCCC1		CHEMBL1991577	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
inactive	9574415	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccccc1Nc1ncnc(Nc2cccc(F)c2)n1		CHEMBL1979933	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9574416	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
inactive	9574417	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574418	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OC1CCCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1976936	<	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
inactive	9574419	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574420	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(O)CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2005387	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
active	9574421	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	=	Ki	nM	7.943	CHEMBL2973	Homo sapiens	pKi		8.1
inactive	9574422	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574423	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL1972362	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9574424	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(Cn2cc(-c3ccc4[nH]nc(-c5ccccc5)c4c3)nn2)cc1		CHEMBL1982400	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
inactive	9574425	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
inactive	9574426	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1cc(-c2c[nH]c3ncccc23)ncn1		CHEMBL1972988	<	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
inactive	9574427	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2007372	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574428	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(OC)c(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1982167	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574429	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1971017	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574430	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1)c1c(F)cccc1F		CHEMBL2006715	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574431	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12		CHEMBL1986597	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
active	9574432	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
inactive	9574433	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574434	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL2000104	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
active	9574435	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1987448	=	Ki	nM	7.943	CHEMBL2973	Homo sapiens	pKi		8.1
active	9574436	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
inactive	9574437	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574438	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9574439	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1=NN(c2ccc(Cl)c(Cl)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1997349	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574440	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9574441	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
active	9574442	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
active	9574443	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
inactive	9574444	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574445	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9574446	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1976732	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574447	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1ccc(-c2ccncc2)cc1NCc1cccc(F)c1		CHEMBL1982982	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9574448	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2005216	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
active	9574449	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
active	9574450	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
inactive	9574451	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574452	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9574453	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(-c2nn(C3CCC(N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1970879	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574454	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1c(C=O)c(O)n2c(nc3ccccc32)c1C#N		CHEMBL1989856	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574455	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
active	9574456	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
inactive	9574457	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574458	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cncc(C=Cc2ccncc2)c1		CHEMBL1972568	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
active	9574459	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCC1COc1cncc(CCc2ccncc2)c1		CHEMBL1996155	=	Ki	nM	1258.93	CHEMBL2973	Homo sapiens	pKi		5.9
active	9574460	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Nc2ccccc2Nc2cc(-c3ccncc3Cl)ccc21		CHEMBL1987745	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
inactive	9574461	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574462	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1682359	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
active	9574463	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL1970903	=	Ki	nM	7.943	CHEMBL2973	Homo sapiens	pKi		8.1
active	9574464	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1ccccc1		CHEMBL1991846	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
active	9574465	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	1.995	CHEMBL2973	Homo sapiens	pKi		8.7
active	9574466	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
inactive	9574467	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1988995	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574468	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(C=O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL207995	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574469	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9574470	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574471	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1		CHEMBL526133	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9574472	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574473	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9574474	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9574475	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1OCC(O)CO		CHEMBL1981045	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574476	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574477	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(Cn2nnc(-c3ccc4[nH]ncc4c3)c2C2CC2)cc1		CHEMBL1975418	=	Ki	nM	2.512	CHEMBL2973	Homo sapiens	pKi		8.6
active	9574478	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1C1=NNC(c2ccccc2)C1		CHEMBL1992796	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9574479	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
inactive	9574480	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9574481	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCC(O)CO)c(Cl)cc1NC(=O)N2		CHEMBL223257	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574482	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	=	Ki	nM	6.31	CHEMBL2973	Homo sapiens	pKi		8.2
inactive	9574483	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574484	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
active	9574485	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
active	9574486	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2ccc(-c3cc(Cc4ccccc4)no3)cc12		CHEMBL1682358	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
active	9574487	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
active	9574488	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL2001751	=	Ki	nM	12.59	CHEMBL2973	Homo sapiens	pKi		7.9
inactive	9574489	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1		CHEMBL2003420	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574490	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
inactive	9574491	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1c(Cl)c(N2CCC(CN)C2)nc2[nH]cc(C(=O)O)c(=O)c12		CHEMBL1999774	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574492	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574493	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1		CHEMBL1973395	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
active	9574494	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
inactive	9574495	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Nc2ccccc2Nc2nnccc21		CHEMBL1971801	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574496	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Nc2ccccc2Nc2nnc(Cl)cc21		CHEMBL1968850	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574497	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574498	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	1.995	CHEMBL2973	Homo sapiens	pKi		8.7
active	9574499	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
active	9574500	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9574501	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574502	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9574503	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574504	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574505	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	=	Ki	nM	10.0	CHEMBL2973	Homo sapiens	pKi		8.0
inactive	9574506	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574507	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
active	9574508	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1992073	=	Ki	nM	12.59	CHEMBL2973	Homo sapiens	pKi		7.9
inactive	9574509	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)cc1Cl		CHEMBL1990212	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574510	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574511	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	3.162	CHEMBL2973	Homo sapiens	pKi		8.5
active	9574512	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
active	9574513	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682341	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
active	9574514	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9574515	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
inactive	9574516	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574517	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	C#Cc1cc2c(cc1OC)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL1972250	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574518	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9574519	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL2004072	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574520	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1ccc(-c2ccncc2)cc1NCc1ccccc1		CHEMBL2001477	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9574521	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(=O)n2[nH]cc(C(=O)NCc3ccccc3)c2n1		CHEMBL1986166	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
active	9574522	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
active	9574523	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9574524	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
inactive	9574525	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCNNc1cc(C)c(C#N)c2nc3ccccc3n12		CHEMBL2000433	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574526	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL1974157	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574527	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574528	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
inactive	9574529	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574530	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9574531	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574532	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574533	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)c1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1		CHEMBL1992363	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
active	9574534	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL260092	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
inactive	9574535	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9574536	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	=	Ki	nM	1258.93	CHEMBL2973	Homo sapiens	pKi		5.9
active	9574537	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2ncc(C#N)c(-c3ccccc3)c12		CHEMBL1965495	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9574538	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574539	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL2000481	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
inactive	9574540	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574541	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1		CHEMBL1173055	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574542	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
inactive	9574543	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574544	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)CC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1982271	=	Ki	nM	7.943	CHEMBL2973	Homo sapiens	pKi		8.1
active	9574545	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9574546	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574547	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
inactive	9574548	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574549	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1		CHEMBL1986530	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574550	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9574551	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O		CHEMBL1999321	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574552	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574553	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(Nc2ncnc3ccc(-c4ccc(CN5CC6C(CO)C6C5)cc4)cc23)ccc1Oc1ccccc1		CHEMBL1999749	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574554	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574555	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9574556	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(C(=O)O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1983006	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574557	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCCC1COc1cncc(CCc2ccccc2)c1		CHEMBL1972183	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574558	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9574559	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1985580	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
active	9574560	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
active	9574561	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1sc2[nH]c(=O)n3nc(-c4ccncc4)nc3c2c1C		CHEMBL1980592	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9574562	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574563	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574564	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
inactive	9574565	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574566	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1		CHEMBL1998193	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574567	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	<	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9574568	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574569	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574570	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=[N+]([O-])c1cccc(-c2nnc3ccc(N4CCCCC4)nn23)c1		CHEMBL2003637	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574571	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccccc1Nc1ncnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL1986666	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9574572	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
inactive	9574573	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
inactive	9574574	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1999556	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574575	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9574576	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
active	9574577	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COc1cc(C=Cc2ccncc2)cnc1Cl)Cc1c[nH]c2ccccc12		CHEMBL1968245	=	Ki	nM	10.0	CHEMBL2973	Homo sapiens	pKi		8.0
active	9574578	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
active	9574579	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	=	Ki	nM	3.981	CHEMBL2973	Homo sapiens	pKi		8.4
inactive	9574580	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574581	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574582	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O		CHEMBL379835	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574583	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9574584	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ncc2nc1OCC(O)C(O)COc1ccc(Cl)cc1NC(=O)N2		CHEMBL1980802	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574585	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1989006	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
active	9574586	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
active	9574587	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1c(NCc2ccc(Cl)cc2Cl)c(Nc2ccc3[nH]ncc3c2)c1=O		CHEMBL1979554	=	Ki	nM	3.162	CHEMBL2973	Homo sapiens	pKi		8.5
active	9574588	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2ccncc2)c1-c1ccccc1		CHEMBL1419458	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9574589	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(C(=O)NCc2ccc(S(N)(=O)=O)cc2)cc(N)c1C#N		CHEMBL2004355	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9574590	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9574591	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574592	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9574593	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	C=CCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1996339	=	Ki	nM	12.59	CHEMBL2973	Homo sapiens	pKi		7.9
active	9574594	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9574595	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574596	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1980142	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9574597	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574598	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
inactive	9574599	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9574600	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
active	9574601	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9574602	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574603	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
active	9574604	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
inactive	9574605	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1996390	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9574606	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1		CHEMBL1990162	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9578185	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCNC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1992220	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
inactive	9578186	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	<	Ki	nM	3.981	CHEMBL2973	Homo sapiens	pKi		8.4
active	9578187	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
inactive	9578188	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578189	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2sc(C(=O)NCCc3ccc(Cl)cc3)cc12		CHEMBL1998414	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578190	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
inactive	9578191	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O		CHEMBL2000345	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578192	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
inactive	9578193	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]sc2c1c(=O)c1cc(F)c(NCc3ccccc3)c(F)c1n2C1CC1		CHEMBL1991640	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578194	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1375418	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578195	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9578196	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9578197	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578198	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	=	Ki	nM	5.012	CHEMBL2973	Homo sapiens	pKi		8.3
active	9578199	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1987948	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
active	9578200	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
active	9578201	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12		CHEMBL1968151	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
inactive	9578202	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1381197	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578203	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9578204	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
inactive	9578205	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578206	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1		CHEMBL336961	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578207	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578208	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(Cl)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1987054	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
inactive	9578209	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578210	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
inactive	9578211	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578212	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578213	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9578214	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL1966279	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
inactive	9578215	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578216	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	<	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9578217	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578218	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCCCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1991728	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
inactive	9578219	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9578220	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc2c(-c3ccc(F)cc3F)cncc2s1		CHEMBL1975787	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9578221	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O		CHEMBL2002407	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578222	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1		CHEMBL1972489	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578223	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578224	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578225	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CN)CNc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL1968930	=	Ki	nM	3.981	CHEMBL2973	Homo sapiens	pKi		8.4
inactive	9578226	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1CC#N		CHEMBL1985566	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578227	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cccc(N2CCOCC2)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1972119	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578228	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1986328	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578229	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578230	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578231	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578232	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578233	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9578234	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1		CHEMBL1983534	=	Ki	nM	3.981	CHEMBL2973	Homo sapiens	pKi		8.4
inactive	9578235	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccccc1Nc1ccnc(NCc2cccc(O)c2)n1		CHEMBL1970950	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578236	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9578237	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578238	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578239	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9578240	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578241	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1		CHEMBL1971245	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578242	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1987648	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578243	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOC(=O)c1cn(-c2ccc(O)cc2C)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL1996780	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
inactive	9578244	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	<	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
active	9578245	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1966514	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
active	9578246	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCCCCCCCCCOc1ccc(NC(=N)N)cc1NC(=N)N		CHEMBL1980715	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
inactive	9578247	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	<	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
active	9578248	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
inactive	9578249	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1		CHEMBL1996066	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578250	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COc1cncc(-c2cc3ccncc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1966524	=	Ki	nM	10.0	CHEMBL2973	Homo sapiens	pKi		8.0
active	9578251	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9578252	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3		CHEMBL1970806	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578253	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
inactive	9578254	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL1979970	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578255	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578256	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCCCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1970821	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
inactive	9578257	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)NC(=O)c1ccc2nc3[nH]c4ccccc4c3nc2c1		CHEMBL1969264	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578258	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1c(O)[nH]c(=O)c2c(=N)oc3ccc(Cl)cc3c12		CHEMBL1973711	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578259	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578260	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
active	9578261	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2005509	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
inactive	9578262	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12		CHEMBL1624529	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578263	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
active	9578264	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
active	9578265	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9578266	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccc(N2C(=O)c3ccccc3C2=O)cc1O		CHEMBL1972820	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578267	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
inactive	9578268	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1		CHEMBL1996208	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9578269	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578270	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1		CHEMBL392642	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578271	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578272	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9578273	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578274	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCNc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682554	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
inactive	9578275	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1972849	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578276	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9578277	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(CNc2cc(-c3c[nH]c4ncccc34)cc(F)n2)cc1		CHEMBL1986855	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
inactive	9578278	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9578279	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9578280	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)OC(=O)n1cc(-c2cncn2C2CCCCC2)c2ccccc21		CHEMBL1975357	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578281	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
active	9578282	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Nc2ccccc2Nc2cc(-c3ccncc3)ccc21		CHEMBL1989136	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9578283	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578284	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578285	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578286	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578287	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578288	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
inactive	9578289	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc2c(NC(=O)Nc3cccc(Br)n3)ccnc2c1		CHEMBL1983932	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578290	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
inactive	9578291	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9578292	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	=	Ki	nM	1258.93	CHEMBL2973	Homo sapiens	pKi		5.9
active	9578293	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL243088	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9578294	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9578295	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9578296	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
active	9578297	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CSc1nn(-c2ccccn2)c(N)c1C(N)=O		CHEMBL2004615	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9578298	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nn(C)c(C)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)O)[nH]c12		CHEMBL1984039	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578299	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9578300	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1		CHEMBL1997872	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9623780	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C		CHEMBL1964290	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9623781	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)c(OC)c1		CHEMBL2003768	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9623782	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
active	9623783	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
inactive	9623784	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)c1		CHEMBL1982880	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9623785	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9623786	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
active	9623787	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
active	9623788	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL1980435	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
active	9623789	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Nc2ccccc2Nc2cc(-c3ccncc3F)ccc21		CHEMBL1989293	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9623790	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9623791	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9627340	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627341	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682345	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
active	9627342	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
inactive	9627343	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627344	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
active	9627345	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
inactive	9627346	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627347	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1c(C)n(Cc2ccccc2)c2ccc(C(=O)Nc3nc[nH]n3)cc12		CHEMBL1979718	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
active	9627348	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
active	9627349	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(Cn2cc(-c3ccc4[nH]nc(-c5cn(Cc6ccccc6)nn5)c4c3)nn2)cc1		CHEMBL1964288	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9627350	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627351	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1(C)CC2=Nc3cc(Cl)ccc3SC2=C(O)C1		CHEMBL1562756	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9627352	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9627353	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2		CHEMBL362558	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627354	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627355	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627356	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	<	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9627357	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1990583	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627358	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627359	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)CCCOc1cc(-c2ccncc2)cc2[nH]nc(N)c12		CHEMBL1988662	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
active	9627360	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9627361	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	=	Ki	nM	1258.93	CHEMBL2973	Homo sapiens	pKi		5.9
active	9627362	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9627363	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627364	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)CNS(C)(=O)=O		CHEMBL1971172	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9627365	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627366	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627367	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccccc1C(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1997643	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627368	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627369	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
inactive	9627370	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	<	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
active	9627371	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
inactive	9627372	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9627373	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9627374	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
active	9627375	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1		CHEMBL1988163	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9627376	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(O)ccc1-n1c2cc(Cl)ccc2c(=O)c2c(N)nc(N)nc21		CHEMBL1995592	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9627377	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2000934	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9627378	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627379	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1cc2nn[nH]c2cc1Cl		CHEMBL1996923	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627380	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C		CHEMBL1983449	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
inactive	9627381	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627382	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627383	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O		CHEMBL2003524	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627384	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9627385	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1983589	=	Ki	nM	3.162	CHEMBL2973	Homo sapiens	pKi		8.5
inactive	9627386	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9627387	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCn1c(C2CCNCC2)nc(-c2ccc(Cl)c(Cl)c2)c1-c1ccnc(NC2CCCCC2)n1		CHEMBL437747	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627388	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2005718	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
inactive	9627389	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627390	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL507936	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
active	9627391	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL1987756	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
active	9627392	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
active	9627393	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
inactive	9627394	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc(Cl)cc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1984788	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627395	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	FC(F)(F)c1ccc(-c2nnc3ccc(NC4CC4)nn23)cc1		CHEMBL451964	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627396	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL1964307	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
inactive	9627397	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627398	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1		CHEMBL1971694	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627399	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627400	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627401	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1F		CHEMBL1994361	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627402	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1		CHEMBL1986603	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627403	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627404	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COc1cncc(-c2cc3cnccc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1972840	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
inactive	9627405	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627406	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1cc(-c2ccc(F)cc2)[nH]c2c(-c3ccc(F)cc3)cnn12		CHEMBL2004443	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627407	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627408	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627409	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9627410	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]cc(I)c2nc(-c3ccccc3)cn12		CHEMBL2001668	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627411	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2c1C(c1ccccc1I)C(C#N)=C(N)O2		CHEMBL1979318	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627412	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9627413	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
inactive	9627414	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cncc1C(OCc1c(-c2ccc(OC(F)(F)F)cc2)cc(C#N)c(=O)n1C)c1ccc(C#N)cc1		CHEMBL127898	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627415	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627416	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CN)CNc1cc(-c2c[nH]c3ncccc23)cc(F)n1		CHEMBL1987261	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
active	9627417	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCNc1cc(-c2c[nH]c3ncccc23)ncn1		CHEMBL1968459	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
active	9627418	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
active	9627419	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)C1CCCN(C(=O)c2cc(-c3ccc4[nH]ncc4c3)on2)C1		CHEMBL1970369	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
active	9627420	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9627421	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9627422	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)c2c(n1)sc1c(N)ncnc12		CHEMBL504950	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
active	9627423	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)CCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1966425	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9627424	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9627425	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627426	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COC(=O)c1c(-c2ccc(NC(=O)Nc3ccccc3)cc2)c2c(N)ncnn2c1C		CHEMBL1977041	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
inactive	9627427	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cccc2c1Nc1nnc(Cl)cc1C(=O)N2		CHEMBL1968070	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627428	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
active	9627429	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
inactive	9627430	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627431	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CN)CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1985723	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
inactive	9627432	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2		CHEMBL178737	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627433	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
inactive	9627434	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627435	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12		CHEMBL539474	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627436	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
active	9627437	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9627438	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1cccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL1977128	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
inactive	9627439	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1997759	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627440	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627441	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
inactive	9627442	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]c2cc(Cl)cc(Cl)c2c(-c2cc(Cl)ccc2O)c1O		CHEMBL1974803	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627443	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627444	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)C1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1965702	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
active	9627445	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
inactive	9627446	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9627447	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
active	9627448	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)Oc1cc(-c2ccncc2)cc2[nH]nc(N)c12		CHEMBL2002456	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
inactive	9627449	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1=NN(c2cccc(Br)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2005112	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627450	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
active	9627451	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9627452	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CC)CCOc1ccc(-c2nc3c(C(N)=O)cccc3[nH]2)cc1		CHEMBL1984044	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627453	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627454	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)cccc12		CHEMBL1966816	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627455	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
inactive	9627456	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627457	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCOn1c2ccc(Cl)cc2c(=O)c2c(C)nn(C)c21		CHEMBL207253	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627458	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=NNC(=O)c1nnn(-c2nonc2N)c1-c1ccccc1)c1ccco1		CHEMBL1890036	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9627459	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1CCCN1CCc1cc2cc(-c3ccc(OC(F)(F)F)cc3)ccc2[nH]1		CHEMBL1990635	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
active	9627460	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
inactive	9627461	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1CC(c2ccc(Cl)cc2Cl)Cc2nc3cc(Cl)ccc3c(O)c21		CHEMBL326282	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627462	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(Cl)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)NCCOCCOCCN)[nH]c12		CHEMBL2002682	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627463	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1ccccc1C=NNC(=O)c1nnn(-c2nonc2N)c1N1CCCC1		CHEMBL1992732	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627464	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627465	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
active	9627466	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)CNC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2006456	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
active	9627467	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
inactive	9627468	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627469	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9627470	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CCC(N2CCCC2)CC1		CHEMBL2007151	=	Ki	nM	1258.93	CHEMBL2973	Homo sapiens	pKi		5.9
inactive	9627471	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9627472	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1964340	=	Ki	nM	5.012	CHEMBL2973	Homo sapiens	pKi		8.3
inactive	9627473	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627474	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1ccc2[nH]ncc2c1)c1cccc(F)c1		CHEMBL1461728	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9627475	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9627476	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
active	9627477	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
active	9627478	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCOc1cccc(Nc2ccnc(N)n2)c1		CHEMBL1995448	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
active	9627479	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL1972158	=	Ki	nM	12.59	CHEMBL2973	Homo sapiens	pKi		7.9
inactive	9627480	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1974457	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627481	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CO)CCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1967662	=	Ki	nM	10.0	CHEMBL2973	Homo sapiens	pKi		8.0
active	9627482	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
inactive	9627483	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Oc1ccc(Nc2ncnc3scc(Cl)c23)cc1		CHEMBL2006580	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627484	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1Cl		CHEMBL2006581	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627485	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCCC1		CHEMBL2006481	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
inactive	9627486	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCC#N)c2)n1		CHEMBL1979855	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627487	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
active	9627488	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
active	9627489	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
inactive	9627490	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCNc1nc2cc(Cl)c(OC)cc2nc1NCC		CHEMBL1995927	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627491	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
active	9627492	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9627493	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1		CHEMBL1993424	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
inactive	9627494	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627495	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(Nc2nccc(Nc3ccccc3C(=O)O)n2)cc1F		CHEMBL243518	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627496	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
active	9627497	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1ccccc1Nc1nc(Nc2ccccc2)ncc1C(F)(F)F		CHEMBL1997554	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
active	9627498	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9627499	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
inactive	9627500	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc2c(-c3ccc(Br)c(F)c3F)cncc2s1		CHEMBL1999918	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627501	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627502	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
active	9627503	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
inactive	9627504	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccc3ccccc3c2)n1		CHEMBL2002240	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627505	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627506	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(-n2nc(C)c3c(=O)c4cc(Cl)ccc4n(O)c32)cc1		CHEMBL1991143	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627507	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9627508	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1980178	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
active	9627509	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
inactive	9627510	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2CCC(N)=O		CHEMBL485556	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627511	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
inactive	9627512	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627513	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627514	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9627515	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(-c2ccc3c(c2)Nc2ccccc2NC3=O)ccn1		CHEMBL1981511	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
inactive	9627516	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627517	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9627518	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1997025	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627519	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
active	9627520	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)csc12		CHEMBL1982476	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
inactive	9627521	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1C(=NNc2cccc3c(=O)[nH][nH]c(=O)c23)C(c2ccccc2)=NN1c1ccccc1		CHEMBL1984274	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627522	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
active	9627523	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
inactive	9627524	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)c(Cl)ccc12		CHEMBL2006010	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627525	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627526	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9627527	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCC(C)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998068	=	Ki	nM	7.943	CHEMBL2973	Homo sapiens	pKi		8.1
active	9627528	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccc12		CHEMBL1997623	=	Ki	nM	1258.93	CHEMBL2973	Homo sapiens	pKi		5.9
active	9627529	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O		CHEMBL2002479	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
active	9627530	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCN(C)CCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1993166	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
inactive	9627531	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627532	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1		CHEMBL1966035	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
active	9627533	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
inactive	9627534	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NS(=O)(=O)c1ccc(NCCSc2ccc(O)cc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1		CHEMBL1992645	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627535	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOC(=O)c1c[nH]n2c(=O)cc(-c3ccncc3)nc12		CHEMBL1990708	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
inactive	9627536	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627537	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627538	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	<	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
active	9627539	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
inactive	9627540	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CC)CCCNc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)n1		CHEMBL1972276	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627541	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9627542	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627543	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
inactive	9627544	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627545	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nc2ccccn2c1-c1csc(Nc2ccc(O)cc2)n1		CHEMBL513846	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627546	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
active	9627547	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9627548	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC		CHEMBL1998112	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627549	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1972290	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
inactive	9627550	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627551	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627552	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)NC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2F)C1		CHEMBL1975208	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627553	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9627554	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1		CHEMBL1991429	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627555	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc2c(Oc3cccc(F)c3)cncc2s1		CHEMBL1964777	=	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627556	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627557	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627558	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Cc1ccccc1Cl)Nc1ccc2cn[nH]c2c1		CHEMBL1987533	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627559	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627560	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	0.5012	CHEMBL2973	Homo sapiens	pKi		9.3
active	9627561	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cc(Nc2ncc(Cl)c(Nc3ccccc3C(N)=O)n2)cn1		CHEMBL1984548	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
active	9627562	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9627563	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627564	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627565	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
inactive	9627566	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627567	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627568	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9627569	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(F)cc12		CHEMBL2007603	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9627570	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627571	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	=	Ki	nM	10.0	CHEMBL2973	Homo sapiens	pKi		8.0
inactive	9627572	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627573	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
inactive	9627574	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9627575	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1		CHEMBL2004771	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
active	9627576	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
active	9627577	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1		CHEMBL1988370	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
active	9627578	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
inactive	9627579	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631141	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
inactive	9631142	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631143	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631144	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(COc1cncc(-c2ccc(F)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1996543	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9631145	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9631146	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
inactive	9631147	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1		CHEMBL1991356	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631148	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(C(=O)Nc2nc3ccc(Cl)cc3s2)c(OC)c1		CHEMBL1983309	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631149	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9631150	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1=NN(c2ccccc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1999126	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631151	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)Oc1ccc(-c2noc(-c3ccc(NC4CCC(C(=O)O)C4)cc3)n2)cc1Cl		CHEMBL1997503	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631152	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1972339	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
active	9631153	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9631154	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)c(C)c(OCCCc2c(C(=O)O)[nH]c3c(-c4ccccc4C)cccc23)c1		CHEMBL1990821	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631155	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631156	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631157	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1Nc2ccccc2Nc2ccccc21		CHEMBL1727312	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631158	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL1969879	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631159	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)c1		CHEMBL1995932	=	Ki	nM	12.59	CHEMBL2973	Homo sapiens	pKi		7.9
inactive	9631160	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631161	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2ccc(-c3cncc(OCCNS(C)(=O)=O)c3)cc12		CHEMBL1967704	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
active	9631162	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
active	9631163	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
active	9631164	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
inactive	9631165	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631166	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(Cl)c1		CHEMBL1983595	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9631167	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631168	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4snc(N)c34)cc2)c1		CHEMBL1976328	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
active	9631169	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
active	9631170	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)cc1OC		CHEMBL1964399	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
inactive	9631171	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631172	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9631173	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCOCC2)n1		CHEMBL1980253	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
active	9631174	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
active	9631175	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
active	9631176	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)c1ccc(-c2c(-c3ccc4[nH]nc(N)c4c3)nnn2Cc2ccccc2)cc1		CHEMBL1969221	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
inactive	9631177	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9631178	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL1989646	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
active	9631179	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(Cc2cc(-c3ccc4[nH]ncc4c3)on2)cc1		CHEMBL1682357	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
active	9631180	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
active	9631181	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(C(=O)NCc2cccnc2)cc(N)c1C#N		CHEMBL209534	=	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631182	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631183	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9631184	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)S(=O)(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2006631	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
inactive	9631185	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631186	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1n[nH]c2nc3ccccc3cc12)c1ccncc1		CHEMBL1990415	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631187	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	C(=Cc1cncc(OC2CCNC2)c1)c1ccncc1		CHEMBL1966087	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
active	9631188	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cc(-c2ccccc2)c2nc(-c3ccncc3)cc(=O)n21		CHEMBL1986767	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
active	9631189	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
active	9631190	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9631191	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
inactive	9631192	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL1973483	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631193	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
active	9631194	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNCC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1996980	=	Ki	nM	7.943	CHEMBL2973	Homo sapiens	pKi		8.1
active	9631195	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C)c1		CHEMBL1984432	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
inactive	9631196	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL1970735	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631197	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL219722	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9631198	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(Cc1ccccc1)c1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1969920	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
active	9631199	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cc(Nc2ncc(Br)c(Nc3ccccc3C(N)=O)n2)cn1		CHEMBL1994669	=	Ki	nM	15.85	CHEMBL2973	Homo sapiens	pKi		7.8
active	9631200	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
inactive	9631201	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOC(=O)C1=C(N)n2c(sc(=Cc3cccs3)c2=O)=C(C(N)=O)C1c1cccs1		CHEMBL2004365	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631202	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631203	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
inactive	9631204	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9631205	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631206	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NCCc2[nH]c(-c3ccnc(Cl)c3)cc21		CHEMBL226232	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9631207	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9631208	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9631209	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
active	9631210	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9631211	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631212	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631213	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9631214	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
active	9631215	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Ki	nM	3162.28	CHEMBL2973	Homo sapiens	pKi		5.5
active	9631216	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1ccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)cc1		CHEMBL2002346	=	Ki	nM	3.981	CHEMBL2973	Homo sapiens	pKi		8.4
inactive	9631217	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631218	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9631219	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1=NN(c2ccc(C(=O)O)cc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2006836	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631220	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#Cc5cccnc5)cnc(N)c34)cc2)c1		CHEMBL1971947	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9631221	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631222	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9631223	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC1CCCCC1Nc1nccc(Nc2ccccc2C(=O)O)n1		CHEMBL1985153	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631224	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9631225	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
active	9631226	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3		CHEMBL1966808	=	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
inactive	9631227	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	<	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
inactive	9631228	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631229	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccccc1Nc1ncnc(Nc2ccc(F)cc2)n1		CHEMBL1992231	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9631230	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9631231	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631232	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCc1ccc(Cl)cc1)Nc1cccc2[nH]ncc12		CHEMBL1977713	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631233	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631234	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=S(=O)(O)c1ccc(NCc2ccc3c(c2)OCO3)c2c(O)cccc12		CHEMBL2004544	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631235	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCNc1cc(-c2ccncc2)cc2[nH]nc(N)c12		CHEMBL1983157	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
inactive	9631236	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631237	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	FC(F)(F)c1cccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)c1		CHEMBL1966040	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9631238	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1		CHEMBL1999496	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631239	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CSc1cnc2c(ccc3cnccc32)c1O		CHEMBL2006933	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9631240	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631241	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9631242	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
active	9631243	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
inactive	9631244	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O		CHEMBL1987359	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631245	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=NNC(=N)N)c1cc(NC(=O)c2cccc(C(=O)Nc3cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c3)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL2000685	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9631246	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631247	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC1CCCCC1Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL1994438	=	Ki	nM	10.0	CHEMBL2973	Homo sapiens	pKi		8.0
active	9631248	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(CO)ccc4F)cc3)c12		CHEMBL1985311	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
inactive	9631249	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)cc3n21		CHEMBL1989265	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631250	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9631251	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2Br)C1		CHEMBL2004647	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631252	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
active	9631253	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CCC(N2CCCC2)CC1		CHEMBL1965910	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9631254	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCCOc1cc(-c2ccncc2)cc2[nH]nc(N)c12		CHEMBL1996447	=	Ki	nM	125.89	CHEMBL2973	Homo sapiens	pKi		6.9
active	9631255	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
inactive	9631256	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(-c2c(-c3ccncc3)nc(NCC(N)Cc3ccccc3)n(C)c2=O)c1		CHEMBL1971430	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631257	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
active	9631258	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
active	9631259	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(CN)Cc4ccccc4)c3)cc12		CHEMBL2000271	=	Ki	nM	7.943	CHEMBL2973	Homo sapiens	pKi		8.1
active	9631260	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
active	9631261	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1ccccc1		CHEMBL2004692	=	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
active	9631262	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
active	9631263	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1		CHEMBL1996234	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
inactive	9631264	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631265	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	=	Ki	nM	5.012	CHEMBL2973	Homo sapiens	pKi		8.3
inactive	9631266	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631267	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	<	Ki	nM	1258.93	CHEMBL2973	Homo sapiens	pKi		5.9
active	9631268	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	=	Ki	nM	3.162	CHEMBL2973	Homo sapiens	pKi		8.5
active	9631269	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	=	Ki	nM	2.512	CHEMBL2973	Homo sapiens	pKi		8.6
inactive	9631270	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1996587	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631271	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9631272	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631273	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631274	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631275	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631276	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631277	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
active	9631278	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
inactive	9631279	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc2c(NC(=O)Nc3cc(C(F)(F)F)ccn3)ccnc2c1		CHEMBL1979176	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631280	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	=	Ki	nM	398.11	CHEMBL2973	Homo sapiens	pKi		6.4
inactive	9631281	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(OC)cc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL2002613	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9631282	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631283	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631284	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
inactive	9631285	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCc1ccccc1)c1c[nH]n2c(=O)cc(-c3ccncc3)nc12		CHEMBL1974250	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631286	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631287	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CC)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1983195	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631288	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1975490	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
inactive	9631289	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
inactive	9631290	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCCNc1cc2cc(-c3ccccc3)ccc2cn1		CHEMBL1989957	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631291	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccsc2)n1		CHEMBL2006567	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631292	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631293	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1985580	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
inactive	9631294	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)cccc12		CHEMBL1980540	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631295	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9631296	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(C)c1cc(-c2ccncc2)cc2[nH]nc(N)c12		CHEMBL2003229	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
active	9631297	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	=	Ki	nM	63.1	CHEMBL2973	Homo sapiens	pKi		7.2
active	9631298	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
active	9631299	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(CNc2cc(-c3c[nH]c4ncccc34)cc(Cl)n2)c1C		CHEMBL1988331	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
active	9631300	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1998432	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
inactive	9631301	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631302	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
active	9631303	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2ccc(-c3cncc(OCCN(C)S(C)(=O)=O)c3)cc12		CHEMBL1998826	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
active	9631304	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1		CHEMBL1682360	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
inactive	9631305	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631306	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21		CHEMBL1870106	=	Ki	nM	0.631	CHEMBL2973	Homo sapiens	pKi		9.2
inactive	9631307	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631308	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	=	Ki	nM	79.43	CHEMBL2973	Homo sapiens	pKi		7.1
inactive	9631309	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631310	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	<	Ki	nM	3981.07	CHEMBL2973	Homo sapiens	pKi		5.4
active	9631311	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
active	9631312	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	=	Ki	nM	2.512	CHEMBL2973	Homo sapiens	pKi		8.6
active	9631313	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1cnc2[nH]cc(-c3ccnc(NCC4CCCCC4)n3)c2c1		CHEMBL213207	=	Ki	nM	6.31	CHEMBL2973	Homo sapiens	pKi		8.2
active	9631314	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
active	9631315	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC		CHEMBL1190711	=	Ki	nM	31.62	CHEMBL2973	Homo sapiens	pKi		7.5
active	9631316	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
active	9631317	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F		CHEMBL1991410	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
active	9631318	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9631319	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9631320	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
active	9631321	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	=	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631322	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9631323	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)c(F)c3n21		CHEMBL1977604	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631324	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Fc1cccc(-c2c[nH]c3ncccc23)c1		CHEMBL1993648	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
active	9631325	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	1995.26	CHEMBL2973	Homo sapiens	pKi		5.7
inactive	9631326	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631327	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
active	9631328	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Ki	nM	158.49	CHEMBL2973	Homo sapiens	pKi		6.8
inactive	9631329	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(F)c2)n1		CHEMBL243298	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
active	9631330	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1ccc(-c2ccnc(N)n2)cc1N1CCCCC1		CHEMBL1971951	=	Ki	nM	1584.89	CHEMBL2973	Homo sapiens	pKi		5.8
active	9631331	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9631332	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631333	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631334	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NN=Cc1ccc(Sc2nc3ccccc3[nH]2)o1)c1cccc([N+](=O)[O-])c1		CHEMBL1992555	=	Ki	nM	251.19	CHEMBL2973	Homo sapiens	pKi		6.6
active	9631335	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
active	9631336	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=c1cc(-c2ccncc2)nc(NCc2cc(F)cc(F)c2)[nH]1		CHEMBL2003682	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
active	9631337	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	=	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
inactive	9631338	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	C(=NNc1nc2ccccc2[nH]1)c1c[nH]c2ccccc12		CHEMBL535331	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631339	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1		CHEMBL1989805	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631340	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccc(F)cc1		CHEMBL1966204	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
active	9631341	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
inactive	9631342	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)=C(C)c1cccc2c(CCCOc3cccc(Cl)c3Cl)c(C(=O)O)[nH]c12		CHEMBL1982980	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631343	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631344	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	=	Ki	nM	100.0	CHEMBL2973	Homo sapiens	pKi		7.0
active	9631345	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	=	Ki	nM	3.981	CHEMBL2973	Homo sapiens	pKi		8.4
active	9631346	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
active	9631347	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	=	Ki	nM	794.33	CHEMBL2973	Homo sapiens	pKi		6.1
inactive	9631348	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1cc2c(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cncc2s1		CHEMBL2002322	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631349	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCCN(CCOC)c1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1985654	=	Ki	nM	39.81	CHEMBL2973	Homo sapiens	pKi		7.4
inactive	9631350	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(F)c(-c2ccc3nnc(N)n3c2)c1		CHEMBL2002323	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631351	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	=	Ki	nM	1258.93	CHEMBL2973	Homo sapiens	pKi		5.9
inactive	9631352	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631353	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COC(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2004513	=	Ki	nM	1258.93	CHEMBL2973	Homo sapiens	pKi		5.9
active	9631354	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NCCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1972258	=	Ki	nM	501.19	CHEMBL2973	Homo sapiens	pKi		6.3
active	9631355	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CNCCOc1cncc(-c2ccc3[nH]nc(C)c3c2)c1		CHEMBL1983855	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
active	9631356	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	=	Ki	nM	199.53	CHEMBL2973	Homo sapiens	pKi		6.7
active	9631357	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(Cl)cc4Cl)c(=O)c3=O)ccc21		CHEMBL2005548	=	Ki	nM	25.12	CHEMBL2973	Homo sapiens	pKi		7.6
inactive	9631358	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccccc1-c1c(C(=O)O)n(CCCOc2cccc3ccccc23)c2ccccc12		CHEMBL1987793	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631359	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	=	Ki	nM	1000.0	CHEMBL2973	Homo sapiens	pKi		6.0
inactive	9631360	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631361	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)c1ccc2c(ccn2-c2cccc(Cl)c2)c1		CHEMBL1966354	=	Ki	nM	2511.89	CHEMBL2973	Homo sapiens	pKi		5.6
inactive	9631362	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	OCCCn1cnc(-c2ccccc2)c1-c1ccncc1		CHEMBL2002373	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631363	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL1973348	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631364	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9631365	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631366	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631367	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3C3CC3)cc12		CHEMBL2004631	=	Ki	nM	19.95	CHEMBL2973	Homo sapiens	pKi		7.7
inactive	9631368	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCOC(=O)c1cccc2[nH]c(-c3ccc(N4CCC(N)C4)cc3)nc12		CHEMBL1995736	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631369	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	6309.57	CHEMBL2973	Homo sapiens	pKi		5.2
inactive	9631370	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631371	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9631372	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)(O)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1998551	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631373	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1977374	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
active	9631374	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O		CHEMBL1991180	=	Ki	nM	630.96	CHEMBL2973	Homo sapiens	pKi		6.2
active	9631375	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	50.12	CHEMBL2973	Homo sapiens	pKi		7.3
active	9631376	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	=	Ki	nM	316.23	CHEMBL2973	Homo sapiens	pKi		6.5
inactive	9631377	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1c(O)cccc1NC(=O)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1978656	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631378	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631379	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCO)c(Cl)cc1NC(=O)N2		CHEMBL413779	<	Ki	nM	7943.28	CHEMBL2973	Homo sapiens	pKi		5.1
inactive	9631380	CHEMBL1963722	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ROCK2	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	<	Ki	nM	5011.87	CHEMBL2973	Homo sapiens	pKi		5.3
	10839477	CHEMBL2015508	Inhibition of ROCK2 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	87.0	CHEMBL2973	Homo sapiens	INH	%	87.0
	10840381	CHEMBL2015805	Inhibition of ROCK 2 assessed as residual activity at 10 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	40.0	CHEMBL2973	Homo sapiens	Activity	%	40.0
	10840410	CHEMBL2016329	Inhibition of ROCK 2 assessed as residual activity at 1 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	85.0	CHEMBL2973	Homo sapiens	Activity	%	85.0
	10850635	CHEMBL2019913	Inhibition of human ROCK2	B	O=C(Nc1ccc(N2CCNCC2)cc1)c1ccc(-c2ccc(Cl)cc2)o1		CHEMBL1938680	>	IC50	nM	30000.0	CHEMBL2973	Homo sapiens	IC50	nM	30000.0
	10850667	CHEMBL2019787	Inhibition of human ROCK2 at 1 uM	B	Cn1cc(-c2cccc(-c3cnc(N)c(C(=O)N[C@H]4C5CC6CC4C[C@@](O)(C6)C5)n3)c2)cn1		CHEMBL2018022	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	10862225	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@H](CO)c1ccccc1		CHEMBL2023158	=	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	uM	0.1
	10862226	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCc1ccccc1)Nc1ccc(-c2ccncc2)cc1		CHEMBL2023156	=	IC50	nM	260.0	CHEMBL2973	Homo sapiens	IC50	uM	0.26
	10862228	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023154	=	IC50	nM	670.0	CHEMBL2973	Homo sapiens	IC50	uM	0.67
	10862229	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	COc1ccc(CCNC(=O)Nc2ccc3[nH]ncc3c2)cc1		CHEMBL2023152	=	IC50	nM	800.0	CHEMBL2973	Homo sapiens	IC50	uM	0.8
	10862230	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCCCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023155	=	IC50	nM	1070.0	CHEMBL2973	Homo sapiens	IC50	uM	1.07
	10862231	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCCc1ccc(Cl)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023153	=	IC50	nM	1100.0	CHEMBL2973	Homo sapiens	IC50	uM	1.1
	10862234	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCC(O)c1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023151	=	IC50	nM	1500.0	CHEMBL2973	Homo sapiens	IC50	uM	1.5
	10862237	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc2[nH]ncc2c1)N[C@H](CO)Cc1ccccc1		CHEMBL2023150	=	IC50	nM	2300.0	CHEMBL2973	Homo sapiens	IC50	uM	2.3
	10862244	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@@H](CO)Cc1ccccc1		CHEMBL2023160	=	IC50	nM	5360.0	CHEMBL2973	Homo sapiens	IC50	uM	5.36
	10862245	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL225282	=	IC50	nM	5500.0	CHEMBL2973	Homo sapiens	IC50	uM	5.5
	10862246	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	CN(CCc1ccccc1)C(=O)Nc1ccc2[nH]ncc2c1		CHEMBL2023149	=	IC50	nM	7500.0	CHEMBL2973	Homo sapiens	IC50	uM	7.5
	10862247	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@@H](CO)c1ccccc1		CHEMBL2023157	=	IC50	nM	7520.0	CHEMBL2973	Homo sapiens	IC50	uM	7.52
	10862251	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(NCCc1ccccc1)Nc1ccc(-c2ccncc2)cc1		CHEMBL2023159	=	IC50	nM	19800.0	CHEMBL2973	Homo sapiens	IC50	uM	19.8
	10862254	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@H](CO)Cc1ccccc1		CHEMBL2023161	=	IC50	nM	32920.0	CHEMBL2973	Homo sapiens	IC50	uM	32.92
	10862256	CHEMBL2025928	Inhibition of ROCK2 at 400 uM after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1ccccn1		CHEMBL2022281	=	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	10862257	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	CN(C)C(=O)Nc1ccc2[nH]ncc2c1		CHEMBL2023147	=	IC50	nM	36100.0	CHEMBL2973	Homo sapiens	IC50	uM	36.1
	10862258	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	CC(=O)Nc1ccc2[nH]ncc2c1		CHEMBL503641	=	IC50	nM	40000.0	CHEMBL2973	Homo sapiens	IC50	uM	40.0
	10862259	CHEMBL2025928	Inhibition of ROCK2 at 400 uM after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1ccncc1		CHEMBL66221	=	Inhibition	%	42.0	CHEMBL2973	Homo sapiens	INH	%	42.0
	10862261	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cccnc1		CHEMBL67352	=	IC50	nM	55900.0	CHEMBL2973	Homo sapiens	IC50	uM	55.9
	10862263	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023148	=	IC50	nM	61800.0	CHEMBL2973	Homo sapiens	IC50	uM	61.8
	10862267	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	Nc1ccc2[nH]ncc2c1		CHEMBL17551	=	IC50	nM	119700.0	CHEMBL2973	Homo sapiens	IC50	uM	119.7
	10862270	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cnccc1Cl		CHEMBL2022282	=	IC50	nM	221400.0	CHEMBL2973	Homo sapiens	IC50	uM	221.4
	10862272	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cncc(Br)c1		CHEMBL1566648	=	IC50	nM	357200.0	CHEMBL2973	Homo sapiens	IC50	uM	357.2
	10862275	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cnccc1-c1ccc(F)cc1		CHEMBL2023144	>	IC50	nM	400000.0	CHEMBL2973	Homo sapiens	IC50	uM	400.0
	10862276	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccncc1)c1cncc(-c2ccc(F)cc2)c1		CHEMBL2023145	>	IC50	nM	400000.0	CHEMBL2973	Homo sapiens	IC50	uM	400.0
Not Determined	10862278	CHEMBL2025931	Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay	B	O=C(Nc1ccc2[nH]ncc2c1)Oc1ccccc1		CHEMBL2023146		IC50			CHEMBL2973	Homo sapiens	IC50		
	10863323	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL297394	=	Kd	nM	7.0	CHEMBL2973	Homo sapiens	Kd	nM	7.0
	10863324	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023714	<	Kd	nM	0.5	CHEMBL2973	Homo sapiens	Kd	nM	0.5
Not Determined	10863325	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	C=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CNC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024651		Kd			CHEMBL2973	Homo sapiens	Kd		
Not Determined	10863326	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024650		Kd			CHEMBL2973	Homo sapiens	Kd		
Not Determined	10863327	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	C=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCNC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024652		Kd			CHEMBL2973	Homo sapiens	Kd		
Not Determined	10863328	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	C=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCNC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024653		Kd			CHEMBL2973	Homo sapiens	Kd		
	10863329	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	C=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)c1ccc(CNC(=O)CNCC(=O)NCCNS(=O)(=O)c2cccc3cnccc23)cc1)C(N)=O		CHEMBL2024654	=	Kd	nM	1200.0	CHEMBL2973	Homo sapiens	Kd	nM	1200.0
	10863330	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@H](CCCCN)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024655	=	Kd	nM	690.0	CHEMBL2973	Homo sapiens	Kd	nM	690.0
Not Determined	10863331	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024656		Kd			CHEMBL2973	Homo sapiens	Kd		
	10863332	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023838	=	Kd	nM	1.5	CHEMBL2973	Homo sapiens	Kd	nM	1.5
	10863333	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCNC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023839	=	Kd	nM	0.7	CHEMBL2973	Homo sapiens	Kd	nM	0.7
	10863334	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023840	=	Kd	nM	6.4	CHEMBL2973	Homo sapiens	Kd	nM	6.4
	10863335	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL297394	=	IC50	nM	162.18	CHEMBL2973	Homo sapiens	pIC50		6.79
	10863336	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023714	=	IC50	nM	2.455	CHEMBL2973	Homo sapiens	pIC50		8.61
	10863337	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	C=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CNC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024651	>	IC50	nM	31622.78	CHEMBL2973	Homo sapiens	pIC50		4.5
	10863338	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024650	>	IC50	nM	31622.78	CHEMBL2973	Homo sapiens	pIC50		4.5
	10863339	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	C=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCNC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024652	>	IC50	nM	31622.78	CHEMBL2973	Homo sapiens	pIC50		4.5
	10863340	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	C=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCNC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024653	>	IC50	nM	31622.78	CHEMBL2973	Homo sapiens	pIC50		4.5
	10863341	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	C=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)c1ccc(CNC(=O)CNCC(=O)NCCNS(=O)(=O)c2cccc3cnccc23)cc1)C(N)=O		CHEMBL2024654	=	IC50	nM	26915.35	CHEMBL2973	Homo sapiens	pIC50		4.57
	10863342	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@H](CCCCN)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024655	=	IC50	nM	16218.1	CHEMBL2973	Homo sapiens	pIC50		4.79
	10863343	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2024656	>	IC50	nM	31622.78	CHEMBL2973	Homo sapiens	pIC50		4.5
	10863344	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023838	=	IC50	nM	34.67	CHEMBL2973	Homo sapiens	pIC50		7.46
	10863345	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCNC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023839	=	IC50	nM	17.78	CHEMBL2973	Homo sapiens	pIC50		7.75
	10863346	CHEMBL2024934	Displacement of fluorescent-ARC-1042 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CNCC(=O)NCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023840	=	IC50	nM	151.36	CHEMBL2973	Homo sapiens	pIC50		6.82
	10863363	CHEMBL2024943	Binding affinity to His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	CN(C)c1ccc2c(c1)OC1=CC(N(C)C)C=CC1=C2c1ccc(C(=O)O)cc1C(=O)N[C@H](CCCCN)C(=O)NC(=N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023845	<	Kd	nM	0.2	CHEMBL2973	Homo sapiens	Kd	nM	0.2
	10863364	CHEMBL2024943	Binding affinity to His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	C=S(=O)(O)c1ccc2c(c1)C(C)(C)C1=[N+]2CCC2OC3CCN4C(=C3C=C12)C(C)(C)c1cc(CC(=O)NCCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCCCNCCNS(=O)(=O)c2cccc3cnccc23)C(N)=O)ccc14		CHEMBL2023841	<	Kd	nM	0.2	CHEMBL2973	Homo sapiens	Kd	nM	0.2
	10863391	CHEMBL2024951	Displacement of fluorescent-ARC-583/ARC-1042/ARC-1059 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023714	<	Kd	nM	0.5	CHEMBL2973	Homo sapiens	Kd	nM	0.5
	10863392	CHEMBL2024951	Displacement of fluorescent-ARC-583/ARC-1042/ARC-1059 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCCCN1CCCN(S(=O)(=O)c2cccc3cnccc23)CC1)C(N)=O		CHEMBL2023842	=	Kd	nM	27.0	CHEMBL2973	Homo sapiens	Kd	nM	27.0
	10863393	CHEMBL2024951	Displacement of fluorescent-ARC-583/ARC-1042/ARC-1059 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNCCNS(=O)(=O)c1cccc2cnccc12)C(N)=O		CHEMBL2023714	=	IC50	nM	2.455	CHEMBL2973	Homo sapiens	pIC50		8.61
	10863394	CHEMBL2024951	Displacement of fluorescent-ARC-583/ARC-1042/ARC-1059 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCCCN1CCCN(S(=O)(=O)c2cccc3cnccc23)CC1)C(N)=O		CHEMBL2023842	=	IC50	nM	630.96	CHEMBL2973	Homo sapiens	pIC50		6.2
Active	10863402	CHEMBL2024959	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by fluorescence anisotropy assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCCCN1CCCN(S(=O)(=O)c2cccc3cnccc23)CC1)C(N)=O		CHEMBL2023843		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	10863419	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL297394	=	Kd	nM	6.4	CHEMBL2973	Homo sapiens	Kd	nM	6.4
	10863420	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	Kd	nM	0.021	CHEMBL2973	Homo sapiens	Kd	nM	0.021
	10863421	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O	Outside typical range	CHEMBL1077375	=	Kd	nM	0.0056	CHEMBL2973	Homo sapiens	Kd	nM	0.0056
	10863422	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL279185	=	Kd	nM	1.5	CHEMBL2973	Homo sapiens	Kd	nM	1.5
	10863423	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Kd	nM	24.0	CHEMBL2973	Homo sapiens	Kd	nM	24.0
	10863424	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Kd	nM	78.0	CHEMBL2973	Homo sapiens	Kd	nM	78.0
	10863425	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCCCN1CCCN(S(=O)(=O)c2cccc3cnccc23)CC1)C(N)=O		CHEMBL2023842	=	Kd	nM	45.0	CHEMBL2973	Homo sapiens	Kd	nM	45.0
	10864338	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCCCN1CCCN(S(=O)(=O)c2cccc3cnccc23)CC1)C(N)=O		CHEMBL2023843	=	Kd	nM	0.02	CHEMBL2973	Homo sapiens	Kd	nM	0.02
	10864339	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL297394	=	IC50	nM	977.24	CHEMBL2973	Homo sapiens	pIC50		6.01
	10864340	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	IC50	nM	10.47	CHEMBL2973	Homo sapiens	pIC50		7.98
	10864341	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077375	=	IC50	nM	2.754	CHEMBL2973	Homo sapiens	pIC50		8.56
	10864342	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL279185	=	IC50	nM	251.19	CHEMBL2973	Homo sapiens	pIC50		6.6
	10864343	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	3630.78	CHEMBL2973	Homo sapiens	pIC50		5.44
	10864344	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	11748.98	CHEMBL2973	Homo sapiens	pIC50		4.93
	10864345	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCCCN1CCCN(S(=O)(=O)c2cccc3cnccc23)CC1)C(N)=O		CHEMBL2023842	=	IC50	nM	6760.83	CHEMBL2973	Homo sapiens	pIC50		5.17
	10864346	CHEMBL2024961	Displacement of fluorescent-ARC-1063 from His6-tagged recombinant human ROCK2 by luminescence intensity assay	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCCCN1CCCN(S(=O)(=O)c2cccc3cnccc23)CC1)C(N)=O		CHEMBL2023843	=	IC50	nM	10.23	CHEMBL2973	Homo sapiens	pIC50		7.99
	10867545	CHEMBL2027435	Inhibition of ROCK2 at 2 uM	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	=	Inhibition	%	8.0	CHEMBL2973	Homo sapiens	INH	%	8.0
	10975658	CHEMBL2064943	Inhibition of Rock2 in presence of 10 uM ATP	B	Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1990583	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	10984758	CHEMBL2072054	Inhibition of human ROCK2 at 1 uM	B	Nc1cc(Nc2cnccn2)nc(-c2ccnc(N3CCNCC3)c2)c1		CHEMBL2069349	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
Not Active	10986938	CHEMBL2072242	Inhibition of ROCK2 at 10 uM	B	NS(=O)(=O)c1cc(-c2nc3ccccc3s2)cs1		CHEMBL2069711		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	12035213	CHEMBL2150556	Inhibition of ROCK2 at 1 uM	B	C[C@H](N)CNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147537	>	Inhibition	%	80.0	CHEMBL2973	Homo sapiens	INH	%	80.0
	12047338	CHEMBL2157615	Inhibition of ROCK2 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	12.6	CHEMBL2973	Homo sapiens	INH	%	12.6
	12060941	CHEMBL2157421	Binding affinity to ROCK2 at 1 uM by high throughput binding assay relative to control	B	Nc1cc(NS(=O)(=O)c2cccc(C(F)(F)F)c2)cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)c1		CHEMBL2152288	=	Activity	%	50.0	CHEMBL2973	Homo sapiens	Activity	%	50.0
	12074699	CHEMBL2161420	Inhibition of ROCK-2 at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	12094382	CHEMBL2166162	Inhibition of human ROCK2 at 10 uM	B	CCOc1ccc(Nc2c(C)c(N[C@H]3CCCNC3)nc3ccnn23)cc1		CHEMBL1235213	=	Inhibition	%	23.0	CHEMBL2973	Homo sapiens	INH	%	23.0
	12094413	CHEMBL2166176	Inhibition of ROK2	B	N[C@H]1CC[C@H](Nc2cc(Nc3ccc(F)c(Cl)c3)n3nccc3n2)CC1		CHEMBL2163999	=	IC50	nM	14000.0	CHEMBL2973	Homo sapiens	IC50	uM	14.0
	12150573	CHEMBL2183199	Inhibition of human recombinant ROCK2 by radiometric kinase assay	B	CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n(C5CCCC5)c4n3)cc2)CC1		CHEMBL2178352	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	12170740	CHEMBL2209461	Inhibition of ROCK 2 assessed as residual activity at 1 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	82.0	CHEMBL2973	Homo sapiens	Activity	%	82.0
	12170871	CHEMBL2213190	Inhibition of ROCK 2 assessed as residual activity at 10 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	85.0	CHEMBL2973	Homo sapiens	Activity	%	85.0
	12172225	CHEMBL2212005	Inhibition of ROCK2 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	47.0	CHEMBL2973	Homo sapiens	Activity	%	47.0
	12188409	CHEMBL2211131	Binding affinity to ROCK2 at 1 uM	B	Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1		CHEMBL2206921	<	Activity	%	50.0	CHEMBL2973	Homo sapiens	Activity	%	50.0
	12195406	CHEMBL2209629	Inhibition of recombinant ROCK2 after 1 hr by scintillation counter analysis in presence of gamma-[33P]ATP	B	CC(C)(C)Nc1c(Nc2ccnc(Nc3ccc(-c4ccncc4)cc3)n2)c(=O)c1=O		CHEMBL2205426	=	Ki	nM	430.0	CHEMBL2973	Homo sapiens	Ki	nM	430.0
	12270431	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	115.0	CHEMBL2973	Homo sapiens	Residual Activity	%	115.0
	12270432	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	105.0	CHEMBL2973	Homo sapiens	Residual Activity	%	105.0
	12270433	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12270434	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12270435	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	100.0	CHEMBL2973	Homo sapiens	Residual Activity	%	100.0
	12270436	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	92.0	CHEMBL2973	Homo sapiens	Residual Activity	%	92.0
	12270437	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	37.0	CHEMBL2973	Homo sapiens	Residual Activity	%	37.0
	12270438	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270439	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	113.0	CHEMBL2973	Homo sapiens	Residual Activity	%	113.0
	12270440	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12270441	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	92.0	CHEMBL2973	Homo sapiens	Residual Activity	%	92.0
	12270442	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	95.0	CHEMBL2973	Homo sapiens	Residual Activity	%	95.0
	12270443	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	89.0	CHEMBL2973	Homo sapiens	Residual Activity	%	89.0
	12270444	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	104.0	CHEMBL2973	Homo sapiens	Residual Activity	%	104.0
	12270445	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12270446	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270447	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270448	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12270449	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12270450	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	57.0	CHEMBL2973	Homo sapiens	Residual Activity	%	57.0
	12270451	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12270452	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	101.0	CHEMBL2973	Homo sapiens	Residual Activity	%	101.0
	12270453	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12270454	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	108.0	CHEMBL2973	Homo sapiens	Residual Activity	%	108.0
	12270455	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	104.0	CHEMBL2973	Homo sapiens	Residual Activity	%	104.0
	12270456	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12270457	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	67.0	CHEMBL2973	Homo sapiens	Residual Activity	%	67.0
	12270458	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	39.0	CHEMBL2973	Homo sapiens	Residual Activity	%	39.0
	12270459	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	98.0	CHEMBL2973	Homo sapiens	Residual Activity	%	98.0
	12270460	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12270461	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12270462	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	76.0	CHEMBL2973	Homo sapiens	Residual Activity	%	76.0
	12270463	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270464	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12270465	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	88.0	CHEMBL2973	Homo sapiens	Residual Activity	%	88.0
	12270466	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12270467	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	90.0	CHEMBL2973	Homo sapiens	Residual Activity	%	90.0
	12270468	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12270469	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270470	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	101.0	CHEMBL2973	Homo sapiens	Residual Activity	%	101.0
	12270471	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	110.0	CHEMBL2973	Homo sapiens	Residual Activity	%	110.0
	12270472	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	92.0	CHEMBL2973	Homo sapiens	Residual Activity	%	92.0
	12270473	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	43.0	CHEMBL2973	Homo sapiens	Residual Activity	%	43.0
	12270474	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	10.0	CHEMBL2973	Homo sapiens	Residual Activity	%	10.0
	12270475	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	87.0	CHEMBL2973	Homo sapiens	Residual Activity	%	87.0
	12270476	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	37.0	CHEMBL2973	Homo sapiens	Residual Activity	%	37.0
	12270477	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	98.0	CHEMBL2973	Homo sapiens	Residual Activity	%	98.0
	12270478	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	88.0	CHEMBL2973	Homo sapiens	Residual Activity	%	88.0
	12270479	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	114.0	CHEMBL2973	Homo sapiens	Residual Activity	%	114.0
	12270480	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270481	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	95.0	CHEMBL2973	Homo sapiens	Residual Activity	%	95.0
	12270482	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	90.0	CHEMBL2973	Homo sapiens	Residual Activity	%	90.0
	12270483	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	5.0	CHEMBL2973	Homo sapiens	Residual Activity	%	5.0
	12270484	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	1.0	CHEMBL2973	Homo sapiens	Residual Activity	%	1.0
	12270485	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270486	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	107.0	CHEMBL2973	Homo sapiens	Residual Activity	%	107.0
	12270487	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	126.0	CHEMBL2973	Homo sapiens	Residual Activity	%	126.0
	12270488	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	109.0	CHEMBL2973	Homo sapiens	Residual Activity	%	109.0
	12270489	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	97.0	CHEMBL2973	Homo sapiens	Residual Activity	%	97.0
	12270490	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	100.0	CHEMBL2973	Homo sapiens	Residual Activity	%	100.0
	12270491	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12270492	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	79.0	CHEMBL2973	Homo sapiens	Residual Activity	%	79.0
	12270493	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	105.0	CHEMBL2973	Homo sapiens	Residual Activity	%	105.0
	12270494	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	109.0	CHEMBL2973	Homo sapiens	Residual Activity	%	109.0
	12270495	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	125.0	CHEMBL2973	Homo sapiens	Residual Activity	%	125.0
	12270496	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	112.0	CHEMBL2973	Homo sapiens	Residual Activity	%	112.0
	12270497	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	106.0	CHEMBL2973	Homo sapiens	Residual Activity	%	106.0
	12270498	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	108.0	CHEMBL2973	Homo sapiens	Residual Activity	%	108.0
	12270499	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	95.0	CHEMBL2973	Homo sapiens	Residual Activity	%	95.0
	12270500	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	104.0	CHEMBL2973	Homo sapiens	Residual Activity	%	104.0
	12270501	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	100.0	CHEMBL2973	Homo sapiens	Residual Activity	%	100.0
	12270502	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	108.0	CHEMBL2973	Homo sapiens	Residual Activity	%	108.0
	12270503	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	119.0	CHEMBL2973	Homo sapiens	Residual Activity	%	119.0
	12270504	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	119.0	CHEMBL2973	Homo sapiens	Residual Activity	%	119.0
	12270505	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	110.0	CHEMBL2973	Homo sapiens	Residual Activity	%	110.0
	12270506	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	71.0	CHEMBL2973	Homo sapiens	Residual Activity	%	71.0
	12270507	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	113.0	CHEMBL2973	Homo sapiens	Residual Activity	%	113.0
	12270508	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	86.0	CHEMBL2973	Homo sapiens	Residual Activity	%	86.0
	12270509	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	110.0	CHEMBL2973	Homo sapiens	Residual Activity	%	110.0
	12270510	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	2.0	CHEMBL2973	Homo sapiens	Residual Activity	%	2.0
	12270511	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270512	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	16.0	CHEMBL2973	Homo sapiens	Residual Activity	%	16.0
	12270513	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12270514	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	19.0	CHEMBL2973	Homo sapiens	Residual Activity	%	19.0
	12270515	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12270516	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	106.0	CHEMBL2973	Homo sapiens	Residual Activity	%	106.0
	12270517	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	101.0	CHEMBL2973	Homo sapiens	Residual Activity	%	101.0
	12270518	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	119.0	CHEMBL2973	Homo sapiens	Residual Activity	%	119.0
	12270519	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	102.0	CHEMBL2973	Homo sapiens	Residual Activity	%	102.0
	12270520	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	85.0	CHEMBL2973	Homo sapiens	Residual Activity	%	85.0
	12270521	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	86.0	CHEMBL2973	Homo sapiens	Residual Activity	%	86.0
	12270522	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	84.0	CHEMBL2973	Homo sapiens	Residual Activity	%	84.0
	12270523	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	90.0	CHEMBL2973	Homo sapiens	Residual Activity	%	90.0
	12270524	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12270525	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	98.0	CHEMBL2973	Homo sapiens	Residual Activity	%	98.0
	12270526	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	25.0	CHEMBL2973	Homo sapiens	Residual Activity	%	25.0
	12270527	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12270528	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	89.0	CHEMBL2973	Homo sapiens	Residual Activity	%	89.0
	12270529	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	87.0	CHEMBL2973	Homo sapiens	Residual Activity	%	87.0
	12270530	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	83.0	CHEMBL2973	Homo sapiens	Residual Activity	%	83.0
	12270531	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	88.0	CHEMBL2973	Homo sapiens	Residual Activity	%	88.0
	12270532	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	15.0	CHEMBL2973	Homo sapiens	Residual Activity	%	15.0
	12270533	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	97.0	CHEMBL2973	Homo sapiens	Residual Activity	%	97.0
	12270534	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	101.0	CHEMBL2973	Homo sapiens	Residual Activity	%	101.0
	12270535	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	85.0	CHEMBL2973	Homo sapiens	Residual Activity	%	85.0
	12270536	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12270537	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	78.0	CHEMBL2973	Homo sapiens	Residual Activity	%	78.0
	12270538	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	89.0	CHEMBL2973	Homo sapiens	Residual Activity	%	89.0
	12270539	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	88.0	CHEMBL2973	Homo sapiens	Residual Activity	%	88.0
	12270540	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	73.0	CHEMBL2973	Homo sapiens	Residual Activity	%	73.0
	12270541	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	87.0	CHEMBL2973	Homo sapiens	Residual Activity	%	87.0
	12270542	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	106.0	CHEMBL2973	Homo sapiens	Residual Activity	%	106.0
	12270543	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	8.0	CHEMBL2973	Homo sapiens	Residual Activity	%	8.0
	12270544	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	98.0	CHEMBL2973	Homo sapiens	Residual Activity	%	98.0
	12270545	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	83.0	CHEMBL2973	Homo sapiens	Residual Activity	%	83.0
	12270546	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12270547	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	89.0	CHEMBL2973	Homo sapiens	Residual Activity	%	89.0
	12270548	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	100.0	CHEMBL2973	Homo sapiens	Residual Activity	%	100.0
	12270549	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12270550	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270551	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12270552	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	78.0	CHEMBL2973	Homo sapiens	Residual Activity	%	78.0
	12270553	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	83.0	CHEMBL2973	Homo sapiens	Residual Activity	%	83.0
	12270554	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	68.0	CHEMBL2973	Homo sapiens	Residual Activity	%	68.0
	12270555	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	88.0	CHEMBL2973	Homo sapiens	Residual Activity	%	88.0
	12270556	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	87.0	CHEMBL2973	Homo sapiens	Residual Activity	%	87.0
	12270557	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	95.0	CHEMBL2973	Homo sapiens	Residual Activity	%	95.0
	12270558	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	100.0	CHEMBL2973	Homo sapiens	Residual Activity	%	100.0
	12270559	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	79.0	CHEMBL2973	Homo sapiens	Residual Activity	%	79.0
	12270560	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	0.0	CHEMBL2973	Homo sapiens	Residual Activity	%	0.0
	12270561	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12270562	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	92.0	CHEMBL2973	Homo sapiens	Residual Activity	%	92.0
	12270563	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	74.0	CHEMBL2973	Homo sapiens	Residual Activity	%	74.0
	12270564	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	45.0	CHEMBL2973	Homo sapiens	Residual Activity	%	45.0
	12270565	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12270566	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12270567	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12270568	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	33.0	CHEMBL2973	Homo sapiens	Residual Activity	%	33.0
	12270569	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	90.0	CHEMBL2973	Homo sapiens	Residual Activity	%	90.0
	12270570	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	104.0	CHEMBL2973	Homo sapiens	Residual Activity	%	104.0
	12270571	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	102.0	CHEMBL2973	Homo sapiens	Residual Activity	%	102.0
	12270572	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	8.0	CHEMBL2973	Homo sapiens	Residual Activity	%	8.0
	12270573	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	119.0	CHEMBL2973	Homo sapiens	Residual Activity	%	119.0
	12270574	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	92.0	CHEMBL2973	Homo sapiens	Residual Activity	%	92.0
	12270575	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	103.0	CHEMBL2973	Homo sapiens	Residual Activity	%	103.0
	12270576	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	98.0	CHEMBL2973	Homo sapiens	Residual Activity	%	98.0
	12270577	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	98.0	CHEMBL2973	Homo sapiens	Residual Activity	%	98.0
	12270578	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	85.0	CHEMBL2973	Homo sapiens	Residual Activity	%	85.0
	12270579	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	104.0	CHEMBL2973	Homo sapiens	Residual Activity	%	104.0
	12270580	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	107.0	CHEMBL2973	Homo sapiens	Residual Activity	%	107.0
	12270581	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12270582	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	121.0	CHEMBL2973	Homo sapiens	Residual Activity	%	121.0
	12270583	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	115.0	CHEMBL2973	Homo sapiens	Residual Activity	%	115.0
	12270584	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	104.0	CHEMBL2973	Homo sapiens	Residual Activity	%	104.0
	12270585	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	113.0	CHEMBL2973	Homo sapiens	Residual Activity	%	113.0
	12270586	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	110.0	CHEMBL2973	Homo sapiens	Residual Activity	%	110.0
	12270587	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	95.0	CHEMBL2973	Homo sapiens	Residual Activity	%	95.0
	12270588	CHEMBL2219153	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	2.0	CHEMBL2973	Homo sapiens	Residual Activity	%	2.0
	12270589	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12270590	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	85.0	CHEMBL2973	Homo sapiens	Residual Activity	%	85.0
	12270591	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	80.0	CHEMBL2973	Homo sapiens	Residual Activity	%	80.0
	12270592	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	79.0	CHEMBL2973	Homo sapiens	Residual Activity	%	79.0
	12270593	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	85.0	CHEMBL2973	Homo sapiens	Residual Activity	%	85.0
	12270594	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	66.0	CHEMBL2973	Homo sapiens	Residual Activity	%	66.0
	12270595	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	13.0	CHEMBL2973	Homo sapiens	Residual Activity	%	13.0
	12270596	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	87.0	CHEMBL2973	Homo sapiens	Residual Activity	%	87.0
	12270597	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12270598	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	81.0	CHEMBL2973	Homo sapiens	Residual Activity	%	81.0
	12270599	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	77.0	CHEMBL2973	Homo sapiens	Residual Activity	%	77.0
	12270600	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	83.0	CHEMBL2973	Homo sapiens	Residual Activity	%	83.0
	12270601	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	88.0	CHEMBL2973	Homo sapiens	Residual Activity	%	88.0
	12270602	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	77.0	CHEMBL2973	Homo sapiens	Residual Activity	%	77.0
	12270603	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	43.0	CHEMBL2973	Homo sapiens	Residual Activity	%	43.0
	12270604	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	85.0	CHEMBL2973	Homo sapiens	Residual Activity	%	85.0
	12270605	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12270606	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	82.0	CHEMBL2973	Homo sapiens	Residual Activity	%	82.0
	12270607	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	80.0	CHEMBL2973	Homo sapiens	Residual Activity	%	80.0
	12270608	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	58.0	CHEMBL2973	Homo sapiens	Residual Activity	%	58.0
	12270609	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	83.0	CHEMBL2973	Homo sapiens	Residual Activity	%	83.0
	12270610	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	78.0	CHEMBL2973	Homo sapiens	Residual Activity	%	78.0
	12270611	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	79.0	CHEMBL2973	Homo sapiens	Residual Activity	%	79.0
	12270612	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	87.0	CHEMBL2973	Homo sapiens	Residual Activity	%	87.0
	12270613	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	90.0	CHEMBL2973	Homo sapiens	Residual Activity	%	90.0
	12270614	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	70.0	CHEMBL2973	Homo sapiens	Residual Activity	%	70.0
	12270615	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	24.0	CHEMBL2973	Homo sapiens	Residual Activity	%	24.0
	12270616	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	40.0	CHEMBL2973	Homo sapiens	Residual Activity	%	40.0
	12270617	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	87.0	CHEMBL2973	Homo sapiens	Residual Activity	%	87.0
	12270618	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	77.0	CHEMBL2973	Homo sapiens	Residual Activity	%	77.0
	12270619	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	76.0	CHEMBL2973	Homo sapiens	Residual Activity	%	76.0
	12270620	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	51.0	CHEMBL2973	Homo sapiens	Residual Activity	%	51.0
	12270621	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	74.0	CHEMBL2973	Homo sapiens	Residual Activity	%	74.0
	12270622	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	67.0	CHEMBL2973	Homo sapiens	Residual Activity	%	67.0
	12270623	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	78.0	CHEMBL2973	Homo sapiens	Residual Activity	%	78.0
	12270624	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	82.0	CHEMBL2973	Homo sapiens	Residual Activity	%	82.0
	12270625	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	70.0	CHEMBL2973	Homo sapiens	Residual Activity	%	70.0
	12270626	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	92.0	CHEMBL2973	Homo sapiens	Residual Activity	%	92.0
	12270627	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	82.0	CHEMBL2973	Homo sapiens	Residual Activity	%	82.0
	12270628	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	82.0	CHEMBL2973	Homo sapiens	Residual Activity	%	82.0
	12270629	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12270630	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	87.0	CHEMBL2973	Homo sapiens	Residual Activity	%	87.0
	12270631	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	31.0	CHEMBL2973	Homo sapiens	Residual Activity	%	31.0
	12270632	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	1.0	CHEMBL2973	Homo sapiens	Residual Activity	%	1.0
	12270633	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	70.0	CHEMBL2973	Homo sapiens	Residual Activity	%	70.0
	12270634	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	6.0	CHEMBL2973	Homo sapiens	Residual Activity	%	6.0
	12270635	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	78.0	CHEMBL2973	Homo sapiens	Residual Activity	%	78.0
	12272277	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	80.0	CHEMBL2973	Homo sapiens	Residual Activity	%	80.0
	12272278	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	89.0	CHEMBL2973	Homo sapiens	Residual Activity	%	89.0
	12272279	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	82.0	CHEMBL2973	Homo sapiens	Residual Activity	%	82.0
	12272280	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	77.0	CHEMBL2973	Homo sapiens	Residual Activity	%	77.0
	12272281	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	70.0	CHEMBL2973	Homo sapiens	Residual Activity	%	70.0
	12272282	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	1.0	CHEMBL2973	Homo sapiens	Residual Activity	%	1.0
	12272283	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	-1.0	CHEMBL2973	Homo sapiens	Residual Activity	%	-1.0
	12272284	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	78.0	CHEMBL2973	Homo sapiens	Residual Activity	%	78.0
	12272285	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12272286	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	82.0	CHEMBL2973	Homo sapiens	Residual Activity	%	82.0
	12272287	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	86.0	CHEMBL2973	Homo sapiens	Residual Activity	%	86.0
	12272288	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	75.0	CHEMBL2973	Homo sapiens	Residual Activity	%	75.0
	12272289	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	73.0	CHEMBL2973	Homo sapiens	Residual Activity	%	73.0
	12272290	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	65.0	CHEMBL2973	Homo sapiens	Residual Activity	%	65.0
	12272291	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	57.0	CHEMBL2973	Homo sapiens	Residual Activity	%	57.0
	12272292	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	82.0	CHEMBL2973	Homo sapiens	Residual Activity	%	82.0
	12272293	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	90.0	CHEMBL2973	Homo sapiens	Residual Activity	%	90.0
	12272294	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12272295	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	38.0	CHEMBL2973	Homo sapiens	Residual Activity	%	38.0
	12272296	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	80.0	CHEMBL2973	Homo sapiens	Residual Activity	%	80.0
	12272297	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	80.0	CHEMBL2973	Homo sapiens	Residual Activity	%	80.0
	12272298	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	80.0	CHEMBL2973	Homo sapiens	Residual Activity	%	80.0
	12272299	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	84.0	CHEMBL2973	Homo sapiens	Residual Activity	%	84.0
	12272300	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12272301	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	88.0	CHEMBL2973	Homo sapiens	Residual Activity	%	88.0
	12272302	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	88.0	CHEMBL2973	Homo sapiens	Residual Activity	%	88.0
	12272303	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	97.0	CHEMBL2973	Homo sapiens	Residual Activity	%	97.0
	12272304	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	81.0	CHEMBL2973	Homo sapiens	Residual Activity	%	81.0
	12272305	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	25.0	CHEMBL2973	Homo sapiens	Residual Activity	%	25.0
	12272306	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	89.0	CHEMBL2973	Homo sapiens	Residual Activity	%	89.0
	12272307	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	32.0	CHEMBL2973	Homo sapiens	Residual Activity	%	32.0
	12272308	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12272309	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	0.0	CHEMBL2973	Homo sapiens	Residual Activity	%	0.0
	12272310	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12272311	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	3.0	CHEMBL2973	Homo sapiens	Residual Activity	%	3.0
	12272312	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	89.0	CHEMBL2973	Homo sapiens	Residual Activity	%	89.0
	12272313	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	4.0	CHEMBL2973	Homo sapiens	Residual Activity	%	4.0
	12272314	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	98.0	CHEMBL2973	Homo sapiens	Residual Activity	%	98.0
	12272315	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12272316	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12272317	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	100.0	CHEMBL2973	Homo sapiens	Residual Activity	%	100.0
	12272318	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	101.0	CHEMBL2973	Homo sapiens	Residual Activity	%	101.0
	12272319	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	82.0	CHEMBL2973	Homo sapiens	Residual Activity	%	82.0
	12272320	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	95.0	CHEMBL2973	Homo sapiens	Residual Activity	%	95.0
	12272321	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	90.0	CHEMBL2973	Homo sapiens	Residual Activity	%	90.0
	12272322	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	98.0	CHEMBL2973	Homo sapiens	Residual Activity	%	98.0
	12272323	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	92.0	CHEMBL2973	Homo sapiens	Residual Activity	%	92.0
	12272324	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12272325	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	4.0	CHEMBL2973	Homo sapiens	Residual Activity	%	4.0
	12272326	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	102.0	CHEMBL2973	Homo sapiens	Residual Activity	%	102.0
	12272327	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12272328	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	90.0	CHEMBL2973	Homo sapiens	Residual Activity	%	90.0
	12272329	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12272330	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	85.0	CHEMBL2973	Homo sapiens	Residual Activity	%	85.0
	12272331	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	2.0	CHEMBL2973	Homo sapiens	Residual Activity	%	2.0
	12272332	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12272333	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	104.0	CHEMBL2973	Homo sapiens	Residual Activity	%	104.0
	12272334	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	89.0	CHEMBL2973	Homo sapiens	Residual Activity	%	89.0
	12272335	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	90.0	CHEMBL2973	Homo sapiens	Residual Activity	%	90.0
	12272336	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	73.0	CHEMBL2973	Homo sapiens	Residual Activity	%	73.0
	12272337	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	86.0	CHEMBL2973	Homo sapiens	Residual Activity	%	86.0
	12272338	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	92.0	CHEMBL2973	Homo sapiens	Residual Activity	%	92.0
	12272339	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	41.0	CHEMBL2973	Homo sapiens	Residual Activity	%	41.0
	12272340	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12272341	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	76.0	CHEMBL2973	Homo sapiens	Residual Activity	%	76.0
	12272342	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	7.0	CHEMBL2973	Homo sapiens	Residual Activity	%	7.0
	12272343	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	81.0	CHEMBL2973	Homo sapiens	Residual Activity	%	81.0
	12272344	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	72.0	CHEMBL2973	Homo sapiens	Residual Activity	%	72.0
	12272345	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	83.0	CHEMBL2973	Homo sapiens	Residual Activity	%	83.0
	12272346	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	53.0	CHEMBL2973	Homo sapiens	Residual Activity	%	53.0
	12272347	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12272348	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12272349	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	101.0	CHEMBL2973	Homo sapiens	Residual Activity	%	101.0
	12272350	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12272351	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	53.0	CHEMBL2973	Homo sapiens	Residual Activity	%	53.0
	12272352	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	66.0	CHEMBL2973	Homo sapiens	Residual Activity	%	66.0
	12272353	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	58.0	CHEMBL2973	Homo sapiens	Residual Activity	%	58.0
	12272354	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	86.0	CHEMBL2973	Homo sapiens	Residual Activity	%	86.0
	12272355	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	83.0	CHEMBL2973	Homo sapiens	Residual Activity	%	83.0
	12272356	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	76.0	CHEMBL2973	Homo sapiens	Residual Activity	%	76.0
	12272357	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	102.0	CHEMBL2973	Homo sapiens	Residual Activity	%	102.0
	12272358	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12272359	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	1.0	CHEMBL2973	Homo sapiens	Residual Activity	%	1.0
	12272360	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12272361	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	92.0	CHEMBL2973	Homo sapiens	Residual Activity	%	92.0
	12272362	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	39.0	CHEMBL2973	Homo sapiens	Residual Activity	%	39.0
	12272363	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	16.0	CHEMBL2973	Homo sapiens	Residual Activity	%	16.0
	12272364	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	87.0	CHEMBL2973	Homo sapiens	Residual Activity	%	87.0
	12272365	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	52.0	CHEMBL2973	Homo sapiens	Residual Activity	%	52.0
	12272366	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	84.0	CHEMBL2973	Homo sapiens	Residual Activity	%	84.0
	12272367	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	4.0	CHEMBL2973	Homo sapiens	Residual Activity	%	4.0
	12272368	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12272369	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	89.0	CHEMBL2973	Homo sapiens	Residual Activity	%	89.0
	12272370	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	95.0	CHEMBL2973	Homo sapiens	Residual Activity	%	95.0
	12272371	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	0.0	CHEMBL2973	Homo sapiens	Residual Activity	%	0.0
	12272372	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	107.0	CHEMBL2973	Homo sapiens	Residual Activity	%	107.0
	12272373	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	40.0	CHEMBL2973	Homo sapiens	Residual Activity	%	40.0
	12272374	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12272375	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	96.0	CHEMBL2973	Homo sapiens	Residual Activity	%	96.0
	12272376	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	95.0	CHEMBL2973	Homo sapiens	Residual Activity	%	95.0
	12272377	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	42.0	CHEMBL2973	Homo sapiens	Residual Activity	%	42.0
	12272378	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	91.0	CHEMBL2973	Homo sapiens	Residual Activity	%	91.0
	12272379	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	82.0	CHEMBL2973	Homo sapiens	Residual Activity	%	82.0
	12272380	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	36.0	CHEMBL2973	Homo sapiens	Residual Activity	%	36.0
	12272381	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	93.0	CHEMBL2973	Homo sapiens	Residual Activity	%	93.0
	12272382	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	98.0	CHEMBL2973	Homo sapiens	Residual Activity	%	98.0
	12272383	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12272384	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	99.0	CHEMBL2973	Homo sapiens	Residual Activity	%	99.0
	12272385	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	94.0	CHEMBL2973	Homo sapiens	Residual Activity	%	94.0
	12272386	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	36.0	CHEMBL2973	Homo sapiens	Residual Activity	%	36.0
	12272387	CHEMBL2219154	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	3.0	CHEMBL2973	Homo sapiens	Residual Activity	%	3.0
	12647863	CHEMBL2329060	Inhibition of ROCK2 (unknown origin) at 1 uM	B	CC(C)(C)[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325895	=	Inhibition	%	26.0	CHEMBL2973	Homo sapiens	INH	%	26.0
	12647864	CHEMBL2329060	Inhibition of ROCK2 (unknown origin) at 1 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325894	=	Inhibition	%	53.0	CHEMBL2973	Homo sapiens	INH	%	53.0
	12647865	CHEMBL2329060	Inhibition of ROCK2 (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C#N		CHEMBL2325906	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	12647866	CHEMBL2329060	Inhibition of ROCK2 (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C		CHEMBL2325903	=	Inhibition	%	45.0	CHEMBL2973	Homo sapiens	INH	%	45.0
	12649558	CHEMBL2329519	Inhibition of ROCK2 (unknown origin) at 10 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325894	=	Inhibition	%	94.0	CHEMBL2973	Homo sapiens	INH	%	94.0
	12649559	CHEMBL2329519	Inhibition of ROCK2 (unknown origin) at 10 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)O		CHEMBL2325904	=	Inhibition	%	85.0	CHEMBL2973	Homo sapiens	INH	%	85.0
	12649560	CHEMBL2329519	Inhibition of ROCK2 (unknown origin) at 10 uM	B	CC(C)NC(=O)c1c[nH]c2ncc(C3CC3)nc12		CHEMBL2325901	=	Inhibition	%	80.0	CHEMBL2973	Homo sapiens	INH	%	80.0
	12660677	CHEMBL2330665	Inhibition of ROCK2 (unknown origin) at 1 uM	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Inhibition	%	75.0	CHEMBL2973	Homo sapiens	INH	%	75.0
	12662030	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	IC50	nM	56.0	CHEMBL2973	Homo sapiens	IC50	nM	56.0
	12662031	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	COCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325740	=	IC50	nM	204.0	CHEMBL2973	Homo sapiens	IC50	nM	204.0
	12662032	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325739	=	IC50	nM	76.0	CHEMBL2973	Homo sapiens	IC50	nM	76.0
	12662033	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325738	=	IC50	nM	112.0	CHEMBL2973	Homo sapiens	IC50	nM	112.0
	12662034	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325737	=	IC50	nM	89.0	CHEMBL2973	Homo sapiens	IC50	nM	89.0
	12662035	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CS(=O)(=O)NCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325736	=	IC50	nM	153.0	CHEMBL2973	Homo sapiens	IC50	nM	153.0
	12662036	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CS(=O)(=O)NCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325735	=	IC50	nM	90.0	CHEMBL2973	Homo sapiens	IC50	nM	90.0
	12662037	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCS(N)(=O)=O)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325734	=	IC50	nM	62.0	CHEMBL2973	Homo sapiens	IC50	nM	62.0
	12662038	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CS(N)(=O)=O)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325733	=	IC50	nM	37.0	CHEMBL2973	Homo sapiens	IC50	nM	37.0
	12662039	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(=O)NCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325732	=	IC50	nM	182.0	CHEMBL2973	Homo sapiens	IC50	nM	182.0
	12662040	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)C(=O)CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325731	=	IC50	nM	266.0	CHEMBL2973	Homo sapiens	IC50	nM	266.0
	12662041	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC(=O)C(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325730	=	IC50	nM	351.0	CHEMBL2973	Homo sapiens	IC50	nM	351.0
	12662042	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCN2CCCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325729	=	IC50	nM	34.0	CHEMBL2973	Homo sapiens	IC50	nM	34.0
	12662043	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCN2CCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325728	=	IC50	nM	39.0	CHEMBL2973	Homo sapiens	IC50	nM	39.0
	12662044	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)CC[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325727	=	IC50	nM	34.0	CHEMBL2973	Homo sapiens	IC50	nM	34.0
	12662045	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCN2CCCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325996	=	IC50	nM	112.0	CHEMBL2973	Homo sapiens	IC50	nM	112.0
	12662046	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCN2CCOCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325995	=	IC50	nM	134.0	CHEMBL2973	Homo sapiens	IC50	nM	134.0
	12662047	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCN2CCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325994	=	IC50	nM	104.0	CHEMBL2973	Homo sapiens	IC50	nM	104.0
	12662048	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)CCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325993	=	IC50	nM	71.0	CHEMBL2973	Homo sapiens	IC50	nM	71.0
	12662049	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)CCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325992	=	IC50	nM	31.0	CHEMBL2973	Homo sapiens	IC50	nM	31.0
	12662050	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	COc1ccc(C(C)NC(=O)C2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1OC		CHEMBL2325991	=	IC50	nM	1072.0	CHEMBL2973	Homo sapiens	IC50	nM	1072.0
	12662051	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(S(C)(=O)=O)cc1		CHEMBL2325990	=	IC50	nM	1144.0	CHEMBL2973	Homo sapiens	IC50	nM	1144.0
	12662052	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccccn1		CHEMBL2325989	=	IC50	nM	3149.0	CHEMBL2973	Homo sapiens	IC50	nM	3149.0
	12662053	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1cccnc1		CHEMBL2325988	=	IC50	nM	1297.0	CHEMBL2973	Homo sapiens	IC50	nM	1297.0
	12662054	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(F)cc1		CHEMBL2325987	=	IC50	nM	135.0	CHEMBL2973	Homo sapiens	IC50	nM	135.0
	12662055	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccccc1		CHEMBL2325986	=	IC50	nM	132.0	CHEMBL2973	Homo sapiens	IC50	nM	132.0
	12662056	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(Cc2ccccc2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325985	=	IC50	nM	586.0	CHEMBL2973	Homo sapiens	IC50	nM	586.0
	12662057	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(c2ccccc2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325984	=	IC50	nM	576.0	CHEMBL2973	Homo sapiens	IC50	nM	576.0
	12662058	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(c2ccc(Cl)cc2)C2CC2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325983	=	IC50	nM	261.0	CHEMBL2973	Homo sapiens	IC50	nM	261.0
	12662059	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325982	=	IC50	nM	126.0	CHEMBL2973	Homo sapiens	IC50	nM	126.0
	12662060	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	C[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325743	=	IC50	nM	55.0	CHEMBL2973	Homo sapiens	IC50	nM	55.0
	12662061	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	C[C@@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325742	=	IC50	nM	1396.0	CHEMBL2973	Homo sapiens	IC50	nM	1396.0
	12662062	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325997	=	IC50	nM	101.0	CHEMBL2973	Homo sapiens	IC50	nM	101.0
	12662063	CHEMBL2330882	Inhibition of recombinant ROCK2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	IC50	nM	66.0	CHEMBL2973	Homo sapiens	IC50	nM	66.0
	12668226	CHEMBL2339638	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(N3CCOCC3)ccc12		CHEMBL2333120	=	Inhibition	%	78.0	CHEMBL2973	Homo sapiens	INH	%	78.0
	12668227	CHEMBL2339638	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333115	=	Inhibition	%	99.0	CHEMBL2973	Homo sapiens	INH	%	99.0
	12668228	CHEMBL2339638	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3ccncc3)cc12		CHEMBL2333114	=	Inhibition	%	88.0	CHEMBL2973	Homo sapiens	INH	%	88.0
	12668229	CHEMBL2339638	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12		CHEMBL2333112	=	Inhibition	%	97.0	CHEMBL2973	Homo sapiens	INH	%	97.0
	12668230	CHEMBL2339638	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCC4)c(C(N)=O)nnc3c2)cc1		CHEMBL2333129	=	Inhibition	%	53.0	CHEMBL2973	Homo sapiens	INH	%	53.0
	12668231	CHEMBL2339638	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1		CHEMBL2333128	=	Inhibition	%	70.0	CHEMBL2973	Homo sapiens	INH	%	70.0
	12668232	CHEMBL2339638	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2333125	=	Inhibition	%	86.0	CHEMBL2973	Homo sapiens	INH	%	86.0
	12672905	CHEMBL2341620	Inhibition of recombinant ROCK2 (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336379	=	Activity	%	65.0	CHEMBL2973	Homo sapiens	Activity	%	65.0
	12672906	CHEMBL2341620	Inhibition of recombinant ROCK2 (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336377	=	Activity	%	61.0	CHEMBL2973	Homo sapiens	Activity	%	61.0
	12693173	CHEMBL2345775	Inhibition of ROCK2 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	12705851	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CNC(=O)N(CCCN(C)C)c2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332096	=	IC50	nM	3324.0	CHEMBL2973	Homo sapiens	IC50	nM	3324.0
	12705854	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CNC(=O)N(CCN(C)C)c2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332094	=	IC50	nM	2984.0	CHEMBL2973	Homo sapiens	IC50	nM	2984.0
	12705859	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(NCCCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332079	=	IC50	nM	1017.0	CHEMBL2973	Homo sapiens	IC50	nM	1017.0
	12705861	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(OC)c1CNC(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332088	=	IC50	nM	924.0	CHEMBL2973	Homo sapiens	IC50	nM	924.0
	12705863	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(NCC1CCCCC1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332084	=	IC50	nM	751.0	CHEMBL2973	Homo sapiens	IC50	nM	751.0
	12705866	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CNC(=O)N(CCO)c2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332093	=	IC50	nM	611.0	CHEMBL2973	Homo sapiens	IC50	nM	611.0
	12705869	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc(OC)c(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332087	=	IC50	nM	570.0	CHEMBL2973	Homo sapiens	IC50	nM	570.0
	12705875	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc1OC		CHEMBL2332089	=	IC50	nM	425.0	CHEMBL2973	Homo sapiens	IC50	nM	425.0
	12705877	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc1F		CHEMBL2332091	=	IC50	nM	357.0	CHEMBL2973	Homo sapiens	IC50	nM	357.0
	12705879	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c(OC)c1		CHEMBL2332086	=	IC50	nM	331.0	CHEMBL2973	Homo sapiens	IC50	nM	331.0
	12705880	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332077	=	IC50	nM	304.0	CHEMBL2973	Homo sapiens	IC50	nM	304.0
	12705881	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc(OC)c1		CHEMBL2332090	=	IC50	nM	281.0	CHEMBL2973	Homo sapiens	IC50	nM	281.0
	12705882	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)N1CCc2ccccc2C1		CHEMBL2332083	=	IC50	nM	280.0	CHEMBL2973	Homo sapiens	IC50	nM	280.0
	12705884	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1OC		CHEMBL2332085	=	IC50	nM	253.0	CHEMBL2973	Homo sapiens	IC50	nM	253.0
	12705890	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2OCCN(C)C)c1		CHEMBL2332062	=	IC50	nM	170.0	CHEMBL2973	Homo sapiens	IC50	nM	170.0
	12705900	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(NCCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332078	=	IC50	nM	88.0	CHEMBL2973	Homo sapiens	IC50	nM	88.0
	12705902	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CNC(=O)N(C)c2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332092	=	IC50	nM	87.0	CHEMBL2973	Homo sapiens	IC50	nM	87.0
	12705924	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)OCCc1ccccc1		CHEMBL2332081	=	IC50	nM	55.0	CHEMBL2973	Homo sapiens	IC50	nM	55.0
	12705962	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(CCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332082	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	nM	24.0
	12705972	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COCCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332066	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
	12705978	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1F)N(CCO)Cc1ccccc1		CHEMBL2332075	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	12705980	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN2CCOCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332071	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	nM	13.0
	12705982	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)N(CCO)Cc1ccccc1		CHEMBL2331562	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	12706002	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)OCc1ccccc1		CHEMBL2332080	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	12706010	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN2CCCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332073	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	12706011	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCCN2CCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332070	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	12706024	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCCN2CCCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332074	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	12706025	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCCN2CCOCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332072	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	12706032	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN2CCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332069	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	12706033	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(C(=O)Nc2ccc(-c3cn[nH]c3)cc2)C(C)C)c1		CHEMBL2332064	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	12706040	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cn2)c1		CHEMBL2332063	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	12706041	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	CN(C)CCC(NC(=O)Nc1ccc(-c2cn[nH]c2)cc1)c1ccccc1		CHEMBL2332059	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	12706042	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CO)c1ccccc1		CHEMBL2332058	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	12706043	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CCO)c1cccc(F)c1		CHEMBL2332056	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	12706044	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(C(CCO)NC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332076	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	12706059	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1O[C@H]1CCN(C)C1		CHEMBL2332060	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12706060	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CCO)c1ccccc1		CHEMBL2332057	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12706061	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332068	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12706062	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332065	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12706063	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(C(=O)Nc2ccc(-c3cn[nH]c3)cc2)C2CC2)c1		CHEMBL2332099	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12706064	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332098	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12706065	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332097	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12708459	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CN(C)CCNc1nc([C@@H]2CNC[C@H]2c2ccc(F)cc2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333881	=	IC50	nM	371.0	CHEMBL2973	Homo sapiens	IC50	nM	371.0
	12708460	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	Fc1ccc([C@@H]2CNC[C@H]2c2nc(N3CCC3)c3cc(-c4cn[nH]c4)ccc3n2)cc1		CHEMBL2333880	=	IC50	nM	71.0	CHEMBL2973	Homo sapiens	IC50	nM	71.0
	12708461	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CN(C)c1nc([C@@H]2CNC[C@H]2c2ccccc2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333879	=	IC50	nM	2.5	CHEMBL2973	Homo sapiens	IC50	nM	2.5
	12708462	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CN(C)c1nc([C@@H](N)Cc2cccc(F)c2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333892	=	IC50	nM	67.0	CHEMBL2973	Homo sapiens	IC50	nM	67.0
	12708463	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CN(CCO)c1nc([C@@H](N)Cc2cccc(F)c2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333891	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	nM	27.0
	12708464	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CN(CCCO)c1nc([C@H](N)Cc2cccc(F)c2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333890	=	IC50	nM	159.0	CHEMBL2973	Homo sapiens	IC50	nM	159.0
	12708465	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CN(CCO)c1nc([C@H](N)Cc2cccc(F)c2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333889	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	nM	27.0
	12708466	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CN(C)CCN(C)c1nc([C@H](N)Cc2cccc(F)c2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333888	=	IC50	nM	627.0	CHEMBL2973	Homo sapiens	IC50	nM	627.0
	12708467	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1ccc([C@@H]2CN(C)C[C@H]2c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2333887	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	12708468	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	C[N+]1(C)C[C@@H](c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)[C@H](c2ccccc2)C1		CHEMBL2333886	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	12708469	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	NCc1cccc(C(=O)NC(c2ccc(Cl)cc2)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)c1		CHEMBL2333885	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
	12708470	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	NCc1ccc(C(=O)NC(c2ccc(Cl)cc2)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2333884	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	12708471	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	NCCC(=O)NC(c1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333883	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	12708472	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CN(C)CC(=O)NC(c1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333882	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12708473	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CCN[C@H](Cc1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333904	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	12708474	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	O=C(Cc1cccnc1)N[C@H](Cc1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333903	=	IC50	nM	239.0	CHEMBL2973	Homo sapiens	IC50	nM	239.0
	12708475	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	O=c1[nH]c([C@@H]2CN(Cc3ccccc3)C[C@H]2c2ccccc2F)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333902	=	IC50	nM	49.0	CHEMBL2973	Homo sapiens	IC50	nM	49.0
	12708476	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	O=c1[nH]c([C@@H]2CN(Cc3ccccc3)C[C@H]2c2cccc(F)c2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333901	=	IC50	nM	225.0	CHEMBL2973	Homo sapiens	IC50	nM	225.0
	12708477	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1ccc([C@@H]2CN(Cc3ccccc3)C[C@H]2c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2333900	=	IC50	nM	88.0	CHEMBL2973	Homo sapiens	IC50	nM	88.0
	12708478	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	O=c1[nH]c([C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)cc2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333899	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	12708479	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	O=c1[nH]c([C@@H]2CNC[C@H]2c2ccc(Cl)cc2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333898	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12708480	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	O=c1[nH]c([C@@H]2CNC[C@H]2c2ccc(F)cc2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333897	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	12708481	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c(C(N)c3cccc(Cl)c3)nc12		CHEMBL2333896	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	12708482	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c(C(N)c3ccc(Cl)cc3)nc12		CHEMBL2333895	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	12708483	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	NC(c1cccc(Cl)c1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333894	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	nM	13.0
	12708484	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	NC(c1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333893	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	12708485	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@H](Cc1cccc(C(F)(F)F)c1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2334284	=	IC50	nM	16.0	CHEMBL2973	Homo sapiens	IC50	nM	16.0
	12708486	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@H](Cc1cccc(F)c1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333914	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	12708487	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@H](Cc1cccc(Cl)c1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333913	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	nM	13.0
	12708488	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@H](Cc1ccc(F)c(F)c1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333912	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	12708489	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1ccc(C[C@H](N)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1OC		CHEMBL2333911	=	IC50	nM	39.0	CHEMBL2973	Homo sapiens	IC50	nM	39.0
	12708490	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	CCOc1ccc(C[C@H](N)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2333910	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	nM	19.0
	12708491	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1ccc(C[C@H](N)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2333909	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	12708492	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c([C@H](N)Cc3cccc(F)c3)nc12		CHEMBL2333908	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	12708493	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c([C@@H](N)Cc3cccc(F)c3)nc12		CHEMBL2333907	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	12708494	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@H](Cc1ccc(F)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333906	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	12708495	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@@H](Cc1ccc(F)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2333905	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	12708496	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@H](Cc1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2334294	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	12708497	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@@H](Cc1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2334293	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	12708498	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	O=c1[nH]c([C@@H]2CNC[C@H]2c2ccccc2)nc2ccc(-c3cn[nH]c3)cc12		CHEMBL2334292	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12708499	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	Cc1n[nH]cc1-c1ccc2nc([C@@H]3CNC[C@H]3c3ccccc3)[nH]c(=O)c2c1		CHEMBL2334291	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	12708500	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	Nc1nccc(-c2ccc3nc([C@@H]4CNC[C@H]4c4ccccc4)[nH]c(=O)c3c2)n1		CHEMBL2334290	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	12708501	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	O=c1[nH]c([C@@H]2CNC[C@H]2c2ccccc2)nc2ccc(-c3ccncc3)cc12		CHEMBL2334289	=	IC50	nM	23.0	CHEMBL2973	Homo sapiens	IC50	nM	23.0
	12708502	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1ccc(C(N)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1		CHEMBL2334288	=	IC50	nM	43.0	CHEMBL2973	Homo sapiens	IC50	nM	43.0
	12708503	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	COc1ccc(C(N)c2nc3ccc(-c4c[nH]nc4C)cc3c(=O)[nH]2)cc1		CHEMBL2334287	=	IC50	nM	98.0	CHEMBL2973	Homo sapiens	IC50	nM	98.0
	12708504	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@@H](Cc1ccccc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1		CHEMBL2334286	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	12708505	CHEMBL2346267	Inhibition of human recombinant 6-His-tagged ROCK2 expressed in baculovirus-infected Sf9 cells using LCB-AKRRRLSSLRA-NH2 as substrate after 25 mins by TR-FRET assay	B	N[C@@H](Cc1ccccc1)c1nc2ccc(-c3ccncc3)cc2c(=O)[nH]1		CHEMBL2334285	=	IC50	nM	52.0	CHEMBL2973	Homo sapiens	IC50	nM	52.0
	12708867	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CNC(=O)N(CCN2CCCC2)c2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332095	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	nM	20000.0
	12708888	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2OCCO)c1		CHEMBL2332061	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12708889	CHEMBL2341182	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1cccc(CN(CCN)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332067	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	12721797	CHEMBL2351854	Inhibition of ROCK2 (unknown origin) at 1 uM relative to control	B	CCNC(=O)Nc1nc2ccc(-c3ccccc3OC)cc2s1		CHEMBL2347710	=	Inhibition	%	100.0	CHEMBL2973	Homo sapiens	INH	%	100.0
	12723640	CHEMBL2350472	Inhibition of ROCK2 (unknown origin) at 10 uM by single point assay	B	C[C@@H](Nc1c(C#N)cnc2cc(-c3ccc(-n4ccoc4=O)cc3)ccc12)C1CC1		CHEMBL2347818	=	Inhibition	%	16.0	CHEMBL2973	Homo sapiens	INH	%	16.0
	12723684	CHEMBL2350778	Inhibition of ROCK2 (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3cnn(C)c3)ccc12		CHEMBL2347824	=	Inhibition	%	14.0	CHEMBL2973	Homo sapiens	INH	%	14.0
	12723685	CHEMBL2350778	Inhibition of ROCK2 (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2347823	=	Inhibition	%	12.0	CHEMBL2973	Homo sapiens	INH	%	12.0
	12727663	CHEMBL2351127	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	91.0	CHEMBL2973	Homo sapiens	Activity	%	91.0
	12728949	CHEMBL2353067	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	101.0	CHEMBL2973	Homo sapiens	Activity	%	101.0
	12729832	CHEMBL2352164	Inhibition of ROCK2 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	94.0	CHEMBL2973	Homo sapiens	Activity	%	94.0
	12730092	CHEMBL2351127	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	95.0	CHEMBL2973	Homo sapiens	Activity	%	95.0
	13281275	CHEMBL2378204	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3ncn4cc(F)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376158	=	Inhibition	%	61.0	CHEMBL2973	Homo sapiens	INH	%	61.0
	13281276	CHEMBL2378204	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@@H](C(=O)N4CC(C#N)C4)C4CC4)c3n2)c2ccc(Cl)cc21		CHEMBL2376154	=	Inhibition	%	30.0	CHEMBL2973	Homo sapiens	INH	%	30.0
	13281277	CHEMBL2378204	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	CC[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376153	=	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	13281278	CHEMBL2378204	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376152	=	Inhibition	%	36.0	CHEMBL2973	Homo sapiens	INH	%	36.0
	13281279	CHEMBL2378204	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376144	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	INH	%	4.0
	13281280	CHEMBL2378204	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3cn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376143	=	Inhibition	%	94.0	CHEMBL2973	Homo sapiens	INH	%	94.0
	13311854	CHEMBL2384677	Inhibition of human ROCK2	B	COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2		CHEMBL2381116	=	IC50	nM	6800.0	CHEMBL2973	Homo sapiens	IC50	nM	6800.0
	13321297	CHEMBL2388366	Inhibition of ROCK2 (unknown origin)	B	O=C1c2oc(-c3ccc(Cl)cc3)cc2Cc2cc(N3CCNCC3)ccc2N1Cc1ccccc1-c1cccnc1		CHEMBL2385543	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	uM	20.0
	13351562	CHEMBL2399773	Inhibition of human ROCK-2 at 10 uM relative to control	B	Cl.O=c1[nH]nc2c(NCCCc3ccncc3)cc(Cl)cn12		CHEMBL2397859	=	Inhibition	%	27.0	CHEMBL2973	Homo sapiens	INH	%	27.0
	13367207	CHEMBL2406324	Inhibition of ROCK2 (unknown origin) after 60 mins	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	IC50	nM	1270.0	CHEMBL2973	Homo sapiens	IC50	uM	1.27
	13374359	CHEMBL2406304	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	13415140	CHEMBL2423375	Inhibition of ROCK2 (unknown origin) at 1 uM	B	Cn1cc(-c2ccncc2)c(-c2ccc(F)cc2)n1		CHEMBL2420700	=	Inhibition	%	52.0	CHEMBL2973	Homo sapiens	INH	%	52.0
	13419718	CHEMBL2422272	Inhibition of ROCK2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1		CHEMBL2420901	=	Inhibition	%	78.0	CHEMBL2973	Homo sapiens	INH	%	78.0
	13419719	CHEMBL2422272	Inhibition of ROCK2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420900	=	Inhibition	%	98.0	CHEMBL2973	Homo sapiens	INH	%	98.0
	13419720	CHEMBL2422272	Inhibition of ROCK2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(C2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420899	=	Inhibition	%	99.0	CHEMBL2973	Homo sapiens	INH	%	99.0
	13434498	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(Cc2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420551	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434499	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420555	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434500	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CCC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420573	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434501	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420572	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434502	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC(C)(NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420570	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434503	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CCC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420565	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434504	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(N[C@H](CO)c1ccccc1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420564	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434505	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420562	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434506	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420560	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434507	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420556	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434508	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420587	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13434509	CHEMBL2424231	Inhibition of ROCK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420585	<	Inhibition	%	35.0	CHEMBL2973	Homo sapiens	INH	%	35.0
	13453011	CHEMBL2429441	Inhibition of ROCK-2 (unknown origin) at 1 uM by [33P]-ATP filter-binding assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1	Outside typical range	CHEMBL2425156	=	Inhibition	%	-16.0	CHEMBL2973	Homo sapiens	INH	%	-16.0
	13453059	CHEMBL2429441	Inhibition of ROCK-2 (unknown origin) at 1 uM by [33P]-ATP filter-binding assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1	Outside typical range	CHEMBL2425145	=	Inhibition	%	-14.0	CHEMBL2973	Homo sapiens	INH	%	-14.0
	13453107	CHEMBL2429441	Inhibition of ROCK-2 (unknown origin) at 1 uM by [33P]-ATP filter-binding assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1	Outside typical range	CHEMBL2425144	=	Inhibition	%	-11.0	CHEMBL2973	Homo sapiens	INH	%	-11.0
	13476372	CHEMBL2439756	Inhibition of wild type human ROCK2 by high throughput ATP-[33P] radiolabeled assay	B	CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1		CHEMBL2436978	=	IC50	nM	111.0	CHEMBL2973	Homo sapiens	IC50	nM	111.0
Active	13488399	CHEMBL2439415	Inhibition of human ROCK2 at 1 uM	B	CN1CCC(Nc2ccc3ncc(-c4cnn(-c5ccc(C#N)cc5)c4)n3n2)CC1		CHEMBL2436446		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	13508477	CHEMBL2447351	Inhibition of ROCK2 (unknown origin) at 30 uM	B	O=C(Nc1ccc2c(c1)B(O)OC2)c1c(C(F)(F)F)ccc(Cl)c1F		CHEMBL2441375		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	13514679	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	COC(=O)c1ccc(-c2cc(C(=O)Nc3ccncc3)ccc2CN)cc1		CHEMBL2440741	=	IC50	nM	102.0	CHEMBL2973	Homo sapiens	IC50	nM	102.0
	13514690	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	CC(C)OCCOC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3F)ccc2CN)c1		CHEMBL2440734	=	IC50	nM	37.0	CHEMBL2973	Homo sapiens	IC50	nM	37.0
	13514691	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	COCCOC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3)ccc2CN)c1		CHEMBL2440732	=	IC50	nM	3.6	CHEMBL2973	Homo sapiens	IC50	nM	3.6
	13514692	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	COCCCOC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3)ccc2CN)c1		CHEMBL2440733	=	IC50	nM	1.5	CHEMBL2973	Homo sapiens	IC50	nM	1.5
	13514693	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2)cc1-c1cccc(C(=O)O)c1		CHEMBL2440739	=	IC50	nM	167.0	CHEMBL2973	Homo sapiens	IC50	nM	167.0
	13514694	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	54.0	CHEMBL2973	Homo sapiens	IC50	nM	54.0
	13514695	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	CC(N)c1ccc(C(=O)Nc2ccncc2)cc1-c1ccc(F)cc1		CHEMBL2440742	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
	13514696	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)OCCO)c1		CHEMBL2440735	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
	13514697	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)OC2CCCOC2)c1		CHEMBL2440736	=	IC50	nM	8.7	CHEMBL2973	Homo sapiens	IC50	nM	8.7
	13514698	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	CCOC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3)ccc2CN)c1		CHEMBL2440744	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	13514699	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	CCCOC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3)ccc2CN)c1		CHEMBL2440745	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
	13514700	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	CCCCOC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3)ccc2CN)c1		CHEMBL2440746	=	IC50	nM	5.5	CHEMBL2973	Homo sapiens	IC50	nM	5.5
	13514701	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	COC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3)ccc2CN)c1		CHEMBL2440743	=	IC50	nM	2.9	CHEMBL2973	Homo sapiens	IC50	nM	2.9
	13514702	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)OCC2CCCO2)c1		CHEMBL2440737	=	IC50	nM	2.5	CHEMBL2973	Homo sapiens	IC50	nM	2.5
	13514703	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)OCC2CCCCO2)c1		CHEMBL2440738	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	13514704	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2)cc1-c1cccc(C(=O)OCc2ccccc2)c1		CHEMBL2440731	=	IC50	nM	45.0	CHEMBL2973	Homo sapiens	IC50	nM	45.0
	13514705	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)OCC2CCC2)c1		CHEMBL2440756	=	IC50	nM	4.3	CHEMBL2973	Homo sapiens	IC50	nM	4.3
	13514706	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)OCC2CC2)c1		CHEMBL2440730	=	IC50	nM	2.7	CHEMBL2973	Homo sapiens	IC50	nM	2.7
	13514707	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	CCCCCOC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3)ccc2CN)c1		CHEMBL2440747	=	IC50	nM	4.9	CHEMBL2973	Homo sapiens	IC50	nM	4.9
	13514708	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	CCCCCCOC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3)ccc2CN)c1		CHEMBL2440748	=	IC50	nM	22.0	CHEMBL2973	Homo sapiens	IC50	nM	22.0
	13514709	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	COC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3F)ccc2CN)c1		CHEMBL2440749	=	IC50	nM	7.8	CHEMBL2973	Homo sapiens	IC50	nM	7.8
	13514710	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	CCCOC(=O)c1cccc(-c2cc(C(=O)Nc3ccncc3F)ccc2CN)c1		CHEMBL2440750	=	IC50	nM	5.1	CHEMBL2973	Homo sapiens	IC50	nM	5.1
	13514711	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2)cc1-c1cccc(C(=O)OC2CCCCC2)c1		CHEMBL2440751	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
	13514712	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Oc2ccccc2)c1		CHEMBL2440752	=	IC50	nM	6.2	CHEMBL2973	Homo sapiens	IC50	nM	6.2
	13514713	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)O)c1		CHEMBL2440740	=	IC50	nM	55.0	CHEMBL2973	Homo sapiens	IC50	nM	55.0
	13514714	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)OCC2CCCC2)c1		CHEMBL2440755	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	nM	13.0
	13514715	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2)cc1-c1cccc(C(=O)OCC2CCCCC2)c1		CHEMBL2440754	=	IC50	nM	48.0	CHEMBL2973	Homo sapiens	IC50	nM	48.0
	13514716	CHEMBL2444040	Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay	B	NCc1ccc(C(=O)Nc2ccncc2)cc1-c1cccc(C(=O)OCC2CCCC2)c1		CHEMBL2440753	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	13836550	CHEMBL3091193	Inhibition of ROCK2 (unknown origin)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	158.0	CHEMBL2973	Homo sapiens	IC50	uM	0.158
Not Active	13863530	CHEMBL3101998	Inhibition of ROCK2 (unknown origin) at 1 uM after 1 hr	B	CC1(C)OC(=O)N([C@H]2CC[C@H](c3cnc(N)c(-c4ncccn4)c3)CC2)[C@H]1c1ccccc1		CHEMBL3099716		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	13863531	CHEMBL3101998	Inhibition of ROCK2 (unknown origin) at 1 uM after 1 hr	B	CC1(C)OC(=O)N(c2ccc(-c3cnc(N)c(-c4ncccn4)c3)cc2)[C@H]1c1ccccc1		CHEMBL3099720		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	13871757	CHEMBL3100923	Inhibition of human ROCK-2 assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	114.0	CHEMBL2973	Homo sapiens	Activity	%	114.0
	13953232	CHEMBL3132639	Inhibition of human ROCK-2 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	108.0	CHEMBL2973	Homo sapiens	Activity	%	108.0
	13953233	CHEMBL3132639	Inhibition of human ROCK-2 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	108.0	CHEMBL2973	Homo sapiens	Activity	%	108.0
	13954637	CHEMBL3132639	Inhibition of human ROCK-2 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	102.0	CHEMBL2973	Homo sapiens	Activity	%	102.0
	13965691	CHEMBL3135776	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 70 uM after 90 mins by microfluidic peptide phosphorylation assay	B	CNCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL376388	=	Inhibition	%	88.5	CHEMBL2973	Homo sapiens	INH	%	88.5
	13966069	CHEMBL3136906	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 1000 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	99.5	CHEMBL2973	Homo sapiens	INH	%	99.5
	13973344	CHEMBL3135744	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.1 uM after 90 mins by microfluidic peptide phosphorylation assay	B	C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N		CHEMBL1928705	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	13974062	CHEMBL3134722	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.35 uM after 90 mins by microfluidic peptide phosphorylation assay	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1		CHEMBL1928692	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	13974153	CHEMBL3136367	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 9 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]c4cnccc4c23)CCO1		CHEMBL1928677	=	Inhibition	%	53.0	CHEMBL2973	Homo sapiens	INH	%	53.0
	13974244	CHEMBL3135625	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 90 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]cnc23)CCO1		CHEMBL560373	=	Inhibition	%	103.0	CHEMBL2973	Homo sapiens	INH	%	103.0
	13974982	CHEMBL3135148	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 420 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1nc(N2CCOCC2)c2nc[nH]c2n1		CHEMBL271138	=	Inhibition	%	101.0	CHEMBL2973	Homo sapiens	INH	%	101.0
	13975073	CHEMBL3136718	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.02 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	Inhibition	%	35.5	CHEMBL2973	Homo sapiens	INH	%	35.5
	13975164	CHEMBL3134947	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.06 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	13975255	CHEMBL3136536	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL259141	=	Inhibition	%	44.0	CHEMBL2973	Homo sapiens	INH	%	44.0
	13975898	CHEMBL3136265	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 8 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL261249	=	Inhibition	%	89.5	CHEMBL2973	Homo sapiens	INH	%	89.5
	13975991	CHEMBL3136300	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1		CHEMBL228133	=	Inhibition	%	97.0	CHEMBL2973	Homo sapiens	INH	%	97.0
	13976082	CHEMBL3136182	Inhibition of human ROCK2 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 95 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL227727	=	Inhibition	%	93.5	CHEMBL2973	Homo sapiens	INH	%	93.5
	14543542	CHEMBL3226384	Inhibition of ROCK2 (unknown origin)	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Ki	nM	300.0	CHEMBL2973	Homo sapiens	Ki	uM	0.3
	14543543	CHEMBL3226384	Inhibition of ROCK2 (unknown origin)	B	C[C@@H](N)c1ccc(C(=O)Nc2ccncc2)cc1.Cl		CHEMBL2419278	=	IC50	nM	390.0	CHEMBL2973	Homo sapiens	IC50	uM	0.39
	14543544	CHEMBL3226384	Inhibition of ROCK2 (unknown origin)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	320.0	CHEMBL2973	Homo sapiens	IC50	uM	0.32
	14543545	CHEMBL3226384	Inhibition of ROCK2 (unknown origin)	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	IC50	nM	0.45	CHEMBL2973	Homo sapiens	IC50	nM	0.45
	14545739	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218005	=	IC50	nM	50.0	CHEMBL2973	Homo sapiens	IC50	uM	0.05
	14545740	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	uM	0.011
	14545741	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1ccccc1CNC(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218007	=	IC50	nM	470.0	CHEMBL2973	Homo sapiens	IC50	uM	0.47
Not Determined	14545742	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218008		IC50			CHEMBL2973	Homo sapiens	IC50		
	14545743	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218009	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	uM	0.02
	14545744	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1cccc2[nH]ccc12)Nc1nc(-c2ccncc2)cs1		CHEMBL3218010	=	IC50	nM	31100.0	CHEMBL2973	Homo sapiens	IC50	uM	31.1
	14545745	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218011	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	uM	0.006
	14545746	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccccc1O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218012	=	IC50	nM	280.0	CHEMBL2973	Homo sapiens	IC50	uM	0.28
	14545747	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccc(O)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218013	=	IC50	nM	140.0	CHEMBL2973	Homo sapiens	IC50	uM	0.14
	14545748	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	NC(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218014	=	IC50	nM	180.0	CHEMBL2973	Homo sapiens	IC50	uM	0.18
	14545749	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CS(=O)(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218015	=	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	uM	0.1
	14545750	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218016	=	IC50	nM	130.0	CHEMBL2973	Homo sapiens	IC50	uM	0.13
	14545751	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COCCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218017	=	IC50	nM	240.0	CHEMBL2973	Homo sapiens	IC50	uM	0.24
	14545752	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218018	=	IC50	nM	290.0	CHEMBL2973	Homo sapiens	IC50	uM	0.29
	14545753	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CCCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218019	=	IC50	nM	680.0	CHEMBL2973	Homo sapiens	IC50	uM	0.68
	14545754	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC(C)Oc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218020	=	IC50	nM	3440.0	CHEMBL2973	Homo sapiens	IC50	uM	3.44
	14545755	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1cccc(F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218021	=	IC50	nM	50.0	CHEMBL2973	Homo sapiens	IC50	uM	0.05
	14545756	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccccc1F)Nc1nc(-c2ccncc2)cs1		CHEMBL3218022	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	uM	0.12
	14545757	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccc(F)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218023	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	uM	0.19
	14545758	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1cccc(Cl)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218024	=	IC50	nM	60.0	CHEMBL2973	Homo sapiens	IC50	uM	0.06
	14545759	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccccc1Cl)Nc1nc(-c2ccncc2)cs1		CHEMBL3217759	=	IC50	nM	110.0	CHEMBL2973	Homo sapiens	IC50	uM	0.11
	14545760	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(NCc1ccc(Cl)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218025	=	IC50	nM	1100.0	CHEMBL2973	Homo sapiens	IC50	uM	1.1
	14545761	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	Cc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218026	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	uM	0.12
	14545762	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	Cc1ccccc1CNC(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218027	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	uM	0.12
	14545763	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	Cc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218028	=	IC50	nM	2000.0	CHEMBL2973	Homo sapiens	IC50	uM	2.0
	14545764	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CN(Cc1ccccc1)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218274	=	IC50	nM	70.0	CHEMBL2973	Homo sapiens	IC50	uM	0.07
	14545765	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc(CNC(=O)N(C)c2nc(-c3ccncc3)cs2)c1		CHEMBL3218275	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	uM	0.007
	14545766	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc(CN(C)C(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218276	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	uM	0.015
	14545767	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218277	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	uM	0.012
	14545768	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@H](CO)c1ccccc1		CHEMBL3218278	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	uM	0.01
	14545769	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218279	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	uM	0.03
	14545770	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	NC(=O)[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218280	=	IC50	nM	42.0	CHEMBL2973	Homo sapiens	IC50	uM	0.042
	14545771	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COC[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218281	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	uM	0.03
	14545772	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc([C@@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218282	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	uM	0.009
	14545773	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218283	=	IC50	nM	42.0	CHEMBL2973	Homo sapiens	IC50	uM	0.042
	14545774	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(Cl)c1		CHEMBL3218284	=	IC50	nM	78.0	CHEMBL2973	Homo sapiens	IC50	uM	0.078
	14545775	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218285	=	IC50	nM	1900.0	CHEMBL2973	Homo sapiens	IC50	uM	1.9
	14545776	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@@H](CO)c1ccccc1		CHEMBL3218286	=	IC50	nM	2500.0	CHEMBL2973	Homo sapiens	IC50	uM	2.5
	14545777	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218287	=	IC50	nM	22000.0	CHEMBL2973	Homo sapiens	IC50	uM	22.0
	14545778	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	NC(=O)[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218288	=	IC50	nM	2100.0	CHEMBL2973	Homo sapiens	IC50	uM	2.1
	14545779	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COC[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218289	=	IC50	nM	12000.0	CHEMBL2973	Homo sapiens	IC50	uM	12.0
	14545780	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	COc1cccc([C@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218290	=	IC50	nM	9300.0	CHEMBL2973	Homo sapiens	IC50	uM	9.3
	14545781	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218291	=	IC50	nM	6300.0	CHEMBL2973	Homo sapiens	IC50	uM	6.3
Not Determined	14545782	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(Cl)c1		CHEMBL3218292		IC50			CHEMBL2973	Homo sapiens	IC50		
	14545783	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@H](c1ccccc1)N(C)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218293	=	IC50	nM	47.0	CHEMBL2973	Homo sapiens	IC50	uM	0.047
	14545784	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	C[C@@H](c1ccccc1)N(C)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218294	=	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	uM	2.7
	14545785	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(Nc1nc(-c2ccncc2)cs1)NC(CO)c1ccccc1		CHEMBL3218295	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	uM	0.03
Not Determined	14545786	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	CC(NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218296		IC50			CHEMBL2973	Homo sapiens	IC50		
	14545831	CHEMBL3224098	Inhibition of N-terminal GST-tagged ROCK2 (1 to 552) (unknown origin) using KKRPQRRSNVF as substrate after 1 hr by Z-Lyte-based FRET assay	B	O=C(Nc1nc(-c2ccncc2)cs1)C1COc2ccccc2O1		CHEMBL510515	=	IC50	nM	0.56	CHEMBL2973	Homo sapiens	IC50	nM	0.56
	14545833	CHEMBL3224494	Inhibition of ROCK2 (unknown origin) at 1 uM	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	Inhibition	%	98.0	CHEMBL2973	Homo sapiens	INH	%	98.0
	14549785	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2		CHEMBL3221807	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	14549786	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2		CHEMBL3221808	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	14549787	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN1CCCC1)CO2		CHEMBL3221809	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	14549788	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN1CCCC1)CO2		CHEMBL3221810	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
	14549789	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1O[C@@H]1CCN(C)C1)CO2		CHEMBL3221811	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	14549790	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1O[C@@H]1CCN(C)C1)CO2		CHEMBL3221812	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	14549791	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1O[C@H]1CCN(C)C1)CO2		CHEMBL3221813	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	14549792	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1O[C@H]1CCN(C)C1)CO2		CHEMBL3221814	=	IC50	nM	34.0	CHEMBL2973	Homo sapiens	IC50	nM	34.0
	14549793	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCCO)CO2		CHEMBL3221815	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	14549794	CHEMBL3226111	Inhibition of ROCK2 (unknown origin) after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCCO)CO2		CHEMBL3221816	=	IC50	nM	35.0	CHEMBL2973	Homo sapiens	IC50	nM	35.0
	14585319	CHEMBL3241835	Inhibition of human ROCK-2 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	113.5	CHEMBL2973	Homo sapiens	Activity	%	113.5
	14591712	CHEMBL3240142	Inhibition of truncated ROCK-2 (unknown origin) after 60 mins by IMAP assay	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	IC50	nM	58.0	CHEMBL2973	Homo sapiens	IC50	nM	58.0
	14591713	CHEMBL3240142	Inhibition of truncated ROCK-2 (unknown origin) after 60 mins by IMAP assay	B	OCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL599163	=	IC50	nM	39.0	CHEMBL2973	Homo sapiens	IC50	nM	39.0
	14591714	CHEMBL3240142	Inhibition of truncated ROCK-2 (unknown origin) after 60 mins by IMAP assay	B	CN(C)CC(O)CN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238163	=	IC50	nM	76.0	CHEMBL2973	Homo sapiens	IC50	nM	76.0
	14591715	CHEMBL3240142	Inhibition of truncated ROCK-2 (unknown origin) after 60 mins by IMAP assay	B	CC(=O)NCC(O)CN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238164	=	IC50	nM	68.0	CHEMBL2973	Homo sapiens	IC50	nM	68.0
	14591716	CHEMBL3240142	Inhibition of truncated ROCK-2 (unknown origin) after 60 mins by IMAP assay	B	CC(=O)NCCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238165	=	IC50	nM	75.0	CHEMBL2973	Homo sapiens	IC50	nM	75.0
	14591717	CHEMBL3240142	Inhibition of truncated ROCK-2 (unknown origin) after 60 mins by IMAP assay	B	c1nc(N2CCCC2)c(N2CCCNCC2)nc1-c1cc2cn[nH]c2cn1		CHEMBL3238166	=	IC50	nM	65.0	CHEMBL2973	Homo sapiens	IC50	nM	65.0
	14591718	CHEMBL3240142	Inhibition of truncated ROCK-2 (unknown origin) after 60 mins by IMAP assay	B	c1cc2[nH]ncc2cc1-c1cncc(N2CCCNCC2)n1		CHEMBL3238167	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	nM	24.0
	14591719	CHEMBL3240142	Inhibition of truncated ROCK-2 (unknown origin) after 60 mins by IMAP assay	B	Cc1n[nH]c2ccc(-c3cncc(N4CCCNCC4)n3)cc12		CHEMBL3238168	=	IC50	nM	36.0	CHEMBL2973	Homo sapiens	IC50	nM	36.0
	14591728	CHEMBL3240144	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	EC50	nM	150.0	CHEMBL2973	Homo sapiens	EC50	nM	150.0
	14591729	CHEMBL3240144	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay	B	OCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL599163	=	EC50	nM	680.0	CHEMBL2973	Homo sapiens	EC50	nM	680.0
	14591730	CHEMBL3240144	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay	B	CN(C)CC(O)CN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238163	=	EC50	nM	1500.0	CHEMBL2973	Homo sapiens	EC50	nM	1500.0
	14591731	CHEMBL3240144	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay	B	CC(=O)NCC(O)CN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238164	=	EC50	nM	1700.0	CHEMBL2973	Homo sapiens	EC50	nM	1700.0
	14591732	CHEMBL3240144	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay	B	CC(=O)NCCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238165	=	EC50	nM	760.0	CHEMBL2973	Homo sapiens	EC50	nM	760.0
	14591733	CHEMBL3240144	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay	B	c1nc(N2CCCC2)c(N2CCCNCC2)nc1-c1cc2cn[nH]c2cn1		CHEMBL3238166	=	EC50	nM	416.0	CHEMBL2973	Homo sapiens	EC50	nM	416.0
	14591734	CHEMBL3240144	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay	B	c1cc2[nH]ncc2cc1-c1cncc(N2CCCNCC2)n1		CHEMBL3238167	=	EC50	nM	260.0	CHEMBL2973	Homo sapiens	EC50	nM	260.0
	14591735	CHEMBL3240144	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay	B	Cc1n[nH]c2ccc(-c3cncc(N4CCCNCC4)n3)cc12		CHEMBL3238168	=	EC50	nM	380.0	CHEMBL2973	Homo sapiens	EC50	nM	380.0
	14591736	CHEMBL3240145	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay relative to fasudil	B	OCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL599163	=	%max	%	83.0	CHEMBL2973	Homo sapiens	%max	%	83.0
	14591737	CHEMBL3240145	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay relative to fasudil	B	CN(C)CC(O)CN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238163	=	%max	%	84.0	CHEMBL2973	Homo sapiens	%max	%	84.0
	14591738	CHEMBL3240145	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay relative to fasudil	B	CC(=O)NCC(O)CN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238164	=	%max	%	78.0	CHEMBL2973	Homo sapiens	%max	%	78.0
	14591739	CHEMBL3240145	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay relative to fasudil	B	CC(=O)NCCCN1CCN(c2nc(-c3ccncc3)cnc2N2CCCC2)CC1		CHEMBL3238165	=	%max	%	79.0	CHEMBL2973	Homo sapiens	%max	%	79.0
	14591740	CHEMBL3240145	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay relative to fasudil	B	c1nc(N2CCCC2)c(N2CCCNCC2)nc1-c1cc2cn[nH]c2cn1		CHEMBL3238166	=	%max	%	103.0	CHEMBL2973	Homo sapiens	%max	%	103.0
	14591741	CHEMBL3240145	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay relative to fasudil	B	c1cc2[nH]ncc2cc1-c1cncc(N2CCCNCC2)n1		CHEMBL3238167	=	%max	%	105.0	CHEMBL2973	Homo sapiens	%max	%	105.0
	14591742	CHEMBL3240145	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay relative to fasudil	B	Cc1n[nH]c2ccc(-c3cncc(N4CCCNCC4)n3)cc12		CHEMBL3238168	=	%max	%	102.0	CHEMBL2973	Homo sapiens	%max	%	102.0
	14591777	CHEMBL3240145	Inhibition of ROCK-2 in human GTM3 cells measured up to 2 days by cell impedance assay relative to fasudil	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	%max	%	100.0	CHEMBL2973	Homo sapiens	%max	%	100.0
	14648070	CHEMBL3266636	Inhibition of human ROCK2 at 1 uM relative to control	B	CC(C)CCNc1ccc(-c2cnc3ccc(NC4CCN(C)CC4)nn23)cn1		CHEMBL2380687	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	14648071	CHEMBL3266636	Inhibition of human ROCK2 at 1 uM relative to control	B	N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1		CHEMBL3264059	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	14659383	CHEMBL3267957	Inhibition of ROCK2 (unknown origin) at 1 uM	B	CCOP(=O)(CC)Cc1cccc(Nc2cc(-c3ccccc3OC)ncn2)c1		CHEMBL3264107	=	Inhibition	%	14.0	CHEMBL2973	Homo sapiens	INH	%	14.0
	14659384	CHEMBL3267957	Inhibition of ROCK2 (unknown origin) at 1 uM	B	CCCP(=O)(Cc1cccc(Nc2cc(-c3ccccc3OC)ncn2)c1)OCC		CHEMBL3264108	=	Inhibition	%	7.0	CHEMBL2973	Homo sapiens	INH	%	7.0
	14664311	CHEMBL3271263	Inhibition of ROCK2 (unknown origin) at 1 uM relative to control	B	CCOC(=O)c1sc(-c2ccncc2)nc1O		CHEMBL3261228	=	Inhibition	%	92.0	CHEMBL2973	Homo sapiens	INH	%	92.0
	14664312	CHEMBL3271263	Inhibition of ROCK2 (unknown origin) at 1 uM relative to control	B	NC(=O)c1sc(-c2ccnc(N)n2)nc1-c1ccc(Cl)cc1Cl		CHEMBL3261514	=	Inhibition	%	34.0	CHEMBL2973	Homo sapiens	INH	%	34.0
	14664313	CHEMBL3271263	Inhibition of ROCK2 (unknown origin) at 1 uM relative to control	B	COc1ccc(-c2nc(-c3ccnc(N)n3)sc2C(N)=O)c(Cl)c1		CHEMBL3261517	=	Inhibition	%	27.0	CHEMBL2973	Homo sapiens	INH	%	27.0
	14710322	CHEMBL3292196	Inhibition of human ROCK-2 assessed as residual activity at 10 uM relative to control	B	CC1=CC(=O)N(Nc2nc(-c3cccs3)nc3scc(-c4ccccc4)c23)C1=O		CHEMBL3290628	=	Activity	%	99.0	CHEMBL2973	Homo sapiens	Activity	%	99.0
	14710323	CHEMBL3292196	Inhibition of human ROCK-2 assessed as residual activity at 10 uM relative to control	B	CC1=CC(=O)N(Nc2nc(-c3cccs3)nc3scc(-c4cccc(OCCN5CCCCC5)c4)c23)C1=O.Cl		CHEMBL3290631	=	Activity	%	96.0	CHEMBL2973	Homo sapiens	Activity	%	96.0
	14926957	CHEMBL3391355	Inhibition of ROCK2 (unknown origin) at 1 uM	B	Nc1ncnc2c1sc1cc(-c3cccc(C(=O)NCCc4cccnc4)c3)ccc12		CHEMBL3347513	=	Inhibition	%	13.0	CHEMBL2973	Homo sapiens	INH	%	13.0
	14926958	CHEMBL3391355	Inhibition of ROCK2 (unknown origin) at 1 uM	B	Nc1ncnc2c1sc1cc(-c3cccc(C(=O)NCC(=O)N4CCOCC4)c3)ccc12		CHEMBL3347694	=	Inhibition	%	18.0	CHEMBL2973	Homo sapiens	INH	%	18.0
	14926959	CHEMBL3391355	Inhibition of ROCK2 (unknown origin) at 1 uM	B	CN1CCN(C(=O)Nc2cccc(-c3ccc4c(c3)sc3c(N)ncnc34)c2)CC1		CHEMBL3347683	=	Inhibition	%	24.0	CHEMBL2973	Homo sapiens	INH	%	24.0
	14926960	CHEMBL3391355	Inhibition of ROCK2 (unknown origin) at 1 uM	B	Nc1ncnc2c1sc1cc(-c3cccc(NC(=O)N4CCCC4)c3)ccc12		CHEMBL3347669	=	Inhibition	%	10.0	CHEMBL2973	Homo sapiens	INH	%	10.0
	14980857	CHEMBL3372437	Inhibition of Rock2 (unknown origin) in presence of 1 mM ATP	B	CN(Cc1ccccc1)C(=O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1		CHEMBL3355482	>	IC50	nM	100000.0	CHEMBL2973	Homo sapiens	IC50	uM	100.0
	14982856	CHEMBL3377890	Inhibition of human Rock2 assessed as incorporation of P33 from ATP into biotinylated-cofilin substrate by scintillation counting analysis in presence of 2 uM ATP	B	Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356433	=	IC50	nM	32.0	CHEMBL2973	Homo sapiens	IC50	nM	32.0
	14982860	CHEMBL3378491	Inhibition of human Rock2 assessed as incorporation of P33 from ATP into biotinylated-cofilin substrate by scintillation counting analysis in presence of 200 uM ATP	B	Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356433	=	IC50	nM	340.0	CHEMBL2973	Homo sapiens	IC50	nM	340.0
	14982866	CHEMBL3378494	Binding affinity to human Rock2	B	Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356433	<	Kd	nM	1000.0	CHEMBL2973	Homo sapiens	Kd	uM	1.0
	15008105	CHEMBL3369112	Inhibition of human ROCK2 at 1 uM by radiometric Assay	B	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)Cc4ccccc4)cc23)c1		CHEMBL3330255	=	Inhibition	%	25.0	CHEMBL2973	Homo sapiens	INH	%	25.0
	15008106	CHEMBL3369112	Inhibition of human ROCK2 at 1 uM by radiometric Assay	B	COC(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)c1ccccc1		CHEMBL3330401	=	Inhibition	%	12.0	CHEMBL2973	Homo sapiens	INH	%	12.0
	15008107	CHEMBL3369112	Inhibition of human ROCK2 at 1 uM by radiometric Assay	B	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1		CHEMBL3330410	=	Inhibition	%	16.0	CHEMBL2973	Homo sapiens	INH	%	16.0
	15018686	CHEMBL3369186	Inhibition of ROCK2 (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	15053961	CHEMBL3371227	Inhibition of ROCK2 (unknown origin)	B	Clc1ccc(-c2ccc(-c3nccn3-c3ccc(N4CCNCC4)cc3)o2)cc1		CHEMBL3314140	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	uM	20.0
	15072475	CHEMBL3380099	Inhibition of ROCK2 (unknown origin) assessed as remaining enzyme activity at 10 uM by radioactive [33P]-ATP filter binding assay	B	Cc1ccc(-c2cc(C(=O)Nc3ccnc(Cl)c3)nn2-c2ccc3ccccc3n2)cc1		CHEMBL3338802	=	Activity	%	85.0	CHEMBL2973	Homo sapiens	Activity	%	85.0
	15077402	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	15077403	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	89.0	CHEMBL2973	Homo sapiens	IC50	nM	89.0
	15077404	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21		CHEMBL1956071	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	15077405	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	NCCNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL1214929	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	IC50	nM	26.0
	15077406	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	CC(C)(N)CNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147538	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	nM	13.0
	15077407	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	CC(C)(N)CNc1nc(-c2ccncc2)nc2cnccc12		CHEMBL3338837	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	15077408	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	CC(C)(N)CNc1nc(-c2ccc3[nH]ncc3c2)nc2cnccc12		CHEMBL3338838	=	IC50	nM	23.0	CHEMBL2973	Homo sapiens	IC50	nM	23.0
	15077409	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	c1cc2c(N3CCNCC3)nc(-c3ccc4[nH]ncc4c3)nc2cn1		CHEMBL3338839	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	15077410	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	c1ccc2c(N3CCNCC3)nc(-c3ccc4[nH]ncc4c3)nc2c1		CHEMBL3338840	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	15077411	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	c1ccc2c(N3CCNCC3)nc(-c3ccc4[nH]ncc4c3)cc2c1		CHEMBL3338841	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	nM	120.0
	15077412	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	NCCNc1nc(-c2ccc3[nH]ncc3c2)nc2ccccc12		CHEMBL3338842	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
	15077413	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	NCCCNc1nc(-c2ccc3[nH]ncc3c2)nc2ccccc12		CHEMBL3338843	=	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
	15077414	CHEMBL3386997	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	B	CN1CCN(c2nc(-c3ccc4[nH]ncc4c3)nc3ccccc23)CC1		CHEMBL3338844	=	IC50	nM	432.0	CHEMBL2973	Homo sapiens	IC50	nM	432.0
	15116501	CHEMBL3377055	Inhibition of ROCK2 (unknown origin)	B	CC(=O)c1ccc(N2CCN(C(=O)CN3CC[C@@H](C(=O)Nc4ccc(O)c(Cl)c4)C3)CC2)cc1		CHEMBL3356117	>	IC50	nM	30000.0	CHEMBL2973	Homo sapiens	IC50	uM	30.0
	15122496	CHEMBL3367702	Inhibition of human ROCK2 assessed as residual activity at 10 uM by KinaseProfiler assay	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3ccc(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331445	=	Activity	%	89.0	CHEMBL2973	Homo sapiens	Activity	%	89.0
	15126973	CHEMBL3367702	Inhibition of human ROCK2 assessed as residual activity at 10 uM by KinaseProfiler assay	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3cc(O)c(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331446	=	Activity	%	108.0	CHEMBL2973	Homo sapiens	Activity	%	108.0
	15127005	CHEMBL3367702	Inhibition of human ROCK2 assessed as residual activity at 10 uM by KinaseProfiler assay	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	Activity	%	73.0	CHEMBL2973	Homo sapiens	Activity	%	73.0
	15146838	CHEMBL3395665	Inhibition of ROCK2 (unknown origin) at 1 uM	B	Nc1ncc(-c2ccc3[nH]nc(-c4cnc5ccccc5c4)c3c2)s1		CHEMBL3394059	>	Inhibition	%	90.0	CHEMBL2973	Homo sapiens	INH	%	90.0
	15150138	CHEMBL3396182	Inhibition of ROCK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CC2)ccn1		CHEMBL3394102	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	15150139	CHEMBL3396182	Inhibition of ROCK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CCCCC2)ccn1		CHEMBL3394105	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	15150140	CHEMBL3396182	Inhibition of ROCK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2CC2CCCO2)ccn1		CHEMBL3394108	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	15150141	CHEMBL3396182	Inhibition of ROCK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	COC(Cn1c(SC2CCC(C(=O)O)CC2O)nc(-c2ccc(F)cc2)c1-c1ccnc(NC(C)=O)c1)OC		CHEMBL3394112	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	15150142	CHEMBL3396182	Inhibition of ROCK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(Sc3cccc(I)n3)n2C2CCCCC2)ccn1		CHEMBL3394118	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	15177474	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccccc1CNC(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL3402441	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	IC50	nM	26.0
	15177475	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc1		CHEMBL3402442	=	IC50	nM	2750.0	CHEMBL2973	Homo sapiens	IC50	nM	2750.0
	15177476	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	Cc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL3402443	=	IC50	nM	33.0	CHEMBL2973	Homo sapiens	IC50	nM	33.0
	15177477	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	Nc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL3402444	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	15177478	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCc1cccc(Cl)c1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL3402445	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
	15177479	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCc1cccc(F)c1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL3402446	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	15177480	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3c[nH]nc3C)cc2)c1		CHEMBL3402447	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	15177481	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3ccncc3)cc2)c1		CHEMBL3402448	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	15177482	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3ccnc(N)n3)cc2)c1		CHEMBL3402449	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	nM	13.0
	15177483	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3ccnc(N)c3)cc2)c1		CHEMBL3402450	=	IC50	nM	44.0	CHEMBL2973	Homo sapiens	IC50	nM	44.0
	15177484	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(C3=NC=NC4NC=CC34)cc2)c1		CHEMBL3402451	=	IC50	nM	188.0	CHEMBL2973	Homo sapiens	IC50	nM	188.0
	15177485	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2N(C)C)c1		CHEMBL3402452	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177486	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3402453	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177487	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2Cl)c1		CHEMBL3402454	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177488	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2F)c1		CHEMBL3402455	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177489	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2OCCN(C)C)c1		CHEMBL3402456	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177490	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2OCCN2CCCC2)c1		CHEMBL3402457	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177491	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2N(C)CCN(C)C)c1		CHEMBL3402458	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177492	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2OCCN(C)C)c1		CHEMBL3402459	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177493	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2OCCN2CCCC2)c1		CHEMBL3402460	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177494	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2N(C)CCN(C)C)c1		CHEMBL3402461	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	15177495	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1OCCN(C)C		CHEMBL3402462	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	15177496	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1OCCN1CCCC1		CHEMBL3402463	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177497	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1N(C)CCN(C)C		CHEMBL3402464	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	15177498	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332098	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	pIC50		9.0
	15177499	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CNC(=O)N(CCN(C)C)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3402469	=	IC50	nM	2985.38	CHEMBL2973	Homo sapiens	pIC50		5.525
	15177500	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc1F		CHEMBL2332091	=	IC50	nM	357.27	CHEMBL2973	Homo sapiens	pIC50		6.447
	15177501	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(OC)c1CNC(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332088	=	IC50	nM	924.7	CHEMBL2973	Homo sapiens	pIC50		6.034
	15177502	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1OC		CHEMBL2332085	=	IC50	nM	252.93	CHEMBL2973	Homo sapiens	pIC50		6.597
	15177503	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCCCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332079	=	IC50	nM	1016.25	CHEMBL2973	Homo sapiens	pIC50		5.993
	15177504	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1N(C)CCN(C)C		CHEMBL3402464	=	IC50	nM	5.998	CHEMBL2973	Homo sapiens	pIC50		8.222
	15177505	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(C3=NC=NC4NC=CC34)cc2)c1		CHEMBL3402451	=	IC50	nM	187.93	CHEMBL2973	Homo sapiens	pIC50		6.726
	15177506	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3ccncc3)cc2)c1		CHEMBL3402448	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	pIC50		8.301
	15177507	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCc1cccc(Cl)c1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL3402445	=	IC50	nM	16.98	CHEMBL2973	Homo sapiens	pIC50		7.77
	15177508	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc1		CHEMBL3402442	=	IC50	nM	2747.89	CHEMBL2973	Homo sapiens	pIC50		5.561
	15177535	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CC(C)N(Cc1ccccc1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL3402475	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	15177536	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CN(C)CCSc1cc(-c2cn[nH]c2)ccc1NC(=O)NCc1ccccc1		CHEMBL3402473	=	IC50	nM	5.6	CHEMBL2973	Homo sapiens	IC50	nM	5.6
	15177537	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)N(CCN(C)C)Cc1ccccc1		CHEMBL3402472	=	IC50	nM	170.0	CHEMBL2973	Homo sapiens	IC50	nM	170.0
	15177538	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CN(C)CCC(NC(=O)Nc1ccc(-c2cn[nH]c2)cc1)c1ccccc1		CHEMBL2332059	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	15177539	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CCO)c1cccc(F)c1		CHEMBL2332056	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	15177540	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)N(CCO)Cc1ccccc1		CHEMBL2331562	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	15177541	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCCN2CCOCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332072	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	15177542	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCN2CCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332069	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	15177543	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COCCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332066	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
	15177544	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C(=O)Nc2ccc(-c3cn[nH]c3)cc2)C2CC2)c1		CHEMBL2332099	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177545	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CNC(=O)N(CCCN(C)C)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3402470	=	IC50	nM	3324.0	CHEMBL2973	Homo sapiens	IC50	nM	3324.0
	15177546	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc1F		CHEMBL2332091	=	IC50	nM	357.0	CHEMBL2973	Homo sapiens	IC50	nM	357.0
	15177547	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c(OC)c1		CHEMBL2332086	=	IC50	nM	331.0	CHEMBL2973	Homo sapiens	IC50	nM	331.0
	15177548	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCC1CCCCC1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332084	=	IC50	nM	751.0	CHEMBL2973	Homo sapiens	IC50	nM	751.0
	15177549	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL3402465	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	15177550	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COCCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332066	=	IC50	nM	16.98	CHEMBL2973	Homo sapiens	pIC50		7.77
	15177551	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332065	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	pIC50		9.0
	15177552	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C(=O)Nc2ccc(-c3cn[nH]c3)cc2)C(C)C)c1		CHEMBL2332064	=	IC50	nM	2.999	CHEMBL2973	Homo sapiens	pIC50		8.523
	15177553	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332097	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	pIC50		9.0
	15177554	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CNC(=O)N(CCO)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3402468	=	IC50	nM	751.62	CHEMBL2973	Homo sapiens	pIC50		6.124
	15177555	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc(OC)c1		CHEMBL2332090	=	IC50	nM	281.19	CHEMBL2973	Homo sapiens	pIC50		6.551
	15177556	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(OC)c(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332087	=	IC50	nM	570.16	CHEMBL2973	Homo sapiens	pIC50		6.244
	15177557	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL3402466	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	pIC50		8.699
	15177558	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332078	=	IC50	nM	88.1	CHEMBL2973	Homo sapiens	pIC50		7.055
	15177559	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1OCCN(C)C		CHEMBL3402462	=	IC50	nM	2.999	CHEMBL2973	Homo sapiens	pIC50		8.523
	15177560	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3ccnc(N)c3)cc2)c1		CHEMBL3402450	=	IC50	nM	43.95	CHEMBL2973	Homo sapiens	pIC50		7.357
	15177561	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3c[nH]nc3C)cc2)c1		CHEMBL3402447	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	pIC50		8.699
	15177562	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	Nc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL3402444	=	IC50	nM	2.999	CHEMBL2973	Homo sapiens	pIC50		8.523
	15177563	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccccc1CNC(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL3402441	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	pIC50		7.585
	15177590	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CN(C)CCN(C)c1cc(-c2cn[nH]c2)ccc1NC(=O)NCc1ccccc1		CHEMBL3402474	=	IC50	nM	8.5	CHEMBL2973	Homo sapiens	IC50	nM	8.5
	15177591	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)N1CCc2ccccc2C1		CHEMBL2332083	=	IC50	nM	280.0	CHEMBL2973	Homo sapiens	IC50	nM	280.0
	15177592	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1O[C@H]1CCN(C)C1		CHEMBL2332060	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177593	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CCO)c1ccccc1		CHEMBL2332057	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177594	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1F)N(CCO)Cc1ccccc1		CHEMBL2332075	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	15177595	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCN2CCCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332073	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	15177596	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCCN2CCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332070	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	15177597	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCN)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332067	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177598	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C(=O)Nc2ccc(-c3cn[nH]c3)cc2)C(C)C)c1		CHEMBL2332064	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	15177599	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332097	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177600	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CNC(=O)N(CCN(C)C)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3402469	=	IC50	nM	2984.0	CHEMBL2973	Homo sapiens	IC50	nM	2984.0
	15177601	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CNC(=O)N(C)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3402467	=	IC50	nM	87.0	CHEMBL2973	Homo sapiens	IC50	nM	87.0
	15177602	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc1OC		CHEMBL2332089	=	IC50	nM	425.0	CHEMBL2973	Homo sapiens	IC50	nM	425.0
	15177603	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(OC)c(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332087	=	IC50	nM	570.0	CHEMBL2973	Homo sapiens	IC50	nM	570.0
	15177604	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL3402466	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	15177605	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332078	=	IC50	nM	88.0	CHEMBL2973	Homo sapiens	IC50	nM	88.0
	15177606	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C(=O)Nc2ccc(-c3cn[nH]c3)cc2)C2CC2)c1		CHEMBL2332099	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	pIC50		9.0
	15177607	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CNC(=O)N(CCCN(C)C)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3402470	=	IC50	nM	3326.6	CHEMBL2973	Homo sapiens	pIC50		5.478
	15177608	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CNC(=O)N(C)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3402467	=	IC50	nM	87.1	CHEMBL2973	Homo sapiens	pIC50		7.06
	15177609	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc1OC		CHEMBL2332089	=	IC50	nM	424.62	CHEMBL2973	Homo sapiens	pIC50		6.372
	15177610	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1ccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c(OC)c1		CHEMBL2332086	=	IC50	nM	331.13	CHEMBL2973	Homo sapiens	pIC50		6.48
	15177611	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCC1CCCCC1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332084	=	IC50	nM	751.62	CHEMBL2973	Homo sapiens	pIC50		6.124
	15177612	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL3402465	=	IC50	nM	17.99	CHEMBL2973	Homo sapiens	pIC50		7.745
	15177613	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2N(C)CCN(C)C)c1		CHEMBL3402461	=	IC50	nM	7.998	CHEMBL2973	Homo sapiens	pIC50		8.097
	15177614	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3ccnc(N)n3)cc2)c1		CHEMBL3402449	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	pIC50		7.886
	15177615	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCc1cccc(F)c1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL3402446	=	IC50	nM	2.999	CHEMBL2973	Homo sapiens	pIC50		8.523
	15177616	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	Cc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL3402443	=	IC50	nM	33.04	CHEMBL2973	Homo sapiens	pIC50		7.481
	15177633	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1OCCO)N(CCO)Cc1ccccc1		CHEMBL3402471	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177634	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CO)c1ccccc1		CHEMBL2332058	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	15177635	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(C(CCO)NC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332076	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	15177636	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCCN2CCCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332074	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	15177637	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCN2CCOCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332071	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	nM	13.0
	15177638	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332068	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177639	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332065	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177640	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332098	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15177641	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CNC(=O)N(CCO)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3402468	=	IC50	nM	611.0	CHEMBL2973	Homo sapiens	IC50	nM	611.0
	15177642	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)cc(OC)c1		CHEMBL2332090	=	IC50	nM	281.0	CHEMBL2973	Homo sapiens	IC50	nM	281.0
	15177643	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(OC)c1CNC(=O)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332088	=	IC50	nM	924.0	CHEMBL2973	Homo sapiens	IC50	nM	924.0
	15177644	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CNC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1OC		CHEMBL2332085	=	IC50	nM	253.0	CHEMBL2973	Homo sapiens	IC50	nM	253.0
	15177645	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(NCCCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1		CHEMBL2332079	=	IC50	nM	1017.0	CHEMBL2973	Homo sapiens	IC50	nM	1017.0
	15177646	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332068	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	pIC50		9.0
	15177647	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCN2CCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332069	=	IC50	nM	2.999	CHEMBL2973	Homo sapiens	pIC50		8.523
	15177648	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCCN2CCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332070	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	pIC50		8.301
	15177649	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCN2CCOCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332071	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	pIC50		7.886
	15177650	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCCN2CCOCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332072	=	IC50	nM	3.999	CHEMBL2973	Homo sapiens	pIC50		8.398
	15177651	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCN2CCCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332073	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	pIC50		8.301
	15177652	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(CN(CCCN2CCCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332074	=	IC50	nM	3.999	CHEMBL2973	Homo sapiens	pIC50		8.398
	15177653	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)N(CCO)Cc1ccccc1		CHEMBL2331562	=	IC50	nM	11.99	CHEMBL2973	Homo sapiens	pIC50		7.921
	15177654	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1F)N(CCO)Cc1ccccc1		CHEMBL2332075	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	pIC50		7.854
	15177655	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	COc1cccc(C(CCO)NC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL2332076	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	pIC50		8.699
	15177656	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CCO)c1cccc(F)c1		CHEMBL2332056	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	pIC50		8.699
	15177657	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CCO)c1ccccc1		CHEMBL2332057	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	pIC50		9.0
	15177658	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CO)c1ccccc1		CHEMBL2332058	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	pIC50		8.699
	15177659	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CN(C)CCC(NC(=O)Nc1ccc(-c2cn[nH]c2)cc1)c1ccccc1		CHEMBL2332059	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	pIC50		8.699
	15177660	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1O[C@H]1CCN(C)C1		CHEMBL2332060	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	pIC50		9.0
	15177661	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)N(CCN(C)C)Cc1ccccc1		CHEMBL3402472	=	IC50	nM	169.82	CHEMBL2973	Homo sapiens	pIC50		6.77
	15177662	CHEMBL3404496	Inhibition of ROCK2 (unknown origin) using STK2 substrate after 4 hrs by HTRF mode	B	O=C(Nc1ccc(-c2cn[nH]c2)cc1)N1CCc2ccccc2C1		CHEMBL2332083	=	IC50	nM	279.9	CHEMBL2973	Homo sapiens	pIC50		6.553
	15188484	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1		CHEMBL3410022	=	IC50	nM	45.0	CHEMBL2973	Homo sapiens	IC50	nM	45.0
	15188485	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccncc3)cc2)c1		CHEMBL1951443	=	IC50	nM	90.0	CHEMBL2973	Homo sapiens	IC50	nM	90.0
	15188486	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc(N)n3)cc2)c1		CHEMBL1951441	=	IC50	nM	166.0	CHEMBL2973	Homo sapiens	IC50	nM	166.0
	15188487	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]ccc34)cc2)c1		CHEMBL1951349	=	IC50	nM	132.0	CHEMBL2973	Homo sapiens	IC50	nM	132.0
	15188488	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	CCn1c(=O)[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c21		CHEMBL1951350	=	IC50	nM	247.0	CHEMBL2973	Homo sapiens	IC50	nM	247.0
	15188489	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cnc34)cc2)c1		CHEMBL3410023	=	IC50	nM	5570.0	CHEMBL2973	Homo sapiens	IC50	nM	5570.0
	15188490	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]ccc34)cc2)c1		CHEMBL1951344	=	IC50	nM	1365.0	CHEMBL2973	Homo sapiens	IC50	nM	1365.0
	15188491	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12		CHEMBL1951346	=	IC50	nM	1608.0	CHEMBL2973	Homo sapiens	IC50	nM	1608.0
	15188492	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1cc2c(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)ncnc2[nH]1		CHEMBL3410024	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	15188493	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c2c1C		CHEMBL3410025	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	15188494	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)c(C(F)(F)F)c3)c12		CHEMBL3410026	=	IC50	nM	976.0	CHEMBL2973	Homo sapiens	IC50	nM	976.0
	15188495	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)c(F)c3)c12		CHEMBL3407526	=	IC50	nM	781.0	CHEMBL2973	Homo sapiens	IC50	nM	781.0
	15188496	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)c(OCCN(C)C)c3)c12		CHEMBL3410027	=	IC50	nM	7083.0	CHEMBL2973	Homo sapiens	IC50	nM	7083.0
	15188497	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL3410028	=	IC50	nM	2358.0	CHEMBL2973	Homo sapiens	IC50	nM	2358.0
	15188498	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL3410029	=	IC50	nM	5421.0	CHEMBL2973	Homo sapiens	IC50	nM	5421.0
	15188499	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1ccccc1NC(=O)Nc1ccc(-c2ncnc3[nH]cc(C)c23)cc1		CHEMBL3410030	=	IC50	nM	6652.0	CHEMBL2973	Homo sapiens	IC50	nM	6652.0
	15188500	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)c1		CHEMBL3410031	=	IC50	nM	2572.0	CHEMBL2973	Homo sapiens	IC50	nM	2572.0
	15188501	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1ccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1		CHEMBL3410032	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	15188502	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4nccs4)cc3)c12		CHEMBL3410033	=	IC50	nM	2290.0	CHEMBL2973	Homo sapiens	IC50	nM	2290.0
	15188503	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4ccccn4)cc3)c12		CHEMBL3410034	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
Not Determined	15188504	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCN4CCCC4)c4ccccc4)cc3)c12		CHEMBL3410035		IC50			CHEMBL2973	Homo sapiens	IC50		
	15188549	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccccc4)cc3)c12		CHEMBL3410036	=	IC50	nM	6565.0	CHEMBL2973	Homo sapiens	IC50	nM	6565.0
	15188550	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccccc4F)cc3)c12		CHEMBL3410037	=	IC50	nM	1605.0	CHEMBL2973	Homo sapiens	IC50	nM	1605.0
	15188551	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4cccc(F)c4)cc3)c12		CHEMBL3410038	=	IC50	nM	1898.0	CHEMBL2973	Homo sapiens	IC50	nM	1898.0
	15188552	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(F)cc4)cc3)c12		CHEMBL3410039	=	IC50	nM	3239.0	CHEMBL2973	Homo sapiens	IC50	nM	3239.0
	15188553	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccccc4Cl)cc3)c12		CHEMBL3410040	=	IC50	nM	3339.0	CHEMBL2973	Homo sapiens	IC50	nM	3339.0
	15188554	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4cccc(Cl)c4)cc3)c12		CHEMBL3410041	=	IC50	nM	11270.0	CHEMBL2973	Homo sapiens	IC50	nM	11270.0
	15188555	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(Cl)cc4)cc3)c12		CHEMBL3410042	=	IC50	nM	4357.0	CHEMBL2973	Homo sapiens	IC50	nM	4357.0
	15188556	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1ccccc1N(CCO)C(=O)Nc1ccc(-c2ncnc3[nH]cc(C)c23)cc1		CHEMBL3410043	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	15188557	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1cccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)c1		CHEMBL3410044	=	IC50	nM	8940.0	CHEMBL2973	Homo sapiens	IC50	nM	8940.0
	15188558	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1ccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1		CHEMBL3410045	=	IC50	nM	5932.0	CHEMBL2973	Homo sapiens	IC50	nM	5932.0
	15188559	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1ccccc1N(CCO)C(=O)Nc1ccc(-c2ncnc3[nH]cc(C)c23)cc1		CHEMBL3410046	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	15188560	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1cccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)c1		CHEMBL3410047	=	IC50	nM	3219.0	CHEMBL2973	Homo sapiens	IC50	nM	3219.0
	15188561	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1ccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1		CHEMBL3410048	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
Not Determined	15188562	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1ccc(N(CCN)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1		CHEMBL3410049		IC50			CHEMBL2973	Homo sapiens	IC50		
	15188563	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCN)c4ccc(Cl)cc4)cc3)c12		CHEMBL3410050	=	IC50	nM	460.0	CHEMBL2973	Homo sapiens	IC50	nM	460.0
	15188564	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COc1ccc(N(CCN(C)C)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1		CHEMBL3410051	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	15188565	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCN(C)C)c4ccc(Cl)cc4)cc3)c12		CHEMBL3410052	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
Not Determined	15188566	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(Cl)cc4)c(F)c3)c2c1C		CHEMBL3410053		IC50			CHEMBL2973	Homo sapiens	IC50		
Not Determined	15188567	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1[nH]c2ncnc(-c3ccc(NC(=O)N(CCN)c4ccc(Cl)cc4)c(F)c3)c2c1C		CHEMBL3410054		IC50			CHEMBL2973	Homo sapiens	IC50		
	15188568	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	Cc1[nH]c2ncnc(-c3ccc(NC(=O)N(CCN(C)C)c4ccc(Cl)cc4)c(F)c3)c2c1C		CHEMBL3410055	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	nM	20000.0
	15188569	CHEMBL3411299	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK peptide substrate, ATP and [gamma33P]ATP	B	COCCN(C(=O)Nc1ccc(-c2ncnc3[nH]c(C)c(C)c23)cc1F)c1ccc(Cl)cc1		CHEMBL3410056	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	nM	20000.0
	15246086	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COC(=O)c1ccc(C(=O)Nc2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426731	=	IC50	nM	3.1	CHEMBL2973	Homo sapiens	IC50	nM	3.1
	15246087	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	CN1CCC(OC(=O)Cc2ccc(NC(=O)c3cccc(-c4cc(C(=O)Nc5ccncc5F)ccc4CN)c3)cc2)CC1		CHEMBL3426729	=	IC50	nM	4.6	CHEMBL2973	Homo sapiens	IC50	nM	4.6
	15246088	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(CC(=O)OC3CCCOC3)cc2)c1		CHEMBL3426728	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246089	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(CC(=O)OC3CCCC3)cc2)c1		CHEMBL3426727	=	IC50	nM	1.3	CHEMBL2973	Homo sapiens	IC50	nM	1.3
	15246090	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(CC(=O)OC3CCC3)cc2)c1		CHEMBL3426726	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
	15246091	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(CC(=O)OC3CCOCC3)cc2)c1		CHEMBL3426725	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246092	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	CC[C@@H](C)OC(=O)Cc1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426724	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246093	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	CC[C@H](C)OC(=O)Cc1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426723	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246094	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	CC(C)OC(=O)Cc1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426647	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246095	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2cccc(C(=O)OC3CCCC3)c2F)c1		CHEMBL3426642	=	IC50	nM	41.0	CHEMBL2973	Homo sapiens	IC50	nM	41.0
	15246096	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COC(=O)c1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1F		CHEMBL3426641	=	IC50	nM	8.8	CHEMBL2973	Homo sapiens	IC50	nM	8.8
	15246097	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COCCOC(=O)c1ccc(F)c(C(=O)Nc2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426640	=	IC50	nM	2.2	CHEMBL2973	Homo sapiens	IC50	nM	2.2
	15246098	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COC(=O)c1ccc(F)c(C(=O)Nc2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426639	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
	15246099	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COC(=O)c1cccc(C(=O)Nc2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426637	=	IC50	nM	2.1	CHEMBL2973	Homo sapiens	IC50	nM	2.1
	15246100	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	CC[C@H](C)OC(=O)c1ccc(F)c(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426635	=	IC50	nM	72.0	CHEMBL2973	Homo sapiens	IC50	nM	72.0
	15246101	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COC(=O)c1ccc(F)c(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426633	=	IC50	nM	46.0	CHEMBL2973	Homo sapiens	IC50	nM	46.0
	15246102	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COC(=O)Cc1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426625	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	15246103	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COC(=O)c1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426624	=	IC50	nM	4.1	CHEMBL2973	Homo sapiens	IC50	nM	4.1
	15246104	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COC(=O)Cc1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426623	=	IC50	nM	144.0	CHEMBL2973	Homo sapiens	IC50	nM	144.0
	15246105	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	COC(=O)c1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426622	=	IC50	nM	125.0	CHEMBL2973	Homo sapiens	IC50	nM	125.0
	15246106	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccccc2)c1		CHEMBL3426620	=	IC50	nM	31.0	CHEMBL2973	Homo sapiens	IC50	nM	31.0
	15246107	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)OCC2CCCO2)c1		CHEMBL2440737	=	IC50	nM	49.0	CHEMBL2973	Homo sapiens	IC50	nM	49.0
	15246108	CHEMBL3429820	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP and 200 uM ATP	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	197.0	CHEMBL2973	Homo sapiens	IC50	nM	197.0
	15246109	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(NC(=O)c2ccc(C(=O)O)cc2)c1		CHEMBL3426732	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246110	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)c1ccc(C(=O)Nc2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426731	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246111	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CCCOC(=O)c1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426730	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246112	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CN1CCC(OC(=O)Cc2ccc(NC(=O)c3cccc(-c4cc(C(=O)Nc5ccncc5F)ccc4CN)c3)cc2)CC1		CHEMBL3426729	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246113	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(CC(=O)OC3CCCOC3)cc2)c1		CHEMBL3426728	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246114	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(CC(=O)OC3CCCC3)cc2)c1		CHEMBL3426727	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246115	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(CC(=O)OC3CCC3)cc2)c1		CHEMBL3426726	=	IC50	nM	1.3	CHEMBL2973	Homo sapiens	IC50	nM	1.3
	15246116	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(CC(=O)OC3CCOCC3)cc2)c1		CHEMBL3426725	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246117	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CC[C@@H](C)OC(=O)Cc1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426724	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246118	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CC[C@H](C)OC(=O)Cc1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426723	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246119	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CC(C)OC(=O)Cc1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426647	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246120	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2cccc(C(=O)O)c2F)c1		CHEMBL3426646	=	IC50	nM	3.5	CHEMBL2973	Homo sapiens	IC50	nM	3.5
	15246121	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(NC(=O)c2cc(C(=O)O)ccc2F)c1		CHEMBL3426645	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246122	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(NC(=O)c2cccc(C(=O)O)c2)c1		CHEMBL3426644	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246123	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2cc(C(=O)O)ccc2F)c1		CHEMBL3426643	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	15246124	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2cccc(C(=O)OC3CCCC3)c2F)c1		CHEMBL3426642	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
	15246125	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)c1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1F		CHEMBL3426641	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
	15246126	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COCCOC(=O)c1ccc(F)c(C(=O)Nc2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426640	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246127	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)c1ccc(F)c(C(=O)Nc2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426639	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246128	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CCCOC(=O)c1cccc(C(=O)Nc2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426638	=	IC50	nM	1.8	CHEMBL2973	Homo sapiens	IC50	nM	1.8
	15246129	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)c1cccc(C(=O)Nc2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426637	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246130	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CC[C@@H](C)OC(=O)c1ccc(F)c(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426636	=	IC50	nM	3.3	CHEMBL2973	Homo sapiens	IC50	nM	3.3
	15246131	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CC[C@H](C)OC(=O)c1ccc(F)c(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426635	=	IC50	nM	5.5	CHEMBL2973	Homo sapiens	IC50	nM	5.5
	15246132	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CCCOC(=O)c1ccc(F)c(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426634	=	IC50	nM	2.1	CHEMBL2973	Homo sapiens	IC50	nM	2.1
	15246133	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)c1ccc(F)c(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426633	=	IC50	nM	1.6	CHEMBL2973	Homo sapiens	IC50	nM	1.6
	15246134	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CCC(C)OC(=O)c1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426632	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
	15246135	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CCCCOC(=O)c1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426631	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	nM	27.0
	15246136	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	CC(C)OC(=O)c1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426630	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	15246137	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(CC(=O)O)cc2)c1		CHEMBL3426629	=	IC50	nM	1.8	CHEMBL2973	Homo sapiens	IC50	nM	1.8
	15246138	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccc(C(=O)O)cc2)c1		CHEMBL3426628	=	IC50	nM	3.3	CHEMBL2973	Homo sapiens	IC50	nM	3.3
	15246139	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2cccc(CC(=O)O)c2)c1		CHEMBL3426627	=	IC50	nM	1.5	CHEMBL2973	Homo sapiens	IC50	nM	1.5
	15246140	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2cccc(C(=O)O)c2)c1		CHEMBL3426626	=	IC50	nM	6.6	CHEMBL2973	Homo sapiens	IC50	nM	6.6
	15246141	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)Cc1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426625	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246142	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)c1ccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)cc1		CHEMBL3426624	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246143	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)Cc1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426623	=	IC50	nM	1.1	CHEMBL2973	Homo sapiens	IC50	nM	1.1
	15246144	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	COC(=O)c1cccc(NC(=O)c2cccc(-c3cc(C(=O)Nc4ccncc4F)ccc3CN)c2)c1		CHEMBL3426622	=	IC50	nM	1.1	CHEMBL2973	Homo sapiens	IC50	nM	1.1
	15246145	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)Nc2ccccc2)c1		CHEMBL3426620	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15246146	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	NCc1ccc(C(=O)Nc2ccncc2F)cc1-c1cccc(C(=O)OCC2CCCO2)c1		CHEMBL2440737	=	IC50	nM	2.5	CHEMBL2973	Homo sapiens	IC50	nM	2.5
	15246147	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	3.8	CHEMBL2973	Homo sapiens	IC50	nM	3.8
	15246148	CHEMBL3429819	Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	54.0	CHEMBL2973	Homo sapiens	IC50	nM	54.0
	15247454	CHEMBL3427931	Inhibition of human ROCK2 at 10 uM after 1 hr by qPCR analysis relative to control	B	C#CCCCn1c(Sc2ccc(Cl)cc2Cl)nc2c(N)ncnc21		CHEMBL365118	=	Inhibition	%	32.0	CHEMBL2973	Homo sapiens	INH	%	32.0
	15251876	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL443738	=	Activity	%	16.0	CHEMBL2973	Homo sapiens	Activity	%	16.0
	15251921	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427170	=	Activity	%	49.0	CHEMBL2973	Homo sapiens	Activity	%	49.0
	15252023	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427171	=	Activity	%	61.0	CHEMBL2973	Homo sapiens	Activity	%	61.0
	15252668	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427172	=	Activity	%	60.0	CHEMBL2973	Homo sapiens	Activity	%	60.0
	15252770	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)CS3)sc2c1		CHEMBL3427173	=	Activity	%	61.0	CHEMBL2973	Homo sapiens	Activity	%	61.0
	15252872	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)CS3)sc2c1		CHEMBL3427174	=	Activity	%	72.0	CHEMBL2973	Homo sapiens	Activity	%	72.0
	15253546	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427175	=	Activity	%	71.0	CHEMBL2973	Homo sapiens	Activity	%	71.0
	15253648	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427176	=	Activity	%	69.0	CHEMBL2973	Homo sapiens	Activity	%	69.0
	15253750	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427177	=	Activity	%	80.0	CHEMBL2973	Homo sapiens	Activity	%	80.0
	15254416	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427178	=	Activity	%	55.0	CHEMBL2973	Homo sapiens	Activity	%	55.0
	15254518	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@H]1C(=O)O		CHEMBL3427179	=	Activity	%	42.0	CHEMBL2973	Homo sapiens	Activity	%	42.0
	15254620	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@@H]1C(=O)O		CHEMBL3427180	=	Activity	%	31.0	CHEMBL2973	Homo sapiens	Activity	%	31.0
	15255311	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427181	=	Activity	%	43.0	CHEMBL2973	Homo sapiens	Activity	%	43.0
	15255413	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427182	=	Activity	%	55.0	CHEMBL2973	Homo sapiens	Activity	%	55.0
	15255516	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427183	=	Activity	%	88.0	CHEMBL2973	Homo sapiens	Activity	%	88.0
	15256247	CHEMBL3427826	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427184	=	Activity	%	92.0	CHEMBL2973	Homo sapiens	Activity	%	92.0
	15600682	CHEMBL3578767	Inhibition of ROCK2 (unknown origin) using substrate FITC-AHA- AKRRRLSSLRA-OH	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)OCc2cnccc2-3)c1		CHEMBL3578250	=	IC50	nM	0.51	CHEMBL2973	Homo sapiens	IC50	nM	0.51
	15600683	CHEMBL3578767	Inhibition of ROCK2 (unknown origin) using substrate FITC-AHA- AKRRRLSSLRA-OH	B	Cc1c(CNC(=O)c2ccc3c(c2)OCc2cnccc2-3)cnn1C		CHEMBL3578251	=	IC50	nM	9920.0	CHEMBL2973	Homo sapiens	IC50	nM	9920.0
	15600684	CHEMBL3578767	Inhibition of ROCK2 (unknown origin) using substrate FITC-AHA- AKRRRLSSLRA-OH	B	CCC1Oc2cnccc2-c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc21		CHEMBL3578252	=	IC50	nM	0.18	CHEMBL2973	Homo sapiens	IC50	nM	0.18
	15600685	CHEMBL3578767	Inhibition of ROCK2 (unknown origin) using substrate FITC-AHA- AKRRRLSSLRA-OH	B	CCn1c2cnccc2c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc21		CHEMBL3578253	=	IC50	nM	1.16	CHEMBL2973	Homo sapiens	IC50	nM	1.16
	15620848	CHEMBL3585207	Inhibition of ROCK2 (unknown origin) at 2 uM relative to control	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1		CHEMBL3580669	=	Inhibition	%	99.0	CHEMBL2973	Homo sapiens	INH	%	99.0
	15709893	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356433	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	15709894	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1		CHEMBL3613598	<	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	15710504	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	Cc1c[nH]c2ncnc(N3CCC(CN(C)C)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3613599	=	IC50	nM	40.0	CHEMBL2973	Homo sapiens	IC50	nM	40.0
	15710505	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1		CHEMBL3613600	=	IC50	nM	8.9	CHEMBL2973	Homo sapiens	IC50	nM	8.9
	15710506	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(N)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1		CHEMBL3613601	=	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
	15710507	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(N(C)C)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1		CHEMBL3613602	=	IC50	nM	63.0	CHEMBL2973	Homo sapiens	IC50	nM	63.0
	15710508	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)COc1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1		CHEMBL3613603	=	IC50	nM	7.9	CHEMBL2973	Homo sapiens	IC50	nM	7.9
	15710509	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)Cc1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1		CHEMBL3613604	=	IC50	nM	56.0	CHEMBL2973	Homo sapiens	IC50	nM	56.0
	15710510	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1ccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]cc(C)c34)CC2)cc1		CHEMBL3613605	=	IC50	nM	7.2	CHEMBL2973	Homo sapiens	IC50	nM	7.2
	15710511	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	CCCOC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1		CHEMBL3613606	=	IC50	nM	41.0	CHEMBL2973	Homo sapiens	IC50	nM	41.0
	15710512	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	Cc1c[nH]c2ncnc(N3CCC(CN(C)C)(C(=O)Nc4cccc(C(=O)OC(C)C)c4)CC3)c12		CHEMBL3613607	=	IC50	nM	53.0	CHEMBL2973	Homo sapiens	IC50	nM	53.0
	15710513	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	CCC(C)OC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1		CHEMBL3613608	=	IC50	nM	137.0	CHEMBL2973	Homo sapiens	IC50	nM	137.0
	15710514	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	C#CCOC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1		CHEMBL3613609	=	IC50	nM	16.0	CHEMBL2973	Homo sapiens	IC50	nM	16.0
	15710515	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]ccc34)CC2)c1		CHEMBL3613610	=	IC50	nM	1.8	CHEMBL2973	Homo sapiens	IC50	nM	1.8
	15710516	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]ncc34)CC2)c1		CHEMBL3613611	=	IC50	nM	62.0	CHEMBL2973	Homo sapiens	IC50	nM	62.0
	15710517	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ccnc4[nH]ncc34)CC2)c1		CHEMBL3613612	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	15710518	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4c3CC(=O)N4)CC2)c1		CHEMBL3613613	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	15710519	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(N)CCN(c3ncnc4[nH]ccc34)CC2)c1		CHEMBL3613614	=	IC50	nM	67.0	CHEMBL2973	Homo sapiens	IC50	nM	67.0
	15710520	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(N)CCN(c3ccncn3)CC2)c1		CHEMBL3613615	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	15710521	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(N)CCN(c3cc(N)ncn3)CC2)c1		CHEMBL3613616	=	IC50	nM	2060.0	CHEMBL2973	Homo sapiens	IC50	nM	2060.0
	15710522	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(N)CCN(c3ccnc(N)n3)CC2)c1		CHEMBL3613617	=	IC50	nM	416.0	CHEMBL2973	Homo sapiens	IC50	nM	416.0
	15710523	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(N)CCN(c3cc(NC(C)=O)ncn3)CC2)c1		CHEMBL3613618	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	15710524	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(N)CCN(c3ccnc(NC(C)=O)n3)CC2)c1		CHEMBL3613619	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	15710525	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]cc(C#N)c34)CC2)c1		CHEMBL3613620	=	IC50	nM	2.5	CHEMBL2973	Homo sapiens	IC50	nM	2.5
	15710526	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]cc(F)c34)CC2)c1		CHEMBL3613621	=	IC50	nM	5.7	CHEMBL2973	Homo sapiens	IC50	nM	5.7
	15710527	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]c(C)cc34)CC2)c1		CHEMBL3613622	=	IC50	nM	652.0	CHEMBL2973	Homo sapiens	IC50	nM	652.0
	15710528	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]c(C)c(C)c34)CC2)c1		CHEMBL3613623	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	15710529	CHEMBL3615478	Inhibition of ROCK2 (unknown origin) by radiometric assay	B	Cc1[nH]c2ncnc(N3CCC(CN(C)C)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c2c1C		CHEMBL3613624	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	15755929	CHEMBL3631580	Inhibition of ROCK2 (unknown origin) assessed as remaining activity at 10 uM by high-throughput assay relative to control	B	O=C1c2ccccc2-c2c1oc1ccccc1c2=O		CHEMBL3629616	=	Activity	%	79.0	CHEMBL2973	Homo sapiens	Activity	%	79.0
	15756826	CHEMBL3631324	Inhibition of ROCK2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	59.06	CHEMBL2973	Homo sapiens	INH	%	59.06
	15757897	CHEMBL3631324	Inhibition of ROCK2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	14.82	CHEMBL2973	Homo sapiens	INH	%	14.82
	15758876	CHEMBL3631324	Inhibition of ROCK2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	6.87	CHEMBL2973	Homo sapiens	INH	%	6.87
	15761198	CHEMBL3631887	Inhibition of ROCK2 (unknown origin) after 4 hrs using 1 uM STK2 as substrate	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccccc4)c(F)c3)c12		CHEMBL3629280	=	IC50	nM	4508.0	CHEMBL2973	Homo sapiens	IC50	nM	4508.0
	15761199	CHEMBL3631887	Inhibition of ROCK2 (unknown origin) after 4 hrs using 1 uM STK2 as substrate	B	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cncnc4)c(F)c3)c12		CHEMBL3629279	=	IC50	nM	1021.0	CHEMBL2973	Homo sapiens	IC50	nM	1021.0
	15761200	CHEMBL3631887	Inhibition of ROCK2 (unknown origin) after 4 hrs using 1 uM STK2 as substrate	B	Cc1cc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2F)ccn1		CHEMBL3629278	=	IC50	nM	2011.0	CHEMBL2973	Homo sapiens	IC50	nM	2011.0
	15761201	CHEMBL3631887	Inhibition of ROCK2 (unknown origin) after 4 hrs using 1 uM STK2 as substrate	B	Cc1ccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2F)cn1		CHEMBL3629277	=	IC50	nM	2114.0	CHEMBL2973	Homo sapiens	IC50	nM	2114.0
	15761202	CHEMBL3631887	Inhibition of ROCK2 (unknown origin) after 4 hrs using 1 uM STK2 as substrate	B	COc1ccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2F)cc1		CHEMBL3629276	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	nM	20000.0
276227	16259724	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COCCNC(=O)COc1ccccc1-c1nc(N(CC(=O)NCCOC)c2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666751	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
213452	16260527	CHEMBL3707620	Inhibition Assay: Inhibition of Rho kinase 2 and Rho kinase 1 activity was determined using the IMAP™ Screening Express Kit (Molecular Devices product number #8073). Rho kinase 2 enzyme (Upstate/Chemicon #14-451), Rho kinase 1 (Upstate/Chemicon #14-601) and Flourescein tagged substrate peptide F1-AKRRRLSSLRA (Molecular Devices product number R7184) was pre-incubated with a test compound for 5 minutes in buffer containing 10 mM Tris-HCl pH 7.2, 10 mM MgCl2, and 0.1% BSA. Following the pre-incubation, 10 μM ATP was added to initiate the reaction. After 60 minutes at room temperature, Molecular Devices IMAP™ binding solution was added to bind phosphorylated substrate. After 30 minutes of incubation in the presence of the IMAP™ beads, the fluorescence polarization was read and the ratio was reported as mP.	B	c1ccc(CN2C3CCC2CC(Nc2cccc4cnccc24)C3)cc1		CHEMBL3647978	=	Ki	nM	220.0	CHEMBL2973	Homo sapiens	Ki	nM	220.0
276278	16260890	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CC[C@H](N(C)C)C4)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666728	=	IC50	nM	0.000018	CHEMBL2973	Homo sapiens	IC50	nM	0.000018
276273	16261121	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666726	=	IC50	nM	0.000061	CHEMBL2973	Homo sapiens	IC50	nM	0.000061
276263	16263692	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCN(C)CC4)ccc3n2)c1	Outside typical range	CHEMBL3666722	=	IC50	nM	0.0095	CHEMBL2973	Homo sapiens	IC50	nM	0.0095
276281	16264553	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4c(cnn4C(=O)OC(C)(C)C)c3)c3cc(OCCOC)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666757	>	IC50	nM	0.0003	CHEMBL2973	Homo sapiens	IC50	nM	0.0003
276279	16264754	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CC[C@H](N(C)C)C4)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666728	=	IC50	nM	0.00001	CHEMBL2973	Homo sapiens	IC50	nM	0.00001
276211	16264823	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CC(C)NC(=O)COc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666745	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276254	16265900	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)ccc3n2)c1	Outside typical range	CHEMBL1997433	=	IC50	nM	0.000095	CHEMBL2973	Homo sapiens	IC50	nM	0.000095
276209	16266206	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COCCN(C)CC(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666731	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
213453	16266788	CHEMBL3707620	Inhibition Assay: Inhibition of Rho kinase 2 and Rho kinase 1 activity was determined using the IMAP™ Screening Express Kit (Molecular Devices product number #8073). Rho kinase 2 enzyme (Upstate/Chemicon #14-451), Rho kinase 1 (Upstate/Chemicon #14-601) and Flourescein tagged substrate peptide F1-AKRRRLSSLRA (Molecular Devices product number R7184) was pre-incubated with a test compound for 5 minutes in buffer containing 10 mM Tris-HCl pH 7.2, 10 mM MgCl2, and 0.1% BSA. Following the pre-incubation, 10 μM ATP was added to initiate the reaction. After 60 minutes at room temperature, Molecular Devices IMAP™ binding solution was added to bind phosphorylated substrate. After 30 minutes of incubation in the presence of the IMAP™ beads, the fluorescence polarization was read and the ratio was reported as mP.	B	c1ccc(CN2CC3CCC2C3Nc2ccc3[nH]ncc3c2)cc1		CHEMBL3647979	=	Ki	nM	464.0	CHEMBL2973	Homo sapiens	Ki	nM	464.0
276258	16268572	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCC4CC4)ccc3n2)c1	Outside typical range	CHEMBL3666755	=	IC50	nM	0.000255	CHEMBL2973	Homo sapiens	IC50	nM	0.000255
276242	16269356	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1	Outside typical range	CHEMBL1968705	=	IC50	nM	0.0095	CHEMBL2973	Homo sapiens	IC50	nM	0.0095
276264	16269504	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4=O)ccc3n2)c1	Outside typical range	CHEMBL3666723	=	IC50	nM	0.000151	CHEMBL2973	Homo sapiens	IC50	nM	0.000151
276228	16269821	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COCCNC(=O)COc1ccccc1-c1nc(N(CC(=O)NCCOC)c2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666751	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276224	16270582	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(CN1CCCC1)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666735	=	IC50	nM	0.036	CHEMBL2973	Homo sapiens	IC50	nM	0.036
276251	16272991	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)ccc3n2)c1	Outside typical range	CHEMBL1997433	=	IC50	nM	0.000068	CHEMBL2973	Homo sapiens	IC50	nM	0.000068
276226	16274589	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(COc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)NCc1ccccc1		CHEMBL3666750	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276286	16275650	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	c1ccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCOCC4)ccc3n2)cc1	Outside typical range	CHEMBL3666760	=	IC50	nM	0.0073	CHEMBL2973	Homo sapiens	IC50	nM	0.0073
213449	16276168	CHEMBL3707620	Inhibition Assay: Inhibition of Rho kinase 2 and Rho kinase 1 activity was determined using the IMAP™ Screening Express Kit (Molecular Devices product number #8073). Rho kinase 2 enzyme (Upstate/Chemicon #14-451), Rho kinase 1 (Upstate/Chemicon #14-601) and Flourescein tagged substrate peptide F1-AKRRRLSSLRA (Molecular Devices product number R7184) was pre-incubated with a test compound for 5 minutes in buffer containing 10 mM Tris-HCl pH 7.2, 10 mM MgCl2, and 0.1% BSA. Following the pre-incubation, 10 μM ATP was added to initiate the reaction. After 60 minutes at room temperature, Molecular Devices IMAP™ binding solution was added to bind phosphorylated substrate. After 30 minutes of incubation in the presence of the IMAP™ beads, the fluorescence polarization was read and the ratio was reported as mP.	B	Cc1ccc(CN2C3CCC2CC(Nc2ccc4[nH]ncc4c2)C3)cc1		CHEMBL3647975	=	Ki	nM	20.0	CHEMBL2973	Homo sapiens	Ki	nM	20.0
276284	16276310	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OC)c(OCCOC)cc3n2)c1	Outside typical range	CHEMBL3666758	=	IC50	nM	0.000024	CHEMBL2973	Homo sapiens	IC50	nM	0.000024
276259	16277179	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCC4CC4)ccc3n2)c1	Outside typical range	CHEMBL3666755	=	IC50	nM	0.000182	CHEMBL2973	Homo sapiens	IC50	nM	0.000182
276295	16277238	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccc(OCCOC)cc3n2)c1		CHEMBL3666759	=	IC50	nM	90.0	CHEMBL2973	Homo sapiens	IC50	nM	90.0
276231	16279381	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COC(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Outside typical range	CHEMBL3639656	=	IC50	nM	0.0029	CHEMBL2973	Homo sapiens	IC50	nM	0.0029
276285	16280661	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	c1ccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCOCC4)ccc3n2)cc1	Outside typical range	CHEMBL3666760	=	IC50	nM	0.0065	CHEMBL2973	Homo sapiens	IC50	nM	0.0065
276204	16283508	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CC(C)NC(=O)CNc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1	Outside typical range	CHEMBL3666743	>	IC50	nM	0.003	CHEMBL2973	Homo sapiens	IC50	nM	0.003
213448	16285239	CHEMBL3707620	Inhibition Assay: Inhibition of Rho kinase 2 and Rho kinase 1 activity was determined using the IMAP™ Screening Express Kit (Molecular Devices product number #8073). Rho kinase 2 enzyme (Upstate/Chemicon #14-451), Rho kinase 1 (Upstate/Chemicon #14-601) and Flourescein tagged substrate peptide F1-AKRRRLSSLRA (Molecular Devices product number R7184) was pre-incubated with a test compound for 5 minutes in buffer containing 10 mM Tris-HCl pH 7.2, 10 mM MgCl2, and 0.1% BSA. Following the pre-incubation, 10 μM ATP was added to initiate the reaction. After 60 minutes at room temperature, Molecular Devices IMAP™ binding solution was added to bind phosphorylated substrate. After 30 minutes of incubation in the presence of the IMAP™ beads, the fluorescence polarization was read and the ratio was reported as mP.	B	c1ccc(CN2C3CCC2CC(Nc2ccc4[nH]ncc4c2)C3)cc1		CHEMBL3647974	=	Ki	nM	29.0	CHEMBL2973	Homo sapiens	Ki	nM	29.0
276282	16286957	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4c(cnn4C)c3)c3cc(OCCN(C)C)ccc3n2)c1	Outside typical range	CHEMBL3666754	>	IC50	nM	0.0003	CHEMBL2973	Homo sapiens	IC50	nM	0.0003
276216	16287126	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CC(C)(C)C(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666732	>	IC50	nM	0.01	CHEMBL2973	Homo sapiens	IC50	nM	0.01
276272	16287169	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4=O)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666725	=	IC50	nM	0.000064	CHEMBL2973	Homo sapiens	IC50	nM	0.000064
276249	16287186	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCCC4)ccc3n2)c1	Outside typical range	CHEMBL3666721	=	IC50	nM	0.000012	CHEMBL2973	Homo sapiens	IC50	nM	0.000012
276225	16289030	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(COc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)NCc1ccccc1		CHEMBL3666750	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276210	16289886	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COCCN(C)CC(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666731	>	IC50	nM	0.01	CHEMBL2973	Homo sapiens	IC50	nM	0.01
276269	16291323	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCC(O)C4)ccc3n2)c1	Outside typical range	CHEMBL3666724	=	IC50	nM	0.000008	CHEMBL2973	Homo sapiens	IC50	nM	0.000008
276239	16291409	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CN(C)CCC(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Outside typical range	CHEMBL3666741	=	IC50	nM	0.0053	CHEMBL2973	Homo sapiens	IC50	nM	0.0053
276280	16291435	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1	Outside typical range	CHEMBL3666756	=	IC50	nM	0.000029	CHEMBL2973	Homo sapiens	IC50	nM	0.000029
276265	16291500	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4=O)ccc3n2)c1	Outside typical range	CHEMBL3666723	=	IC50	nM	0.000106	CHEMBL2973	Homo sapiens	IC50	nM	0.000106
276205	16291629	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Oc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1	Outside typical range	CHEMBL3666729	=	IC50	nM	0.000129	CHEMBL2973	Homo sapiens	IC50	nM	0.000129
276232	16291952	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)N1CCOCC1		CHEMBL3666737	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276257	16292328	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)ccc3n2)c1	Outside typical range	CHEMBL1997433	=	IC50	nM	0.000064	CHEMBL2973	Homo sapiens	IC50	nM	0.000064
276237	16292489	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)c1ccccn1		CHEMBL3666740	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276267	16293465	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCC(O)C4)ccc3n2)c1	Outside typical range	CHEMBL3666724	=	IC50	nM	0.000011	CHEMBL2973	Homo sapiens	IC50	nM	0.000011
276240	16293885	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COCC(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Outside typical range	CHEMBL3666742	=	IC50	nM	0.0017	CHEMBL2973	Homo sapiens	IC50	nM	0.0017
276248	16294633	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCCC4)ccc3n2)c1	Outside typical range	CHEMBL3666721	=	IC50	nM	0.000017	CHEMBL2973	Homo sapiens	IC50	nM	0.000017
276289	16295917	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COCCNC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL3666715	=	IC50	nM	150.0	CHEMBL2973	Homo sapiens	IC50	nM	150.0
276255	16297927	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)ccc3n2)c1	Outside typical range	CHEMBL1997433	=	IC50	nM	0.00012	CHEMBL2973	Homo sapiens	IC50	nM	0.00012
276292	16299858	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COc1cc2nc(-c3cccc(NC(=O)CN4CCOCC4)c3)nc(Nc3ccc4[nH]ncc4c3)c2cc1OCCN1CCCC1		CHEMBL3666720	=	IC50	nM	60.0	CHEMBL2973	Homo sapiens	IC50	nM	60.0
276266	16301419	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4=O)ccc3n2)c1	Outside typical range	CHEMBL3666723	=	IC50	nM	0.000067	CHEMBL2973	Homo sapiens	IC50	nM	0.000067
276271	16304551	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4=O)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666725	=	IC50	nM	0.000048	CHEMBL2973	Homo sapiens	IC50	nM	0.000048
276294	16305973	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN(C)C)ccc3n2)c1		CHEMBL3666718	=	IC50	nM	40.0	CHEMBL2973	Homo sapiens	IC50	nM	40.0
276247	16306010	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCCC4)ccc3n2)c1	Outside typical range	CHEMBL3666721	=	IC50	nM	0.000032	CHEMBL2973	Homo sapiens	IC50	nM	0.000032
276245	16306943	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1	Outside typical range	CHEMBL1968705	=	IC50	nM	0.00001	CHEMBL2973	Homo sapiens	IC50	nM	0.00001
276260	16308267	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCN(C)CC4)ccc3n2)c1	Outside typical range	CHEMBL3666722	=	IC50	nM	0.000012	CHEMBL2973	Homo sapiens	IC50	nM	0.000012
276283	16309720	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4c(cnn4C)c3)c3cc(OCCN(C)C)ccc3n2)c1	Outside typical range	CHEMBL3666754	=	IC50	nM	0.004	CHEMBL2973	Homo sapiens	IC50	nM	0.004
276233	16310649	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CN(C)C(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666738	=	IC50	nM	0.049	CHEMBL2973	Homo sapiens	IC50	nM	0.049
276215	16312511	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CC(C)(C)C(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666732	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276276	16315204	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCN(C)CC4)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666727	=	IC50	nM	0.000016	CHEMBL2973	Homo sapiens	IC50	nM	0.000016
213450	16316346	CHEMBL3707620	Inhibition Assay: Inhibition of Rho kinase 2 and Rho kinase 1 activity was determined using the IMAP™ Screening Express Kit (Molecular Devices product number #8073). Rho kinase 2 enzyme (Upstate/Chemicon #14-451), Rho kinase 1 (Upstate/Chemicon #14-601) and Flourescein tagged substrate peptide F1-AKRRRLSSLRA (Molecular Devices product number R7184) was pre-incubated with a test compound for 5 minutes in buffer containing 10 mM Tris-HCl pH 7.2, 10 mM MgCl2, and 0.1% BSA. Following the pre-incubation, 10 μM ATP was added to initiate the reaction. After 60 minutes at room temperature, Molecular Devices IMAP™ binding solution was added to bind phosphorylated substrate. After 30 minutes of incubation in the presence of the IMAP™ beads, the fluorescence polarization was read and the ratio was reported as mP.	B	OCCOc1cccc(CN2C3CCC2CC(Nc2ccc4[nH]ncc4c2)C3)c1		CHEMBL3647976	=	Ki	nM	21.0	CHEMBL2973	Homo sapiens	Ki	nM	21.0
276207	16317810	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666730	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276234	16319441	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666752	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276230	16320403	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)C1CCCNC1		CHEMBL3666736	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276238	16320429	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)c1ccccn1	Outside typical range	CHEMBL3666740	=	IC50	nM	0.0083	CHEMBL2973	Homo sapiens	IC50	nM	0.0083
276277	16320578	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCN(C)CC4)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666727	=	IC50	nM	0.000014	CHEMBL2973	Homo sapiens	IC50	nM	0.000014
276244	16321843	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1	Outside typical range	CHEMBL1968705	=	IC50	nM	0.000012	CHEMBL2973	Homo sapiens	IC50	nM	0.000012
276243	16326795	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1	Outside typical range	CHEMBL1968705	=	IC50	nM	0.000026	CHEMBL2973	Homo sapiens	IC50	nM	0.000026
213451	16327681	CHEMBL3707620	Inhibition Assay: Inhibition of Rho kinase 2 and Rho kinase 1 activity was determined using the IMAP™ Screening Express Kit (Molecular Devices product number #8073). Rho kinase 2 enzyme (Upstate/Chemicon #14-451), Rho kinase 1 (Upstate/Chemicon #14-601) and Flourescein tagged substrate peptide F1-AKRRRLSSLRA (Molecular Devices product number R7184) was pre-incubated with a test compound for 5 minutes in buffer containing 10 mM Tris-HCl pH 7.2, 10 mM MgCl2, and 0.1% BSA. Following the pre-incubation, 10 μM ATP was added to initiate the reaction. After 60 minutes at room temperature, Molecular Devices IMAP™ binding solution was added to bind phosphorylated substrate. After 30 minutes of incubation in the presence of the IMAP™ beads, the fluorescence polarization was read and the ratio was reported as mP.	B	Cc1ccc(CN2C3CCC2CC(Nc2ccc4[nH]ncc4c2)C3)cc1OCCO		CHEMBL3647977	=	Ki	nM	10.0	CHEMBL2973	Homo sapiens	Ki	nM	10.0
276217	16328007	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CNCC(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666733	=	IC50	nM	0.017	CHEMBL2973	Homo sapiens	IC50	nM	0.017
276252	16328804	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)ccc3n2)c1	Outside typical range	CHEMBL1997433	=	IC50	nM	0.000032	CHEMBL2973	Homo sapiens	IC50	nM	0.000032
276208	16329014	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666730	>	IC50	nM	0.01	CHEMBL2973	Homo sapiens	IC50	nM	0.01
276221	16330042	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(COc1ccccc1-c1nc(N(CC(=O)NCC2CC2)c2ccc3[nH]ncc3c2)c2ccccc2n1)NCC1CC1		CHEMBL3666748	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276206	16330091	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(CN1CCOCC1)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Outside typical range	CHEMBL3666744	>	IC50	nM	0.003	CHEMBL2973	Homo sapiens	IC50	nM	0.003
276212	16330283	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CC(C)NC(=O)COc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Outside typical range	CHEMBL3666745	>	IC50	nM	0.003	CHEMBL2973	Homo sapiens	IC50	nM	0.003
276222	16331173	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)c1ccoc1		CHEMBL3666734	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276275	16334330	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666726	=	IC50	nM	0.000029	CHEMBL2973	Homo sapiens	IC50	nM	0.000029
276223	16335478	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(COc1ccccc1-c1nc(N(CC(=O)NCc2ccccc2)c2ccc3[nH]ncc3c2)c2ccccc2n1)NCc1ccccc1		CHEMBL3666749	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276288	16335676	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CC(=O)Oc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL3666762	=	IC50	nM	570.0	CHEMBL2973	Homo sapiens	IC50	nM	570.0
276268	16335830	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCC(O)C4)ccc3n2)c1	Outside typical range	CHEMBL3666724	=	IC50	nM	0.000012	CHEMBL2973	Homo sapiens	IC50	nM	0.000012
276220	16336682	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COCCNC(=O)COc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Outside typical range	CHEMBL3666747	>	IC50	nM	0.003	CHEMBL2973	Homo sapiens	IC50	nM	0.003
276270	16337809	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCC(O)C4)ccc3n2)c1	Outside typical range	CHEMBL3666724	=	IC50	nM	0.000013	CHEMBL2973	Homo sapiens	IC50	nM	0.000013
276229	16337935	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)C1CCCNC1		CHEMBL3666736	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276214	16338438	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	Oc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Outside typical range	CHEMBL3666746	=	IC50	nM	0.0025	CHEMBL2973	Homo sapiens	IC50	nM	0.0025
276253	16340050	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)ccc3n2)c1	Outside typical range	CHEMBL1997433	=	IC50	nM	0.000011	CHEMBL2973	Homo sapiens	IC50	nM	0.000011
276261	16340956	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCN(C)CC4)ccc3n2)c1	Outside typical range	CHEMBL3666722	=	IC50	nM	0.000012	CHEMBL2973	Homo sapiens	IC50	nM	0.000012
276219	16341604	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	COCCNC(=O)COc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666747	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276250	16341961	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)ccc3n2)c1	Outside typical range	CHEMBL1997433	=	IC50	nM	0.000035	CHEMBL2973	Homo sapiens	IC50	nM	0.000035
276235	16342683	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)c1ccncc1		CHEMBL3666739	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276290	16342835	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1)Nc1cccnc1		CHEMBL3666716	=	IC50	nM	90.0	CHEMBL2973	Homo sapiens	IC50	nM	90.0
276218	16343924	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CNCC(=O)Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666733	>	IC50	nM	0.01	CHEMBL2973	Homo sapiens	IC50	nM	0.01
276274	16344031	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)c(OC)cc3n2)c1	Outside typical range	CHEMBL3666726	=	IC50	nM	0.000044	CHEMBL2973	Homo sapiens	IC50	nM	0.000044
276262	16344107	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCN(C)CC4)ccc3n2)c1	Outside typical range	CHEMBL3666722	=	IC50	nM	0.000012	CHEMBL2973	Homo sapiens	IC50	nM	0.000012
276246	16344144	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCCC4)ccc3n2)c1	Outside typical range	CHEMBL3666721	=	IC50	nM	0.000014	CHEMBL2973	Homo sapiens	IC50	nM	0.000014
276293	16350311	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCCN4CCOCC4)c(OC)cc3n2)c1		CHEMBL3666719	=	IC50	nM	50.0	CHEMBL2973	Homo sapiens	IC50	nM	50.0
276256	16350760	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCOC)ccc3n2)c1	Outside typical range	CHEMBL1997433	=	IC50	nM	0.000051	CHEMBL2973	Homo sapiens	IC50	nM	0.000051
276213	16351052	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	Oc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Outside typical range	CHEMBL3666746	=	IC50	nM	0.002	CHEMBL2973	Homo sapiens	IC50	nM	0.002
276236	16352146	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	O=C(Nc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1)c1ccncc1		CHEMBL3666739	>	IC50	nM	0.1	CHEMBL2973	Homo sapiens	IC50	nM	0.1
276241	16352726	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	CC(=O)Oc1ccccc1-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1		CHEMBL3666753	=	IC50	nM	0.023	CHEMBL2973	Homo sapiens	IC50	nM	0.023
276291	16352949	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL3666717	=	IC50	nM	520.0	CHEMBL2973	Homo sapiens	IC50	nM	520.0
276287	16353424	CHEMBL3705523	Binding Assay: ROCK-II inhibitory activity can be measured using the ROCK-II Assay Kit (Molecular Devices, inc.; Sunnyvale, Calif.).	B	Oc1ccc2nc(-c3ccccc3)nc(Nc3ccc4[nH]ncc4c3)c2c1	Outside typical range	CHEMBL3666761	=	IC50	nM	0.0039	CHEMBL2973	Homo sapiens	IC50	nM	0.0039
	16376479	CHEMBL3734503	Inhibition of recombinant human ROCK2 using fluorescein-labeled peptide as substrate by fluorescence-electrophoretic mobility shift assay	B	Cl.NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL3732044	=	Inhibition	%	-1.0	CHEMBL2973	Homo sapiens	INH	%	-1.0
	16388325	CHEMBL3737500	Inhibition of ROCK2 (unknown origin) at 1 uM by selectscreen kinase profiling assay in presence of ATP	B	COc1cc2c(cc1OC)CN(CC(=O)Nc1ccc3c(c1)/C(=C/c1cnc[nH]1)C(=O)N3)CC2		CHEMBL3091673	=	Inhibition	%	-5.0	CHEMBL2973	Homo sapiens	INH	%	-5.0
	16413512	CHEMBL3743746	Inhibition of ROCK2 (unknown origin)	B	O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1		CHEMBL3741589	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	16417304	CHEMBL3750774	Inhibition of ROCK2 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCN(S(C)(=O)=O)CC3)nc21		CHEMBL3747699	=	Inhibition	%	6.0	CHEMBL2973	Homo sapiens	INH	%	6.0
	16417305	CHEMBL3750774	Inhibition of ROCK2 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(Nc3ccc(N4CCC(O)CC4)cc3)nc21		CHEMBL3746959	=	Inhibition	%	12.0	CHEMBL2973	Homo sapiens	INH	%	12.0
	16417306	CHEMBL3750774	Inhibition of ROCK2 (unknown origin) at 10 uM	B	CN1CCN(CCCNc2ncc3cc(Oc4ccc(F)cc4F)c(=O)n(C)c3n2)CC1		CHEMBL3746022	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	INH	%	3.0
	16417307	CHEMBL3750774	Inhibition of ROCK2 (unknown origin) at 10 uM	B	CN1CCN(c2ccc(Nc3ncc4cc(Oc5ccc(F)cc5F)c(=O)n(C)c4n3)cc2)CC1		CHEMBL3745734	=	Inhibition	%	14.0	CHEMBL2973	Homo sapiens	INH	%	14.0
	16417308	CHEMBL3750774	Inhibition of ROCK2 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2c(Cl)cccc2Cl)cc2cnc(NC3CCOCC3)nc21		CHEMBL3747351	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	INH	%	4.0
	16417309	CHEMBL3750774	Inhibition of ROCK2 (unknown origin) at 10 uM	B	CN1CCN(c2ccc(Nc3ncc4cc(Oc5c(Cl)cccc5Cl)c(=O)n(C)c4n3)cc2)CC1		CHEMBL3747023	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	INH	%	3.0
	16417310	CHEMBL3750774	Inhibition of ROCK2 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NCCc3ccccn3)nc21		CHEMBL3746951	=	Inhibition	%	3.0	CHEMBL2973	Homo sapiens	INH	%	3.0
	16417311	CHEMBL3750774	Inhibition of ROCK2 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(Nc3ccc(N4CCCCC4)cc3)nc21		CHEMBL3746973	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	INH	%	5.0
	16417312	CHEMBL3750774	Inhibition of ROCK2 (unknown origin) at 10 uM	B	CN(C)CCNc1ncc2cc(Oc3ccc(F)cc3F)c(=O)n(C)c2n1		CHEMBL3745857	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	16421943	CHEMBL3748460	Inhibition of ROCK2 (unknown origin)	B	C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1		CHEMBL3651966	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	16426139	CHEMBL3750466	Inhibition of ROCK2 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1	Outside typical range	CHEMBL3746293	=	Inhibition	%	-18.1	CHEMBL2973	Homo sapiens	INH	%	-18.1
	16429071	CHEMBL3750809	Inhibition of ROCK2 (unknown origin) at 1 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCN(S(N)(=O)=O)CC3)nc21		CHEMBL3747489	=	Inhibition	%	13.0	CHEMBL2973	Homo sapiens	INH	%	13.0
	16431992	CHEMBL3750031	Inhibition of human ROCK2 using [KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	16451598	CHEMBL3761179	Inhibition of ROCK2 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	-10.0	CHEMBL2973	Homo sapiens	INH	%	-10.0
	16486388	CHEMBL3772122	Inhibition of human recombinant ROCK2 assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control	B	Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3		CHEMBL3771285	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	16493393	CHEMBL3772097	Inhibition of ROCK2 (unknown origin)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	320.0	CHEMBL2973	Homo sapiens	IC50	nM	320.0
	16493395	CHEMBL3772097	Inhibition of ROCK2 (unknown origin)	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	nM	19.0
	16493397	CHEMBL3772097	Inhibition of ROCK2 (unknown origin)	B	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	=	IC50	nM	140.0	CHEMBL2973	Homo sapiens	IC50	nM	140.0
	16493399	CHEMBL3772095	Inhibition of ROCK2 (unknown origin) using STK2 as substrate after 1 hr	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	16493401	CHEMBL3772097	Inhibition of ROCK2 (unknown origin)	B	NC(C(=O)Nc1ccc2cnccc2c1)c1ccccc1		CHEMBL3770730	=	IC50	nM	1.5	CHEMBL2973	Homo sapiens	IC50	nM	1.5
	16493403	CHEMBL3772097	Inhibition of ROCK2 (unknown origin)	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccccc1		CHEMBL3770836	=	IC50	nM	1.1	CHEMBL2973	Homo sapiens	IC50	nM	1.1
	16495211	CHEMBL3777753	Inhibition of N-terminal His6-tagged recombinant human ROCK2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	-9.0	CHEMBL2973	Homo sapiens	Activity	%	-9.0
	16496130	CHEMBL3777753	Inhibition of N-terminal His6-tagged recombinant human ROCK2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	-4.0	CHEMBL2973	Homo sapiens	Activity	%	-4.0
	16507168	CHEMBL3779009	Inhibition of recombinant ROCK2 (unknown origin) assessed as residual activity at 1 uM relative to control	B	CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1		CHEMBL3774632	>=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	16508920	CHEMBL3777753	Inhibition of N-terminal His6-tagged recombinant human ROCK2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	3.0	CHEMBL2973	Homo sapiens	Activity	%	3.0
Not Active	16515653	CHEMBL3782394	Inhibition of partial length human ROCK2 expressed in mammalian system at 1 uM	B	Cc1cnc(N)nc1OCC(C)(C)CO		CHEMBL3780032		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	16525676	CHEMBL3790307	Inhibition of ROCK2 (unknown origin) in presence of [gamma33P]ATP	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL3787112	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	uM	0.009
	16525677	CHEMBL3790307	Inhibition of ROCK2 (unknown origin) in presence of [gamma33P]ATP	B	Nc1ncnc2c1c(-c1cccc(OCC34CCC(CC3)O4)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL3785500	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	16525678	CHEMBL3790307	Inhibition of ROCK2 (unknown origin) in presence of [gamma33P]ATP	B	CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cccc(OC[C@@H]5CCCO5)c4F)c4c(N)ncnc43)C2)CC1		CHEMBL3786167	=	IC50	nM	6800.0	CHEMBL2973	Homo sapiens	IC50	uM	6.8
	16525679	CHEMBL3790307	Inhibition of ROCK2 (unknown origin) in presence of [gamma33P]ATP	B	CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cc(OC[C@@H]5CCCO5)ccc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3785951	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	16534400	CHEMBL3789300	Inhibition of human ROCK2 at 1 uM after 30 mins by fluorescence assay in presence of ATP	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCC(N)C2(C)C		CHEMBL3786892	=	Inhibition	%	92.0	CHEMBL2973	Homo sapiens	INH	%	92.0
	16547859	CHEMBL3796432	Inhibition of ROCK-2 (unknown origin)	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL3793353	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	16547861	CHEMBL3796430	Inhibition of human ROCK-2 using S6 peptide as substrate after 5 mins in presence of [gamma-32P]-ATP	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
Not Determined	16557609	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	CNCC(=O)OCc1ccc(C(CN)C(=O)Nc2ccc3cnccc3c2)cc1		CHEMBL3794308		Ki			CHEMBL2973	Homo sapiens	Ki		
	16557610	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(COC(=O)c2cccnc2)cc1		CHEMBL3793788	=	Ki	nM	0.7	CHEMBL2973	Homo sapiens	Ki	nM	0.7
	16557611	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	CCCCC(=O)OCc1ccc(C(CN)C(=O)Nc2ccc3cnccc3c2)cc1		CHEMBL3793688	=	Ki	nM	1.6	CHEMBL2973	Homo sapiens	Ki	nM	1.6
	16557612	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	Cc1cc(C)cc(C(=O)OCc2ccc(C(CN)C(=O)Nc3ccc4cnccc4c3)cc2)c1		CHEMBL3792412	=	Ki	nM	0.9	CHEMBL2973	Homo sapiens	Ki	nM	0.9
	16557613	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	Cc1ccc(C(=O)OCc2ccc(C(CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1		CHEMBL3794389	=	Ki	nM	4.2	CHEMBL2973	Homo sapiens	Ki	nM	4.2
	16557614	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(COC(=O)Cc2ccccc2)cc1		CHEMBL3793029	=	Ki	nM	0.8	CHEMBL2973	Homo sapiens	Ki	nM	0.8
	16557615	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(COC(=O)c2ccccc2)cc1		CHEMBL3792969	=	Ki	nM	1.7	CHEMBL2973	Homo sapiens	Ki	nM	1.7
	16557616	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	CC(C)(C)C(=O)OCc1ccc(C(CN)C(=O)Nc2ccc3cnccc3c2)cc1		CHEMBL3793243	=	Ki	nM	21.8	CHEMBL2973	Homo sapiens	Ki	nM	21.8
	16557617	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	CC(C)C(=O)OCc1ccc(C(CN)C(=O)Nc2ccc3cnccc3c2)cc1		CHEMBL3794444	=	Ki	nM	3.2	CHEMBL2973	Homo sapiens	Ki	nM	3.2
	16557618	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(=O)Oc1ccc(C(CN)C(=O)Nc2ccc3cnccc3c2)cc1		CHEMBL3792435	=	Ki	nM	1.0	CHEMBL2973	Homo sapiens	Ki	nM	1.0
	16557619	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(OC(=O)c2cccnc2)cc1		CHEMBL3792612	=	Ki	nM	4.8	CHEMBL2973	Homo sapiens	Ki	nM	4.8
	16557620	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	Cc1cc(C)cc(C(=O)Oc2ccc(C(CN)C(=O)Nc3ccc4cnccc4c3)cc2)c1		CHEMBL3793870	=	Ki	nM	275.0	CHEMBL2973	Homo sapiens	Ki	nM	275.0
	16557621	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	Cc1ccc(C(=O)Oc2ccc(C(CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1		CHEMBL3792603	=	Ki	nM	821.0	CHEMBL2973	Homo sapiens	Ki	nM	821.0
	16557622	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(OC(=O)Cc2ccccc2)cc1		CHEMBL3792599	=	Ki	nM	1.8	CHEMBL2973	Homo sapiens	Ki	nM	1.8
	16557623	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(OC(=O)c2ccccc2)cc1		CHEMBL3794435	=	Ki	nM	6.8	CHEMBL2973	Homo sapiens	Ki	nM	6.8
	16557624	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	CC(C)(C)C(=O)Oc1ccc(C(CN)C(=O)Nc2ccc3cnccc3c2)cc1		CHEMBL3793659	=	Ki	nM	359.0	CHEMBL2973	Homo sapiens	Ki	nM	359.0
	16557625	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	CC(C)C(=O)Oc1ccc(C(CN)C(=O)Nc2ccc3cnccc3c2)cc1		CHEMBL3793381	=	Ki	nM	42.0	CHEMBL2973	Homo sapiens	Ki	nM	42.0
	16557626	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc2ccccc2c1		CHEMBL3793497	=	Ki	nM	0.7	CHEMBL2973	Homo sapiens	Ki	nM	0.7
	16557627	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1cccc2ccccc12		CHEMBL3793296	=	Ki	nM	1.0	CHEMBL2973	Homo sapiens	Ki	nM	1.0
	16557628	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(C(F)(F)F)cc1		CHEMBL3793235	=	Ki	nM	1.8	CHEMBL2973	Homo sapiens	Ki	nM	1.8
	16557629	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1cccc(C(F)(F)F)c1		CHEMBL3793203	=	Ki	nM	2.7	CHEMBL2973	Homo sapiens	Ki	nM	2.7
	16557630	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1		CHEMBL3792888	=	Ki	nM	0.2	CHEMBL2973	Homo sapiens	Ki	nM	0.2
	16557631	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1cccc(CO)c1		CHEMBL3792689	=	Ki	nM	3.0	CHEMBL2973	Homo sapiens	Ki	nM	3.0
	16557632	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(OCc2ccccc2)cc1		CHEMBL3792593	=	Ki	nM	2.0	CHEMBL2973	Homo sapiens	Ki	nM	2.0
	16557633	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	COc1ccc(C(CN)C(=O)Nc2ccc3cnccc3c2)cc1		CHEMBL3793516	=	Ki	nM	1.3	CHEMBL2973	Homo sapiens	Ki	nM	1.3
	16557634	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	COc1cccc(C(CN)C(=O)Nc2ccc3cnccc3c2)c1		CHEMBL3793153	=	Ki	nM	2.0	CHEMBL2973	Homo sapiens	Ki	nM	2.0
	16557635	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	COc1cc(C(CN)C(=O)Nc2ccc3cnccc3c2)ccc1O		CHEMBL3793368	=	Ki	nM	10.3	CHEMBL2973	Homo sapiens	Ki	nM	10.3
	16557636	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	Cc1cc(C(CN)C(=O)Nc2ccc3cnccc3c2)ccc1O		CHEMBL3794298	=	Ki	nM	1.0	CHEMBL2973	Homo sapiens	Ki	nM	1.0
	16557637	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(O)c(O)c1		CHEMBL3794254	=	Ki	nM	5.5	CHEMBL2973	Homo sapiens	Ki	nM	5.5
	16557638	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(O)cc1		CHEMBL3792663	=	Ki	nM	0.6	CHEMBL2973	Homo sapiens	Ki	nM	0.6
	16557639	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1cccc(O)c1		CHEMBL3792734	=	Ki	nM	1.3	CHEMBL2973	Homo sapiens	Ki	nM	1.3
	16557640	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	Cc1ccc(C(CN)C(=O)Nc2ccc3cnccc3c2)cc1		CHEMBL3792673	=	Ki	nM	0.4	CHEMBL2973	Homo sapiens	Ki	nM	0.4
	16557641	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	Cc1cccc(C(CN)C(=O)Nc2ccc3cnccc3c2)c1		CHEMBL3794198	=	Ki	nM	3.3	CHEMBL2973	Homo sapiens	Ki	nM	3.3
	16557642	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	Cc1ccccc1C(CN)C(=O)Nc1ccc2cnccc2c1		CHEMBL3793489	=	Ki	nM	1.0	CHEMBL2973	Homo sapiens	Ki	nM	1.0
	16557643	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(Cl)cc1Cl		CHEMBL3793404	=	Ki	nM	0.8	CHEMBL2973	Homo sapiens	Ki	nM	0.8
	16557644	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(Cl)cc1		CHEMBL3794104	=	Ki	nM	0.4	CHEMBL2973	Homo sapiens	Ki	nM	0.4
	16557645	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1cccc(Cl)c1		CHEMBL3793505	=	Ki	nM	0.9	CHEMBL2973	Homo sapiens	Ki	nM	0.9
	16557646	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccccc1Cl		CHEMBL3792549	=	Ki	nM	1.3	CHEMBL2973	Homo sapiens	Ki	nM	1.3
	16557647	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(F)c(F)c1		CHEMBL3793969	=	Ki	nM	1.2	CHEMBL2973	Homo sapiens	Ki	nM	1.2
	16557648	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2c(O)nccc2c1)c1ccc(F)cc1		CHEMBL3792581	=	Ki	nM	2.0	CHEMBL2973	Homo sapiens	Ki	nM	2.0
	16557649	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(F)cc1		CHEMBL3792921	=	Ki	nM	1.0	CHEMBL2973	Homo sapiens	Ki	nM	1.0
	16557650	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1cccc(F)c1		CHEMBL3792666	=	Ki	nM	1.0	CHEMBL2973	Homo sapiens	Ki	nM	1.0
	16557651	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccccc1F		CHEMBL3794270	=	Ki	nM	1.0	CHEMBL2973	Homo sapiens	Ki	nM	1.0
	16557652	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2c(O)nccc2c1)c1ccccc1		CHEMBL3792781	=	Ki	nM	2.2	CHEMBL2973	Homo sapiens	Ki	nM	2.2
	16557653	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCCC(C(=O)Nc1ccc2cnccc2c1)c1ccccc1		CHEMBL3793538	=	Ki	nM	1.5	CHEMBL2973	Homo sapiens	Ki	nM	1.5
	16557654	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NC[C@H](C(=O)Nc1ccc2cnccc2c1)c1ccccc1		CHEMBL3793245	=	Ki	nM	16.0	CHEMBL2973	Homo sapiens	Ki	nM	16.0
	16557655	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NC[C@@H](C(=O)Nc1ccc2cnccc2c1)c1ccccc1		CHEMBL3793004	=	Ki	nM	0.4	CHEMBL2973	Homo sapiens	Ki	nM	0.4
	16557656	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccccc1		CHEMBL3770836	=	Ki	nM	0.8	CHEMBL2973	Homo sapiens	Ki	nM	0.8
	16557657	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	NC(C(=O)Nc1ccc2cnccc2c1)c1ccccc1		CHEMBL3770730	=	Ki	nM	1.5	CHEMBL2973	Homo sapiens	Ki	nM	1.5
	16557658	CHEMBL3796494	Inhibition of ROCK2 (unknown origin) using RSK2 peptide (KKRNRTLTK) as substrate after 180 mins by luminescent kinase assay	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1.Cl		CHEMBL3794409	=	Ki	nM	2.3	CHEMBL2973	Homo sapiens	Ki	nM	2.3
	16557687	CHEMBL3796592	Inhibition of human ROCK2 at 500 nM	B	Cc1ccc(C(=O)OCc2ccc(C(CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1		CHEMBL3794389	=	Inhibition	%	93.0	CHEMBL2973	Homo sapiens	INH	%	93.0
	16557698	CHEMBL3796592	Inhibition of human ROCK2 at 500 nM	B	NCC(C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1		CHEMBL3792888	=	Inhibition	%	100.0	CHEMBL2973	Homo sapiens	INH	%	100.0
	16565462	CHEMBL3802851	Inhibition of ROCK2 (unknown origin)	B	C[C@H](c1ccccc1)N1c2cc(-n3c(=O)[nH]c4ncccc43)ccc2C(=O)NC1(C)C		CHEMBL3798011	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	16565770	CHEMBL3801112	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP/10 uM ATP addition measured after 120 mins by radiometric assay	B	Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356433	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
	16565771	CHEMBL3801112	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP/10 uM ATP addition measured after 120 mins by radiometric assay	B	Cc1[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c2c1C		CHEMBL3799326	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	16565772	CHEMBL3801112	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP/10 uM ATP addition measured after 120 mins by radiometric assay	B	CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(c3ncnc4[nH]c5c(c34)CCCC5)CC2)c1		CHEMBL3797874	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	16566187	CHEMBL3803177	Inhibition of ROCK2 (unknown origin)	B	C[C@H]1CN(c2cccc3nc(-c4nc(-c5cc(C(=O)N(C)C)ccn5)cnc4N)n(C)c23)CCN1		CHEMBL3800585	=	IC50	nM	370.0	CHEMBL2973	Homo sapiens	IC50	uM	0.37
	16578367	CHEMBL3802052	Inhibition of partial length wild type human ROCK2 expressed in mammalian system assessed as enzyme activity at 1 uM relative to control	B	CN(C)S(=O)(=O)Nc1ccc(F)c(Nc2ncccc2-c2ncnc3[nH]cnc23)c1F		CHEMBL3798256	=	Activity	%	92.0	CHEMBL2973	Homo sapiens	Activity	%	92.0
	16593523	CHEMBL3811358	Inhibition of GST-tagged human recombinant ROCK2 ( 1 to 552 residues) expressed in baculovirus using Fluorescein-PKC as substrate at 100 nM	B	COC(=O)c1cc2cc(NCc3cc(NC(=O)c4cc(-n5cnc(C)c5)cc(C(F)(F)F)c4)ccc3C)cnc2[nH]1		CHEMBL3808884	<	Inhibition	%	40.0	CHEMBL2973	Homo sapiens	INH	%	40.0
	16594841	CHEMBL3812896	Inhibition of human ROCK2 (1 to 431 amino acid residues) assessed as enzyme activity at 10 uM by KINOMEScan assay	B	O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2		CHEMBL1987813	=	Activity	%	77.0	CHEMBL2973	Homo sapiens	Activity	%	77.0
	16609154	CHEMBL3816308	Inhibition of ROCK2 (unknown origin) by kinomescan analysis	B	CN(C)CCCn1cc(-c2ccc3c(c2)-c2[nH]c4cc(-c5cn[nH]c5)ccc4c2C3=O)cn1		CHEMBL3815054	=	IC50	nM	936.0	CHEMBL2973	Homo sapiens	IC50	nM	936.0
	16614619	CHEMBL3816765	Inhibition of human ROCK2 at 1 uM using [KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK] as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	INH	%	4.0
	16618134	CHEMBL3816520	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 552 residues) expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	16627572	CHEMBL3820503	Inhibition of recombinant human N-terminal His6-tagged ROCK2 (11 to 552 residues) expressed in baculovirus infected Sf21 cells at 1 uM by radiometric assay relative to control	B	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4ccccc4)nc23)ccc1C(=O)NC1CC1		CHEMBL3819210	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	16627573	CHEMBL3820503	Inhibition of recombinant human N-terminal His6-tagged ROCK2 (11 to 552 residues) expressed in baculovirus infected Sf21 cells at 1 uM by radiometric assay relative to control	B	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1		CHEMBL3818239	=	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	16642018	CHEMBL3826429	Inhibition of catalytic recombinant GST-tagged human ROCK2 expressed in baculovirus system at 100 nM by Z-lyte assay	B	O=C(CNC(=O)c1cccn(Cc2ccc(F)c(F)c2)c1=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL3824119	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	16668115	CHEMBL3854813	Inhibition of ROCK-2 (unknown origin)	B	Nc1n[nH]c2ccc(C(=O)N3CCC[C@H]3c3ccc(Cl)cc3)cc12		CHEMBL3911320	=	IC50	nM	1330.0	CHEMBL2973	Homo sapiens	IC50	nM	1330.0
	16668145	CHEMBL3854820	Inhibition of ROCK-2 (unknown origin) at 1 uM relative to control	B	Nc1n[nH]c2ccc(C(=O)N3CCC[C@H]3c3ccc(Cl)cc3)cc12		CHEMBL3911320	=	Inhibition	%	42.0	CHEMBL2973	Homo sapiens	INH	%	42.0
	16668146	CHEMBL3854820	Inhibition of ROCK-2 (unknown origin) at 1 uM relative to control	B	Nc1n[nH]c2ccc(C(=O)N3CCC[C@H]3c3ccc(Br)cc3)cc12		CHEMBL3939280	=	Inhibition	%	65.0	CHEMBL2973	Homo sapiens	INH	%	65.0
	16668147	CHEMBL3854820	Inhibition of ROCK-2 (unknown origin) at 1 uM relative to control	B	Nc1n[nH]c2ccc(C(=O)N3CCC[C@H]3c3ccc(F)cc3)cc12		CHEMBL3975326	=	Inhibition	%	27.0	CHEMBL2973	Homo sapiens	INH	%	27.0
	16668148	CHEMBL3854820	Inhibition of ROCK-2 (unknown origin) at 1 uM relative to control	B	Nc1n[nH]c2ccc(C(=O)N3CC[C@H]3c3ccc(F)cc3)cc12		CHEMBL3964636	=	Inhibition	%	12.0	CHEMBL2973	Homo sapiens	INH	%	12.0
	16668149	CHEMBL3854820	Inhibition of ROCK-2 (unknown origin) at 1 uM relative to control	B	Nc1n[nH]c2ccc(C(=O)N3CCCC[C@H]3c3ccc(F)cc3)cc12		CHEMBL3984494	=	Inhibition	%	22.0	CHEMBL2973	Homo sapiens	INH	%	22.0
	16668150	CHEMBL3854820	Inhibition of ROCK-2 (unknown origin) at 1 uM relative to control	B	Nc1n[nH]c2ccc(C(=O)N3CC[C@@H](c4ccc(Cl)cc4)C3)cc12		CHEMBL3955876	=	Inhibition	%	20.0	CHEMBL2973	Homo sapiens	INH	%	20.0
	16668151	CHEMBL3854820	Inhibition of ROCK-2 (unknown origin) at 1 uM relative to control	B	CNc1n[nH]c2ccc(C(=O)N3CCC[C@H]3c3ccc(Cl)cc3)cc12		CHEMBL3895703	=	Inhibition	%	17.0	CHEMBL2973	Homo sapiens	INH	%	17.0
	16737969	CHEMBL3856686	Inhibition of human recombinant ROCK-2 expressed in sf21 cells assessed as remaining activity at 10 uM preincubated for 15 mins followed by Long S6 kinase substrate addition measured after 30 mins in presence of [gamma-32P]ATP by TR-FRET assay	B	CNCCOc1ccc(-c2sc3nc(-c4cccs4)nc(NN4C(=O)C=C(C)C4=O)c3c2C)cc1.Cl		CHEMBL3966536	=	Activity	%	93.0	CHEMBL2973	Homo sapiens	Activity	%	93.0
	16815468	CHEMBL3871629	Inhibition of human recombinant N-terminal GST-tagged ROCK2 catalytic domain (1 to 552 residues) expressed in baculovirus expression system at 1 uM	B	O=C(O)/C=C\C(=O)Nc1cccc(-c2n[nH]c3ccc(NS(=O)(=O)c4ccccc4)cc23)c1		CHEMBL3986609	=	Inhibition	%	8.0	CHEMBL2973	Homo sapiens	INH	%	8.0
	16837466	CHEMBL3876128	Inhibition of human recombinant N-terminal GST-tagged ROCK2 cytoplasmic domain (1 to 552 residues) expressed in baculovirus expression system	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	16888333	CHEMBL3881298	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK substrate and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	<	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
227770	17616170	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)c1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689345	=	IC50	nM	358.0	CHEMBL2973	Homo sapiens	IC50	nM	358.0
227771	17616171	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	N#Cc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689346	=	IC50	nM	1230.0	CHEMBL2973	Homo sapiens	IC50	nM	1230.0
227772	17616172	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(=O)Nc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689347	=	IC50	nM	6190.0	CHEMBL2973	Homo sapiens	IC50	nM	6190.0
227773	17616173	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)c1ccc(CN2CCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689348	=	IC50	nM	254.0	CHEMBL2973	Homo sapiens	IC50	nM	254.0
227774	17616174	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	N#Cc1cccc(CN2CCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689349	=	IC50	nM	2290.0	CHEMBL2973	Homo sapiens	IC50	nM	2290.0
227775	17616175	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(=O)Nc1ccc(CN2CCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689350	=	IC50	nM	2750.0	CHEMBL2973	Homo sapiens	IC50	nM	2750.0
227776	17616176	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CN(C)CCCOc1ccc(CN2CCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689351	=	IC50	nM	3440.0	CHEMBL2973	Homo sapiens	IC50	nM	3440.0
227777	17616177	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CSc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689352	=	IC50	nM	65.8	CHEMBL2973	Homo sapiens	IC50	nM	65.8
227778	17616178	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1ccc(-c2ccc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)cc2)cc1		CHEMBL3689353	=	IC50	nM	1610.0	CHEMBL2973	Homo sapiens	IC50	nM	1610.0
227779	17616179	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cn(-c2ccc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)cc2)cn1		CHEMBL3689354	=	IC50	nM	2800.0	CHEMBL2973	Homo sapiens	IC50	nM	2800.0
227780	17616180	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(N2CCCC2)ccc1CN1CCCC(Nc2ccc3[nH]ncc3c2)C1		CHEMBL3689355	=	IC50	nM	12200.0	CHEMBL2973	Homo sapiens	IC50	nM	12200.0
227781	17616181	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(N2CCOCC2)ccc1CN1CCCC(Nc2ccc3[nH]ncc3c2)C1		CHEMBL3689356	=	IC50	nM	12200.0	CHEMBL2973	Homo sapiens	IC50	nM	12200.0
227782	17616182	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(C)Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689357	=	IC50	nM	3660.0	CHEMBL2973	Homo sapiens	IC50	nM	3660.0
227783	17616183	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCCCc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689358	=	IC50	nM	4690.0	CHEMBL2973	Homo sapiens	IC50	nM	4690.0
227784	17616184	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(C)Oc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689359	=	IC50	nM	9980.0	CHEMBL2973	Homo sapiens	IC50	nM	9980.0
227785	17616185	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Cc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1C		CHEMBL3689360	=	IC50	nM	135.0	CHEMBL2973	Homo sapiens	IC50	nM	135.0
227786	17616186	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCSc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689361	=	IC50	nM	215.0	CHEMBL2973	Homo sapiens	IC50	nM	215.0
227787	17616187	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689362	=	IC50	nM	2410.0	CHEMBL2973	Homo sapiens	IC50	nM	2410.0
227788	17616188	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CN(C)Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689363	=	IC50	nM	13400.0	CHEMBL2973	Homo sapiens	IC50	nM	13400.0
227789	17616189	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(C2CC2)ccc1CN1CCCC(Nc2ccc3[nH]ncc3c2)C1		CHEMBL3689364	=	IC50	nM	251.0	CHEMBL2973	Homo sapiens	IC50	nM	251.0
227790	17616190	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc(C2CC2)c1		CHEMBL3689365	=	IC50	nM	553.0	CHEMBL2973	Homo sapiens	IC50	nM	553.0
227791	17616191	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	FC(F)(F)Oc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689366	=	IC50	nM	1610.0	CHEMBL2973	Homo sapiens	IC50	nM	1610.0
227792	17616192	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(C)c1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689367	=	IC50	nM	334.0	CHEMBL2973	Homo sapiens	IC50	nM	334.0
227793	17616193	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c(C)c1		CHEMBL3689368	=	IC50	nM	107.0	CHEMBL2973	Homo sapiens	IC50	nM	107.0
227794	17616194	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689369	=	IC50	nM	588.0	CHEMBL2973	Homo sapiens	IC50	nM	588.0
227795	17616195	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(SC2CC2)ccc1CN1CCCC(Nc2ccc3[nH]ncc3c2)C1		CHEMBL3689370	=	IC50	nM	2130.0	CHEMBL2973	Homo sapiens	IC50	nM	2130.0
227796	17616196	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(C)(C)OC(=O)NCc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689371	=	IC50	nM	6600.0	CHEMBL2973	Homo sapiens	IC50	nM	6600.0
227797	17616197	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCSc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689361	=	IC50	nM	1310.0	CHEMBL2973	Homo sapiens	IC50	nM	1310.0
227798	17616198	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689372	=	IC50	nM	11700.0	CHEMBL2973	Homo sapiens	IC50	nM	11700.0
227799	17616199	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)CC2)cc1		CHEMBL3689373	=	IC50	nM	1750.0	CHEMBL2973	Homo sapiens	IC50	nM	1750.0
227800	17616200	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CN(C)c1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689374	=	IC50	nM	1940.0	CHEMBL2973	Homo sapiens	IC50	nM	1940.0
227801	17616201	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689375	=	IC50	nM	86.9	CHEMBL2973	Homo sapiens	IC50	nM	86.9
227802	17616202	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C#Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689376	=	IC50	nM	69.1	CHEMBL2973	Homo sapiens	IC50	nM	69.1
227803	17616203	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NCc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689377	=	IC50	nM	208.0	CHEMBL2973	Homo sapiens	IC50	nM	208.0
227804	17616204	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(=O)c1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689378	=	IC50	nM	1020.0	CHEMBL2973	Homo sapiens	IC50	nM	1020.0
227805	17616205	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C=Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689379	=	IC50	nM	69.5	CHEMBL2973	Homo sapiens	IC50	nM	69.5
227806	17616206	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	N#Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689380	=	IC50	nM	2760.0	CHEMBL2973	Homo sapiens	IC50	nM	2760.0
227807	17616207	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689381	=	IC50	nM	328.0	CHEMBL2973	Homo sapiens	IC50	nM	328.0
227808	17616208	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CSc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689382	=	IC50	nM	144.0	CHEMBL2973	Homo sapiens	IC50	nM	144.0
227809	17616209	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Cc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689383	=	IC50	nM	137.0	CHEMBL2973	Homo sapiens	IC50	nM	137.0
227810	17616210	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCC#Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689384	=	IC50	nM	4400.0	CHEMBL2973	Homo sapiens	IC50	nM	4400.0
227811	17616211	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCC#Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689385	=	IC50	nM	11700.0	CHEMBL2973	Homo sapiens	IC50	nM	11700.0
227812	17616212	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C(#CC1CC1)c1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689386	=	IC50	nM	6510.0	CHEMBL2973	Homo sapiens	IC50	nM	6510.0
227813	17616213	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Brc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689387	=	IC50	nM	586.0	CHEMBL2973	Homo sapiens	IC50	nM	586.0
227814	17616214	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Oc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689388	=	IC50	nM	156.0	CHEMBL2973	Homo sapiens	IC50	nM	156.0
227815	17616215	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C#Cc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689389	=	IC50	nM	57.0	CHEMBL2973	Homo sapiens	IC50	nM	57.0
227816	17616216	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)c1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689390	=	IC50	nM	721.0	CHEMBL2973	Homo sapiens	IC50	nM	721.0
227817	17616217	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Cc1n[nH]c2ccc(NC3CCCN(Cc4ccccc4)C3)cc12		CHEMBL373487	=	IC50	nM	604.0	CHEMBL2973	Homo sapiens	IC50	nM	604.0
227818	17616218	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Nc1n[nH]c2ccc(NC3CCCN(Cc4ccccc4)C3)cc12		CHEMBL3689391	=	IC50	nM	1040.0	CHEMBL2973	Homo sapiens	IC50	nM	1040.0
227819	17616219	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689392	=	IC50	nM	62.6	CHEMBL2973	Homo sapiens	IC50	nM	62.6
227820	17616220	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc2cc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)ccc2o1		CHEMBL3689393	=	IC50	nM	15.3	CHEMBL2973	Homo sapiens	IC50	nM	15.3
227821	17616221	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc2c(cc1CN1CCCC(Nc3ccc4[nH]ncc4c3)C1)OCCO2		CHEMBL3689394	=	IC50	nM	189.0	CHEMBL2973	Homo sapiens	IC50	nM	189.0
227822	17616222	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc2cc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)ccc2s1		CHEMBL3689395	=	IC50	nM	132.0	CHEMBL2973	Homo sapiens	IC50	nM	132.0
227823	17616223	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NC(=O)c1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689396	=	IC50	nM	472.0	CHEMBL2973	Homo sapiens	IC50	nM	472.0
227824	17616224	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NS(=O)(=O)c1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689397	=	IC50	nM	435.0	CHEMBL2973	Homo sapiens	IC50	nM	435.0
227825	17616225	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(C)(C)OC(=O)NCc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689398	=	IC50	nM	194.0	CHEMBL2973	Homo sapiens	IC50	nM	194.0
227826	17616226	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1OCCO		CHEMBL3689399	=	IC50	nM	47.5	CHEMBL2973	Homo sapiens	IC50	nM	47.5
227827	17616227	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1O		CHEMBL3689400	=	IC50	nM	32.0	CHEMBL2973	Homo sapiens	IC50	nM	32.0
227828	17616228	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCOC(=O)COc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689401	=	IC50	nM	87.2	CHEMBL2973	Homo sapiens	IC50	nM	87.2
227829	17616229	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NCc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689402	=	IC50	nM	282.0	CHEMBL2973	Homo sapiens	IC50	nM	282.0
227830	17616230	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Clc1ccc(CN2CCC(Nc3ccc4[nH]ncc4c3)C2)cc1Cl		CHEMBL3689403	=	IC50	nM	155.0	CHEMBL2973	Homo sapiens	IC50	nM	155.0
227831	17616231	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	FC(F)(F)c1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689404	=	IC50	nM	223.0	CHEMBL2973	Homo sapiens	IC50	nM	223.0
227832	17616232	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	FC(F)(F)c1cccc(CN2CCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689405	=	IC50	nM	165.0	CHEMBL2973	Homo sapiens	IC50	nM	165.0
227833	17616233	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCOc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689406	=	IC50	nM	326.0	CHEMBL2973	Homo sapiens	IC50	nM	326.0
227834	17616234	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Cc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689407	=	IC50	nM	232.0	CHEMBL2973	Homo sapiens	IC50	nM	232.0
227835	17616235	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	COc1ccccc1CN1CCCC(Nc2ccc3[nH]ncc3c2)C1		CHEMBL3639882	=	IC50	nM	1850.0	CHEMBL2973	Homo sapiens	IC50	nM	1850.0
227836	17616236	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Oc1cc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)ccc1I		CHEMBL3689408	=	IC50	nM	660.0	CHEMBL2973	Homo sapiens	IC50	nM	660.0
227837	17616237	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Clc1ccc(Oc2cccc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)c2)cc1		CHEMBL3689409	=	IC50	nM	6050.0	CHEMBL2973	Homo sapiens	IC50	nM	6050.0
227838	17616238	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	FC(F)(F)c1cccc(Oc2cccc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)c2)c1		CHEMBL3689410	=	IC50	nM	6680.0	CHEMBL2973	Homo sapiens	IC50	nM	6680.0
227839	17616239	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Brc1ccc(Br)c(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689411	=	IC50	nM	5590.0	CHEMBL2973	Homo sapiens	IC50	nM	5590.0
227840	17616240	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Fc1ccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)cc1F		CHEMBL3689412	=	IC50	nM	58.5	CHEMBL2973	Homo sapiens	IC50	nM	58.5
227841	17616241	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Fc1ccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)cc1F		CHEMBL3689413	=	IC50	nM	111.0	CHEMBL2973	Homo sapiens	IC50	nM	111.0
227842	17616242	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CSc1ccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689414	=	IC50	nM	71.6	CHEMBL2973	Homo sapiens	IC50	nM	71.6
227843	17616243	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CSc1ccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689415	=	IC50	nM	74.5	CHEMBL2973	Homo sapiens	IC50	nM	74.5
227844	17616244	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C#Cc1ccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689416	=	IC50	nM	111.0	CHEMBL2973	Homo sapiens	IC50	nM	111.0
227845	17616245	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C#Cc1ccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689417	=	IC50	nM	53.1	CHEMBL2973	Homo sapiens	IC50	nM	53.1
227846	17616246	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Cc1ccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689418	=	IC50	nM	63.1	CHEMBL2973	Homo sapiens	IC50	nM	63.1
227847	17616247	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	COc1ccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689419	=	IC50	nM	102.0	CHEMBL2973	Homo sapiens	IC50	nM	102.0
227848	17616248	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Clc1ccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)cc1Cl		CHEMBL3689420	=	IC50	nM	162.0	CHEMBL2973	Homo sapiens	IC50	nM	162.0
227849	17616249	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Clc1ccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)cc1		CHEMBL3689421	=	IC50	nM	30.1	CHEMBL2973	Homo sapiens	IC50	nM	30.1
227850	17616250	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc2ccc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)cc2[nH]1		CHEMBL3689422	=	IC50	nM	30.4	CHEMBL2973	Homo sapiens	IC50	nM	30.4
227851	17616251	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C#Cc1ccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)cc1O		CHEMBL3689423	=	IC50	nM	7310.0	CHEMBL2973	Homo sapiens	IC50	nM	7310.0
227852	17616252	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCCOc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689424	=	IC50	nM	274.0	CHEMBL2973	Homo sapiens	IC50	nM	274.0
227853	17616253	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NCCOc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689425	=	IC50	nM	1680.0	CHEMBL2973	Homo sapiens	IC50	nM	1680.0
227854	17616254	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	O=C(O)COc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689426	=	IC50	nM	310.0	CHEMBL2973	Homo sapiens	IC50	nM	310.0
227855	17616255	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689427	=	IC50	nM	280.0	CHEMBL2973	Homo sapiens	IC50	nM	280.0
227856	17616256	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689428	=	IC50	nM	651.0	CHEMBL2973	Homo sapiens	IC50	nM	651.0
227857	17616257	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Nc1cc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)ccc1Cl		CHEMBL3689429	=	IC50	nM	29.4	CHEMBL2973	Homo sapiens	IC50	nM	29.4
227858	17616258	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689430	=	IC50	nM	354.0	CHEMBL2973	Homo sapiens	IC50	nM	354.0
227859	17616259	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689431	=	IC50	nM	49.4	CHEMBL2973	Homo sapiens	IC50	nM	49.4
227860	17616260	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689432	=	IC50	nM	406.0	CHEMBL2973	Homo sapiens	IC50	nM	406.0
227861	17616261	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689433	=	IC50	nM	101.0	CHEMBL2973	Homo sapiens	IC50	nM	101.0
227862	17616262	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CC[C@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689434	=	IC50	nM	466.0	CHEMBL2973	Homo sapiens	IC50	nM	466.0
227863	17616263	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CC[C@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689435	=	IC50	nM	647.0	CHEMBL2973	Homo sapiens	IC50	nM	647.0
227864	17616264	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CC[C@@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689436	=	IC50	nM	1300.0	CHEMBL2973	Homo sapiens	IC50	nM	1300.0
227865	17616265	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CC[C@@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689437	=	IC50	nM	276.0	CHEMBL2973	Homo sapiens	IC50	nM	276.0
227866	17616266	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NC(=O)COc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689438	=	IC50	nM	250.0	CHEMBL2973	Homo sapiens	IC50	nM	250.0
227867	17616267	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NC(=O)Cn1ccc2ccc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)cc21		CHEMBL3689439	=	IC50	nM	25.8	CHEMBL2973	Homo sapiens	IC50	nM	25.8
227868	17616268	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc2cc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)ccc2[nH]1		CHEMBL3689440	=	IC50	nM	42.9	CHEMBL2973	Homo sapiens	IC50	nM	42.9
227869	17616269	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCn1ccc2ccc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)cc21		CHEMBL3689441	=	IC50	nM	68.5	CHEMBL2973	Homo sapiens	IC50	nM	68.5
227870	17616270	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)ccc1Cl		CHEMBL3689442	=	IC50	nM	34.3	CHEMBL2973	Homo sapiens	IC50	nM	34.3
227871	17616271	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCN1CCc2ccc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)cc21		CHEMBL3689443	=	IC50	nM	107.0	CHEMBL2973	Homo sapiens	IC50	nM	107.0
227872	17616272	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NC(=O)Cn1ccc2cc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)ccc21		CHEMBL3689444	=	IC50	nM	172.0	CHEMBL2973	Homo sapiens	IC50	nM	172.0
227873	17616273	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NC(=O)Cn1ccc2ccc(CN3CCC[C@@H](Nc4ccc5[nH]ncc5c4)C3)cc21		CHEMBL3689445	=	IC50	nM	69.2	CHEMBL2973	Homo sapiens	IC50	nM	69.2
227874	17616274	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NC(=O)Cn1ccc2ccc(CN3CCC[C@H](Nc4ccc5[nH]ncc5c4)C3)cc21		CHEMBL3689446	=	IC50	nM	148.0	CHEMBL2973	Homo sapiens	IC50	nM	148.0
227875	17616275	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCn1ccc2ccc(CN3CCC[C@@H](Nc4ccc5[nH]ncc5c4)C3)cc21		CHEMBL3689447	=	IC50	nM	367.0	CHEMBL2973	Homo sapiens	IC50	nM	367.0
227876	17616276	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCn1ccc2ccc(CN3CCC[C@H](Nc4ccc5[nH]ncc5c4)C3)cc21		CHEMBL3689448	=	IC50	nM	242.0	CHEMBL2973	Homo sapiens	IC50	nM	242.0
227877	17616277	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(=O)NCCOc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689449	=	IC50	nM	591.0	CHEMBL2973	Homo sapiens	IC50	nM	591.0
227878	17616278	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(C)(C)OC(=O)Cn1ccc2cc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)ccc21		CHEMBL3689450	=	IC50	nM	2030.0	CHEMBL2973	Homo sapiens	IC50	nM	2030.0
227879	17616279	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OC[C@H](O)COc1cccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689451	=	IC50	nM	859.0	CHEMBL2973	Homo sapiens	IC50	nM	859.0
227880	17616280	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCn1ccc2cc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)ccc21		CHEMBL3689452	=	IC50	nM	1490.0	CHEMBL2973	Homo sapiens	IC50	nM	1490.0
227881	17616281	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OC[C@@H](O)COc1cccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689453	=	IC50	nM	555.0	CHEMBL2973	Homo sapiens	IC50	nM	555.0
227882	17616282	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C[C@@H](O)COc1cccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689454	=	IC50	nM	862.0	CHEMBL2973	Homo sapiens	IC50	nM	862.0
227883	17616283	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OC(O)COc1cccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689455	=	IC50	nM	323.0	CHEMBL2973	Homo sapiens	IC50	nM	323.0
227884	17616284	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C[C@@H](O)COc1cccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689456	=	IC50	nM	1400.0	CHEMBL2973	Homo sapiens	IC50	nM	1400.0
227885	17616285	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	O=C(O)Cn1ccc2cc(CN3CCCC(Nc4ccc5[nH]ncc5c4)C3)ccc21		CHEMBL3689457	=	IC50	nM	3630.0	CHEMBL2973	Homo sapiens	IC50	nM	3630.0
227886	17616286	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCS(=O)(=O)Nc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689458	=	IC50	nM	109.0	CHEMBL2973	Homo sapiens	IC50	nM	109.0
227887	17616287	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CN(c1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1)S(C)(=O)=O		CHEMBL3689459	=	IC50	nM	578.0	CHEMBL2973	Homo sapiens	IC50	nM	578.0
227888	17616288	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(=O)NCc1cccc(CN2CCCC(Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689460	=	IC50	nM	254.0	CHEMBL2973	Homo sapiens	IC50	nM	254.0
227889	17616289	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCS(=O)(=O)Nc1cccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689461	=	IC50	nM	135.0	CHEMBL2973	Homo sapiens	IC50	nM	135.0
227890	17616290	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCS(=O)(=O)Nc1cccc(CN2CCC[C@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689462	=	IC50	nM	59.2	CHEMBL2973	Homo sapiens	IC50	nM	59.2
227891	17616291	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	O=C(O)COc1cccc(CN2CCC[C@@H](Nc3ccc4[nH]ncc4c3)C2)c1		CHEMBL3689463	=	IC50	nM	879.0	CHEMBL2973	Homo sapiens	IC50	nM	879.0
227892	17616292	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CCC(Nc3ccc4[nH]ncc4c3)CC2)c1		CHEMBL3689464	=	IC50	nM	2710.0	CHEMBL2973	Homo sapiens	IC50	nM	2710.0
227893	17616293	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	COc1ccc(CN2CCCC(Nc3cccc4cnccc34)C2)cc1		CHEMBL3689465	=	IC50	nM	98.8	CHEMBL2973	Homo sapiens	IC50	nM	98.8
227894	17616294	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)c1ccc(CN2CCCC(Nc3cccc4cnccc34)C2)cc1		CHEMBL3689466	=	IC50	nM	2580.0	CHEMBL2973	Homo sapiens	IC50	nM	2580.0
227895	17616295	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	N#Cc1cccc(CN2CCCC(Nc3cccc4cnccc34)C2)c1		CHEMBL3689467	=	IC50	nM	5720.0	CHEMBL2973	Homo sapiens	IC50	nM	5720.0
227896	17616296	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(=O)Nc1ccc(CN2CCCC(Nc3cccc4cnccc34)C2)cc1		CHEMBL3689468	=	IC50	nM	3710.0	CHEMBL2973	Homo sapiens	IC50	nM	3710.0
227897	17616297	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)c1ccc(CN2CCC(Nc3cccc4cnccc34)C2)cc1		CHEMBL3689469	=	IC50	nM	1780.0	CHEMBL2973	Homo sapiens	IC50	nM	1780.0
227898	17616298	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1ccc(CN2CCC(Nc3cccc4cnccc34)C2)cc1		CHEMBL3689470	=	IC50	nM	73.9	CHEMBL2973	Homo sapiens	IC50	nM	73.9
227899	17616299	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	N#Cc1cccc(CN2CCC(Nc3cccc4cnccc34)C2)c1		CHEMBL3689471	=	IC50	nM	3620.0	CHEMBL2973	Homo sapiens	IC50	nM	3620.0
227900	17616300	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CC(=O)Nc1ccc(CN2CCC(Nc3cccc4cnccc34)C2)cc1		CHEMBL3689472	=	IC50	nM	3650.0	CHEMBL2973	Homo sapiens	IC50	nM	3650.0
227901	17616301	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CSc1ccc(CN2CCCC(Nc3cccc4cnccc34)C2)cc1		CHEMBL3689473	=	IC50	nM	368.0	CHEMBL2973	Homo sapiens	IC50	nM	368.0
227902	17616302	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(NC2CCCN(Cc3ccc(C4CC4)cc3)C2)c2ccncc2c1		CHEMBL3689474	=	IC50	nM	1240.0	CHEMBL2973	Homo sapiens	IC50	nM	1240.0
227903	17616303	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(CN2CCCC(Nc3cccc4cnccc34)C2)cc(C2CC2)c1		CHEMBL3689475	=	IC50	nM	4090.0	CHEMBL2973	Homo sapiens	IC50	nM	4090.0
227904	17616304	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(NC2CCCN(Cc3ccc(SC4CC4)cc3)C2)c2ccncc2c1		CHEMBL3689476	=	IC50	nM	14900.0	CHEMBL2973	Homo sapiens	IC50	nM	14900.0
227905	17616305	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1ccc(CN2CCCC(Nc3cccc4cnccc34)CC2)cc1		CHEMBL3689477	=	IC50	nM	1490.0	CHEMBL2973	Homo sapiens	IC50	nM	1490.0
227906	17616306	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Clc1ccc(CN2CCCC(Nc3cccc4cnccc34)C2)cc1Cl		CHEMBL3689478	=	IC50	nM	1670.0	CHEMBL2973	Homo sapiens	IC50	nM	1670.0
227907	17616307	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	FC(F)(F)c1cccc(CN2CCCC(Nc3cccc4cnccc34)C2)c1		CHEMBL3689479	=	IC50	nM	4190.0	CHEMBL2973	Homo sapiens	IC50	nM	4190.0
227908	17616308	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Clc1ccc(CN2CCC(Nc3cccc4cnccc34)C2)cc1Cl		CHEMBL3689480	=	IC50	nM	716.0	CHEMBL2973	Homo sapiens	IC50	nM	716.0
227909	17616309	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	COc1ccc(CN2CCC(Nc3cccc4cnccc34)C2)cc1		CHEMBL3689481	=	IC50	nM	322.0	CHEMBL2973	Homo sapiens	IC50	nM	322.0
227910	17616310	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	FC(F)(F)c1cccc(CN2CCC(Nc3cccc4cnccc34)C2)c1		CHEMBL3689482	=	IC50	nM	632.0	CHEMBL2973	Homo sapiens	IC50	nM	632.0
227911	17616311	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(N[C@H]2CCN(Cc3ccc(C4CC4)cc3)C2)c2ccncc2c1		CHEMBL3689483	=	IC50	nM	4080.0	CHEMBL2973	Homo sapiens	IC50	nM	4080.0
227912	17616312	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)cc(C2CC2)c1		CHEMBL3689484	=	IC50	nM	820.0	CHEMBL2973	Homo sapiens	IC50	nM	820.0
227913	17616313	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(N[C@@H]2CCN(Cc3ccc(SC4CC4)cc3)C2)c2ccncc2c1		CHEMBL3689485	=	IC50	nM	1900.0	CHEMBL2973	Homo sapiens	IC50	nM	1900.0
227914	17616314	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(N[C@@H]2CCN(Cc3ccc(C4CC4)cc3)C2)c2ccncc2c1		CHEMBL3689486	=	IC50	nM	311.0	CHEMBL2973	Homo sapiens	IC50	nM	311.0
227915	17616315	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(CN2CC[C@H](Nc3cccc4cnccc34)C2)cc(C2CC2)c1		CHEMBL3689487	=	IC50	nM	15700.0	CHEMBL2973	Homo sapiens	IC50	nM	15700.0
227916	17616316	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	c1cc(N[C@H]2CCN(Cc3ccc(SC4CC4)cc3)C2)c2ccncc2c1		CHEMBL3689488	=	IC50	nM	8920.0	CHEMBL2973	Homo sapiens	IC50	nM	8920.0
227917	17616317	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Cc1ccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)cc1		CHEMBL3689489	=	IC50	nM	29.9	CHEMBL2973	Homo sapiens	IC50	nM	29.9
227918	17616318	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CSc1ccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)cc1		CHEMBL3689490	=	IC50	nM	6330.0	CHEMBL2973	Homo sapiens	IC50	nM	6330.0
227919	17616319	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Clc1ccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)cc1		CHEMBL3689491	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	nM	120.0
227920	17616320	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Cc1ccc(CN2CC[C@H](Nc3cccc4cnccc34)C2)cc1		CHEMBL3689492	=	IC50	nM	789.0	CHEMBL2973	Homo sapiens	IC50	nM	789.0
227921	17616321	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CSc1ccc(CN2CC[C@H](Nc3cccc4cnccc34)C2)cc1		CHEMBL3689493	=	IC50	nM	3140.0	CHEMBL2973	Homo sapiens	IC50	nM	3140.0
227922	17616322	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	Clc1ccc(CN2CC[C@H](Nc3cccc4cnccc34)C2)cc1		CHEMBL3689494	=	IC50	nM	2460.0	CHEMBL2973	Homo sapiens	IC50	nM	2460.0
227923	17616323	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	C#Cc1ccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)cc1		CHEMBL3689495	=	IC50	nM	87.1	CHEMBL2973	Homo sapiens	IC50	nM	87.1
227924	17616324	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CC[C@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689496	=	IC50	nM	5330.0	CHEMBL2973	Homo sapiens	IC50	nM	5330.0
227925	17616325	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CCC[C@@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689497	=	IC50	nM	3060.0	CHEMBL2973	Homo sapiens	IC50	nM	3060.0
227926	17616326	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CCC[C@@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689498	=	IC50	nM	4010.0	CHEMBL2973	Homo sapiens	IC50	nM	4010.0
227927	17616327	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CC[C@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689499	=	IC50	nM	3240.0	CHEMBL2973	Homo sapiens	IC50	nM	3240.0
227928	17616328	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CCC[C@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689500	=	IC50	nM	160.0	CHEMBL2973	Homo sapiens	IC50	nM	160.0
227929	17616329	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CCC[C@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689501	=	IC50	nM	3060.0	CHEMBL2973	Homo sapiens	IC50	nM	3060.0
227930	17616330	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CS(=O)(=O)Nc1cccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689502	=	IC50	nM	112.0	CHEMBL2973	Homo sapiens	IC50	nM	112.0
227931	17616331	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	OCCOc1cccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689503	=	IC50	nM	101.0	CHEMBL2973	Homo sapiens	IC50	nM	101.0
227932	17616332	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	NC(=O)COc1cccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689504	=	IC50	nM	273.0	CHEMBL2973	Homo sapiens	IC50	nM	273.0
227933	17616333	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	CCS(=O)(=O)Nc1cccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3689505	=	IC50	nM	168.0	CHEMBL2973	Homo sapiens	IC50	nM	168.0
227934	17616334	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	O=C(COc1cccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)c1)N1CCOCC1		CHEMBL3689506	=	IC50	nM	383.0	CHEMBL2973	Homo sapiens	IC50	nM	383.0
227935	17616335	CHEMBL3705637	Kinase Inhibition Assay: Inhibition of ROCK2 activity was determined using the IMAP Screening Express Kit (Molecular Devices product number #8073). ROCK2 kinase (UpstateChemicon #14-451) and Flourescein tagged substrate peptide Fl-AKRRRLSSLRA (Molecular Devices product number R7184).	B	O=C(O)COc1cccc(CN2CC[C@@H](Nc3cccc4cnccc34)C2)c1		CHEMBL3639883	=	IC50	nM	433.0	CHEMBL2973	Homo sapiens	IC50	nM	433.0
247036	17630350	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cn[nH]c5)c4)c3)cc2C1		CHEMBL3680695	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
247037	17630351	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cccnc5)c4)c3)sc2C1		CHEMBL3639795	=	IC50	nM	22.5	CHEMBL2973	Homo sapiens	IC50	nM	22.5
247038	17630352	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3680696	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
247039	17630353	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1nnnn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1		CHEMBL3680697	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
247040	17630354	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5cccnc5)n4)c3)sc2C1		CHEMBL3680699	=	IC50	nM	4.8	CHEMBL2973	Homo sapiens	IC50	nM	4.8
247041	17630355	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cn5ccc(C#N)cc5n4)c3)cc2C1		CHEMBL3680700	=	IC50	nM	19.3	CHEMBL2973	Homo sapiens	IC50	nM	19.3
247042	17630356	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cn5cc(C(N)=O)ccc5n4)c3)cc2C1		CHEMBL3680702	=	IC50	nM	5.9	CHEMBL2973	Homo sapiens	IC50	nM	5.9
247043	17630357	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3680703	=	IC50	nM	5.8	CHEMBL2973	Homo sapiens	IC50	nM	5.8
247044	17630358	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	N[C@@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5csnn5)cc4)c3)sc2C1		CHEMBL3680704	=	IC50	nM	14.3	CHEMBL2973	Homo sapiens	IC50	nM	14.3
247045	17630359	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	N[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5csnn5)cc4)c3)sc2C1		CHEMBL3680705	=	IC50	nM	7.6	CHEMBL2973	Homo sapiens	IC50	nM	7.6
247046	17630360	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4csc(-c5cccnc5)n4)c3)cc2C1		CHEMBL3680706	=	IC50	nM	9.8	CHEMBL2973	Homo sapiens	IC50	nM	9.8
247047	17630361	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	N[C@@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3680707	=	IC50	nM	1.1	CHEMBL2973	Homo sapiens	IC50	nM	1.1
247048	17630362	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc5cc(O)ccc5c4)c3)cc2C1		CHEMBL3680708	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
247049	17630363	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	N[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3680709	=	IC50	nM	0.72	CHEMBL2973	Homo sapiens	IC50	nM	0.72
247050	17630364	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(C5CSN=N5)cc4)c3)cc2C1		CHEMBL3680710	=	IC50	nM	4.6	CHEMBL2973	Homo sapiens	IC50	nM	4.6
247051	17630365	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	N[C@@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3680711	=	IC50	nM	1.8	CHEMBL2973	Homo sapiens	IC50	nM	1.8
247052	17630366	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4csc(-c5ccncc5)n4)c3)cc2C1		CHEMBL3680712	=	IC50	nM	33.0	CHEMBL2973	Homo sapiens	IC50	nM	33.0
247053	17630367	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	N[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3680713	=	IC50	nM	1.1	CHEMBL2973	Homo sapiens	IC50	nM	1.1
247054	17630368	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1nnnn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@H](N)CC4)c2)cc1		CHEMBL3680714	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
247055	17630369	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1nnnn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1		CHEMBL3680715	=	IC50	nM	43.5	CHEMBL2973	Homo sapiens	IC50	nM	43.5
247056	17630370	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1nnnn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N)CC4)c2)cc1		CHEMBL3680716	=	IC50	nM	1.1	CHEMBL2973	Homo sapiens	IC50	nM	1.1
247057	17630371	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-n5ccnc5)cc4)c3)cc2C1		CHEMBL3680717	=	IC50	nM	4.9	CHEMBL2973	Homo sapiens	IC50	nM	4.9
247058	17630372	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	N[C@@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cccnc5)c4)c3)sc2C1		CHEMBL3680718	=	IC50	nM	1.9	CHEMBL2973	Homo sapiens	IC50	nM	1.9
247059	17630373	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	N[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cccnc5)c4)c3)sc2C1		CHEMBL3680719	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
247060	17630374	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1c(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)nnn1-c1nonc1N		CHEMBL3680720	=	IC50	nM	1.8	CHEMBL2973	Homo sapiens	IC50	nM	1.8
247061	17630375	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4nnn(-c5nonc5N)c4-c4ccccc4)c3)sc2C1		CHEMBL3680721	=	IC50	nM	1.8	CHEMBL2973	Homo sapiens	IC50	nM	1.8
247062	17630376	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cn5cc(C#N)ccc5n4)c3)cc2C1		CHEMBL3680722	=	IC50	nM	35.5	CHEMBL2973	Homo sapiens	IC50	nM	35.5
247063	17630377	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cnco5)cc4)c3)cc2C1		CHEMBL3680723	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
247064	17630378	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cn5ccc(C(N)=O)cc5n4)c3)cc2C1		CHEMBL3680724	=	IC50	nM	2.9	CHEMBL2973	Homo sapiens	IC50	nM	2.9
247065	17630379	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5ccc(C#N)cc5[nH]4)c3)cc2C1		CHEMBL3680725	=	IC50	nM	2.2	CHEMBL2973	Homo sapiens	IC50	nM	2.2
247066	17630380	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cccnc5)c4)c3)cc2C1		CHEMBL3680726	=	IC50	nM	28.0	CHEMBL2973	Homo sapiens	IC50	nM	28.0
247067	17630381	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5ccc(C(N)=O)cc5[nH]4)c3)cc2C1		CHEMBL3680727	=	IC50	nM	1.3	CHEMBL2973	Homo sapiens	IC50	nM	1.3
247068	17630382	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1sc(-c2ccncc2)nc1C(=O)NCc1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3680729	=	IC50	nM	2.1	CHEMBL2973	Homo sapiens	IC50	nM	2.1
247069	17630383	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cccnc5)s4)c3)cc2C1		CHEMBL3680730	=	IC50	nM	18.5	CHEMBL2973	Homo sapiens	IC50	nM	18.5
247070	17630384	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cnco5)s4)c3)cc2C1		CHEMBL3680731	=	IC50	nM	1.5	CHEMBL2973	Homo sapiens	IC50	nM	1.5
247071	17630385	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cn5ccc(C#N)cc5n4)c3)sc2C1		CHEMBL3680732	=	IC50	nM	2.5	CHEMBL2973	Homo sapiens	IC50	nM	2.5
247072	17630386	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1ncc(-c2ccc(C(=O)NCc3cccc(C(=O)Nc4ccc5c(c4)CN(C)CC5)c3)s2)o1		CHEMBL3680733	=	IC50	nM	64.2	CHEMBL2973	Homo sapiens	IC50	nM	64.2
247073	17630387	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5ccncc5)c4)c3)cc2C1		CHEMBL3680734	=	IC50	nM	44.5	CHEMBL2973	Homo sapiens	IC50	nM	44.5
247074	17630388	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cc(-c5ccncc5)n[nH]4)c3)sc2C1		CHEMBL3680736	=	IC50	nM	1.3	CHEMBL2973	Homo sapiens	IC50	nM	1.3
247075	17630389	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1nc(-c2ccncc2)sc1C(=O)NCc1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3680737	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
247076	17630390	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C#N)ccc5[nH]4)c3)cc2C1		CHEMBL3680739	=	IC50	nM	1.5	CHEMBL2973	Homo sapiens	IC50	nM	1.5
247077	17630391	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C(N)=O)ccc5[nH]4)c3)cc2C1		CHEMBL3680741	=	IC50	nM	1.7	CHEMBL2973	Homo sapiens	IC50	nM	1.7
247078	17630392	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cn5cc(C#N)ccc5n4)c3)sc2C1		CHEMBL3680742	=	IC50	nM	45.7	CHEMBL2973	Homo sapiens	IC50	nM	45.7
247079	17630393	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)N4CCc5c(C#N)cccc54)c3)sc2C1		CHEMBL3680743	=	IC50	nM	3.1	CHEMBL2973	Homo sapiens	IC50	nM	3.1
247080	17630394	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5ccc(C#N)cc5n4C)c3)cc2C1		CHEMBL3680744	=	IC50	nM	4.1	CHEMBL2973	Homo sapiens	IC50	nM	4.1
247081	17630395	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C#N)ccc5n4C)c3)cc2C1		CHEMBL3680745	=	IC50	nM	8.1	CHEMBL2973	Homo sapiens	IC50	nM	8.1
247082	17630396	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1nc(-c2ccncc2)sc1C(=O)NCc1cccc(C(=O)Nc2ccc3c(c2)CN(C)CC3)c1		CHEMBL3680746	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
247083	17630397	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C(N)=O)ccc5n4C)c3)cc2C1		CHEMBL3680747	=	IC50	nM	3.8	CHEMBL2973	Homo sapiens	IC50	nM	3.8
247084	17630398	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cn5cc(C#N)ccc5n4)c3)sc2C1		CHEMBL3680749	=	IC50	nM	1.7	CHEMBL2973	Homo sapiens	IC50	nM	1.7
247085	17630399	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CCn1c(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc2cc(C#N)ccc21		CHEMBL3680750	=	IC50	nM	47.0	CHEMBL2973	Homo sapiens	IC50	nM	47.0
247086	17630400	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cccnc5)s4)c3)sc2C1		CHEMBL3680754	=	IC50	nM	15.5	CHEMBL2973	Homo sapiens	IC50	nM	15.5
247087	17630401	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1ncc(-c2ccc(C(=O)NCc3cccc(C(=O)Nc4nc5c(s4)CN(C)CC5)c3)s2)o1		CHEMBL3680757	=	IC50	nM	14.5	CHEMBL2973	Homo sapiens	IC50	nM	14.5
247088	17630402	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CCn1c(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc2ccc(C#N)cc21		CHEMBL3680758	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	nM	24.0
247089	17630403	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc(-c5ccncc5)n[nH]4)c3)cc2C1		CHEMBL3680759	=	IC50	nM	1.3	CHEMBL2973	Homo sapiens	IC50	nM	1.3
247090	17630404	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc5c(=O)[nH]ccc5n4)c3)cc2C1		CHEMBL3680761	=	IC50	nM	27.5	CHEMBL2973	Homo sapiens	IC50	nM	27.5
247091	17630405	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4nnn(-c5nonc5N)c4-c4ccccc4)c3)cc2C1		CHEMBL3680762	=	IC50	nM	1.7	CHEMBL2973	Homo sapiens	IC50	nM	1.7
247092	17630406	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C#N)ccc5n4C)c3)sc2C1		CHEMBL3680763	=	IC50	nM	3.8	CHEMBL2973	Homo sapiens	IC50	nM	3.8
247093	17630407	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1c(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)nnn1-c1nonc1N		CHEMBL3680764	=	IC50	nM	5.9	CHEMBL2973	Homo sapiens	IC50	nM	5.9
247094	17630408	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5ccncc5)cc4)c3)cc2C1		CHEMBL3680767	=	IC50	nM	1.3	CHEMBL2973	Homo sapiens	IC50	nM	1.3
247095	17630409	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5cccc(O)c5cc4O)c3)cc2C1		CHEMBL3680770	=	IC50	nM	80.0	CHEMBL2973	Homo sapiens	IC50	nM	80.0
247096	17630410	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1cc(-c2ccc(C(=O)NCc3cccc(C(=O)Nc4nc5c(s4)CN(C)CC5)c3)cc2)ccn1		CHEMBL3680776	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
247097	17630411	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5nnco5)cc4)c3)cc2C1		CHEMBL3680777	=	IC50	nM	49.3	CHEMBL2973	Homo sapiens	IC50	nM	49.3
247098	17630412	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1c(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)nnn1-c1nonc1N		CHEMBL3680781	=	IC50	nM	1.9	CHEMBL2973	Homo sapiens	IC50	nM	1.9
247099	17630413	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1cc(-c2ncc(C(=O)NCc3cccc(C(=O)Nc4nc5c(s4)CN(C)CC5)c3)s2)ccn1		CHEMBL3680782	=	IC50	nM	9.5	CHEMBL2973	Homo sapiens	IC50	nM	9.5
247100	17630414	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cc[nH]n5)cc4)c3)cc2C1		CHEMBL3680783	=	IC50	nM	8.1	CHEMBL2973	Homo sapiens	IC50	nM	8.1
247101	17630415	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc5[nH]c(=O)ccc5c4)c3)cc2C1		CHEMBL3680791	=	IC50	nM	22.5	CHEMBL2973	Homo sapiens	IC50	nM	22.5
247102	17630416	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5ccc(N)nc5)s4)c3)cc2C1		CHEMBL3680793	=	IC50	nM	68.0	CHEMBL2973	Homo sapiens	IC50	nM	68.0
247103	17630417	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-n5cncn5)cc4)c3)cc2C1		CHEMBL3680794	=	IC50	nM	5.7	CHEMBL2973	Homo sapiens	IC50	nM	5.7
247104	17630418	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cc[nH]n5)cc4)c3)cc2C1		CHEMBL3680783	=	IC50	nM	6.6	CHEMBL2973	Homo sapiens	IC50	nM	6.6
247105	17630419	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc5c(c4)OCC(=O)N5)c3)cc2C1		CHEMBL3639796	=	IC50	nM	81.0	CHEMBL2973	Homo sapiens	IC50	nM	81.0
247106	17630420	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc5c(c4)CCC(=O)N5)c3)cc2C1		CHEMBL3680795	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
247107	17630421	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cccc(-n5ccnc5)c4)c3)cc2C1		CHEMBL3680796	=	IC50	nM	14.5	CHEMBL2973	Homo sapiens	IC50	nM	14.5
247108	17630422	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc(-c5cccnc5)n[nH]4)c3)cc2C1		CHEMBL3680797	=	IC50	nM	91.5	CHEMBL2973	Homo sapiens	IC50	nM	91.5
247109	17630423	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cnco5)c4)c3)cc2C1		CHEMBL3680798	=	IC50	nM	6.5	CHEMBL2973	Homo sapiens	IC50	nM	6.5
247110	17630424	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cnc(-c5cccnc5)s4)c3)cc2C1		CHEMBL3680799	=	IC50	nM	4.8	CHEMBL2973	Homo sapiens	IC50	nM	4.8
247111	17630425	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1nc2cnccc2n1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1		CHEMBL3680800	=	IC50	nM	38.0	CHEMBL2973	Homo sapiens	IC50	nM	38.0
247112	17630426	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	Cc1nccn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1		CHEMBL3680801	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
247113	17630427	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)N4CCc5c(C#N)cccc54)c3)cc2C1		CHEMBL3680802	=	IC50	nM	6.9	CHEMBL2973	Homo sapiens	IC50	nM	6.9
247114	17630428	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4nc(-c5cccnc5)cs4)c3)cc2C1		CHEMBL3680803	=	IC50	nM	11.9	CHEMBL2973	Homo sapiens	IC50	nM	11.9
247115	17630429	CHEMBL3705212	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase is measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay is performed in 384-well low-volume, white, non-binding surface microtiter plates (Corning). The assay buffer is 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 μg/mL, are serially diluted for dose response for a final starting concentration of 3 μg/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408 Da) is diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 μL.	B	CCN1C(=O)CSc2ccc(C(=O)NCc3cccc(C(=O)Nc4ccc5c(c4)CN(C)CC5)c3)cc21		CHEMBL3680807	=	IC50	nM	86.0	CHEMBL2973	Homo sapiens	IC50	nM	86.0
247116	17630430	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-n5ccnc5)cc4)c3)sc2C1		CHEMBL3680694	=	IC50	nM	1.9	CHEMBL2973	Homo sapiens	IC50	nM	1.9
247117	17630431	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cn[nH]c5)c4)c3)cc2C1		CHEMBL3680695	=	IC50	nM	5.1	CHEMBL2973	Homo sapiens	IC50	nM	5.1
247118	17630432	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cccnc5)c4)c3)sc2C1		CHEMBL3639795	=	IC50	nM	73.0	CHEMBL2973	Homo sapiens	IC50	nM	73.0
247119	17630433	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3680696	=	IC50	nM	0.53	CHEMBL2973	Homo sapiens	IC50	nM	0.53
247120	17630434	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nnnn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1		CHEMBL3680697	=	IC50	nM	9.8	CHEMBL2973	Homo sapiens	IC50	nM	9.8
247121	17630435	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cnco5)cc4)c3)sc2C1		CHEMBL3680698	=	IC50	nM	0.21	CHEMBL2973	Homo sapiens	IC50	nM	0.21
247122	17630436	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5cccnc5)n4)c3)sc2C1		CHEMBL3680699	=	IC50	nM	7.9	CHEMBL2973	Homo sapiens	IC50	nM	7.9
247123	17630437	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc5cc(O)ccc5c4)c3)sc2C1		CHEMBL3680701	=	IC50	nM	0.39	CHEMBL2973	Homo sapiens	IC50	nM	0.39
247124	17630438	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cn5cc(C(N)=O)ccc5n4)c3)cc2C1		CHEMBL3680702	=	IC50	nM	25.0	CHEMBL2973	Homo sapiens	IC50	nM	25.0
247125	17630439	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3680703	=	IC50	nM	37.0	CHEMBL2973	Homo sapiens	IC50	nM	37.0
247126	17630440	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	N[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5csnn5)cc4)c3)sc2C1		CHEMBL3680705	=	IC50	nM	40.0	CHEMBL2973	Homo sapiens	IC50	nM	40.0
247127	17630441	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4csc(-c5cccnc5)n4)c3)cc2C1		CHEMBL3680706	=	IC50	nM	45.0	CHEMBL2973	Homo sapiens	IC50	nM	45.0
247128	17630442	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	N[C@@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3680707	=	IC50	nM	0.45	CHEMBL2973	Homo sapiens	IC50	nM	0.45
247129	17630443	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc5cc(O)ccc5c4)c3)cc2C1		CHEMBL3680708	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
247130	17630444	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	N[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3680709	=	IC50	nM	0.16	CHEMBL2973	Homo sapiens	IC50	nM	0.16
247131	17630445	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(C5CSN=N5)cc4)c3)cc2C1		CHEMBL3680710	=	IC50	nM	4.6	CHEMBL2973	Homo sapiens	IC50	nM	4.6
247132	17630446	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	N[C@@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3680711	=	IC50	nM	4.8	CHEMBL2973	Homo sapiens	IC50	nM	4.8
247133	17630447	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	N[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3680713	=	IC50	nM	1.1	CHEMBL2973	Homo sapiens	IC50	nM	1.1
247134	17630448	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nnnn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@H](N)CC4)c2)cc1		CHEMBL3680714	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
247135	17630449	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nnnn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N)CC4)c2)cc1		CHEMBL3680716	=	IC50	nM	0.67	CHEMBL2973	Homo sapiens	IC50	nM	0.67
247136	17630450	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-n5ccnc5)cc4)c3)cc2C1		CHEMBL3680717	=	IC50	nM	9.9	CHEMBL2973	Homo sapiens	IC50	nM	9.9
247137	17630451	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	N[C@@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cccnc5)c4)c3)sc2C1		CHEMBL3680718	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
247138	17630452	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	N[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cccnc5)c4)c3)sc2C1		CHEMBL3680719	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
247139	17630453	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1c(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)nnn1-c1nonc1N		CHEMBL3680720	=	IC50	nM	9.3	CHEMBL2973	Homo sapiens	IC50	nM	9.3
247140	17630454	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4nnn(-c5nonc5N)c4-c4ccccc4)c3)sc2C1		CHEMBL3680721	=	IC50	nM	4.9	CHEMBL2973	Homo sapiens	IC50	nM	4.9
247141	17630455	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cnco5)cc4)c3)cc2C1		CHEMBL3680723	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	IC50	nM	26.0
247142	17630456	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cn5ccc(C(N)=O)cc5n4)c3)cc2C1		CHEMBL3680724	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
247143	17630457	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5ccc(C#N)cc5[nH]4)c3)cc2C1		CHEMBL3680725	=	IC50	nM	8.1	CHEMBL2973	Homo sapiens	IC50	nM	8.1
247144	17630458	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5ccc(C(N)=O)cc5[nH]4)c3)cc2C1		CHEMBL3680727	=	IC50	nM	0.45	CHEMBL2973	Homo sapiens	IC50	nM	0.45
247145	17630459	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5ccncc5)cc4)c3)sc2C1		CHEMBL3680728	=	IC50	nM	0.26	CHEMBL2973	Homo sapiens	IC50	nM	0.26
247146	17630460	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1sc(-c2ccncc2)nc1C(=O)NCc1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3680729	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
247147	17630461	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cnco5)s4)c3)cc2C1		CHEMBL3680731	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
247148	17630462	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cn5ccc(C#N)cc5n4)c3)sc2C1		CHEMBL3680732	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
247149	17630463	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5ccncc5)s4)c3)cc2C1		CHEMBL3680735	=	IC50	nM	0.25	CHEMBL2973	Homo sapiens	IC50	nM	0.25
247150	17630464	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cc(-c5ccncc5)n[nH]4)c3)sc2C1		CHEMBL3680736	=	IC50	nM	0.23	CHEMBL2973	Homo sapiens	IC50	nM	0.23
247151	17630465	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nc(-c2ccncc2)sc1C(=O)NCc1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3680737	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
247152	17630466	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cn[nH]c5)s4)c3)cc2C1		CHEMBL3680738	=	IC50	nM	0.17	CHEMBL2973	Homo sapiens	IC50	nM	0.17
247153	17630467	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C#N)ccc5[nH]4)c3)cc2C1		CHEMBL3680739	=	IC50	nM	0.58	CHEMBL2973	Homo sapiens	IC50	nM	0.58
247154	17630468	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5ccc(C(N)=O)cc5n4C)c3)cc2C1		CHEMBL3680740	=	IC50	nM	0.26	CHEMBL2973	Homo sapiens	IC50	nM	0.26
247155	17630469	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C(N)=O)ccc5[nH]4)c3)cc2C1		CHEMBL3680741	=	IC50	nM	0.85	CHEMBL2973	Homo sapiens	IC50	nM	0.85
247156	17630470	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)N4CCc5c(C#N)cccc54)c3)sc2C1		CHEMBL3680743	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
247157	17630471	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5ccc(C#N)cc5n4C)c3)cc2C1		CHEMBL3680744	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
247158	17630472	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C#N)ccc5n4C)c3)cc2C1		CHEMBL3680745	=	IC50	nM	46.0	CHEMBL2973	Homo sapiens	IC50	nM	46.0
247159	17630473	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nc(-c2ccncc2)sc1C(=O)NCc1cccc(C(=O)Nc2ccc3c(c2)CN(C)CC3)c1		CHEMBL3680746	=	IC50	nM	1.25	CHEMBL2973	Homo sapiens	IC50	nM	1.25
247160	17630474	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C(N)=O)ccc5n4C)c3)cc2C1		CHEMBL3680747	=	IC50	nM	12.25	CHEMBL2973	Homo sapiens	IC50	nM	12.25
247161	17630475	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cn5ccc(C#N)cc5n4)c3)sc2C1		CHEMBL3680748	=	IC50	nM	0.27	CHEMBL2973	Homo sapiens	IC50	nM	0.27
247162	17630476	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cn5cc(C#N)ccc5n4)c3)sc2C1		CHEMBL3680749	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
247163	17630477	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nnnn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N(C)C)CC4)c2)cc1		CHEMBL3680751	=	IC50	nM	0.43	CHEMBL2973	Homo sapiens	IC50	nM	0.43
247164	17630478	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5ccncc5)cc4)c3)sc2C1		CHEMBL3680752	=	IC50	nM	0.22	CHEMBL2973	Homo sapiens	IC50	nM	0.22
247165	17630479	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5cccnc5)n4)c3)sc2C1		CHEMBL3680753	=	IC50	nM	0.32	CHEMBL2973	Homo sapiens	IC50	nM	0.32
247166	17630480	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5ccncc5)s4)c3)sc2C1		CHEMBL3680755	=	IC50	nM	0.18	CHEMBL2973	Homo sapiens	IC50	nM	0.18
247167	17630481	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cnco5)s4)c3)sc2C1		CHEMBL3680756	=	IC50	nM	0.45	CHEMBL2973	Homo sapiens	IC50	nM	0.45
247168	17630482	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cc(-c5ccncc5)n[nH]4)c3)cc2C1		CHEMBL3680759	=	IC50	nM	0.22	CHEMBL2973	Homo sapiens	IC50	nM	0.22
247169	17630483	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cn[nH]c5)s4)c3)sc2C1		CHEMBL3680760	=	IC50	nM	0.77	CHEMBL2973	Homo sapiens	IC50	nM	0.77
247170	17630484	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4nnn(-c5nonc5N)c4-c4ccccc4)c3)cc2C1		CHEMBL3680762	=	IC50	nM	3.9	CHEMBL2973	Homo sapiens	IC50	nM	3.9
247171	17630485	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cc5cc(C#N)ccc5n4C)c3)sc2C1		CHEMBL3680763	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
247172	17630486	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1c(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)nnn1-c1nonc1N		CHEMBL3680764	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	IC50	nM	26.0
247173	17630487	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5ccncc5)s4)c3)sc2C1		CHEMBL3680765	=	IC50	nM	0.27	CHEMBL2973	Homo sapiens	IC50	nM	0.27
247174	17630488	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cnco5)s4)c3)sc2C1		CHEMBL3680766	=	IC50	nM	0.37	CHEMBL2973	Homo sapiens	IC50	nM	0.37
247175	17630489	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5ccncc5)cc4)c3)cc2C1		CHEMBL3680767	=	IC50	nM	0.195	CHEMBL2973	Homo sapiens	IC50	nM	0.195
247176	17630490	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cn[nH]c5)s4)c3)sc2C1		CHEMBL3680768	=	IC50	nM	0.22	CHEMBL2973	Homo sapiens	IC50	nM	0.22
247177	17630491	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3680769	=	IC50	nM	0.32	CHEMBL2973	Homo sapiens	IC50	nM	0.32
247178	17630492	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-n5ccnc5)cc4)c3)sc2C1		CHEMBL3680771	=	IC50	nM	0.24	CHEMBL2973	Homo sapiens	IC50	nM	0.24
247179	17630493	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cnco5)cc4)c3)sc2C1		CHEMBL3680772	=	IC50	nM	0.2	CHEMBL2973	Homo sapiens	IC50	nM	0.2
247180	17630494	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4nnn(-c5nonc5N)c4-c4ccccc4)c3)sc2C1		CHEMBL3680773	=	IC50	nM	0.21	CHEMBL2973	Homo sapiens	IC50	nM	0.21
247181	17630495	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3680774	=	IC50	nM	0.87	CHEMBL2973	Homo sapiens	IC50	nM	0.87
247182	17630496	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1c(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N(C)C)CC4)c2)nnn1-c1nonc1N		CHEMBL3680775	=	IC50	nM	0.33	CHEMBL2973	Homo sapiens	IC50	nM	0.33
247183	17630497	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1cc(-c2ccc(C(=O)NCc3cccc(C(=O)Nc4nc5c(s4)CN(C)CC5)c3)cc2)ccn1		CHEMBL3680776	=	IC50	nM	4.35	CHEMBL2973	Homo sapiens	IC50	nM	4.35
247184	17630498	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc(CNC(=O)c2csc(-c3cccnc3)n2)c1		CHEMBL3680778	=	IC50	nM	0.73	CHEMBL2973	Homo sapiens	IC50	nM	0.73
247185	17630499	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	N#Cc1ccn2cc(C(=O)NCc3cccc(C(=O)Nc4nc5c(s4)C[C@@H](N4CCOCC4)CC5)c3)nc2c1		CHEMBL3680779	=	IC50	nM	0.52	CHEMBL2973	Homo sapiens	IC50	nM	0.52
247186	17630500	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Nc1nonc1-n1nnc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)c1-c1ccccc1		CHEMBL3680780	=	IC50	nM	2.65	CHEMBL2973	Homo sapiens	IC50	nM	2.65
247187	17630501	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1c(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)nnn1-c1nonc1N		CHEMBL3680781	=	IC50	nM	0.57	CHEMBL2973	Homo sapiens	IC50	nM	0.57
247188	17630502	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1cc(-c2ncc(C(=O)NCc3cccc(C(=O)Nc4nc5c(s4)CN(C)CC5)c3)s2)ccn1		CHEMBL3680782	=	IC50	nM	39.0	CHEMBL2973	Homo sapiens	IC50	nM	39.0
247189	17630503	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cc[nH]n5)cc4)c3)cc2C1		CHEMBL3680783	=	IC50	nM	47.0	CHEMBL2973	Homo sapiens	IC50	nM	47.0
247190	17630504	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	O=C(NCc1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N2CCOCC2)CC3)c1)c1ccc(-c2cnco2)cc1		CHEMBL3680784	=	IC50	nM	0.43	CHEMBL2973	Homo sapiens	IC50	nM	0.43
247191	17630505	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc(CNC(=O)c2csc(-c3ccncc3)n2)c1		CHEMBL3680785	=	IC50	nM	0.93	CHEMBL2973	Homo sapiens	IC50	nM	0.93
247192	17630506	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc(CNC(=O)c2cc(-c3ccncc3)n[nH]2)c1		CHEMBL3680786	=	IC50	nM	0.34	CHEMBL2973	Homo sapiens	IC50	nM	0.34
247193	17630507	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nc(-c2ccncc2)sc1C(=O)NCc1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N2CCOCC2)CC3)c1		CHEMBL3680787	=	IC50	nM	0.37	CHEMBL2973	Homo sapiens	IC50	nM	0.37
247194	17630508	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	O=C(NCc1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N2CCOCC2)CC3)c1)c1cccc(-c2cn[nH]c2)c1		CHEMBL3680788	=	IC50	nM	0.41	CHEMBL2973	Homo sapiens	IC50	nM	0.41
247195	17630509	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	O=C(NCc1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N2CCOCC2)CC3)c1)c1ccc(-n2ccnc2)cc1		CHEMBL3680789	=	IC50	nM	0.38	CHEMBL2973	Homo sapiens	IC50	nM	0.38
247196	17630510	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nnnn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)cc1		CHEMBL3680790	=	IC50	nM	0.35	CHEMBL2973	Homo sapiens	IC50	nM	0.35
247197	17630511	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	N#Cc1ccc2cc(C(=O)NCc3cccc(C(=O)Nc4nc5c(s4)C[C@@H](N4CCOCC4)CC5)c3)[nH]c2c1		CHEMBL3680792	=	IC50	nM	0.87	CHEMBL2973	Homo sapiens	IC50	nM	0.87
247198	17630512	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-n5cncn5)cc4)c3)cc2C1		CHEMBL3680794	=	IC50	nM	48.0	CHEMBL2973	Homo sapiens	IC50	nM	48.0
247199	17630513	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4ccc(-c5cc[nH]n5)cc4)c3)cc2C1		CHEMBL3680783	=	IC50	nM	34.0	CHEMBL2973	Homo sapiens	IC50	nM	34.0
247200	17630514	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cccc(-c5cnco5)c4)c3)cc2C1		CHEMBL3680798	=	IC50	nM	56.0	CHEMBL2973	Homo sapiens	IC50	nM	56.0
247201	17630515	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4cnc(-c5cccnc5)s4)c3)cc2C1		CHEMBL3680799	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
247202	17630516	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nccn1-c1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1		CHEMBL3680801	=	IC50	nM	1.6	CHEMBL2973	Homo sapiens	IC50	nM	1.6
247203	17630517	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)N4CCc5c(C#N)cccc54)c3)cc2C1		CHEMBL3680802	=	IC50	nM	34.0	CHEMBL2973	Homo sapiens	IC50	nM	34.0
247204	17630518	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2ccc(NC(=O)c3cccc(CNC(=O)c4nc(-c5cccnc5)cs4)c3)cc2C1		CHEMBL3680803	=	IC50	nM	72.0	CHEMBL2973	Homo sapiens	IC50	nM	72.0
247205	17630519	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	Cc1nc(-c2ccncc2)sc1C(=O)NCc1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N(C)C)CC3)c1		CHEMBL3680804	=	IC50	nM	0.25	CHEMBL2973	Homo sapiens	IC50	nM	0.25
247206	17630520	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cc(-c5ccncc5)n[nH]4)c3)sc2C1		CHEMBL3680805	=	IC50	nM	0.2	CHEMBL2973	Homo sapiens	IC50	nM	0.2
247207	17630521	CHEMBL3705211	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, Calif.) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 μg/mL in 1% DMSO. 10 μL aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 μL of a mixture of 600 nM FAM S6 peptide and 300 μM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 μM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(CNC(=O)c4cn5cc(C(N)=O)ccc5n4)c3)sc2C1		CHEMBL3680806	=	IC50	nM	3.7	CHEMBL2973	Homo sapiens	IC50	nM	3.7
259193	17641721	CHEMBL3706000	Inhibition Assay: In a final reaction volume of 25 ul, ROCK-II (h) (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK (SEQ ID NO:1), 10 mM MgAcetate and [gamma-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ul of a 3% phosphoric acid solution. 10 ul of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CC(C)(C)OC(=O)NC1CCN(c2ncnc3[nH]c(=O)[nH]c23)CC1		CHEMBL3694786	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
259194	17641722	CHEMBL3706000	Inhibition Assay: In a final reaction volume of 25 ul, ROCK-II (h) (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK (SEQ ID NO:1), 10 mM MgAcetate and [gamma-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ul of a 3% phosphoric acid solution. 10 ul of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CC(C)(C)OC(=O)N1CCC(C#N)(c2ccc(Cl)cc2)CC1		CHEMBL3694787	<	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
259195	17641723	CHEMBL3706000	Inhibition Assay: In a final reaction volume of 25 ul, ROCK-II (h) (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK (SEQ ID NO:1), 10 mM MgAcetate and [gamma-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ul of a 3% phosphoric acid solution. 10 ul of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	<	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
259196	17641724	CHEMBL3706000	Inhibition Assay: In a final reaction volume of 25 ul, ROCK-II (h) (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK (SEQ ID NO:1), 10 mM MgAcetate and [gamma-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ul of a 3% phosphoric acid solution. 10 ul of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	NCC1(c2ccc(OC(F)(F)F)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL3694788	<	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
259197	17641725	CHEMBL3706000	Inhibition Assay: In a final reaction volume of 25 ul, ROCK-II (h) (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK (SEQ ID NO:1), 10 mM MgAcetate and [gamma-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ul of a 3% phosphoric acid solution. 10 ul of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL596991	<	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
259198	17641726	CHEMBL3706000	Inhibition Assay: In a final reaction volume of 25 ul, ROCK-II (h) (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK (SEQ ID NO:1), 10 mM MgAcetate and [gamma-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ul of a 3% phosphoric acid solution. 10 ul of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	IC50	nM	143.0	CHEMBL2973	Homo sapiens	IC50	nM	143.0
259199	17641727	CHEMBL3706000	Inhibition Assay: In a final reaction volume of 25 ul, ROCK-II (h) (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK (SEQ ID NO:1), 10 mM MgAcetate and [gamma-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ul of a 3% phosphoric acid solution. 10 ul of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	NC1(Cc2ccccc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598439	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
259200	17641728	CHEMBL3706000	Inhibition Assay: In a final reaction volume of 25 ul, ROCK-II (h) (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK (SEQ ID NO:1), 10 mM MgAcetate and [gamma-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ul of a 3% phosphoric acid solution. 10 ul of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1		CHEMBL597211	=	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	nM	2700.0
259201	17641729	CHEMBL3706000	Inhibition Assay: In a final reaction volume of 25 ul, ROCK-II (h) (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK (SEQ ID NO:1), 10 mM MgAcetate and [gamma-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ul of a 3% phosphoric acid solution. 10 ul of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	NC1(Cc2ccc(Cl)cc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597414	<	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
262162	17644690	CHEMBL3706009	Inhibition Assay: In a final reaction volume of 25 uL, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 [uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and gamma-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 uL of a 3% phosphoric acid solution. 10 uL of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3cn[nH]c3)cc2)NC(=O)c2cc(Cl)ccc21		CHEMBL3649655	=	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
262163	17644691	CHEMBL3706009	Inhibition Assay: In a final reaction volume of 25 uL, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 [uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and gamma-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 uL of a 3% phosphoric acid solution. 10 uL of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@@H](Cc2ccc(-c3ccnc(N)c3)cc2)NC(=O)c2cc(Cl)ccc21		CHEMBL3649656	=	IC50	nM	7100.0	CHEMBL2973	Homo sapiens	IC50	nM	7100.0
262164	17644692	CHEMBL3706009	Inhibition Assay: In a final reaction volume of 25 uL, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 [uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and gamma-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 uL of a 3% phosphoric acid solution. 10 uL of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	COc1ccc2c(c1)C(=O)N[C@@H](Cc1ccc(-c3ccnc(N)c3)cc1)C(=O)N2C		CHEMBL3649657	=	IC50	nM	2400.0	CHEMBL2973	Homo sapiens	IC50	nM	2400.0
262165	17644693	CHEMBL3706009	Inhibition Assay: In a final reaction volume of 25 uL, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 [uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and gamma-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 uL of a 3% phosphoric acid solution. 10 uL of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	CN1C(=O)[C@H](Cc2ccc(-c3ccnc4[nH]ccc34)cc2)NC(=O)c2cc(Cl)ccc21		CHEMBL3649658	=	IC50	nM	250.0	CHEMBL2973	Homo sapiens	IC50	nM	250.0
262166	17644694	CHEMBL3706009	Inhibition Assay: In a final reaction volume of 25 uL, ROCK-II (h, amino acids 11-552) (5-10 mU) was incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 30 [uM KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 10 mM magnesium acetate and gamma-32P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction was stopped by the addition of 5 uL of a 3% phosphoric acid solution. 10 uL of the reaction was then spotted onto a P30 filter-mat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.	B	COc1ccc2c(c1)C(=O)N[C@@H](Cc1ccc(-c3ccnc4[nH]ccc34)cc1)C(=O)N2C		CHEMBL3649659	=	IC50	nM	200.0	CHEMBL2973	Homo sapiens	IC50	nM	200.0
313372	17693572	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc(OCC(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3700902	=	IC50	nM	23.4	CHEMBL2973	Homo sapiens	IC50	nM	23.4
313373	17693573	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N[C@@H](c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)C2CC2)cc1Cl		CHEMBL3700903	=	IC50	nM	2.8	CHEMBL2973	Homo sapiens	IC50	nM	2.8
313374	17693574	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CCCC[C@@H](NC(=O)Nc1cccc(C#N)c1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700904	=	IC50	nM	22.4	CHEMBL2973	Homo sapiens	IC50	nM	22.4
313375	17693575	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc(N4CCC[C@@H]4C(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3700905	=	IC50	nM	19.1	CHEMBL2973	Homo sapiens	IC50	nM	19.1
313376	17693576	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CCCC[C@@H](NC(=O)c1ccc(OC)c(Cl)c1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700906	=	IC50	nM	38.1	CHEMBL2973	Homo sapiens	IC50	nM	38.1
313377	17693577	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(OCC(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3700907	=	IC50	nM	1.7	CHEMBL2973	Homo sapiens	IC50	nM	1.7
313378	17693578	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CC[C@@H](NC(=O)Nc1cccc(C#N)c1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700908	=	IC50	nM	5.7	CHEMBL2973	Homo sapiens	IC50	nM	5.7
313379	17693579	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1ccc(NC(=O)COc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N)CC4)c2)cc1		CHEMBL3700909	=	IC50	nM	3.7	CHEMBL2973	Homo sapiens	IC50	nM	3.7
313380	17693580	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CC[C@@H](NC(=O)Nc1ccc(C#N)cc1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700910	=	IC50	nM	23.1	CHEMBL2973	Homo sapiens	IC50	nM	23.1
313381	17693581	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1ccc(NC(=O)COc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)cc1		CHEMBL3700911	=	IC50	nM	3.4	CHEMBL2973	Homo sapiens	IC50	nM	3.4
313382	17693582	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CC[C@@H](NC(=O)c1ccc(OC)c(Cl)c1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700912	=	IC50	nM	3.8	CHEMBL2973	Homo sapiens	IC50	nM	3.8
313383	17693583	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CNC[C@@H]4C(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3700913	=	IC50	nM	21.2	CHEMBL2973	Homo sapiens	IC50	nM	21.2
313384	17693584	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3ccc(CCN4CCOCC4)cc3)c2)c1		CHEMBL3700914	=	IC50	nM	5.8	CHEMBL2973	Homo sapiens	IC50	nM	5.8
313385	17693585	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3ccc(CCN4CCCC4)cc3)c2)c1		CHEMBL3700915	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
313386	17693586	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	C[C@@H](Oc1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1)C(=O)Nc1ccc(C#N)cc1		CHEMBL3700916	=	IC50	nM	35.0	CHEMBL2973	Homo sapiens	IC50	nM	35.0
313387	17693587	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N)CC4)c2)c1		CHEMBL3700917	=	IC50	nM	1.7	CHEMBL2973	Homo sapiens	IC50	nM	1.7
313388	17693588	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc(N4CCC[C@@H]4C(=O)Nc4cccc(C#N)c4)c3)sc2C1		CHEMBL3700918	=	IC50	nM	95.5	CHEMBL2973	Homo sapiens	IC50	nM	95.5
313389	17693589	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@H](N)CC4)c2)c1		CHEMBL3700919	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
313390	17693590	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	Cc1nc(-c2ccncc2)sc1C(=O)N1CCC[C@@H]1c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700921	=	IC50	nM	12.5	CHEMBL2973	Homo sapiens	IC50	nM	12.5
313391	17693591	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-c5ccncc5)cc4)c3)sc2C1		CHEMBL3700922	=	IC50	nM	1.7	CHEMBL2973	Homo sapiens	IC50	nM	1.7
313392	17693592	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4nnn(-c5nonc5N)c4-c4ccccc4)c3)sc2C1		CHEMBL3700923	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
313393	17693593	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CCCN[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4cccc(C#N)c4)c3)sc2C1		CHEMBL3700924	=	IC50	nM	1.6	CHEMBL2973	Homo sapiens	IC50	nM	1.6
313394	17693594	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	Cc1c(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)nnn1-c1nonc1N		CHEMBL3700925	=	IC50	nM	33.4	CHEMBL2973	Homo sapiens	IC50	nM	33.4
313395	17693595	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CCCN[C@H]1CCc2nc(NC(=O)c3cccc([C@@H](C)NC(=O)c4ccc(OC)c(OC)c4)c3)sc2C1		CHEMBL3700926	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
313396	17693596	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1OC		CHEMBL3700927	=	IC50	nM	30.7	CHEMBL2973	Homo sapiens	IC50	nM	30.7
313397	17693597	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CCCN[C@H]1CCc2nc(NC(=O)c3cccc([C@@H](C)NC(=O)c4ccc(OC)c(Cl)c4)c3)sc2C1		CHEMBL3700928	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
313398	17693598	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1C		CHEMBL3700929	=	IC50	nM	45.1	CHEMBL2973	Homo sapiens	IC50	nM	45.1
313399	17693599	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CCCN[C@H]1CCc2nc(NC(=O)c3cccc([C@@H](C)NC(=O)c4ccc(OC)c(C)c4)c3)sc2C1		CHEMBL3700930	=	IC50	nM	0.9	CHEMBL2973	Homo sapiens	IC50	nM	0.9
313400	17693600	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1Cl		CHEMBL3700931	=	IC50	nM	38.0	CHEMBL2973	Homo sapiens	IC50	nM	38.0
313401	17693601	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3700933	=	IC50	nM	15.3	CHEMBL2973	Homo sapiens	IC50	nM	15.3
313402	17693602	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc5cc(O)ccc5c4)c3)sc2C1		CHEMBL3700935	=	IC50	nM	2.1	CHEMBL2973	Homo sapiens	IC50	nM	2.1
313403	17693603	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)N4CCc5c(C#N)cccc54)c3)sc2C1		CHEMBL3700936	=	IC50	nM	6.9	CHEMBL2973	Homo sapiens	IC50	nM	6.9
313404	17693604	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4ccc(C(N)=O)cc4)c3)sc2C1		CHEMBL3700937	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
313405	17693605	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4cccc(C(N)=O)c4)c3)sc2C1		CHEMBL3700938	=	IC50	nM	94.6	CHEMBL2973	Homo sapiens	IC50	nM	94.6
313406	17693606	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1cccc(NC(=O)N2CCCC2c2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)c1		CHEMBL3700939	=	IC50	nM	17.8	CHEMBL2973	Homo sapiens	IC50	nM	17.8
313407	17693607	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	Cc1nc(-c2ccncc2)sc1C(=O)N1CCC[C@@H]1c1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N(C)C)CC3)c1		CHEMBL3700940	=	IC50	nM	2.8	CHEMBL2973	Homo sapiens	IC50	nM	2.8
313408	17693608	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4nnn(-c5nonc5N)c4-c4ccccc4)c3)sc2C1		CHEMBL3700941	=	IC50	nM	2.2	CHEMBL2973	Homo sapiens	IC50	nM	2.2
313409	17693609	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	Cc1nnnn1-c1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1		CHEMBL3700942	=	IC50	nM	91.4	CHEMBL2973	Homo sapiens	IC50	nM	91.4
313410	17693610	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)c1		CHEMBL3700943	=	IC50	nM	11.5	CHEMBL2973	Homo sapiens	IC50	nM	11.5
313411	17693611	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4csc(-c5cccnc5)n4)c3)sc2C1		CHEMBL3700944	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
313412	17693612	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc(C4CCCN4C(=O)Nc4cccc(C#N)c4)c3)sc2C1		CHEMBL3700945	=	IC50	nM	8.8	CHEMBL2973	Homo sapiens	IC50	nM	8.8
313413	17693613	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cccc(-c5cccnc5)c4)c3)sc2C1		CHEMBL3700946	=	IC50	nM	80.4	CHEMBL2973	Homo sapiens	IC50	nM	80.4
313414	17693614	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1cccc(NC(=O)N2CCCC2c2cccc(C(=O)Nc3nc4c(s3)CN(Cc3ccccc3)CC4)c2)c1		CHEMBL3700947	=	IC50	nM	20.9	CHEMBL2973	Homo sapiens	IC50	nM	20.9
313415	17693615	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3700948	=	IC50	nM	6.1	CHEMBL2973	Homo sapiens	IC50	nM	6.1
313416	17693616	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2ccc(NC(=O)c3cccc(C4CCCN4C(=O)Nc4cccc(C#N)c4)c3)cc2C1		CHEMBL3700949	=	IC50	nM	22.4	CHEMBL2973	Homo sapiens	IC50	nM	22.4
313417	17693617	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc(C4CCCN4C(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3700951	=	IC50	nM	74.4	CHEMBL2973	Homo sapiens	IC50	nM	74.4
313418	17693618	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-n5ccnc5)cc4)c3)sc2C1		CHEMBL3700952	=	IC50	nM	14.5	CHEMBL2973	Homo sapiens	IC50	nM	14.5
313419	17693619	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-c5cnco5)cc4)c3)sc2C1		CHEMBL3700953	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
313420	17693620	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cn5cc(C(N)=O)ccc5n4)c3)sc2C1		CHEMBL3700954	=	IC50	nM	2.5	CHEMBL2973	Homo sapiens	IC50	nM	2.5
313421	17693621	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc(C4CCCN4C(=O)Nc4ccc(C(N)=O)cc4)c3)sc2C1		CHEMBL3700955	=	IC50	nM	5.4	CHEMBL2973	Homo sapiens	IC50	nM	5.4
313422	17693622	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3700956	=	IC50	nM	1.9	CHEMBL2973	Homo sapiens	IC50	nM	1.9
313423	17693623	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	C[C@@H](NC(=O)Nc1cccc(C#N)c1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700957	=	IC50	nM	5.5	CHEMBL2973	Homo sapiens	IC50	nM	5.5
313424	17693624	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	C[C@H](NC(=O)Nc1ccc(C#N)cc1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700959	=	IC50	nM	37.8	CHEMBL2973	Homo sapiens	IC50	nM	37.8
313425	17693625	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc5[nH]c(=O)ccc5c4)c3)sc2C1		CHEMBL3700960	=	IC50	nM	20.8	CHEMBL2973	Homo sapiens	IC50	nM	20.8
313426	17693626	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	C[C@@H](NC(=O)Nc1ccc(C#N)cc1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700961	=	IC50	nM	22.4	CHEMBL2973	Homo sapiens	IC50	nM	22.4
313427	17693627	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-c5cc[nH]n5)cc4)c3)sc2C1		CHEMBL3700962	=	IC50	nM	44.9	CHEMBL2973	Homo sapiens	IC50	nM	44.9
313428	17693628	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N[C@H](C)c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1Cl		CHEMBL3700964	=	IC50	nM	3.9	CHEMBL2973	Homo sapiens	IC50	nM	3.9
313429	17693629	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N[C@H](C)c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1C		CHEMBL3700967	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
313430	17693630	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N[C@H](C)c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1OC		CHEMBL3700970	=	IC50	nM	3.1	CHEMBL2973	Homo sapiens	IC50	nM	3.1
313431	17693631	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CCCC[C@@H](NC(=O)c1ccc(OC)c(OC)c1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700971	=	IC50	nM	6.2	CHEMBL2973	Homo sapiens	IC50	nM	6.2
313432	17693632	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4cccc(C#N)c4)c3)sc2C1		CHEMBL3700973	=	IC50	nM	3.1	CHEMBL2973	Homo sapiens	IC50	nM	3.1
313433	17693633	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-n5ccnc5)cc4)c3)sc2C1		CHEMBL3700974	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
313434	17693634	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)CN(Cc3ccccc3)CC4)c2)c1		CHEMBL3700976	=	IC50	nM	12.5	CHEMBL2973	Homo sapiens	IC50	nM	12.5
313435	17693635	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc5[nH]c(=O)ccc5c4)c3)sc2C1		CHEMBL3700978	=	IC50	nM	2.3	CHEMBL2973	Homo sapiens	IC50	nM	2.3
313436	17693636	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2ccc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4cccc(C#N)c4)c3)cc2C1		CHEMBL3700979	=	IC50	nM	9.5	CHEMBL2973	Homo sapiens	IC50	nM	9.5
313437	17693637	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1cccc2c1CCN2C(=O)N1CCC[C@@H]1c1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N2CCOCC2)CC3)c1		CHEMBL3700980	=	IC50	nM	2.9	CHEMBL2973	Homo sapiens	IC50	nM	2.9
313438	17693638	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc(C4CCCCN4C(=O)Nc4cccc(C#N)c4)c3)sc2C1		CHEMBL3700981	=	IC50	nM	39.3	CHEMBL2973	Homo sapiens	IC50	nM	39.3
313439	17693639	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)cc1OC		CHEMBL3700982	=	IC50	nM	3.6	CHEMBL2973	Homo sapiens	IC50	nM	3.6
313440	17693640	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)cc1Cl		CHEMBL3700983	=	IC50	nM	5.8	CHEMBL2973	Homo sapiens	IC50	nM	5.8
313441	17693641	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc(C4CCCN(C(=O)Nc5cccc(C#N)c5)C4)c3)sc2C1		CHEMBL3704369	=	IC50	nM	77.5	CHEMBL2973	Homo sapiens	IC50	nM	77.5
313442	17693642	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)cc1C		CHEMBL3704370	=	IC50	nM	7.8	CHEMBL2973	Homo sapiens	IC50	nM	7.8
313443	17693643	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc(C4CCCCN4C(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3704371	=	IC50	nM	18.7	CHEMBL2973	Homo sapiens	IC50	nM	18.7
313444	17693644	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc(-c3cnco3)cc2)c1		CHEMBL3704372	=	IC50	nM	2.5	CHEMBL2973	Homo sapiens	IC50	nM	2.5
313445	17693645	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2csc(-c3ccncc3)n2)c1		CHEMBL3704373	=	IC50	nM	3.2	CHEMBL2973	Homo sapiens	IC50	nM	3.2
313446	17693646	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc(-n3ccnc3)cc2)c1		CHEMBL3704374	=	IC50	nM	3.5	CHEMBL2973	Homo sapiens	IC50	nM	3.5
313447	17693647	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	NC(=O)c1ccc2nc(C(=O)N3CCC[C@@H]3c3cccc(C(=O)Nc4nc5c(s4)C[C@@H](N4CCOCC4)CC5)c3)cn2c1		CHEMBL3704375	=	IC50	nM	2.3	CHEMBL2973	Homo sapiens	IC50	nM	2.3
313448	17693648	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc3[nH]c(=O)ccc3c2)c1		CHEMBL3704376	=	IC50	nM	2.7	CHEMBL2973	Homo sapiens	IC50	nM	2.7
313449	17693649	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	Cc1nc(-c2ccncc2)sc1C(=O)N1CCC[C@@H]1c1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N2CCOCC2)CC3)c1		CHEMBL3704377	=	IC50	nM	3.6	CHEMBL2973	Homo sapiens	IC50	nM	3.6
313450	17693650	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc3cc(O)ccc3c2)c1		CHEMBL3704378	=	IC50	nM	2.5	CHEMBL2973	Homo sapiens	IC50	nM	2.5
313451	17693651	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL3704379	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
313452	17693652	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	Nc1nonc1-n1nnc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)c1-c1ccccc1		CHEMBL3704380	=	IC50	nM	2.7	CHEMBL2973	Homo sapiens	IC50	nM	2.7
313453	17693653	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2csc(-c3cccnc3)n2)c1		CHEMBL3704381	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
313454	17693654	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2cccc(-c3cn[nH]c3)c2)c1		CHEMBL3704383	=	IC50	nM	2.5	CHEMBL2973	Homo sapiens	IC50	nM	2.5
313455	17693655	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N[C@H](C)c2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC		CHEMBL3704384	=	IC50	nM	8.9	CHEMBL2973	Homo sapiens	IC50	nM	8.9
313456	17693656	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#CCCN[C@H]1CCc2nc(NC(=O)c3cccc(COC(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3704385	=	IC50	nM	5.2	CHEMBL2973	Homo sapiens	IC50	nM	5.2
313457	17693657	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N[C@H](C)c2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1Cl		CHEMBL3704386	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
313458	17693658	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COc1ccc(C(=O)N[C@H](C)c2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1C		CHEMBL3704387	=	IC50	nM	10.5	CHEMBL2973	Homo sapiens	IC50	nM	10.5
313459	17693659	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1ccc(NC(=O)OCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](NCCC(F)(F)F)CC4)c2)cc1		CHEMBL3704388	=	IC50	nM	5.1	CHEMBL2973	Homo sapiens	IC50	nM	5.1
313460	17693660	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	C[C@@H](NC(=O)Nc1cccc(C#N)c1)c1cccc(C(=O)Nc2ccc3c(c2)CN(C)CC3)c1		CHEMBL3704389	=	IC50	nM	18.9	CHEMBL2973	Homo sapiens	IC50	nM	18.9
313461	17693661	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cn5ccc(C#N)cc5n4)c3)sc2C1		CHEMBL3704390	=	IC50	nM	2.9	CHEMBL2973	Homo sapiens	IC50	nM	2.9
313462	17693662	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	C[C@@H](NC(=O)Nc1ccc(C#N)cc1)c1cccc(C(=O)Nc2ccc3c(c2)CN(C)CC3)c1		CHEMBL3704391	=	IC50	nM	57.5	CHEMBL2973	Homo sapiens	IC50	nM	57.5
313463	17693663	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cn5cc(C#N)ccc5n4)c3)sc2C1		CHEMBL3704392	=	IC50	nM	25.5	CHEMBL2973	Homo sapiens	IC50	nM	25.5
313464	17693664	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	N#Cc1ccc(NC(=O)COc2cccc(C(=O)Nc3nc4c(s3)CC(N3CCN(C5CC5)CC3)CC4)c2)cc1		CHEMBL3704393	=	IC50	nM	6.1	CHEMBL2973	Homo sapiens	IC50	nM	6.1
313465	17693665	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	C[C@@H](NC(=O)Nc1ccc(C(N)=O)cc1)c1cccc(C(=O)Nc2ccc3c(c2)CN(C)CC3)c1		CHEMBL3704394	=	IC50	nM	9.5	CHEMBL2973	Homo sapiens	IC50	nM	9.5
313466	17693666	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCN(C2CCc3nc(NC(=O)c4cccc(OCC(=O)Nc5ccc(C#N)cc5)c4)sc3C2)CC1		CHEMBL3704395	=	IC50	nM	6.5	CHEMBL2973	Homo sapiens	IC50	nM	6.5
313467	17693667	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H](NC(=O)Nc4cccc(C#N)c4)C4CC4)c3)sc2C1		CHEMBL3704396	=	IC50	nM	9.7	CHEMBL2973	Homo sapiens	IC50	nM	9.7
313468	17693668	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	COCCN(C)C1CCc2nc(NC(=O)c3cccc(OCC(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3704397	=	IC50	nM	7.2	CHEMBL2973	Homo sapiens	IC50	nM	7.2
313469	17693669	CHEMBL3705831	Luciferin-Luciferase Assay: The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase.	B	CN1CCc2nc(NC(=O)c3cccc([C@H](NC(=O)Nc4ccc(C#N)cc4)C4CC4)c3)sc2C1		CHEMBL3704398	=	IC50	nM	45.7	CHEMBL2973	Homo sapiens	IC50	nM	45.7
313470	17693670	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc(OCC(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3700907	=	IC50	nM	2.2	CHEMBL2973	Homo sapiens	IC50	nM	2.2
313471	17693671	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1ccc(NC(=O)COc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N)CC4)c2)cc1		CHEMBL3700909	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
313472	17693672	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1ccc(NC(=O)COc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)cc1		CHEMBL3700911	=	IC50	nM	8.5	CHEMBL2973	Homo sapiens	IC50	nM	8.5
313473	17693673	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3ccc(CCN4CCOCC4)cc3)c2)c1		CHEMBL3700914	=	IC50	nM	23.0	CHEMBL2973	Homo sapiens	IC50	nM	23.0
313474	17693674	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3ccc(CCN4CCCC4)cc3)c2)c1		CHEMBL3700915	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	nM	19.0
313475	17693675	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N)CC4)c2)c1		CHEMBL3700917	=	IC50	nM	0.39	CHEMBL2973	Homo sapiens	IC50	nM	0.39
313476	17693676	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@H](N)CC4)c2)c1		CHEMBL3700919	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
313477	17693677	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc(OCC(=O)Nc4ccc5[nH]ncc5c4)c3)sc2C1		CHEMBL3700920	=	IC50	nM	0.8	CHEMBL2973	Homo sapiens	IC50	nM	0.8
313478	17693678	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-c5ccncc5)cc4)c3)sc2C1		CHEMBL3700922	=	IC50	nM	5.8	CHEMBL2973	Homo sapiens	IC50	nM	5.8
313479	17693679	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4nnn(-c5nonc5N)c4-c4ccccc4)c3)sc2C1		CHEMBL3700923	=	IC50	nM	44.0	CHEMBL2973	Homo sapiens	IC50	nM	44.0
313480	17693680	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CCCN[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4cccc(C#N)c4)c3)sc2C1		CHEMBL3700924	=	IC50	nM	0.8	CHEMBL2973	Homo sapiens	IC50	nM	0.8
313481	17693681	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CCCN[C@H]1CCc2nc(NC(=O)c3cccc([C@@H](C)NC(=O)c4ccc(OC)c(OC)c4)c3)sc2C1		CHEMBL3700926	=	IC50	nM	0.3	CHEMBL2973	Homo sapiens	IC50	nM	0.3
313482	17693682	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CCCN[C@H]1CCc2nc(NC(=O)c3cccc([C@@H](C)NC(=O)c4ccc(OC)c(Cl)c4)c3)sc2C1		CHEMBL3700928	=	IC50	nM	0.5	CHEMBL2973	Homo sapiens	IC50	nM	0.5
313483	17693683	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CCCN[C@H]1CCc2nc(NC(=O)c3cccc([C@@H](C)NC(=O)c4ccc(OC)c(C)c4)c3)sc2C1		CHEMBL3700930	=	IC50	nM	0.4	CHEMBL2973	Homo sapiens	IC50	nM	0.4
313484	17693684	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4cccc(C#N)c4)c3)sc2C1		CHEMBL3700932	=	IC50	nM	0.3	CHEMBL2973	Homo sapiens	IC50	nM	0.3
313485	17693685	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1cccc(NC(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)c1		CHEMBL3700934	=	IC50	nM	0.6	CHEMBL2973	Homo sapiens	IC50	nM	0.6
313486	17693686	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc5cc(O)ccc5c4)c3)sc2C1		CHEMBL3700935	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
313487	17693687	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)N4CCc5c(C#N)cccc54)c3)sc2C1		CHEMBL3700936	=	IC50	nM	44.5	CHEMBL2973	Homo sapiens	IC50	nM	44.5
313488	17693688	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4ccc(C(N)=O)cc4)c3)sc2C1		CHEMBL3700937	=	IC50	nM	0.7	CHEMBL2973	Homo sapiens	IC50	nM	0.7
313489	17693689	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	Cc1nc(-c2ccncc2)sc1C(=O)N1CCC[C@@H]1c1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N(C)C)CC3)c1		CHEMBL3700940	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
313490	17693690	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4nnn(-c5nonc5N)c4-c4ccccc4)c3)sc2C1		CHEMBL3700941	=	IC50	nM	8.7	CHEMBL2973	Homo sapiens	IC50	nM	8.7
313491	17693691	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4csc(-c5cccnc5)n4)c3)sc2C1		CHEMBL3700944	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	nM	13.0
313492	17693692	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3700948	=	IC50	nM	16.0	CHEMBL2973	Homo sapiens	IC50	nM	16.0
313493	17693693	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cc(-c5ccncc5)[nH]n4)c3)sc2C1		CHEMBL3700950	=	IC50	nM	4.1	CHEMBL2973	Homo sapiens	IC50	nM	4.1
313494	17693694	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-c5cnco5)cc4)c3)sc2C1		CHEMBL3700953	=	IC50	nM	11.2	CHEMBL2973	Homo sapiens	IC50	nM	11.2
313495	17693695	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cn5cc(C(N)=O)ccc5n4)c3)sc2C1		CHEMBL3700954	=	IC50	nM	7.4	CHEMBL2973	Homo sapiens	IC50	nM	7.4
313496	17693696	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3700956	=	IC50	nM	2.1	CHEMBL2973	Homo sapiens	IC50	nM	2.1
313497	17693697	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1ccn2cc(C(=O)N3CCC[C@@H]3c3cccc(C(=O)Nc4nc5c(s4)C[C@@H](N4CCOCC4)CC5)c3)nc2c1		CHEMBL3700958	=	IC50	nM	1.7	CHEMBL2973	Homo sapiens	IC50	nM	1.7
313498	17693698	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-c5ccncc5)cc4)c3)sc2C1		CHEMBL3700963	=	IC50	nM	3.8	CHEMBL2973	Homo sapiens	IC50	nM	3.8
313499	17693699	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	COc1ccc(C(=O)N[C@H](C)c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1Cl		CHEMBL3700964	=	IC50	nM	13.0	CHEMBL2973	Homo sapiens	IC50	nM	13.0
313500	17693700	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-c5cnco5)cc4)c3)sc2C1		CHEMBL3700965	=	IC50	nM	2.1	CHEMBL2973	Homo sapiens	IC50	nM	2.1
313501	17693701	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4csc(-c5cccnc5)n4)c3)sc2C1		CHEMBL3700966	=	IC50	nM	1.3	CHEMBL2973	Homo sapiens	IC50	nM	1.3
313502	17693702	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	COc1ccc(C(=O)N[C@H](C)c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1C		CHEMBL3700967	=	IC50	nM	29.0	CHEMBL2973	Homo sapiens	IC50	nM	29.0
313503	17693703	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4csc(-c5ccncc5)n4)c3)sc2C1		CHEMBL3700968	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
313504	17693704	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cc(-c5ccncc5)[nH]n4)c3)sc2C1		CHEMBL3700969	=	IC50	nM	0.8	CHEMBL2973	Homo sapiens	IC50	nM	0.8
313505	17693705	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	COc1ccc(C(=O)N[C@H](C)c2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)cc1OC		CHEMBL3700970	=	IC50	nM	5.8	CHEMBL2973	Homo sapiens	IC50	nM	5.8
313506	17693706	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CCCC[C@@H](NC(=O)c1ccc(OC)c(OC)c1)c1cccc(C(=O)Nc2nc3c(s2)CN(C)CC3)c1		CHEMBL3700971	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
313507	17693707	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc5cc(O)ccc5c4)c3)sc2C1		CHEMBL3700972	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
313508	17693708	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)Nc4cccc(C#N)c4)c3)sc2C1		CHEMBL3700973	=	IC50	nM	6.8	CHEMBL2973	Homo sapiens	IC50	nM	6.8
313509	17693709	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc(-n5ccnc5)cc4)c3)sc2C1		CHEMBL3700974	=	IC50	nM	3.6	CHEMBL2973	Homo sapiens	IC50	nM	3.6
313510	17693710	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cn5cc(C(N)=O)ccc5n4)c3)sc2C1		CHEMBL3700975	=	IC50	nM	1.7	CHEMBL2973	Homo sapiens	IC50	nM	1.7
313511	17693711	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cccc(-c5cn[nH]c5)c4)c3)sc2C1		CHEMBL3700977	=	IC50	nM	1.9	CHEMBL2973	Homo sapiens	IC50	nM	1.9
313512	17693712	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN(C)[C@H]1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4ccc5[nH]c(=O)ccc5c4)c3)sc2C1		CHEMBL3700978	=	IC50	nM	3.6	CHEMBL2973	Homo sapiens	IC50	nM	3.6
313513	17693713	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1cccc2c1CCN2C(=O)N1CCC[C@@H]1c1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N2CCOCC2)CC3)c1		CHEMBL3700980	=	IC50	nM	2.9	CHEMBL2973	Homo sapiens	IC50	nM	2.9
313514	17693714	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	COc1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)cc1OC		CHEMBL3700982	=	IC50	nM	6.8	CHEMBL2973	Homo sapiens	IC50	nM	6.8
313515	17693715	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	COc1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)cc1Cl		CHEMBL3700983	=	IC50	nM	7.9	CHEMBL2973	Homo sapiens	IC50	nM	7.9
313516	17693716	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	COc1ccc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)cc1C		CHEMBL3704370	=	IC50	nM	9.7	CHEMBL2973	Homo sapiens	IC50	nM	9.7
313517	17693717	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc(-c3cnco3)cc2)c1		CHEMBL3704372	=	IC50	nM	6.9	CHEMBL2973	Homo sapiens	IC50	nM	6.9
313518	17693718	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2csc(-c3ccncc3)n2)c1		CHEMBL3704373	=	IC50	nM	7.9	CHEMBL2973	Homo sapiens	IC50	nM	7.9
313519	17693719	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc(-n3ccnc3)cc2)c1		CHEMBL3704374	=	IC50	nM	8.3	CHEMBL2973	Homo sapiens	IC50	nM	8.3
313520	17693720	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	NC(=O)c1ccc2nc(C(=O)N3CCC[C@@H]3c3cccc(C(=O)Nc4nc5c(s4)C[C@@H](N4CCOCC4)CC5)c3)cn2c1		CHEMBL3704375	=	IC50	nM	6.7	CHEMBL2973	Homo sapiens	IC50	nM	6.7
313521	17693721	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc3[nH]c(=O)ccc3c2)c1		CHEMBL3704376	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
313522	17693722	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	Cc1nc(-c2ccncc2)sc1C(=O)N1CCC[C@@H]1c1cccc(C(=O)Nc2nc3c(s2)C[C@@H](N2CCOCC2)CC3)c1		CHEMBL3704377	=	IC50	nM	29.0	CHEMBL2973	Homo sapiens	IC50	nM	29.0
313523	17693723	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc3cc(O)ccc3c2)c1		CHEMBL3704378	=	IC50	nM	6.3	CHEMBL2973	Homo sapiens	IC50	nM	6.3
313524	17693724	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL3704379	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
313525	17693725	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	Nc1nonc1-n1nnc(C(=O)N2CCC[C@@H]2c2cccc(C(=O)Nc3nc4c(s3)C[C@@H](N3CCOCC3)CC4)c2)c1-c1ccccc1		CHEMBL3704380	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
313526	17693726	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2csc(-c3cccnc3)n2)c1		CHEMBL3704381	=	IC50	nM	6.9	CHEMBL2973	Homo sapiens	IC50	nM	6.9
313527	17693727	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2cc(-c3ccncc3)[nH]n2)c1		CHEMBL3704382	=	IC50	nM	4.2	CHEMBL2973	Homo sapiens	IC50	nM	4.2
313528	17693728	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	O=C(Nc1nc2c(s1)C[C@@H](N1CCOCC1)CC2)c1cccc([C@H]2CCCN2C(=O)c2cccc(-c3cn[nH]c3)c2)c1		CHEMBL3704383	=	IC50	nM	4.9	CHEMBL2973	Homo sapiens	IC50	nM	4.9
313529	17693729	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#CCCN[C@H]1CCc2nc(NC(=O)c3cccc(COC(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3704385	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	nM	27.0
313530	17693730	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1ccc(NC(=O)OCc2cccc(C(=O)Nc3nc4c(s3)C[C@@H](NCCC(F)(F)F)CC4)c2)cc1		CHEMBL3704388	=	IC50	nM	32.0	CHEMBL2973	Homo sapiens	IC50	nM	32.0
313531	17693731	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCc2nc(NC(=O)c3cccc([C@H]4CCCN4C(=O)c4cn5ccc(C#N)cc5n4)c3)sc2C1		CHEMBL3704390	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
313532	17693732	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	N#Cc1ccc(NC(=O)COc2cccc(C(=O)Nc3nc4c(s3)CC(N3CCN(C5CC5)CC3)CC4)c2)cc1		CHEMBL3704393	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	nM	24.0
313533	17693733	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	CN1CCN(C2CCc3nc(NC(=O)c4cccc(OCC(=O)Nc5ccc(C#N)cc5)c4)sc3C2)CC1		CHEMBL3704395	=	IC50	nM	33.0	CHEMBL2973	Homo sapiens	IC50	nM	33.0
313534	17693734	CHEMBL3705771	IMAP Assay: This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 Î¼L of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP.	B	COCCN(C)C1CCc2nc(NC(=O)c3cccc(OCC(=O)Nc4ccc(C#N)cc4)c3)sc2C1		CHEMBL3704397	=	IC50	nM	31.0	CHEMBL2973	Homo sapiens	IC50	nM	31.0
351456	17727625	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(F)cc2C1		CHEMBL3938988	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
351457	17727626	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)Nc1nc2ccccc2o1		CHEMBL3968518	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
351458	17727627	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	COC[C@@H]1CCCN1C(=O)Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1		CHEMBL3974064	=	IC50	nM	9733.0	CHEMBL2973	Homo sapiens	IC50	nM	9733.0
351459	17727628	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)NC1CCC1		CHEMBL3944615	=	IC50	nM	5834.0	CHEMBL2973	Homo sapiens	IC50	nM	5834.0
351460	17727629	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	CCOc1ccc2c(c1)N(C(=O)Cc1ccc(-c3n[nH]c(=O)c4ccccc34)cc1)CC2		CHEMBL3953195	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
351461	17727630	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Cc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1CCCc2ccccc21		CHEMBL3929004	=	IC50	nM	553.0	CHEMBL2973	Homo sapiens	IC50	nM	553.0
351462	17727631	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)c1csc(-c2ccc(C(F)(F)F)cc2)n1		CHEMBL3957734	=	IC50	nM	39.0	CHEMBL2973	Homo sapiens	IC50	nM	39.0
351463	17727632	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	Cn1ccnc1C(=O)Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1		CHEMBL3930239	=	IC50	nM	225.0	CHEMBL2973	Homo sapiens	IC50	nM	225.0
351464	17727633	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	CN(C)c1ccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)cc1		CHEMBL3968772	=	IC50	nM	0.3	CHEMBL2973	Homo sapiens	IC50	nM	0.3
351465	17727634	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)c1ccc(N2CCCCC2)cc1		CHEMBL3935660	=	IC50	nM	2.1	CHEMBL2973	Homo sapiens	IC50	nM	2.1
351466	17727635	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)c1ccccc1		CHEMBL3980970	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
351467	17727636	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Oc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1CCC(c2ccccc2)C1		CHEMBL3952135	=	IC50	nM	894.0	CHEMBL2973	Homo sapiens	IC50	nM	894.0
351468	17727637	CHEMBL3887752	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LabChip 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity. Compounds were tested in dose-response format, and the inhibition of kinase activity was calculated at each concentration of compound.	B	O=C(Nc1ccc(-c2c[nH]c(=O)c3ccccc23)cc1)N1CCc2ccccc21		CHEMBL3921800	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
354484	17730315	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218005	=	IC50	nM	90.0	CHEMBL2973	Homo sapiens	IC50	nM	90.0
354485	17730316	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218005	=	IC50	nM	50.0	CHEMBL2973	Homo sapiens	IC50	nM	50.0
354486	17730317	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCCc1ccccc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218299	=	IC50	nM	380.0	CHEMBL2973	Homo sapiens	IC50	nM	380.0
354487	17730318	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CN(Cc1ccccc1)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218274	=	IC50	nM	70.0	CHEMBL2973	Homo sapiens	IC50	nM	70.0
354488	17730319	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
354489	17730320	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
354490	17730321	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	nM	10.0
354491	17730322	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218006	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
354492	17730323	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1ccccc1CNC(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218007	=	IC50	nM	470.0	CHEMBL2973	Homo sapiens	IC50	nM	470.0
354493	17730324	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218008	=	IC50	nM	7420.0	CHEMBL2973	Homo sapiens	IC50	nM	7420.0
354494	17730325	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1cccc(CNC(=O)N(C)c2nc(-c3ccncc3)cs2)c1		CHEMBL3218275	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
354495	17730326	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1cccc(CN(C)C(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218276	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	nM	15.0
354496	17730327	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218009	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
354497	17730328	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	Nc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3954084	=	IC50	nM	17400.0	CHEMBL2973	Homo sapiens	IC50	nM	17400.0
354498	17730329	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccc2[nH]ccc12)Nc1nc(-c2ccncc2)cs1		CHEMBL3218010	=	IC50	nM	31090.0	CHEMBL2973	Homo sapiens	IC50	nM	31090.0
354499	17730330	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CNc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3923247	=	IC50	nM	240.0	CHEMBL2973	Homo sapiens	IC50	nM	240.0
354500	17730331	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218011	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
354501	17730332	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218011	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
354502	17730333	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218011	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
354503	17730334	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	NC(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218014	=	IC50	nM	180.0	CHEMBL2973	Homo sapiens	IC50	nM	180.0
354504	17730335	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CC(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218016	=	IC50	nM	130.0	CHEMBL2973	Homo sapiens	IC50	nM	130.0
354505	17730336	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CS(=O)(=O)Nc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218015	=	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
354506	17730337	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccccc1O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218012	=	IC50	nM	280.0	CHEMBL2973	Homo sapiens	IC50	nM	280.0
354507	17730338	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccc(O)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218013	=	IC50	nM	140.0	CHEMBL2973	Homo sapiens	IC50	nM	140.0
354508	17730339	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COCCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218017	=	IC50	nM	240.0	CHEMBL2973	Homo sapiens	IC50	nM	240.0
354509	17730340	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218018	=	IC50	nM	290.0	CHEMBL2973	Homo sapiens	IC50	nM	290.0
354510	17730341	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CCCOc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218019	=	IC50	nM	680.0	CHEMBL2973	Homo sapiens	IC50	nM	680.0
354511	17730342	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CC(C)Oc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218020	=	IC50	nM	3440.0	CHEMBL2973	Homo sapiens	IC50	nM	3440.0
354512	17730343	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccc(OC(F)F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3932202	=	IC50	nM	350.0	CHEMBL2973	Homo sapiens	IC50	nM	350.0
354513	17730344	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccc(F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218021	=	IC50	nM	60.0	CHEMBL2973	Homo sapiens	IC50	nM	60.0
354514	17730345	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccc(F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218021	=	IC50	nM	50.0	CHEMBL2973	Homo sapiens	IC50	nM	50.0
354515	17730346	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccccc1F)Nc1nc(-c2ccncc2)cs1		CHEMBL3218022	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	nM	120.0
354516	17730347	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccc(F)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218023	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	nM	190.0
354517	17730348	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccc(Cl)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218024	=	IC50	nM	60.0	CHEMBL2973	Homo sapiens	IC50	nM	60.0
354518	17730349	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccccc1Cl)Nc1nc(-c2ccncc2)cs1		CHEMBL3217759	=	IC50	nM	110.0	CHEMBL2973	Homo sapiens	IC50	nM	110.0
354519	17730350	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccc(Cl)cc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218025	=	IC50	nM	1100.0	CHEMBL2973	Homo sapiens	IC50	nM	1100.0
354520	17730351	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	Cc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218026	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	nM	120.0
354521	17730352	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	Cc1ccccc1CNC(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218027	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	nM	120.0
354522	17730353	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	Cc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL3218028	=	IC50	nM	2050.0	CHEMBL2973	Homo sapiens	IC50	nM	2050.0
354523	17730354	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1cccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)c1OC		CHEMBL3894166	=	IC50	nM	19730.0	CHEMBL2973	Homo sapiens	IC50	nM	19730.0
354524	17730355	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1ccc(CNC(=O)Nc2nc(-c3ccncc3)cs2)cc1OC		CHEMBL3963188	=	IC50	nM	25020.0	CHEMBL2973	Homo sapiens	IC50	nM	25020.0
354525	17730356	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccc(Cl)cc1Cl)Nc1nc(-c2ccncc2)cs1		CHEMBL3935950	=	IC50	nM	400.0	CHEMBL2973	Homo sapiens	IC50	nM	400.0
354526	17730357	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cc(F)cc(F)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3958434	=	IC50	nM	960.0	CHEMBL2973	Homo sapiens	IC50	nM	960.0
354527	17730358	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccc2ccccc12)Nc1nc(-c2ccncc2)cs1		CHEMBL3987124	=	IC50	nM	580.0	CHEMBL2973	Homo sapiens	IC50	nM	580.0
354528	17730359	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccco1)Nc1nc(-c2ccncc2)cs1		CHEMBL3963845	=	IC50	nM	380.0	CHEMBL2973	Homo sapiens	IC50	nM	380.0
354529	17730360	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1cccnc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3926492	=	IC50	nM	490.0	CHEMBL2973	Homo sapiens	IC50	nM	490.0
354530	17730361	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccccn1)Nc1nc(-c2ccncc2)cs1		CHEMBL3944452	=	IC50	nM	1440.0	CHEMBL2973	Homo sapiens	IC50	nM	1440.0
354531	17730362	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(NCc1ccncc1)Nc1nc(-c2ccncc2)cs1		CHEMBL3973907	=	IC50	nM	1470.0	CHEMBL2973	Homo sapiens	IC50	nM	1470.0
354532	17730363	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218277	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
354533	17730364	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218277	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
354534	17730365	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	C[C@H](c1ccccc1)N(C)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218293	=	IC50	nM	47.0	CHEMBL2973	Homo sapiens	IC50	nM	47.0
354535	17730366	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218285	=	IC50	nM	1600.0	CHEMBL2973	Homo sapiens	IC50	nM	1600.0
354536	17730367	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218285	=	IC50	nM	1900.0	CHEMBL2973	Homo sapiens	IC50	nM	1900.0
354537	17730368	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	C[C@@H](c1ccccc1)N(C)C(=O)Nc1nc(-c2ccncc2)cs1		CHEMBL3218294	=	IC50	nM	2670.0	CHEMBL2973	Homo sapiens	IC50	nM	2670.0
354538	17730369	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@H](CO)c1ccccc1		CHEMBL3218278	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
354539	17730370	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)NC(CO)c1ccccc1		CHEMBL3218295	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
354540	17730371	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@@H](CO)c1ccccc1		CHEMBL3218286	=	IC50	nM	2500.0	CHEMBL2973	Homo sapiens	IC50	nM	2500.0
354541	17730372	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CC[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218279	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
354542	17730373	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CC[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218287	=	IC50	nM	22040.0	CHEMBL2973	Homo sapiens	IC50	nM	22040.0
354543	17730374	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	NC(=O)[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218280	=	IC50	nM	40.0	CHEMBL2973	Homo sapiens	IC50	nM	40.0
354544	17730375	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	NC(=O)[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218288	=	IC50	nM	2100.0	CHEMBL2973	Homo sapiens	IC50	nM	2100.0
354545	17730376	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COC[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218281	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
354546	17730377	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COC[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3218289	=	IC50	nM	11480.0	CHEMBL2973	Homo sapiens	IC50	nM	11480.0
354547	17730378	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CC(C)(NC(=O)Nc1nc(-c2ccncc2)cs1)c1ccccc1		CHEMBL3966306	=	IC50	nM	70.0	CHEMBL2973	Homo sapiens	IC50	nM	70.0
354548	17730379	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)NC(c1ccccc1)c1ccccc1		CHEMBL3914256	=	IC50	nM	530.0	CHEMBL2973	Homo sapiens	IC50	nM	530.0
354549	17730380	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1cccc([C@@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218282	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
354550	17730381	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1cccc([C@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)c1		CHEMBL3218290	=	IC50	nM	3250.0	CHEMBL2973	Homo sapiens	IC50	nM	3250.0
354551	17730382	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	COc1ccc([C@@H](C)NC(=O)Nc2nc(-c3ccncc3)cs2)cc1		CHEMBL4107622	=	IC50	nM	11940.0	CHEMBL2973	Homo sapiens	IC50	nM	11940.0
354552	17730383	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	C[C@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218291	=	IC50	nM	10970.0	CHEMBL2973	Homo sapiens	IC50	nM	10970.0
354553	17730384	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218283	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
354554	17730385	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	CC(NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(F)c1		CHEMBL3218296	=	IC50	nM	280.0	CHEMBL2973	Homo sapiens	IC50	nM	280.0
354555	17730386	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	C[C@@H](NC(=O)Nc1nc(-c2ccncc2)cs1)c1cccc(Cl)c1		CHEMBL3218284	=	IC50	nM	70.0	CHEMBL2973	Homo sapiens	IC50	nM	70.0
354556	17730387	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)Nc1ccccc1Cl		CHEMBL3978510	=	IC50	nM	3750.0	CHEMBL2973	Homo sapiens	IC50	nM	3750.0
354557	17730388	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@@H]1CCc2ccccc21		CHEMBL4114172	=	IC50	nM	52470.0	CHEMBL2973	Homo sapiens	IC50	nM	52470.0
354558	17730389	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@H]1CCc2ccccc21		CHEMBL3916739	=	IC50	nM	1830.0	CHEMBL2973	Homo sapiens	IC50	nM	1830.0
354559	17730390	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@@H]1CCCc2ccccc21		CHEMBL4112033	=	IC50	nM	3820.0	CHEMBL2973	Homo sapiens	IC50	nM	3820.0
354560	17730391	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)N[C@H]1CCCc2ccccc21		CHEMBL3903548	=	IC50	nM	3350.0	CHEMBL2973	Homo sapiens	IC50	nM	3350.0
354561	17730392	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)N1CCc2ccccc2C1		CHEMBL3915031	=	IC50	nM	1950.0	CHEMBL2973	Homo sapiens	IC50	nM	1950.0
354562	17730393	CHEMBL3887787	Inhibition Assay: Attention was focused on exploring, in turn, the SAR around the phenyl ring A, branching and substitution at the benzylic position, urea linkage of 1aa, without varying the [4-(4-pyridinyl)-2-thiazolyl] terminus (FIG. 4). The [4-(4-pyridinyl)-2-thiazolyl] group was believed to act as a hinge-binding moiety with the nitrogen of the pyridyl H-bonding to the back bone NH of the hinge Met156, as seen in the crystal complex of ROCK1 with Fasudil (PDB ID 2ESM) (Jacobs, et al., The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J Biol Chem, 2006, 281:260-8).All compounds were systematically screened against ROCK1 and ROCK2. IC50 values were systematically determined only for compounds that inhibit 40% of ROCK1 kinase activities at 50 μM.	B	O=C(Nc1nc(-c2ccncc2)cs1)N1CCN(c2ccncc2)CC1		CHEMBL3890560	=	IC50	nM	8350.0	CHEMBL2973	Homo sapiens	IC50	nM	8350.0
380824	17754450	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2ccccc2C1		CHEMBL3915867	=	Ki	nM	3.6	CHEMBL2973	Homo sapiens	Ki	nM	3.6
380825	17754451	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2cncc3ccccc23)cc1)N1Cc2ccccc2C1		CHEMBL3951643	=	Ki	nM	4060.0	CHEMBL2973	Homo sapiens	Ki	nM	4060.0
380826	17754452	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2c[nH]c(=O)c3ccccc23)cc1)N1Cc2ccccc2C1		CHEMBL3943820	=	Ki	nM	5.26	CHEMBL2973	Homo sapiens	Ki	nM	5.26
380827	17754453	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3c2CCCC3)cc1)N1Cc2ccccc2C1		CHEMBL3891301	=	Ki	nM	19.5	CHEMBL2973	Homo sapiens	Ki	nM	19.5
380828	17754454	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3cccc(F)c23)cc1)N1Cc2ccccc2C1		CHEMBL3956902	=	Ki	nM	2.37	CHEMBL2973	Homo sapiens	Ki	nM	2.37
380829	17754455	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(F)cc2C1		CHEMBL3896775	=	Ki	nM	2.4	CHEMBL2973	Homo sapiens	Ki	nM	2.4
380830	17754456	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(CN3CCCC3)cc2C1		CHEMBL3967932	=	Ki	nM	2.3	CHEMBL2973	Homo sapiens	Ki	nM	2.3
380831	17754457	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2c[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(CN3CCOCC3)cc2C1		CHEMBL3933851	=	Ki	nM	4.12	CHEMBL2973	Homo sapiens	Ki	nM	4.12
380832	17754458	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	COc1ccc2c(c1)CN(C(=O)Nc1ccc(-c3c[nH]c(=O)c4ccccc34)cc1)C2		CHEMBL3909474	=	Ki	nM	6.14	CHEMBL2973	Homo sapiens	Ki	nM	6.14
380833	17754459	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	CN1CCN(Cc2ccc3c(c2)CN(C(=O)Nc2ccc(-c4n[nH]c(=O)c5ccccc45)cc2)C3)CC1		CHEMBL3946294	=	Ki	nM	3.61	CHEMBL2973	Homo sapiens	Ki	nM	3.61
380834	17754460	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	N#Cc1ccc2c(c1)CN(C(=O)Nc1ccc(-c3c[nH]c(=O)c4ccccc34)cc1)C2		CHEMBL3918406	=	Ki	nM	4.24	CHEMBL2973	Homo sapiens	Ki	nM	4.24
380835	17754461	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2c[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(Cl)cc2C1		CHEMBL3981575	=	Ki	nM	6.51	CHEMBL2973	Homo sapiens	Ki	nM	6.51
380836	17754462	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C1Cc2ccccc2C(c2ccc(NC(=O)N3Cc4ccccc4C3)cc2)=NN1		CHEMBL3914997	=	Ki	nM	10000.0	CHEMBL2973	Homo sapiens	Ki	nM	10000.0
380837	17754463	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2c[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(CN3CCCC3)cc2C1		CHEMBL3976744	=	Ki	nM	1.39	CHEMBL2973	Homo sapiens	Ki	nM	1.39
380838	17754464	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3cccc(C(F)(F)F)c23)cc1)N1Cc2ccccc2C1		CHEMBL3906020	=	Ki	nM	11.2	CHEMBL2973	Homo sapiens	Ki	nM	11.2
380839	17754465	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	CN(C)Cc1ccc2c(c1)CN(C(=O)Nc1ccc(-c3c[nH]c(=O)c4ccccc34)cc1)C2		CHEMBL3933101	=	Ki	nM	1.74	CHEMBL2973	Homo sapiens	Ki	nM	1.74
380840	17754466	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	CCN(CC)Cc1ccc2c(c1)CN(C(=O)Nc1ccc(-c3c[nH]c(=O)c4ccccc34)cc1)C2		CHEMBL3957123	=	Ki	nM	2.45	CHEMBL2973	Homo sapiens	Ki	nM	2.45
380841	17754467	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	CN1CCN(Cc2ccc3c(c2)CN(C(=O)Nc2ccc(-c4c[nH]c(=O)c5ccccc45)cc2)C3)CC1		CHEMBL3892516	=	Ki	nM	0.49	CHEMBL2973	Homo sapiens	Ki	nM	0.49
380842	17754468	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3cccc(C(F)(F)F)c23)cc1)N1Cc2ccc(CN3CCCC3)cc2C1		CHEMBL3979773	=	Ki	nM	9.3	CHEMBL2973	Homo sapiens	Ki	nM	9.3
380843	17754469	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	CN1CCC(Oc2ccc3c(c2)CN(C(=O)Nc2ccc(-c4n[nH]c(=O)c5ccccc45)cc2)C3)CC1		CHEMBL3968828	=	Ki	nM	32.1	CHEMBL2973	Homo sapiens	Ki	nM	32.1
380844	17754470	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(CN3CC[C@@H](F)C3)cc2C1		CHEMBL3897661	=	Ki	nM	182.0	CHEMBL2973	Homo sapiens	Ki	nM	182.0
380845	17754471	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(CN3CC[C@H](F)C3)cc2C1		CHEMBL3974102	=	Ki	nM	138.0	CHEMBL2973	Homo sapiens	Ki	nM	138.0
380846	17754472	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2ccc(CN3CCC3)cc2C1		CHEMBL3906668	=	Ki	nM	2.2	CHEMBL2973	Homo sapiens	Ki	nM	2.2
380847	17754473	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3cccn23)cc1)N1Cc2ccc(CN3CCCC3)cc2C1		CHEMBL3912166	=	Ki	nM	25.1	CHEMBL2973	Homo sapiens	Ki	nM	25.1
380848	17754474	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C1NCc2c1cccc2-c1ccc(NC(=O)N2Cc3ccccc3C2)cc1		CHEMBL3956064	=	Ki	nM	179.0	CHEMBL2973	Homo sapiens	Ki	nM	179.0
380849	17754475	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2ccncc2C1		CHEMBL3981441	=	Ki	nM	14.0	CHEMBL2973	Homo sapiens	Ki	nM	14.0
380850	17754476	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(Nc1ccc(-c2n[nH]c(=O)c3ccccc23)cc1)N1Cc2cccnc2C1		CHEMBL3901432	=	Ki	nM	3.1	CHEMBL2973	Homo sapiens	Ki	nM	3.1
380851	17754477	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(NC1CC=C(c2c[nH]c(=O)c3ccccc23)CC1)N1Cc2ccccc2C1		CHEMBL3929373	=	Ki	nM	15.4	CHEMBL2973	Homo sapiens	Ki	nM	15.4
380852	17754478	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(NC1CC=C(c2n[nH]c(=O)c3ccccc23)CC1)N1Cc2ccccc2C1		CHEMBL3906890	=	Ki	nM	18.4	CHEMBL2973	Homo sapiens	Ki	nM	18.4
380853	17754479	CHEMBL3888192	ROCK2 Kinase Activity Assays: HTRF assay: This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 uM biotinylated substrate peptide (S2, CisBio), 5 uM, 100 uM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay below. [33P]-ATP assay: ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 mM final; S6-short for ROCK2), γ-[33P]-ATP (5 uM, 2 mCi/mmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.	B	O=C(NC1CC=C(c2n[nH]c(=O)c3ccccc23)CC1)N1Cc2ccc(CN3CCCC3)cc2C1		CHEMBL3938422	=	Ki	nM	3270.0	CHEMBL2973	Homo sapiens	Ki	nM	3270.0
412046	17776761	CHEMBL3888689	Mobility Shift Assay: Agents: 1-fold kinase buffer without MnCl2: 50 mM HEPES, pH 7.5, 0.0015% Brij-35, 10 mM MgCl2, 2 mM DTT. 1-fold kinase buffer with MnCl2: 50 mM HEPES, pH 7.5, 0.0015% Brij-35, 10 mM MgCl2, 10 mM MnCl2, 2 mM DTT. Termination solution: 100 mM HEPES, pH 7.5, 0.0015% Brij-35, 0.2% Coating Reagent#3, 50 mM EDTA. 2.5-fold kinase solution: The kinase was added to the 1-fold kinase buffer to form a 2.5-fold kinase solution. 2.5-fold substrate solution: FAM fluorescence-labelled polypeptide and ATP were added to the 1-fold kinase buffer to form a 2.5-fold substrate solution. Compounds: The final test concentration of the compound was 10 μM at maximum. Firstly, a 50-fold concentration (i.e. 500 μM) was prepared with 100% DMSO. The compound was diluted with 100% DMSO by 5 folds at 5 concentrations (successively 500 μM, 100 μM, 20 μM, 4 μM, and 0.8 μM). After diluting with 1-fold kinase buffer by 10 folds, 5 μl of the samples were transferred to a 384-well reaction plate. Two negative control wells and two positive control wells were set at each line respectively. Replication was made in a 96-well plate in five concentrations of 5-fold compound. 10% DMSO was added to the positive control well, and 5 μl of EDTA (250 mM) was added to the negative control well. Procedure: To the 384-well reaction plate was added 5-fold compound dissolved in 10% DMSO at 5 μl/well. To the 384-well reaction plate was added 2.5-fold kinase solution at 10 Î¼l/well. The plate was incubated at room temperature for 10 mins. To the 384-well reaction plate was added 2.5-fold substrate solution at 10 μl/well. The plate was incubated at 28° C. for a certain period. 25 μl termination solution was added to terminate the reaction.	B	Nc1ccc(-c2ccc3ncc4c(=O)[nH]c(=O)n(-c5cccc(C(F)(F)F)c5)c4c3n2)cn1		CHEMBL3903725	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
417311	17780773	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cccnc1		CHEMBL67352	=	IC50	nM	55900.0	CHEMBL2973	Homo sapiens	IC50	nM	55900.0
417312	17780774	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cnccc1Cl	Outside typical range	CHEMBL2022282	=	IC50	nM	221400.0	CHEMBL2973	Homo sapiens	IC50	nM	221400.0
417313	17780775	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cncc(Br)c1	Outside typical range	CHEMBL1566648	=	IC50	nM	357200.0	CHEMBL2973	Homo sapiens	IC50	nM	357200.0
417314	17780776	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cnccc1-c1ccc(F)cc1	Outside typical range	CHEMBL2023144	>	IC50	nM	4000000.0	CHEMBL2973	Homo sapiens	IC50	nM	4000000.0
417315	17780777	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccncc1)c1cncc(-c2ccc(F)cc2)c1	Outside typical range	CHEMBL2023145	>	IC50	nM	4000000.0	CHEMBL2973	Homo sapiens	IC50	nM	4000000.0
417316	17780778	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	Nc1ccc2[nH]ncc2c1	Outside typical range	CHEMBL17551	=	IC50	nM	119700.0	CHEMBL2973	Homo sapiens	IC50	nM	119700.0
417317	17780779	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	CN(C)C(=O)Nc1ccc2[nH]ncc2c1		CHEMBL2023147	=	IC50	nM	36100.0	CHEMBL2973	Homo sapiens	IC50	nM	36100.0
417318	17780780	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023148	=	IC50	nM	61800.0	CHEMBL2973	Homo sapiens	IC50	nM	61800.0
417319	17780781	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL225282	=	IC50	nM	5500.0	CHEMBL2973	Homo sapiens	IC50	nM	5500.0
417320	17780782	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	CN(CCc1ccccc1)C(=O)Nc1ccc2[nH]ncc2c1		CHEMBL2023149	=	IC50	nM	7500.0	CHEMBL2973	Homo sapiens	IC50	nM	7500.0
417322	17780783	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCC(O)c1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023151	=	IC50	nM	1500.0	CHEMBL2973	Homo sapiens	IC50	nM	1500.0
417323	17780784	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	COc1ccc(CCNC(=O)Nc2ccc3[nH]ncc3c2)cc1		CHEMBL2023152	=	IC50	nM	800.0	CHEMBL2973	Homo sapiens	IC50	nM	800.0
417324	17780785	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCCc1ccc(Cl)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023153	=	IC50	nM	1100.0	CHEMBL2973	Homo sapiens	IC50	nM	1100.0
417325	17780786	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023154	=	IC50	nM	670.0	CHEMBL2973	Homo sapiens	IC50	nM	670.0
417326	17780787	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCCCc1ccccc1)Nc1ccc2[nH]ncc2c1		CHEMBL2023155	=	IC50	nM	1070.0	CHEMBL2973	Homo sapiens	IC50	nM	1070.0
417327	17780788	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCc1ccccc1)Nc1ccc(-c2ccncc2)cc1		CHEMBL2023156	=	IC50	nM	260.0	CHEMBL2973	Homo sapiens	IC50	nM	260.0
417328	17780789	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@@H](CO)c1ccccc1		CHEMBL2023157	=	IC50	nM	7520.0	CHEMBL2973	Homo sapiens	IC50	nM	7520.0
417329	17780790	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@H](CO)c1ccccc1		CHEMBL2023158	=	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
417330	17780791	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(NCCc1ccccc1)Nc1ccc(-c2ccncc2)cc1		CHEMBL2023159	=	IC50	nM	19800.0	CHEMBL2973	Homo sapiens	IC50	nM	19800.0
417331	17780792	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@@H](CO)Cc1ccccc1		CHEMBL2023160	=	IC50	nM	5360.0	CHEMBL2973	Homo sapiens	IC50	nM	5360.0
417332	17780793	CHEMBL3888819	FRET-Based Enzyme-Coupled Assay: A robust FRET-based, enzyme-coupled assay format, Z-Lyte® Kinase Assay Ser/Thr 13 Peptide Kit (Invitrogen, cat. PV3793), was employed in this study to monitor inhibition of ROCK1 (Invitrogen, cat. PV3691) and ROCK2 (Invitrogen, cat. PV3759) enzyme activities. Compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average IC50 values. The assay conditions were optimized to 15 μl of kinase reaction volume with 5 ng of enzyme in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reaction was incubated 1 hr. at room temperature in the presence of 1.5 μM of substrate with 12.5 μM of ATP (ROCK1 assay) or 2 μM of substrate with 50 μM of ATP (ROCK2 assay) in the presence of various concentrations of the compounds. The reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the unphosphorylated peptide as described by the manufacturer (Invitrogen, cat. PV3793). This was followed by excitation of coumarin at 400 nm resulting in emission at 445 nm and energy transfer to fluorescein and final emission at 520 nm. The substrate contains both coumarin and fluorescein and only uncleaved phosphorylated substrate will undergo FRET.	B	O=C(Nc1ccc(-c2ccncc2)cc1)N[C@H](CO)Cc1ccccc1		CHEMBL2023161	=	IC50	nM	32920.0	CHEMBL2973	Homo sapiens	IC50	nM	32920.0
439364	17799108	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3951271	=	IC50	nM	1.19	CHEMBL2973	Homo sapiens	IC50	nM	1.19
439365	17799109	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC2(c3ccccc3Cl)CC2)ccc1-c1cn[nH]c1		CHEMBL3923391	=	IC50	nM	4.73	CHEMBL2973	Homo sapiens	IC50	nM	4.73
439366	17799110	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3960736	=	IC50	nM	2.28	CHEMBL2973	Homo sapiens	IC50	nM	2.28
439367	17799111	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3984075	=	IC50	nM	8.99	CHEMBL2973	Homo sapiens	IC50	nM	8.99
439368	17799112	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3955445	=	IC50	nM	2.9	CHEMBL2973	Homo sapiens	IC50	nM	2.9
439369	17799113	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(O)c2)ccc1-c1cn[nH]c1		CHEMBL3986802	=	IC50	nM	0.85	CHEMBL2973	Homo sapiens	IC50	nM	0.85
439370	17799114	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3913336	=	IC50	nM	0.85	CHEMBL2973	Homo sapiens	IC50	nM	0.85
439371	17799115	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3928809	=	IC50	nM	0.85	CHEMBL2973	Homo sapiens	IC50	nM	0.85
439372	17799116	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2csc(-c3ccccc3)n2)ccc1-c1cn[nH]c1		CHEMBL3900840	=	IC50	nM	61.9	CHEMBL2973	Homo sapiens	IC50	nM	61.9
439373	17799117	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN2CCOCC2)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3956456	=	IC50	nM	44.5	CHEMBL2973	Homo sapiens	IC50	nM	44.5
439374	17799118	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(COC(=O)NC(C)(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3925445	=	IC50	nM	36.0	CHEMBL2973	Homo sapiens	IC50	nM	36.0
439375	17799119	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3955270	=	IC50	nM	1.89	CHEMBL2973	Homo sapiens	IC50	nM	1.89
439376	17799120	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN2CCN(C)CC2)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3980726	=	IC50	nM	77.1	CHEMBL2973	Homo sapiens	IC50	nM	77.1
439377	17799121	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN2CCCC2)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3943121	=	IC50	nM	86.4	CHEMBL2973	Homo sapiens	IC50	nM	86.4
439378	17799122	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccn2)ccc1-c1cn[nH]c1		CHEMBL3972689	=	IC50	nM	60.4	CHEMBL2973	Homo sapiens	IC50	nM	60.4
439379	17799123	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2nc3ccccc3s2)ccc1-c1cn[nH]c1		CHEMBL3906029	=	IC50	nM	438.0	CHEMBL2973	Homo sapiens	IC50	nM	438.0
439380	17799124	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(F)c2)ccc1-c1cn[nH]c1		CHEMBL3967386	=	IC50	nM	4.01	CHEMBL2973	Homo sapiens	IC50	nM	4.01
439381	17799125	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(-c3ccccc3)c2)ccc1-c1cn[nH]c1		CHEMBL3900611	=	IC50	nM	129.0	CHEMBL2973	Homo sapiens	IC50	nM	129.0
439382	17799126	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccnc2)ccc1-c1cn[nH]c1		CHEMBL3928583	=	IC50	nM	23.8	CHEMBL2973	Homo sapiens	IC50	nM	23.8
439383	17799127	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3891623	=	IC50	nM	2.24	CHEMBL2973	Homo sapiens	IC50	nM	2.24
439384	17799128	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccccc1CNC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1		CHEMBL3951573	=	IC50	nM	65.9	CHEMBL2973	Homo sapiens	IC50	nM	65.9
439385	17799129	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2OC(F)(F)F)ccc1-c1cn[nH]c1		CHEMBL3981137	=	IC50	nM	60.2	CHEMBL2973	Homo sapiens	IC50	nM	60.2
439386	17799130	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2C)ccc1-c1cn[nH]c1		CHEMBL3952342	=	IC50	nM	2.13	CHEMBL2973	Homo sapiens	IC50	nM	2.13
439387	17799131	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL3892048	=	IC50	nM	15.6	CHEMBL2973	Homo sapiens	IC50	nM	15.6
439388	17799132	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3966859	=	IC50	nM	2.65	CHEMBL2973	Homo sapiens	IC50	nM	2.65
439389	17799133	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2C(F)(F)F)ccc1-c1cn[nH]c1		CHEMBL3987039	=	IC50	nM	20.9	CHEMBL2973	Homo sapiens	IC50	nM	20.9
439390	17799134	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3910168	=	IC50	nM	2.6	CHEMBL2973	Homo sapiens	IC50	nM	2.6
439391	17799135	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(OC(F)(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3976301	=	IC50	nM	40.9	CHEMBL2973	Homo sapiens	IC50	nM	40.9
439392	17799136	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(Cl)c2Cl)ccc1-c1cn[nH]c1		CHEMBL3915532	=	IC50	nM	2.53	CHEMBL2973	Homo sapiens	IC50	nM	2.53
439393	17799137	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)(C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3916624	=	IC50	nM	129.0	CHEMBL2973	Homo sapiens	IC50	nM	129.0
439394	17799138	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2O)ccc1-c1cn[nH]c1		CHEMBL3986384	=	IC50	nM	5.62	CHEMBL2973	Homo sapiens	IC50	nM	5.62
439395	17799139	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(F)(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3952741	=	IC50	nM	11.5	CHEMBL2973	Homo sapiens	IC50	nM	11.5
439396	17799140	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2)ccc1-c1cn[nH]c1		CHEMBL3965421	=	IC50	nM	4.93	CHEMBL2973	Homo sapiens	IC50	nM	4.93
439397	17799141	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(Cl)c2)ccc1-c1cn[nH]c1		CHEMBL3987001	=	IC50	nM	49.7	CHEMBL2973	Homo sapiens	IC50	nM	49.7
439398	17799142	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3920786	=	IC50	nM	6.6	CHEMBL2973	Homo sapiens	IC50	nM	6.6
439399	17799143	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3963314	=	IC50	nM	10.5	CHEMBL2973	Homo sapiens	IC50	nM	10.5
439400	17799144	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2S(=O)(=O)CC(C)C)ccc1-c1cn[nH]c1		CHEMBL3926252	=	IC50	nM	1408.0	CHEMBL2973	Homo sapiens	IC50	nM	1408.0
439401	17799145	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc3c(c2)OCO3)ccc1-c1cn[nH]c1		CHEMBL3980727	=	IC50	nM	14.2	CHEMBL2973	Homo sapiens	IC50	nM	14.2
439402	17799146	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)c(C(F)(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3907073	=	IC50	nM	33.3	CHEMBL2973	Homo sapiens	IC50	nM	33.3
439403	17799147	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](C)[C@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3902021	=	IC50	nM	224.0	CHEMBL2973	Homo sapiens	IC50	nM	224.0
439404	17799148	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(F)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3969934	=	IC50	nM	2.54	CHEMBL2973	Homo sapiens	IC50	nM	2.54
439405	17799149	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)[C@@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3915358	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
439406	17799150	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3890863	=	IC50	nM	1.31	CHEMBL2973	Homo sapiens	IC50	nM	1.31
439407	17799151	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](C)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3934496	=	IC50	nM	52.5	CHEMBL2973	Homo sapiens	IC50	nM	52.5
439408	17799152	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Br)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3906535	=	IC50	nM	4.69	CHEMBL2973	Homo sapiens	IC50	nM	4.69
439409	17799153	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(OCC(C)C)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3929051	=	IC50	nM	786.0	CHEMBL2973	Homo sapiens	IC50	nM	786.0
439410	17799154	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2SCC(C)C)ccc1-c1cn[nH]c1		CHEMBL3894920	=	IC50	nM	1320.0	CHEMBL2973	Homo sapiens	IC50	nM	1320.0
439411	17799155	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Oc3ccccc3)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3920141	=	IC50	nM	1320.0	CHEMBL2973	Homo sapiens	IC50	nM	1320.0
439412	17799156	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3892122	=	IC50	nM	2.47	CHEMBL2973	Homo sapiens	IC50	nM	2.47
439413	17799157	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(F)c(OC)c2F)ccc1-c1cn[nH]c1		CHEMBL3951004	=	IC50	nM	16.7	CHEMBL2973	Homo sapiens	IC50	nM	16.7
439414	17799158	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)ccc(OC)c2F)ccc1-c1cn[nH]c1		CHEMBL3926788	=	IC50	nM	5.35	CHEMBL2973	Homo sapiens	IC50	nM	5.35
439415	17799159	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)cc(F)c2)ccc1-c1cn[nH]c1		CHEMBL3912625	=	IC50	nM	63.4	CHEMBL2973	Homo sapiens	IC50	nM	63.4
439416	17799160	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1ccccc1Cl		CHEMBL3914530	=	IC50	nM	6.2	CHEMBL2973	Homo sapiens	IC50	nM	6.2
439417	17799161	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3944065	=	IC50	nM	4.81	CHEMBL2973	Homo sapiens	IC50	nM	4.81
439418	17799162	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3907133	=	IC50	nM	1.13	CHEMBL2973	Homo sapiens	IC50	nM	1.13
439419	17799163	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3c[nH]nc3C)c(OC)c2)c1		CHEMBL3942539	=	IC50	nM	204.0	CHEMBL2973	Homo sapiens	IC50	nM	204.0
439420	17799164	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2Cl)ccc1-c1c[nH]nc1C		CHEMBL3941476	=	IC50	nM	101.0	CHEMBL2973	Homo sapiens	IC50	nM	101.0
439421	17799165	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL3967606	=	IC50	nM	2.28	CHEMBL2973	Homo sapiens	IC50	nM	2.28
439422	17799166	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(F)c2)c1		CHEMBL3928973	=	IC50	nM	18.9	CHEMBL2973	Homo sapiens	IC50	nM	18.9
439423	17799167	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2C)c1		CHEMBL4111347	=	IC50	nM	110.0	CHEMBL2973	Homo sapiens	IC50	nM	110.0
439424	17799168	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2S(C)(=O)=O)c1		CHEMBL4107460	=	IC50	nM	4590.0	CHEMBL2973	Homo sapiens	IC50	nM	4590.0
439425	17799169	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2F)c1		CHEMBL4110256	=	IC50	nM	8.87	CHEMBL2973	Homo sapiens	IC50	nM	8.87
439426	17799170	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CN(C)CCOc1cc(C(=O)NCc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3949659	=	IC50	nM	844.0	CHEMBL2973	Homo sapiens	IC50	nM	844.0
439427	17799171	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)O)c2)ccc1-c1cn[nH]c1		CHEMBL3921882	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
439428	17799172	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CNC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3958305	=	IC50	nM	0.85	CHEMBL2973	Homo sapiens	IC50	nM	0.85
439429	17799173	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)N3CCCC3)c2)ccc1-c1cn[nH]c1		CHEMBL3935094	=	IC50	nM	23.5	CHEMBL2973	Homo sapiens	IC50	nM	23.5
439430	17799174	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2cc(F)cc(F)c2)ccc1-c1cn[nH]c1		CHEMBL3934001	=	IC50	nM	9.29	CHEMBL2973	Homo sapiens	IC50	nM	9.29
439431	17799175	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H]2C[C@H]2c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3965294	=	IC50	nM	8.52	CHEMBL2973	Homo sapiens	IC50	nM	8.52
439432	17799176	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)ccc2F)ccc1-c1cn[nH]c1		CHEMBL3921599	=	IC50	nM	5.2	CHEMBL2973	Homo sapiens	IC50	nM	5.2
439433	17799177	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N(C)CCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3956876	=	IC50	nM	164.0	CHEMBL2973	Homo sapiens	IC50	nM	164.0
439434	17799178	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N(C)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3904808	=	IC50	nM	494.0	CHEMBL2973	Homo sapiens	IC50	nM	494.0
439435	17799179	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3936323	=	IC50	nM	1.48	CHEMBL2973	Homo sapiens	IC50	nM	1.48
439436	17799180	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL3901566	=	IC50	nM	2.69	CHEMBL2973	Homo sapiens	IC50	nM	2.69
439437	17799181	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccc3ccccc3c2)ccc1-c1cn[nH]c1		CHEMBL3916608	=	IC50	nM	9.18	CHEMBL2973	Homo sapiens	IC50	nM	9.18
439438	17799182	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)c(F)c(F)c2)ccc1-c1cn[nH]c1		CHEMBL3953239	=	IC50	nM	8.26	CHEMBL2973	Homo sapiens	IC50	nM	8.26
439439	17799183	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(Cl)ccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3922088	=	IC50	nM	2.2	CHEMBL2973	Homo sapiens	IC50	nM	2.2
439440	17799184	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc3nc(N)sc3c2)ccc1-c1cn[nH]c1		CHEMBL3911197	=	IC50	nM	401.0	CHEMBL2973	Homo sapiens	IC50	nM	401.0
439441	17799185	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(OC(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3943648	=	IC50	nM	3.94	CHEMBL2973	Homo sapiens	IC50	nM	3.94
439442	17799186	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(F)c(F)c2)ccc1-c1cn[nH]c1		CHEMBL3969590	=	IC50	nM	7.96	CHEMBL2973	Homo sapiens	IC50	nM	7.96
439443	17799187	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)ccc(C)c2F)ccc1-c1cn[nH]c1		CHEMBL3943471	=	IC50	nM	2.97	CHEMBL2973	Homo sapiens	IC50	nM	2.97
439444	17799188	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2cccc(CN3CCN(C)CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3936832	=	IC50	nM	28.3	CHEMBL2973	Homo sapiens	IC50	nM	28.3
439445	17799189	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)ccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3908876	=	IC50	nM	4.39	CHEMBL2973	Homo sapiens	IC50	nM	4.39
439446	17799190	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NC3(C)CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3920062	=	IC50	nM	1.14	CHEMBL2973	Homo sapiens	IC50	nM	1.14
439447	17799191	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4111337	=	IC50	nM	3.51	CHEMBL2973	Homo sapiens	IC50	nM	3.51
439448	17799192	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(CN(C)C)c2)ccc1-c1cn[nH]c1		CHEMBL3947868	=	IC50	nM	474.0	CHEMBL2973	Homo sapiens	IC50	nM	474.0
439449	17799193	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc3[nH]ncc23)ccc1-c1cn[nH]c1		CHEMBL3936240	=	IC50	nM	7.99	CHEMBL2973	Homo sapiens	IC50	nM	7.99
439450	17799194	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(N3CCCC3)c2)ccc1-c1cn[nH]c1		CHEMBL3974586	=	IC50	nM	130.0	CHEMBL2973	Homo sapiens	IC50	nM	130.0
439451	17799195	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)ccc(F)c2Cl)ccc1-c1cn[nH]c1		CHEMBL3948586	=	IC50	nM	3.99	CHEMBL2973	Homo sapiens	IC50	nM	3.99
439452	17799196	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)cc(F)cc2F)ccc1-c1cn[nH]c1		CHEMBL3985933	=	IC50	nM	11.1	CHEMBL2973	Homo sapiens	IC50	nM	11.1
439453	17799197	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3957255	=	IC50	nM	6.4	CHEMBL2973	Homo sapiens	IC50	nM	6.4
439454	17799198	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cc(F)cc(F)c2F)ccc1-c1cn[nH]c1		CHEMBL3973474	=	IC50	nM	7.66	CHEMBL2973	Homo sapiens	IC50	nM	7.66
439455	17799199	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)C[C@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1ccccc1		CHEMBL3902479	=	IC50	nM	21.4	CHEMBL2973	Homo sapiens	IC50	nM	21.4
439456	17799200	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3914458	=	IC50	nM	27.6	CHEMBL2973	Homo sapiens	IC50	nM	27.6
439457	17799201	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(NS(C)(=O)=O)c2)ccc1-c1cn[nH]c1		CHEMBL3965403	=	IC50	nM	6.33	CHEMBL2973	Homo sapiens	IC50	nM	6.33
439458	17799202	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(N(C)C)c2)ccc1-c1cn[nH]c1		CHEMBL3957117	=	IC50	nM	47.6	CHEMBL2973	Homo sapiens	IC50	nM	47.6
439459	17799203	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)ccc1F		CHEMBL3985775	=	IC50	nM	2.41	CHEMBL2973	Homo sapiens	IC50	nM	2.41
439460	17799204	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)ccc(F)c2F)ccc1-c1cn[nH]c1		CHEMBL3965554	=	IC50	nM	2.46	CHEMBL2973	Homo sapiens	IC50	nM	2.46
439461	17799205	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3896978	=	IC50	nM	2.95	CHEMBL2973	Homo sapiens	IC50	nM	2.95
439462	17799206	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(Cl)cc2F)ccc1-c1cn[nH]c1		CHEMBL3938495	=	IC50	nM	1.36	CHEMBL2973	Homo sapiens	IC50	nM	1.36
439463	17799207	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(N(C)C(C)=O)c2)ccc1-c1cn[nH]c1		CHEMBL3968042	=	IC50	nM	299.0	CHEMBL2973	Homo sapiens	IC50	nM	299.0
439464	17799208	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccc3c(c2)OCCO3)ccc1-c1cn[nH]c1		CHEMBL3973591	=	IC50	nM	189.0	CHEMBL2973	Homo sapiens	IC50	nM	189.0
439465	17799209	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC2=CCC3NC(=O)NC3=C2)ccc1-c1cn[nH]c1		CHEMBL3908696	=	IC50	nM	662.0	CHEMBL2973	Homo sapiens	IC50	nM	662.0
439466	17799210	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(Cl)c2)c1		CHEMBL4109840	=	IC50	nM	0.67	CHEMBL2973	Homo sapiens	IC50	nM	0.67
439467	17799211	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc3sccc3c2)ccc1-c1cn[nH]c1		CHEMBL3964208	=	IC50	nM	9.44	CHEMBL2973	Homo sapiens	IC50	nM	9.44
439468	17799212	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3960608	=	IC50	nM	3.59	CHEMBL2973	Homo sapiens	IC50	nM	3.59
439469	17799213	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](C)c2ccc3c(c2)CCO3)ccc1-c1cn[nH]c1		CHEMBL4110015	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	nM	27.0
439470	17799214	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL4111655	=	IC50	nM	1.89	CHEMBL2973	Homo sapiens	IC50	nM	1.89
439471	17799215	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL3934418	=	IC50	nM	2.61	CHEMBL2973	Homo sapiens	IC50	nM	2.61
439472	17799216	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2Cl)c1		CHEMBL4106851	=	IC50	nM	144.0	CHEMBL2973	Homo sapiens	IC50	nM	144.0
439473	17799217	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2F)c1		CHEMBL4111518	=	IC50	nM	1.03	CHEMBL2973	Homo sapiens	IC50	nM	1.03
439474	17799218	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)Cc2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL3969281	=	IC50	nM	21.2	CHEMBL2973	Homo sapiens	IC50	nM	21.2
439475	17799219	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CO)[C@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4108938	=	IC50	nM	2.72	CHEMBL2973	Homo sapiens	IC50	nM	2.72
439476	17799220	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC[C@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)[C@@H](O)c1ccccc1		CHEMBL3893663	=	IC50	nM	330.0	CHEMBL2973	Homo sapiens	IC50	nM	330.0
439477	17799221	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CCNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3965912	=	IC50	nM	59.6	CHEMBL2973	Homo sapiens	IC50	nM	59.6
439478	17799222	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](Cc2ccccc2)C(N)=O)ccc1-c1cn[nH]c1		CHEMBL3918124	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
439479	17799223	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(C2(NC(=O)c3ccc(-c4cn[nH]c4)c(OC)c3)CC2)c1		CHEMBL3978630	=	IC50	nM	17.9	CHEMBL2973	Homo sapiens	IC50	nM	17.9
439480	17799224	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3912670	=	IC50	nM	30.2	CHEMBL2973	Homo sapiens	IC50	nM	30.2
439481	17799225	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(C#N)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3903819	=	IC50	nM	27.7	CHEMBL2973	Homo sapiens	IC50	nM	27.7
439482	17799226	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N(C)C)ccc1-c1cn[nH]c1		CHEMBL3903654	=	IC50	nM	1010.0	CHEMBL2973	Homo sapiens	IC50	nM	1010.0
439483	17799227	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2cccc(C(F)(F)F)c2)ccc1-c1cn[nH]c1		CHEMBL3928122	=	IC50	nM	52.0	CHEMBL2973	Homo sapiens	IC50	nM	52.0
439484	17799228	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2ccc(C(F)(F)F)cc2)ccc1-c1cn[nH]c1		CHEMBL3963293	=	IC50	nM	78.1	CHEMBL2973	Homo sapiens	IC50	nM	78.1
439485	17799229	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(O)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3937215	=	IC50	nM	23.2	CHEMBL2973	Homo sapiens	IC50	nM	23.2
439486	17799230	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4113575	=	IC50	nM	41.6	CHEMBL2973	Homo sapiens	IC50	nM	41.6
439487	17799231	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCCc2cccc(O)c2)ccc1-c1cn[nH]c1		CHEMBL3976118	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
439488	17799232	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(c2ccccc2)N2CCCC2)ccc1-c1cn[nH]c1		CHEMBL3947236	=	IC50	nM	84.9	CHEMBL2973	Homo sapiens	IC50	nM	84.9
439489	17799233	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccccc1CCNC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1		CHEMBL3919941	=	IC50	nM	1349.0	CHEMBL2973	Homo sapiens	IC50	nM	1349.0
439490	17799234	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@@H](O)c2cccc(Cl)c2)ccc1-c1cn[nH]c1		CHEMBL4109715	=	IC50	nM	32.1	CHEMBL2973	Homo sapiens	IC50	nM	32.1
439491	17799235	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CO)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3896691	=	IC50	nM	5.7	CHEMBL2973	Homo sapiens	IC50	nM	5.7
439492	17799236	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4109752	=	IC50	nM	33.1	CHEMBL2973	Homo sapiens	IC50	nM	33.1
439493	17799237	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC[C@H](O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3898415	=	IC50	nM	33.4	CHEMBL2973	Homo sapiens	IC50	nM	33.4
439494	17799238	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(O)c2cccc(Cl)c2)ccc1-c1cn[nH]c1		CHEMBL3891207	=	IC50	nM	12.7	CHEMBL2973	Homo sapiens	IC50	nM	12.7
439495	17799239	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCC(c2ccccc2)N2CCNCC2)ccc1-c1cn[nH]c1		CHEMBL3919291	=	IC50	nM	103.0	CHEMBL2973	Homo sapiens	IC50	nM	103.0
439496	17799240	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](CO)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4112104	=	IC50	nM	34.0	CHEMBL2973	Homo sapiens	IC50	nM	34.0
439497	17799241	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1cc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)ccc1F		CHEMBL3928198	=	IC50	nM	0.82	CHEMBL2973	Homo sapiens	IC50	nM	0.82
439498	17799242	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)n1		CHEMBL3905628	=	IC50	nM	16.9	CHEMBL2973	Homo sapiens	IC50	nM	16.9
439499	17799243	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C(F)(F)F)c2)c1		CHEMBL4114533	=	IC50	nM	1.36	CHEMBL2973	Homo sapiens	IC50	nM	1.36
439500	17799244	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(Cn2ccnn2)c1)c1ccccc1		CHEMBL4111045	=	IC50	nM	1896.0	CHEMBL2973	Homo sapiens	IC50	nM	1896.0
439501	17799245	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C#N)c2)ccc1-c1cn[nH]c1		CHEMBL3914478	=	IC50	nM	8.24	CHEMBL2973	Homo sapiens	IC50	nM	8.24
439502	17799246	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3898965	=	IC50	nM	47.2	CHEMBL2973	Homo sapiens	IC50	nM	47.2
439503	17799247	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3898965	=	IC50	nM	0.83	CHEMBL2973	Homo sapiens	IC50	nM	0.83
439504	17799248	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3946084	=	IC50	nM	1.01	CHEMBL2973	Homo sapiens	IC50	nM	1.01
439505	17799249	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3946084	=	IC50	nM	43.3	CHEMBL2973	Homo sapiens	IC50	nM	43.3
439506	17799250	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(C#N)cc2)ccc1-c1cn[nH]c1		CHEMBL3953311	=	IC50	nM	82.5	CHEMBL2973	Homo sapiens	IC50	nM	82.5
439507	17799251	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(C#N)c2)c1		CHEMBL3937334	=	IC50	nM	6.74	CHEMBL2973	Homo sapiens	IC50	nM	6.74
439508	17799252	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3957255	=	IC50	nM	282.0	CHEMBL2973	Homo sapiens	IC50	nM	282.0
439509	17799253	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3957255	=	IC50	nM	2.17	CHEMBL2973	Homo sapiens	IC50	nM	2.17
439510	17799254	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OC)c1		CHEMBL3950642	=	IC50	nM	5.09	CHEMBL2973	Homo sapiens	IC50	nM	5.09
439511	17799255	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(CNC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL3922917	=	IC50	nM	51.2	CHEMBL2973	Homo sapiens	IC50	nM	51.2
439512	17799256	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2ccc(F)cc2Cl)ccc1-c1cn[nH]c1		CHEMBL3982461	=	IC50	nM	11.6	CHEMBL2973	Homo sapiens	IC50	nM	11.6
439513	17799257	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4108570	=	IC50	nM	18.9	CHEMBL2973	Homo sapiens	IC50	nM	18.9
439514	17799258	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3921203	=	IC50	nM	9.83	CHEMBL2973	Homo sapiens	IC50	nM	9.83
439515	17799259	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OC)c1		CHEMBL3950642	=	IC50	nM	627.0	CHEMBL2973	Homo sapiens	IC50	nM	627.0
439516	17799260	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c(C)n[nH]c3C)c(C)c2)c1		CHEMBL4110660	=	IC50	nM	415.0	CHEMBL2973	Homo sapiens	IC50	nM	415.0
439517	17799261	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OCC(C)(C)O)c1)c1ccccc1		CHEMBL4111265	=	IC50	nM	452.0	CHEMBL2973	Homo sapiens	IC50	nM	452.0
439518	17799262	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C)c1)c1ccccc1		CHEMBL4113955	=	IC50	nM	70.2	CHEMBL2973	Homo sapiens	IC50	nM	70.2
439519	17799263	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC(F)F)c1)c1ccccc1		CHEMBL4108218	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
439520	17799264	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1ccccc1		CHEMBL4112614	=	IC50	nM	3.94	CHEMBL2973	Homo sapiens	IC50	nM	3.94
439521	17799265	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3965274	=	IC50	nM	1.28	CHEMBL2973	Homo sapiens	IC50	nM	1.28
439522	17799266	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2cccc(O)n2)ccc1-c1cn[nH]c1		CHEMBL3965517	=	IC50	nM	6.76	CHEMBL2973	Homo sapiens	IC50	nM	6.76
439523	17799267	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(N[C@H](CO)c1ccccc1)c1ccc(-c2cn[nH]c2)c(OC(F)F)c1		CHEMBL4107796	=	IC50	nM	6.94	CHEMBL2973	Homo sapiens	IC50	nM	6.94
439524	17799268	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)cc2CO)c1		CHEMBL3976502	=	IC50	nM	185.0	CHEMBL2973	Homo sapiens	IC50	nM	185.0
439525	17799269	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CO)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3947211	=	IC50	nM	2.94	CHEMBL2973	Homo sapiens	IC50	nM	2.94
439526	17799270	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3965274	=	IC50	nM	7.43	CHEMBL2973	Homo sapiens	IC50	nM	7.43
439527	17799271	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC(F)F)c1)c1ccc(F)cc1		CHEMBL4114240	=	IC50	nM	7.49	CHEMBL2973	Homo sapiens	IC50	nM	7.49
439528	17799272	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3965274	=	IC50	nM	1.27	CHEMBL2973	Homo sapiens	IC50	nM	1.27
439529	17799273	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CO)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3947211	=	IC50	nM	2.17	CHEMBL2973	Homo sapiens	IC50	nM	2.17
439530	17799274	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CO)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3947211	=	IC50	nM	16.7	CHEMBL2973	Homo sapiens	IC50	nM	16.7
439531	17799275	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NC(C)c2cccc(O)n2)ccc1-c1cn[nH]c1		CHEMBL3975539	=	IC50	nM	46.7	CHEMBL2973	Homo sapiens	IC50	nM	46.7
439532	17799276	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCN(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3901295	=	IC50	nM	1.93	CHEMBL2973	Homo sapiens	IC50	nM	1.93
439533	17799277	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C=CC(NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1c(F)cccc1F		CHEMBL3939661	=	IC50	nM	10.5	CHEMBL2973	Homo sapiens	IC50	nM	10.5
439534	17799278	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3930451	=	IC50	nM	10.6	CHEMBL2973	Homo sapiens	IC50	nM	10.6
439535	17799279	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](C)c2cccc3ccccc23)ccc1-c1cn[nH]c1		CHEMBL3969951	=	IC50	nM	2.32	CHEMBL2973	Homo sapiens	IC50	nM	2.32
439536	17799280	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](C)c2ccccc2OC)ccc1-c1cn[nH]c1		CHEMBL3893355	=	IC50	nM	27.2	CHEMBL2973	Homo sapiens	IC50	nM	27.2
439537	17799281	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(c2ccccc2F)C(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL3962377	=	IC50	nM	12.3	CHEMBL2973	Homo sapiens	IC50	nM	12.3
439538	17799282	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](c2c(F)cccc2F)C(O)CO)ccc1-c1cn[nH]c1		CHEMBL4115278	=	IC50	nM	19.3	CHEMBL2973	Homo sapiens	IC50	nM	19.3
439539	17799283	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3920393	=	IC50	nM	3.69	CHEMBL2973	Homo sapiens	IC50	nM	3.69
439540	17799284	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3920393	=	IC50	nM	37.7	CHEMBL2973	Homo sapiens	IC50	nM	37.7
439541	17799285	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCN(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3901295	=	IC50	nM	31.9	CHEMBL2973	Homo sapiens	IC50	nM	31.9
439542	17799286	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CCN(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3901295	=	IC50	nM	7.75	CHEMBL2973	Homo sapiens	IC50	nM	7.75
439543	17799287	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCc1ccccc1CNC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1		CHEMBL3932451	=	IC50	nM	15.3	CHEMBL2973	Homo sapiens	IC50	nM	15.3
439544	17799288	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(c2ccccc2F)C(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL3962377	=	IC50	nM	165.0	CHEMBL2973	Homo sapiens	IC50	nM	165.0
439545	17799289	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(c2ccccc2F)C(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL3962377	=	IC50	nM	2.07	CHEMBL2973	Homo sapiens	IC50	nM	2.07
439546	17799290	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(O)c1)c1ccc(F)cc1		CHEMBL4113669	=	IC50	nM	7.68	CHEMBL2973	Homo sapiens	IC50	nM	7.68
439547	17799291	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2c[nH]nc2C)ccc1C(=O)NCc1c(F)cccc1Cl		CHEMBL3930850	=	IC50	nM	101.0	CHEMBL2973	Homo sapiens	IC50	nM	101.0
439548	17799292	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1c(F)cccc1Cl		CHEMBL3978005	=	IC50	nM	6.48	CHEMBL2973	Homo sapiens	IC50	nM	6.48
439549	17799293	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1cc(F)c(-c2cn[nH]c2)cc1F)c1ccccc1		CHEMBL4113186	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	nM	190.0
439550	17799294	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(Cc2ccccc2)C(C)=O)ccc1-c1cn[nH]c1		CHEMBL3982811	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
439551	17799295	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(S(C)(=O)=O)c1)c1ccccc1		CHEMBL4107114	=	IC50	nM	208.0	CHEMBL2973	Homo sapiens	IC50	nM	208.0
439552	17799296	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2c[nH]nc2C(F)(F)F)ccc1C(=O)NCc1c(F)cccc1Cl		CHEMBL3957411	=	IC50	nM	42.5	CHEMBL2973	Homo sapiens	IC50	nM	42.5
439553	17799297	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)c(F)cc1C(=O)N[C@H](C)c1ccccc1		CHEMBL4108065	=	IC50	nM	16.7	CHEMBL2973	Homo sapiens	IC50	nM	16.7
439554	17799298	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCOc1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4112775	=	IC50	nM	74.6	CHEMBL2973	Homo sapiens	IC50	nM	74.6
439555	17799299	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCOc1cc(C(=O)N[C@H](CO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4108225	=	IC50	nM	11.4	CHEMBL2973	Homo sapiens	IC50	nM	11.4
439556	17799300	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C#N)c1)c1ccc(F)cc1		CHEMBL4109237	=	IC50	nM	289.0	CHEMBL2973	Homo sapiens	IC50	nM	289.0
439557	17799301	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	N#Cc1cc(C(=O)N[C@H](CO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4109949	=	IC50	nM	152.0	CHEMBL2973	Homo sapiens	IC50	nM	152.0
439558	17799302	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCOc1cc(C(=O)N[C@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4106845	=	IC50	nM	16.0	CHEMBL2973	Homo sapiens	IC50	nM	16.0
439559	17799303	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(N[C@H](CO)c1c(F)cccc1F)c1ccc(-c2cn[nH]c2)c(OC(F)F)c1		CHEMBL4114203	=	IC50	nM	13.8	CHEMBL2973	Homo sapiens	IC50	nM	13.8
439560	17799304	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4110689	=	IC50	nM	17.6	CHEMBL2973	Homo sapiens	IC50	nM	17.6
439561	17799305	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	N#Cc1cc(C(=O)N[C@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4107876	=	IC50	nM	140.0	CHEMBL2973	Homo sapiens	IC50	nM	140.0
439562	17799306	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1c(-c2cn[nH]c2)ccc(C(=O)N[C@H](CO)c2c(F)cccc2F)c1F		CHEMBL4114195	=	IC50	nM	21.6	CHEMBL2973	Homo sapiens	IC50	nM	21.6
439563	17799307	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(N[C@H](CO)c1c(F)cccc1F)c1ccc(-c2cn[nH]c2)c(Cl)c1		CHEMBL4107563	=	IC50	nM	12.3	CHEMBL2973	Homo sapiens	IC50	nM	12.3
439564	17799308	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](CO)c1c(F)cccc1F		CHEMBL4109193	=	IC50	nM	11.5	CHEMBL2973	Homo sapiens	IC50	nM	11.5
439565	17799309	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(N[C@H](CO)c1c(F)cccc1F)c1ccc(-c2cn[nH]c2)c(C(F)(F)F)c1		CHEMBL4107473	=	IC50	nM	55.7	CHEMBL2973	Homo sapiens	IC50	nM	55.7
439566	17799310	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3899661	=	IC50	nM	6.66	CHEMBL2973	Homo sapiens	IC50	nM	6.66
439567	17799311	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](CO)Cc1ccccc1		CHEMBL3959761	=	IC50	nM	15.2	CHEMBL2973	Homo sapiens	IC50	nM	15.2
439568	17799312	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(CO)c1ccccc1F		CHEMBL3890689	=	IC50	nM	5.62	CHEMBL2973	Homo sapiens	IC50	nM	5.62
439569	17799313	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](C)c1ccc(F)cc1		CHEMBL4112558	=	IC50	nM	2.77	CHEMBL2973	Homo sapiens	IC50	nM	2.77
439570	17799314	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1c(F)cccc1F		CHEMBL3939886	=	IC50	nM	4.39	CHEMBL2973	Homo sapiens	IC50	nM	4.39
439571	17799315	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(CCN(C)C)c1ccccc1		CHEMBL3975905	=	IC50	nM	15.2	CHEMBL2973	Homo sapiens	IC50	nM	15.2
439572	17799316	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](CCO)c1ccccc1		CHEMBL4108559	=	IC50	nM	2.78	CHEMBL2973	Homo sapiens	IC50	nM	2.78
439573	17799317	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1ccc(F)cc1Cl		CHEMBL3904054	=	IC50	nM	1.75	CHEMBL2973	Homo sapiens	IC50	nM	1.75
439574	17799318	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	O=C(NCc1ccccc1)c1ccc(-c2cn[nH]c2)cc1CCO		CHEMBL3965615	=	IC50	nM	6510.0	CHEMBL2973	Homo sapiens	IC50	nM	6510.0
439575	17799319	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(c1ccccc1F)C(C)(C)O		CHEMBL3965594	=	IC50	nM	7.32	CHEMBL2973	Homo sapiens	IC50	nM	7.32
439576	17799320	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OC)c1		CHEMBL3950642	=	IC50	nM	5.16	CHEMBL2973	Homo sapiens	IC50	nM	5.16
439577	17799321	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)cc2N)c1		CHEMBL3960761	=	IC50	nM	32.3	CHEMBL2973	Homo sapiens	IC50	nM	32.3
439578	17799322	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](CO)[C@H](O)c1ccccc1		CHEMBL4106810	=	IC50	nM	23.4	CHEMBL2973	Homo sapiens	IC50	nM	23.4
439579	17799323	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CO)ccc1-c1cn[nH]c1		CHEMBL3928475	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
439580	17799324	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@@H](Cc1ccccc1)[C@H](O)CO		CHEMBL3896967	=	IC50	nM	12.9	CHEMBL2973	Homo sapiens	IC50	nM	12.9
439581	17799325	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(c1ccccc1F)C(C)(C)O		CHEMBL3965594	=	IC50	nM	6.52	CHEMBL2973	Homo sapiens	IC50	nM	6.52
439582	17799326	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(c1ccccc1F)C(C)(C)O		CHEMBL3965594	=	IC50	nM	201.0	CHEMBL2973	Homo sapiens	IC50	nM	201.0
439583	17799327	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Nc1cc(-c2cn[nH]c2)ccc1C(=O)NCCCc1ccccc1		CHEMBL3950431	=	IC50	nM	201.0	CHEMBL2973	Homo sapiens	IC50	nM	201.0
439584	17799328	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(C)c2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3926244	=	IC50	nM	3.43	CHEMBL2973	Homo sapiens	IC50	nM	3.43
439585	17799329	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC2(c3ccccc3)CCC2)ccc1-c1cn[nH]c1		CHEMBL3931254	=	IC50	nM	26.0	CHEMBL2973	Homo sapiens	IC50	nM	26.0
439586	17799330	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(C)c1c(F)cccc1Cl		CHEMBL3908187	=	IC50	nM	14.7	CHEMBL2973	Homo sapiens	IC50	nM	14.7
439587	17799331	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@@H](c2ccccc2)[C@H](O)CO)ccc1-c1cn[nH]c1		CHEMBL4107687	=	IC50	nM	1.98	CHEMBL2973	Homo sapiens	IC50	nM	1.98
439588	17799332	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@@H](c1ccccc1)[C@H](O)CO		CHEMBL4107177	=	IC50	nM	1.09	CHEMBL2973	Homo sapiens	IC50	nM	1.09
439589	17799333	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(C)c1c(F)cccc1F		CHEMBL3894616	=	IC50	nM	5.13	CHEMBL2973	Homo sapiens	IC50	nM	5.13
439590	17799334	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(C)c1c(F)cccc1F		CHEMBL3894616	=	IC50	nM	1200.0	CHEMBL2973	Homo sapiens	IC50	nM	1200.0
439591	17799335	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3899661	=	IC50	nM	3.05	CHEMBL2973	Homo sapiens	IC50	nM	3.05
439592	17799336	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3899661	=	IC50	nM	76.3	CHEMBL2973	Homo sapiens	IC50	nM	76.3
439593	17799337	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1cccc(S(N)(=O)=O)c1		CHEMBL3985681	=	IC50	nM	1.86	CHEMBL2973	Homo sapiens	IC50	nM	1.86
439594	17799338	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(S(N)(=O)=O)c2)ccc1-c1cn[nH]c1		CHEMBL3915928	=	IC50	nM	0.99	CHEMBL2973	Homo sapiens	IC50	nM	0.99
439595	17799339	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NC(CN)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3964418	=	IC50	nM	0.36	CHEMBL2973	Homo sapiens	IC50	nM	0.36
439596	17799340	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NC(CN)Cc1ccccc1		CHEMBL3956875	=	IC50	nM	2.53	CHEMBL2973	Homo sapiens	IC50	nM	2.53
439597	17799341	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NCC(C)(C)O)c2)ccc1-c1cn[nH]c1		CHEMBL3961024	=	IC50	nM	0.46	CHEMBL2973	Homo sapiens	IC50	nM	0.46
439598	17799342	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)N(C)C)c2)ccc1-c1cn[nH]c1		CHEMBL3980770	=	IC50	nM	93.7	CHEMBL2973	Homo sapiens	IC50	nM	93.7
439599	17799343	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NCC3CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3910152	=	IC50	nM	0.37	CHEMBL2973	Homo sapiens	IC50	nM	0.37
439600	17799344	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCNC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3956238	=	IC50	nM	0.4	CHEMBL2973	Homo sapiens	IC50	nM	0.4
439601	17799345	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NC3CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3947008	=	IC50	nM	0.32	CHEMBL2973	Homo sapiens	IC50	nM	0.32
439602	17799346	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2cccc(C(=O)O)c2)ccc1-c1cn[nH]c1		CHEMBL3985261	=	IC50	nM	11.5	CHEMBL2973	Homo sapiens	IC50	nM	11.5
439603	17799347	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCNC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL3986370	=	IC50	nM	2.61	CHEMBL2973	Homo sapiens	IC50	nM	2.61
439604	17799348	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCN1CCCC1CNC(=O)c1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3957651	=	IC50	nM	0.85	CHEMBL2973	Homo sapiens	IC50	nM	0.85
439605	17799349	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccc(F)c(C(=O)O)c2)ccc1-c1cn[nH]c1		CHEMBL3964232	=	IC50	nM	4.41	CHEMBL2973	Homo sapiens	IC50	nM	4.41
439606	17799350	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2cccc(C(=O)NCC3CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3977577	=	IC50	nM	0.5	CHEMBL2973	Homo sapiens	IC50	nM	0.5
439607	17799351	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2cccc(C(=O)NC3CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3939581	=	IC50	nM	0.86	CHEMBL2973	Homo sapiens	IC50	nM	0.86
439608	17799352	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)NCc2cccc(C(=O)NC[C@H]3CCCN3)c2)ccc1-c1cn[nH]c1		CHEMBL4107343	=	IC50	nM	0.71	CHEMBL2973	Homo sapiens	IC50	nM	0.71
439609	17799353	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)CNCC4)c2)ccc1-c1cn[nH]c1		CHEMBL3902471	=	IC50	nM	0.23	CHEMBL2973	Homo sapiens	IC50	nM	0.23
439610	17799354	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)Nc3nc4c(s3)CN(C)CC4)c2)ccc1-c1cn[nH]c1		CHEMBL3961538	=	IC50	nM	0.33	CHEMBL2973	Homo sapiens	IC50	nM	0.33
439611	17799355	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(=O)NC3CCN(C)CC3)c2)ccc1-c1cn[nH]c1		CHEMBL3949136	=	IC50	nM	0.19	CHEMBL2973	Homo sapiens	IC50	nM	0.19
439612	17799356	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)NCc1cccc(C(=O)NC2CCN(C)CC2)c1		CHEMBL3925017	=	IC50	nM	0.36	CHEMBL2973	Homo sapiens	IC50	nM	0.36
439613	17799357	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2cccc(C(N)=O)c2)ccc1-c1cn[nH]c1		CHEMBL3985772	=	IC50	nM	0.72	CHEMBL2973	Homo sapiens	IC50	nM	0.72
439614	17799358	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CC(=O)O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4113981	=	IC50	nM	33.7	CHEMBL2973	Homo sapiens	IC50	nM	33.7
439615	17799359	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CNC(=O)C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C)c1)c1ccccc1		CHEMBL4109757	=	IC50	nM	21.7	CHEMBL2973	Homo sapiens	IC50	nM	21.7
439616	17799360	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CC(=O)NCC(C)(C)O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4111334	=	IC50	nM	255.0	CHEMBL2973	Homo sapiens	IC50	nM	255.0
439617	17799361	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4114628	=	IC50	nM	0.28	CHEMBL2973	Homo sapiens	IC50	nM	0.28
439618	17799362	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(=O)NC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C)c1)c1ccccc1		CHEMBL4109115	=	IC50	nM	10.9	CHEMBL2973	Homo sapiens	IC50	nM	10.9
439619	17799363	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107839	=	IC50	nM	0.72	CHEMBL2973	Homo sapiens	IC50	nM	0.72
439620	17799364	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(C)(O)COc1cc(C(=O)N[C@H](CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107181	=	IC50	nM	52.8	CHEMBL2973	Homo sapiens	IC50	nM	52.8
439621	17799365	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	NC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OCCO)c1)c1ccccc1		CHEMBL4111527	=	IC50	nM	3.45	CHEMBL2973	Homo sapiens	IC50	nM	3.45
439622	17799366	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CNC(C)=O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4110514	=	IC50	nM	9.37	CHEMBL2973	Homo sapiens	IC50	nM	9.37
439623	17799367	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CNS(C)(=O)=O)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107374	=	IC50	nM	1.9	CHEMBL2973	Homo sapiens	IC50	nM	1.9
439624	17799368	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CNS(=O)(=O)C2CC2)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107417	=	IC50	nM	2.89	CHEMBL2973	Homo sapiens	IC50	nM	2.89
439625	17799369	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCS(=O)(=O)NC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1ccccc1		CHEMBL4113161	=	IC50	nM	36.0	CHEMBL2973	Homo sapiens	IC50	nM	36.0
439626	17799370	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1cc(C(=O)N[C@H](CN(C)C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4109081	=	IC50	nM	3.94	CHEMBL2973	Homo sapiens	IC50	nM	3.94
439627	17799371	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1c(F)cccc1F		CHEMBL4115593	=	IC50	nM	23.4	CHEMBL2973	Homo sapiens	IC50	nM	23.4
439628	17799372	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCNC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1)c1c(F)cccc1F		CHEMBL4107997	=	IC50	nM	1.29	CHEMBL2973	Homo sapiens	IC50	nM	1.29
439629	17799373	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N[C@H](CNC2CC2)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4110459	=	IC50	nM	4.53	CHEMBL2973	Homo sapiens	IC50	nM	4.53
439630	17799374	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)NCc2ccccc2C(C)C)ccc1-c1cn[nH]c1		CHEMBL3983535	=	IC50	nM	104.0	CHEMBL2973	Homo sapiens	IC50	nM	104.0
439631	17799375	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4114269	=	IC50	nM	48.1	CHEMBL2973	Homo sapiens	IC50	nM	48.1
439632	17799376	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@H](O)c1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4107581	=	IC50	nM	7.9	CHEMBL2973	Homo sapiens	IC50	nM	7.9
439633	17799377	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](O)c1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4111557	=	IC50	nM	1930.0	CHEMBL2973	Homo sapiens	IC50	nM	1930.0
439634	17799378	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(CO)c1)c1ccc(F)cc1		CHEMBL4113796	=	IC50	nM	75.0	CHEMBL2973	Homo sapiens	IC50	nM	75.0
439635	17799379	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(CO)c1)c1ccccc1		CHEMBL4114083	=	IC50	nM	58.8	CHEMBL2973	Homo sapiens	IC50	nM	58.8
439636	17799380	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4112045	=	IC50	nM	7.73	CHEMBL2973	Homo sapiens	IC50	nM	7.73
439637	17799381	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C(C)O)c1)c1ccccc1		CHEMBL4110038	=	IC50	nM	263.0	CHEMBL2973	Homo sapiens	IC50	nM	263.0
439638	17799382	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(NC(=O)c1ccc(-c2cn[nH]c2)c(C=O)c1)c1ccccc1F		CHEMBL3928424	=	IC50	nM	1420.0	CHEMBL2973	Homo sapiens	IC50	nM	1420.0
439639	17799383	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(NC(=O)c1ccc(-c2cn[nH]c2)c(C=O)c1)c1ccccc1F		CHEMBL3928424	=	IC50	nM	409.0	CHEMBL2973	Homo sapiens	IC50	nM	409.0
439640	17799384	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C(C)O)c1)c1ccccc1		CHEMBL4110038	=	IC50	nM	44.2	CHEMBL2973	Homo sapiens	IC50	nM	44.2
439641	17799385	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3890248	=	IC50	nM	1320.0	CHEMBL2973	Homo sapiens	IC50	nM	1320.0
439642	17799386	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NC(C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL3890248	=	IC50	nM	15.7	CHEMBL2973	Homo sapiens	IC50	nM	15.7
439643	17799387	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4112045	=	IC50	nM	443.0	CHEMBL2973	Homo sapiens	IC50	nM	443.0
439644	17799388	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4112045	=	IC50	nM	9.73	CHEMBL2973	Homo sapiens	IC50	nM	9.73
439645	17799389	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL4113260	=	IC50	nM	336.0	CHEMBL2973	Homo sapiens	IC50	nM	336.0
439646	17799390	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL4113260	=	IC50	nM	5.43	CHEMBL2973	Homo sapiens	IC50	nM	5.43
439647	17799391	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCC(O)c1cc(C(=O)NC(C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3930519	=	IC50	nM	183.0	CHEMBL2973	Homo sapiens	IC50	nM	183.0
439648	17799392	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4108515	=	IC50	nM	1480.0	CHEMBL2973	Homo sapiens	IC50	nM	1480.0
439649	17799393	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCC(O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4108515	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	nM	190.0
439650	17799394	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NC(C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3893554	=	IC50	nM	27.8	CHEMBL2973	Homo sapiens	IC50	nM	27.8
439651	17799395	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NC(C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL3893554	=	IC50	nM	446.0	CHEMBL2973	Homo sapiens	IC50	nM	446.0
439652	17799396	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3936330	=	IC50	nM	74.3	CHEMBL2973	Homo sapiens	IC50	nM	74.3
439653	17799397	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3936330	=	IC50	nM	1760.0	CHEMBL2973	Homo sapiens	IC50	nM	1760.0
439654	17799398	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)NCc2c(F)cccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3936330	=	IC50	nM	104.0	CHEMBL2973	Homo sapiens	IC50	nM	104.0
439655	17799399	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4114494	=	IC50	nM	1510.0	CHEMBL2973	Homo sapiens	IC50	nM	1510.0
439656	17799400	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(O)c1cc(C(=O)N[C@H](C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4114494	=	IC50	nM	16.16	CHEMBL2973	Homo sapiens	IC50	nM	16.16
439657	17799401	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(=O)c1cc(C(=O)N[C@H](C)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4107912	=	IC50	nM	613.0	CHEMBL2973	Homo sapiens	IC50	nM	613.0
439658	17799402	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4110398	=	IC50	nM	563.0	CHEMBL2973	Homo sapiens	IC50	nM	563.0
439659	17799403	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(N(C)C)c1)c1ccc(F)cc1		CHEMBL4111864	=	IC50	nM	54.6	CHEMBL2973	Homo sapiens	IC50	nM	54.6
439660	17799404	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CNc1cc(C(=O)N[C@H](C)c2ccc(F)cc2)ccc1-c1cn[nH]c1		CHEMBL4112708	=	IC50	nM	518.0	CHEMBL2973	Homo sapiens	IC50	nM	518.0
439661	17799405	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(C(=O)N(Cc2ccccc2F)CC(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL3902850	=	IC50	nM	667.0	CHEMBL2973	Homo sapiens	IC50	nM	667.0
439662	17799406	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CC(NC(=O)c1ccc(-c2cn[nH]c2)c(C(F)F)c1)c1ccccc1F		CHEMBL3899293	=	IC50	nM	53.27	CHEMBL2973	Homo sapiens	IC50	nM	53.27
439663	17799407	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C(F)F)c1)c1ccccc1F		CHEMBL4111492	=	IC50	nM	77.1	CHEMBL2973	Homo sapiens	IC50	nM	77.1
439664	17799408	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@H](NC(=O)c1ccc(-c2cn[nH]c2)c(C(F)F)c1)c1ccccc1F		CHEMBL3912987	=	IC50	nM	361.0	CHEMBL2973	Homo sapiens	IC50	nM	361.0
439665	17799409	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COC(=O)c1n[nH]cc1-c1ccc(C(=O)N[C@H](C)c2cccc(OC)c2)c(OC)c1		CHEMBL4109268	=	IC50	nM	69.6	CHEMBL2973	Homo sapiens	IC50	nM	69.6
439666	17799410	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3C#N)cc2OC)c1		CHEMBL4113511	=	IC50	nM	21.0	CHEMBL2973	Homo sapiens	IC50	nM	21.0
439667	17799411	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c(C)n[nH]c3C)cc2OC)c1		CHEMBL4107632	=	IC50	nM	24.5	CHEMBL2973	Homo sapiens	IC50	nM	24.5
439668	17799412	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OC)c1		CHEMBL4115244	=	IC50	nM	0.65	CHEMBL2973	Homo sapiens	IC50	nM	0.65
439669	17799413	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3CO)cc2OC)c1		CHEMBL4110004	=	IC50	nM	43.5	CHEMBL2973	Homo sapiens	IC50	nM	43.5
439670	17799414	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3C(C)O)cc2OC)c1		CHEMBL4111252	=	IC50	nM	205.0	CHEMBL2973	Homo sapiens	IC50	nM	205.0
439671	17799415	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OCCN(C)C)c1		CHEMBL4115302	=	IC50	nM	37.5	CHEMBL2973	Homo sapiens	IC50	nM	37.5
439672	17799416	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	Cc1n[nH]cc1-c1cc(OCCN(C)C)c(C(=O)N[C@H](C)c2ccccc2)cc1F		CHEMBL4107027	=	IC50	nM	771.0	CHEMBL2973	Homo sapiens	IC50	nM	771.0
439673	17799417	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	C[C@H](NC(=O)c1cc(F)c(-c2cn[nH]c2)cc1OCCN(C)C)c1ccccc1		CHEMBL3963276	=	IC50	nM	675.0	CHEMBL2973	Homo sapiens	IC50	nM	675.0
439674	17799418	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3c[nH]nc3C)cc2OCCN(C)C)c1		CHEMBL4114333	=	IC50	nM	34.79	CHEMBL2973	Homo sapiens	IC50	nM	34.79
439675	17799419	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cc(-c2cn[nH]c2)cc(F)c1C(=O)N[C@H](C)c1ccccc1		CHEMBL4112130	=	IC50	nM	1490.0	CHEMBL2973	Homo sapiens	IC50	nM	1490.0
439676	17799420	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	CCOc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](C)c1cccc(OC)c1		CHEMBL4111653	=	IC50	nM	1.6	CHEMBL2973	Homo sapiens	IC50	nM	1.6
439677	17799421	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COCCOc1cc(-c2cn[nH]c2)ccc1C(=O)N[C@H](C)c1cccc(OC)c1		CHEMBL4110456	=	IC50	nM	3.37	CHEMBL2973	Homo sapiens	IC50	nM	3.37
439678	17799422	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OCCO)c1		CHEMBL4114112	=	IC50	nM	2.31	CHEMBL2973	Homo sapiens	IC50	nM	2.31
439679	17799423	CHEMBL3889186	In Vitro Assay: The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20 mM MgCl2, 0.015% Brij-35, 4 mM DTT, 5 μM ATP and 1.5 μM peptide substrate (FITC-AHA-AKRRRLSSLRA-OH). Compounds were dissolved in DMSO so that the final concentration of DMSO was <2%, and the reaction was initiated with Rho kinase variants. After incubation, the reaction was terminated by the addition of EDTA and the phosphorylated and non-phosphorylated peptides separated using a LABCHIP® 3000 Reader (Caliper Life Sciences). Controls consisted of assays that did not contain compound, and backgrounds consisted of assays that contained enzyme and substrate but had EDTA from the beginning of the reaction to inhibit kinase activity.	B	COc1ccc(F)c(C(C)NC(=O)c2ccc(-c3cn[nH]c3)c(C(C)O)c2)c1		CHEMBL3950612	=	IC50	nM	10.9	CHEMBL2973	Homo sapiens	IC50	nM	10.9
Inactive	17935981	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935982	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935983	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935984	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935985	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935986	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935987	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935988	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935989	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935990	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935991	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935992	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935993	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935994	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935995	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935996	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935997	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935998	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17935999	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936000	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936001	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936002	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	=	Kd	nM	219.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	219.0
Inactive	17936003	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936004	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936005	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936006	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936007	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936008	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936009	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936010	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936011	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936012	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936013	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936014	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936015	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936016	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936017	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936018	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936019	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	Kd	nM	9.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	9.0
Inactive	17936020	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936021	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	=	Kd	nM	2402.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	2402.0
Inactive	17936022	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936023	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936024	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936025	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936026	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936027	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936028	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936029	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936030	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936031	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936032	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936033	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936034	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	=	Kd	nM	756.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	756.0
Inactive	17936035	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936036	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936037	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936038	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936039	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936040	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	956.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	956.0
Inactive	17936041	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936042	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936043	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936044	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936045	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936046	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936047	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936048	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936049	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936050	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936051	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936052	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936053	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	5947.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	5947.0
Inactive	17936054	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936055	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936056	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936057	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936058	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	Kd	nM	2277.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	2277.0
Inactive	17936059	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936060	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936061	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936062	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936063	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936064	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936065	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936066	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936067	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936068	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936069	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936070	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936071	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936072	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936073	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936074	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936075	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936076	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936077	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17936078	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	Kd	nM	2977.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	2977.0
Inactive	17936079	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936080	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936081	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936082	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936083	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936084	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936085	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936086	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936087	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936088	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936089	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936090	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936091	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936092	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936093	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936094	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936095	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936096	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936097	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936098	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936099	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936100	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	=	Kd	nM	3974.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	3974.0
Active	17936101	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	=	Kd	nM	1349.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	1349.0
Inactive	17936102	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936103	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936104	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936105	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936106	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936107	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936108	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936109	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	=	Kd	nM	26.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	26.0
Inactive	17936110	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936111	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936112	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936113	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936114	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936115	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936116	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936117	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936118	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936119	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936120	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936121	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Kd	nM	8885.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	8885.0
Inactive	17936122	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936123	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936124	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936125	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936126	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936127	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936128	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936129	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17936130	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	=	Kd	nM	58977.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	58977.0
Inactive	17936131	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936132	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936133	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936134	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936135	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936136	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	1096.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	1096.0
Inactive	17936137	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936138	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	=	Kd	nM	56066.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	56066.0
Inactive	17936139	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936140	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936141	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936142	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936143	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936144	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936145	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936146	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936147	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936148	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936149	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936150	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936151	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936152	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936153	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936154	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936155	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936156	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936157	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936158	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936159	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936160	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	=	Kd	nM	4733.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	4733.0
Inactive	17936161	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936162	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936163	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	=	Kd	nM	18265.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	18265.0
Inactive	17936164	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936165	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936166	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	Kd	nM	324.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	324.0
Inactive	17936167	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936168	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936169	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936170	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Kd	nM	943.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	943.0
Inactive	17936171	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936172	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936173	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936174	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936175	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936176	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936177	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936178	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936179	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936180	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936181	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936182	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936183	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936184	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936185	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936186	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936187	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936188	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936189	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936190	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936191	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936192	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936193	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	Kd	nM	83.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	83.0
Inactive	17936194	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936195	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936196	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936197	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936198	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936199	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936200	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936201	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Active	17936202	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	=	Kd	nM	16.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	16.0
Inactive	17936203	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936204	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936205	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936206	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936207	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936208	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936209	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936210	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936211	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936212	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936213	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936214	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936215	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936216	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936217	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936218	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936219	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936220	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936221	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936222	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17936223	CHEMBL3991871	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL2973	Homo sapiens	Kd apparent	nM	30000.0
	18024571	CHEMBL4006634	Inhibition of ROCK2 (unknown origin)	B	COc1ccc2nc(CNC(=O)c3ccc(-c4cnccc4OCC4CCNCC4)cc3)[nH]c2c1		CHEMBL4071823	=	IC50	nM	7800.0	CHEMBL2973	Homo sapiens	IC50	uM	7.8
	18024572	CHEMBL4006634	Inhibition of ROCK2 (unknown origin)	B	O=C(CNC(=O)c1ccc(-c2cnccc2OCC2CCNCC2)cc1)Nc1ccccc1		CHEMBL4093545	=	IC50	nM	360.0	CHEMBL2973	Homo sapiens	IC50	uM	0.36
	18031857	CHEMBL4007743	Inhibition of ROCK2 (unknown origin) after 60 mins by TR-FRET assay	B	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	IC50	nM	248.0	CHEMBL2973	Homo sapiens	IC50	uM	0.248
	18031858	CHEMBL4007743	Inhibition of ROCK2 (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccoc12		CHEMBL4078893	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	18031859	CHEMBL4007743	Inhibition of ROCK2 (unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	=	IC50	nM	6320.0	CHEMBL2973	Homo sapiens	IC50	uM	6.32
	18031860	CHEMBL4007743	Inhibition of ROCK2 (unknown origin) after 60 mins by TR-FRET assay	B	Cc1n[nH]c2cc(Nc3nc(NC4CC4)c4occc4n3)ccc12		CHEMBL4062803	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	18114836	CHEMBL4025366	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	92.0	CHEMBL2973	Homo sapiens	Activity	%	92.0
Not Active	18139174	CHEMBL4030455	Inhibition of ROCK-2 (unknown origin) at 10 uM	B	Cn1c([S+](C)[O-])nc(-c2ccc(F)cc2)c1-c1ccnc(N)c1		CHEMBL4075428		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	18141399	CHEMBL4031316	Inhibition of wild type human ROCK2 (M1 to T431 residues) expressed in mammalian cells assessed as residual activity at 1 uM by KINOMEscan assay relative to control	B	O=C(CCCCCCn1cc(-c2ncnc3[nH]ccc23)cn1)NO		CHEMBL4060201	=	Activity	%	29.0	CHEMBL2973	Homo sapiens	Activity	%	29.0
	18153037	CHEMBL4034479	Inhibition of ROCK2 Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	7.4	CHEMBL2973	Homo sapiens	INH	%	7.4
	18184487	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(CNc1ccccc1)N/N=C/c1ccncc1		CHEMBL3727506	=	IC50	nM	640.0	CHEMBL2973	Homo sapiens	IC50	nM	640.0
	18184488	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(CNc1ccccc1Cl)N/N=C/c1ccncc1		CHEMBL4103971	=	IC50	nM	2600.0	CHEMBL2973	Homo sapiens	IC50	nM	2600.0
	18184489	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(CNc1cccc(Cl)c1)N/N=C/c1ccncc1		CHEMBL3728445	=	IC50	nM	300.0	CHEMBL2973	Homo sapiens	IC50	nM	300.0
	18184490	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(CNc1ccc(Cl)cc1)N/N=C/c1ccncc1		CHEMBL3731521	=	IC50	nM	540.0	CHEMBL2973	Homo sapiens	IC50	nM	540.0
	18184491	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1ccccc1NCC(=O)N/N=C/c1ccncc1		CHEMBL3730059	=	IC50	nM	7400.0	CHEMBL2973	Homo sapiens	IC50	nM	7400.0
	18184492	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1cccc(NCC(=O)N/N=C/c2ccncc2)c1		CHEMBL3728772	=	IC50	nM	62.0	CHEMBL2973	Homo sapiens	IC50	nM	62.0
	18184493	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1ccc(NCC(=O)N/N=C/c2ccncc2)cc1		CHEMBL4101520	=	IC50	nM	3700.0	CHEMBL2973	Homo sapiens	IC50	nM	3700.0
	18184494	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(CNc1ccccc1)N/N=C1\CCCc2cnccc21		CHEMBL4100576	=	IC50	nM	1800.0	CHEMBL2973	Homo sapiens	IC50	nM	1800.0
	18184495	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1cccc(NCC(=O)N/N=C2\CCCc3cnccc32)c1		CHEMBL4082559	=	IC50	nM	390.0	CHEMBL2973	Homo sapiens	IC50	nM	390.0
	18184496	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CCOc1cccc(NCC(=O)N/N=C2\CCCc3cnccc32)c1		CHEMBL4063621	=	IC50	nM	5700.0	CHEMBL2973	Homo sapiens	IC50	nM	5700.0
	18184497	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(CNc1cccc(Oc2ccccc2)c1)N/N=C1\CCCc2cnccc21		CHEMBL4085247	=	IC50	nM	6200.0	CHEMBL2973	Homo sapiens	IC50	nM	6200.0
	18184498	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(CNc1cccc(OCc2ccccc2)c1)N/N=C1\CCCc2cnccc21		CHEMBL4072224	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	18184499	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(CNc1cccc(C(=O)N2CCOCC2)c1)N/N=C1\CCCc2cnccc21		CHEMBL4092989	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	18184500	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(CNc1cccc(C(=O)NCc2ccccc2)c1)N/N=C1\CCCc2cnccc21		CHEMBL4082713	=	IC50	nM	58.0	CHEMBL2973	Homo sapiens	IC50	nM	58.0
	18184501	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Clc1ccc(SCc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL4100707	=	IC50	nM	590.0	CHEMBL2973	Homo sapiens	IC50	nM	590.0
	18184502	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Clc1cccc(OCc2n[nH]c(-c3ccncc3)n2)c1		CHEMBL1563842	=	IC50	nM	1700.0	CHEMBL2973	Homo sapiens	IC50	nM	1700.0
	18184503	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Clc1ccc(NCc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL4062560	=	IC50	nM	94.0	CHEMBL2973	Homo sapiens	IC50	nM	94.0
	18184504	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Clc1ccc(CSc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL4098243	=	IC50	nM	1900.0	CHEMBL2973	Homo sapiens	IC50	nM	1900.0
	18184505	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Clc1ccc(CNc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL4071201	=	IC50	nM	270.0	CHEMBL2973	Homo sapiens	IC50	nM	270.0
	18184506	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(Nc1nc(-c2ccncc2)n[nH]1)c1ccc(Cl)cc1		CHEMBL4101676	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	18184507	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	c1ccc(CNCc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL4083675	=	IC50	nM	5100.0	CHEMBL2973	Homo sapiens	IC50	nM	5100.0
	18184508	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Clc1ccc(NCCc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL4063622	=	IC50	nM	900.0	CHEMBL2973	Homo sapiens	IC50	nM	900.0
	18184509	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	c1ccc(NCc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL4091451	=	IC50	nM	630.0	CHEMBL2973	Homo sapiens	IC50	nM	630.0
	18184510	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1ccccc1NCc1nc(-c2ccncc2)n[nH]1		CHEMBL4077117	=	IC50	nM	1800.0	CHEMBL2973	Homo sapiens	IC50	nM	1800.0
	18184511	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4062967	=	IC50	nM	720.0	CHEMBL2973	Homo sapiens	IC50	nM	720.0
	18184512	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1ccc(NCc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL4082714	=	IC50	nM	280.0	CHEMBL2973	Homo sapiens	IC50	nM	280.0
	18184513	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Clc1ccccc1NCc1nc(-c2ccncc2)n[nH]1		CHEMBL4060836	=	IC50	nM	1700.0	CHEMBL2973	Homo sapiens	IC50	nM	1700.0
	18184514	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Clc1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4093686	=	IC50	nM	380.0	CHEMBL2973	Homo sapiens	IC50	nM	380.0
	18184515	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	NS(=O)(=O)c1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4072686	=	IC50	nM	160.0	CHEMBL2973	Homo sapiens	IC50	nM	160.0
	18184516	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	NS(=O)(=O)c1ccc(NCc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL4100891	=	IC50	nM	360.0	CHEMBL2973	Homo sapiens	IC50	nM	360.0
	18184517	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	c1ccc(Oc2cccc(NCc3nc(-c4ccncc4)n[nH]3)c2)cc1		CHEMBL4074131	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	18184518	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	c1ccc(COc2cccc(NCc3nc(-c4ccncc4)n[nH]3)c2)cc1		CHEMBL4093174	=	IC50	nM	1400.0	CHEMBL2973	Homo sapiens	IC50	nM	1400.0
	18184519	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	c1ccc(CCOc2cccc(NCc3nc(-c4ccncc4)n[nH]3)c2)cc1		CHEMBL4065514	=	IC50	nM	2700.0	CHEMBL2973	Homo sapiens	IC50	nM	2700.0
	18184520	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	c1ccc(CSc2cccc(NCc3nc(-c4ccncc4)n[nH]3)c2)cc1		CHEMBL4064596	=	IC50	nM	1200.0	CHEMBL2973	Homo sapiens	IC50	nM	1200.0
	18184521	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=S(=O)(NCc1ccccc1)c1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4091566	=	IC50	nM	98.0	CHEMBL2973	Homo sapiens	IC50	nM	98.0
	18184522	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=S(=O)(Cc1ccccc1)c1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4075183	=	IC50	nM	1100.0	CHEMBL2973	Homo sapiens	IC50	nM	1100.0
	18184523	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CNC(=O)c1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4095595	=	IC50	nM	220.0	CHEMBL2973	Homo sapiens	IC50	nM	220.0
	18184524	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(Nc1ccccc1)c1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4076320	=	IC50	nM	31.0	CHEMBL2973	Homo sapiens	IC50	nM	31.0
	18184525	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4082775	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	nM	24.0
	18184526	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCCc1ccccc1)c1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4101739	=	IC50	nM	47.0	CHEMBL2973	Homo sapiens	IC50	nM	47.0
	18184527	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCCCc1ccccc1)c1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4075063	=	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
	18184528	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CN(Cc1ccccc1)C(=O)c1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4063713	=	IC50	nM	2200.0	CHEMBL2973	Homo sapiens	IC50	nM	2200.0
	18184529	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CC(=O)Nc1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4085317	=	IC50	nM	70.0	CHEMBL2973	Homo sapiens	IC50	nM	70.0
	18184530	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CC(=O)Nc1cc(NCc2nc(-c3ccncc3)n[nH]2)ccc1Cl		CHEMBL4072308	=	IC50	nM	74.0	CHEMBL2973	Homo sapiens	IC50	nM	74.0
	18184531	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(Cc1ccccc1)Nc1cc(NCc2nc(-c3ccncc3)n[nH]2)ccc1Cl		CHEMBL4093075	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	18184532	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)Nc1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1		CHEMBL4082805	=	IC50	nM	30.0	CHEMBL2973	Homo sapiens	IC50	nM	30.0
	18184533	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(Cc1cccc(NCc2nc(-c3ccncc3)n[nH]2)c1)NCc1ccccc1		CHEMBL4100779	=	IC50	nM	480.0	CHEMBL2973	Homo sapiens	IC50	nM	480.0
	18184534	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cc1cc(-c2n[nH]c(CNc3ccc(Cl)cc3)n2)ccn1		CHEMBL4090612	=	IC50	nM	7100.0	CHEMBL2973	Homo sapiens	IC50	nM	7100.0
	18184535	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cc1cnccc1-c1n[nH]c(CNc2cccc(C(=O)NCc3ccccc3)c2)n1		CHEMBL4062649	=	IC50	nM	94.0	CHEMBL2973	Homo sapiens	IC50	nM	94.0
	18184536	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2nc(-c3ccncc3CO)n[nH]2)c1		CHEMBL4098177	=	IC50	nM	540.0	CHEMBL2973	Homo sapiens	IC50	nM	540.0
	18184537	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	OCCc1cnccc1-c1n[nH]c(CNc2ccc(Cl)cc2)n1		CHEMBL4080151	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	18184538	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	NC(=O)OCc1cnccc1-c1n[nH]c(CNc2cccc(C(=O)NCc3ccccc3)c2)n1		CHEMBL4090462	=	IC50	nM	2300.0	CHEMBL2973	Homo sapiens	IC50	nM	2300.0
	18184539	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CC(=O)Nc1cc(-c2nnc(CNc3cccc(C(=O)NCc4ccccc4C(F)(F)F)c3)n2C)ccn1		CHEMBL4069432	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	18184540	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CNc1cc(-c2nnc(CNc3cccc(C(=O)NCc4c(F)cccc4F)c3)n2C)ccn1		CHEMBL4066027	=	IC50	nM	7400.0	CHEMBL2973	Homo sapiens	IC50	nM	7400.0
	18184541	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3c(F)cccc3F)c2)nnc1-c1ccnc(NCc2ccccc2)c1		CHEMBL4095742	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	18184542	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3c(F)cccc3F)c2)nnc1-c1ccnc(NCCc2ccccc2)c1		CHEMBL4059737	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	18184543	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3c(F)cccc3F)c2)nnc1-c1ccnc(NCCCc2ccccc2)c1		CHEMBL4088026	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	nM	10000.0
	18184544	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2cc(-c3ccncc3)n[nH]2)c1		CHEMBL4087117	=	IC50	nM	60.0	CHEMBL2973	Homo sapiens	IC50	nM	60.0
	18184545	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cc1c(-c2ccncc2)n[nH]c1CNc1cccc(C(=O)NCc2ccccc2)c1		CHEMBL4065690	=	IC50	nM	23.0	CHEMBL2973	Homo sapiens	IC50	nM	23.0
	18184546	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2nc(-c3ccncc3)c[nH]2)c1		CHEMBL4067877	=	IC50	nM	7.3	CHEMBL2973	Homo sapiens	IC50	nM	7.3
	18184547	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2cc(-c3ccncc3)on2)c1		CHEMBL4089087	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	18184548	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2cc(-c3ccncc3)no2)c1		CHEMBL4105466	=	IC50	nM	130.0	CHEMBL2973	Homo sapiens	IC50	nM	130.0
	18184549	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2c[nH]c(-c3ccncc3)n2)c1		CHEMBL4081217	=	IC50	nM	160.0	CHEMBL2973	Homo sapiens	IC50	nM	160.0
	18184550	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3ccccc3)c2)nnc1-c1ccncc1		CHEMBL4086619	=	IC50	nM	550.0	CHEMBL2973	Homo sapiens	IC50	nM	550.0
	18184551	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2cc(-c3ccncc3)c[nH]2)c1		CHEMBL4104512	=	IC50	nM	52.0	CHEMBL2973	Homo sapiens	IC50	nM	52.0
	18184552	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2ccn(-c3ccncc3)c2)c1		CHEMBL4078768	=	IC50	nM	340.0	CHEMBL2973	Homo sapiens	IC50	nM	340.0
	18184553	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2nnc(-c3ccncc3)o2)c1		CHEMBL4096791	=	IC50	nM	320.0	CHEMBL2973	Homo sapiens	IC50	nM	320.0
	18184554	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2nc(-c3ccncc3)no2)c1		CHEMBL4082173	=	IC50	nM	350.0	CHEMBL2973	Homo sapiens	IC50	nM	350.0
	18184555	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2nc(-c3ccncc3)cs2)c1		CHEMBL4100175	=	IC50	nM	22.0	CHEMBL2973	Homo sapiens	IC50	nM	22.0
	18184556	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2csc(-c3ccncc3)n2)c1		CHEMBL4072362	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	nM	120.0
	18184557	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2[nH]nc(-c3ccncc3)c2-c2ccccc2)c1		CHEMBL4099309	=	IC50	nM	170.0	CHEMBL2973	Homo sapiens	IC50	nM	170.0
	18184558	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1ccc(CNC(=O)c2cccc(NCc3nnc(-c4ccncc4)[nH]3)c2)cc1		CHEMBL4082853	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	nM	27.0
	18184559	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1cccc(CNC(=O)c2cccc(NCc3nnc(-c4ccncc4)[nH]3)c2)c1		CHEMBL4060973	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
	18184560	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1ccccc1CNC(=O)c1cccc(NCc2nnc(-c3ccncc3)[nH]2)c1		CHEMBL4095659	=	IC50	nM	85.0	CHEMBL2973	Homo sapiens	IC50	nM	85.0
	18184561	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1Cl)c1cccc(NCc2nnc(-c3ccncc3)[nH]2)c1		CHEMBL4077447	=	IC50	nM	50.0	CHEMBL2973	Homo sapiens	IC50	nM	50.0
	18184562	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3ccc(C(F)(F)F)cc3)c2)nnc1-c1ccncc1		CHEMBL4063774	=	IC50	nM	620.0	CHEMBL2973	Homo sapiens	IC50	nM	620.0
	18184563	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3cccc(C(F)(F)F)c3)c2)nnc1-c1ccncc1		CHEMBL4091573	=	IC50	nM	530.0	CHEMBL2973	Homo sapiens	IC50	nM	530.0
	18184564	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3ccccc3C(F)(F)F)c2)nnc1-c1ccncc1		CHEMBL1738877	=	IC50	nM	1400.0	CHEMBL2973	Homo sapiens	IC50	nM	1400.0
	18184565	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COc1ccccc1CNC(=O)c1cccc(NCc2nnc(-c3ccncc3)n2C)c1		CHEMBL4075992	=	IC50	nM	1600.0	CHEMBL2973	Homo sapiens	IC50	nM	1600.0
	18184566	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3ccccc3Cl)c2)nnc1-c1ccncc1		CHEMBL4061438	=	IC50	nM	1600.0	CHEMBL2973	Homo sapiens	IC50	nM	1600.0
	18184567	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CCn1c(CNc2cccc(C(=O)NCc3ccccc3)c2)nnc1-c1ccncc1		CHEMBL4083276	=	IC50	nM	76.0	CHEMBL2973	Homo sapiens	IC50	nM	76.0
	18184568	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CCCn1c(CNc2cccc(C(=O)NCc3ccccc3)c2)nnc1-c1ccncc1		CHEMBL4070100	=	IC50	nM	110.0	CHEMBL2973	Homo sapiens	IC50	nM	110.0
	18184569	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CC(C)n1c(CNc2cccc(C(=O)NCc3ccccc3)c2)nnc1-c1ccncc1		CHEMBL4091067	=	IC50	nM	260.0	CHEMBL2973	Homo sapiens	IC50	nM	260.0
	18184570	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1)c1cccc(NCc2nnc(-c3ccncc3)n2Cc2ccccc2)c1		CHEMBL4091972	=	IC50	nM	3200.0	CHEMBL2973	Homo sapiens	IC50	nM	3200.0
	18184571	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	COCCn1c(CNc2cccc(C(=O)NCc3ccccc3)c2)nnc1-c1ccncc1		CHEMBL4064232	=	IC50	nM	320.0	CHEMBL2973	Homo sapiens	IC50	nM	320.0
	18184572	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1C(F)(F)F)c1cccc(NCc2nnc(-c3ccncc3)n2CCO)c1		CHEMBL4071398	=	IC50	nM	320.0	CHEMBL2973	Homo sapiens	IC50	nM	320.0
	18184573	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1ccccc1C(F)(F)F)c1cccc(NCc2nnc3n2CCOc2cnccc2-3)c1		CHEMBL4072828	=	IC50	nM	49.0	CHEMBL2973	Homo sapiens	IC50	nM	49.0
	18184574	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	O=C(NCc1c(F)cccc1F)c1cccc(NCc2nnc3n2CCOc2cnccc2-3)c1		CHEMBL4073882	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	nM	190.0
	18184575	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3ccccc3C(F)(F)F)c2)nnc1-c1ccncn1		CHEMBL4094447	=	IC50	nM	720.0	CHEMBL2973	Homo sapiens	IC50	nM	720.0
	18184576	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	Cn1c(CNc2cccc(C(=O)NCc3c(F)cccc3F)c2)nnc1-c1ccncn1		CHEMBL4103972	=	IC50	nM	1900.0	CHEMBL2973	Homo sapiens	IC50	nM	1900.0
	18184577	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CCCn1c(CNc2cccc(C(=O)NCc3ccccc3C(F)(F)F)c2)nnc1-c1ccncn1		CHEMBL4086046	=	IC50	nM	140.0	CHEMBL2973	Homo sapiens	IC50	nM	140.0
	18184578	CHEMBL4040374	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 553 residues) expressed in baculovirus expression system using STK 2-biotin as substrate measured after 60 mins by HTRF/TR-FRET assay	B	CCCn1c(CNc2cccc(C(=O)NCc3c(F)cccc3F)c2)nnc1-c1ccncn1		CHEMBL1738878	=	IC50	nM	190.0	CHEMBL2973	Homo sapiens	IC50	nM	190.0
	18203890	CHEMBL4044177	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	18232136	CHEMBL4050367	Inhibition of human ROCK2 assessed as residual activity at 1 uM in presence of [33P]ATP by filter binding assay relative to control	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Activity	%	90.0	CHEMBL2973	Homo sapiens	Activity	%	90.0
	18248621	CHEMBL4053904	Inhibition of ROCK2 (unknown origin) at 1 uM relative to control	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4104658	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	18253206	CHEMBL4054886	Inhibition of Rho-associated protein kinase 2 (unknown origin)	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	IC50	nM	43.0	CHEMBL2973	Homo sapiens	IC50	nM	43.0
	18253221	CHEMBL4054894	Inhibition of human ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by KINOMEscan assay relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	3.6	CHEMBL2973	Homo sapiens	Activity	%	3.6
	18253222	CHEMBL4054894	Inhibition of human ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by KINOMEscan assay relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	18.0	CHEMBL2973	Homo sapiens	Activity	%	18.0
	18265796	CHEMBL4057246	Inhibition of ROCK2 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	0.7	CHEMBL2973	Homo sapiens	INH	%	0.7
	18265994	CHEMBL4057444	Inhibition of ROCK2 (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	8.7	CHEMBL2973	Homo sapiens	INH	%	8.7
	18266177	CHEMBL4057627	Inhibition of ROCK2 (unknown origin) at 0.078 uM relative to control	B	COC(=O)Nc1noc2cc(-c3c(-c4ccccn4)n[nH]c3C)ccc12		CHEMBL4066592	=	Inhibition	%	-2.0	CHEMBL2973	Homo sapiens	INH	%	-2.0
	18282205	CHEMBL4120160	Inhibition of recombinant N-terminal GST-tagged human ROCK2 catalytic domain (1 to 552 residues) expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	7.2	CHEMBL2973	Homo sapiens	INH	%	7.2
	18282524	CHEMBL4120160	Inhibition of recombinant N-terminal GST-tagged human ROCK2 catalytic domain (1 to 552 residues) expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	-7.5	CHEMBL2973	Homo sapiens	INH	%	-7.5
	18282718	CHEMBL4120303	Inhibition of ROCK2 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	0.7	CHEMBL2973	Homo sapiens	INH	%	0.7
	18282945	CHEMBL4120530	Inhibition of ROCK2 (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	-1.0	CHEMBL2973	Homo sapiens	INH	%	-1.0
	18283118	CHEMBL4120703	Inhibition of ROCK2 (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	-3.0	CHEMBL2973	Homo sapiens	INH	%	-3.0
	18288059	CHEMBL4121775	Inhibition of histidine-tagged human recombinant ROCK2 (11 to 552 residues) expressed in insect cells using RFARKGSLRQKNV substrate incubated for 60 mins measured at apparent ATP Km level by kinase ADP-FP assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(-c5ccc(F)c(C(F)(F)F)c5)cn4CCN4CCCC4)CC3)c21		CHEMBL4128457	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	uM	20.0
	18288060	CHEMBL4121775	Inhibition of histidine-tagged human recombinant ROCK2 (11 to 552 residues) expressed in insect cells using RFARKGSLRQKNV substrate incubated for 60 mins measured at apparent ATP Km level by kinase ADP-FP assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(C(F)(F)F)cn4CCN4CCCC4)CC3)c21		CHEMBL4129817	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	uM	20.0
	18288061	CHEMBL4121775	Inhibition of histidine-tagged human recombinant ROCK2 (11 to 552 residues) expressed in insect cells using RFARKGSLRQKNV substrate incubated for 60 mins measured at apparent ATP Km level by kinase ADP-FP assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(C5CCOCC5)cn4CCN4CCCC4)CC3)c21		CHEMBL4126067	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	uM	20.0
	18288062	CHEMBL4121775	Inhibition of histidine-tagged human recombinant ROCK2 (11 to 552 residues) expressed in insect cells using RFARKGSLRQKNV substrate incubated for 60 mins measured at apparent ATP Km level by kinase ADP-FP assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(CCC(F)(F)F)cn4CCN4CCCC4)CC3)c21		CHEMBL4129379	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	uM	20.0
	18376086	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	uM	0.009
	18376087	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	CC(/C=C/C1CC1)=C\[C@H]1[C@H](O)[C@@](C)(O)[C@H]2[C@@H]3O[C@@H]3CCN12		CHEMBL4172688	>	IC50	nM	100000.0	CHEMBL2973	Homo sapiens	IC50	uM	100.0
	18376088	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	C/C(=C/C=C/CCO)C[C@H]1[C@H](O)[C@@](C)(O)[C@H]2[C@H](O)[C@@H](Cl)CCN12		CHEMBL4176366	=	IC50	nM	39000.0	CHEMBL2973	Homo sapiens	IC50	uM	39.0
	18376089	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	C/C(=C\C=C\CCO)C[C@H]1[C@H](O)[C@@](C)(O)[C@H]2[C@H](O)[C@@H](Cl)CCN12		CHEMBL4165754	=	IC50	nM	42000.0	CHEMBL2973	Homo sapiens	IC50	uM	42.0
	18376090	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	C/C(=C\C=C\CCO)C[C@H]1[C@H](O)[C@@](C)(O)[C@H]2CCCCN12		CHEMBL4171044	>	IC50	nM	100000.0	CHEMBL2973	Homo sapiens	IC50	uM	100.0
	18376091	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	CC(/C=C/C1CC1)=C\[C@H]1[C@H](O)[C@@](C)(O)c2c(O)ccc[n+]21		CHEMBL4160438	=	IC50	nM	27000.0	CHEMBL2973	Homo sapiens	IC50	uM	27.0
	18376092	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	CC(/C=C/C1CC1)=C\[C@H]1[C@H](O)[C@@](C)(O)c2cccc[n+]21		CHEMBL4174482	>	IC50	nM	100000.0	CHEMBL2973	Homo sapiens	IC50	uM	100.0
	18376093	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	CC(/C=C/C1CC1)=C\[C@H]1[C@H](O)[C@@](C)(O)[C@H]2[C@H](O)[C@@H](Cl)CCN12		CHEMBL4163816	>	IC50	nM	100000.0	CHEMBL2973	Homo sapiens	IC50	uM	100.0
	18376094	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	CC(/C=C/C1CC1)=C\[C@H]1[C@H](O)[C@@](C)(O)[C@H]2[C@H](O)[C@@H](O)CCN12		CHEMBL4159348	=	IC50	nM	7000.0	CHEMBL2973	Homo sapiens	IC50	uM	7.0
	18376095	CHEMBL4144661	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	CC(/C=C/C1CC1)=C\[C@H]1[C@H](O)[C@@](C)(O)[C@H]2CCCCN12		CHEMBL4167272	>	IC50	nM	100000.0	CHEMBL2973	Homo sapiens	IC50	uM	100.0
	18434150	CHEMBL4156132	Inhibition of recombinant human N-terminal GST-tagged ROCK2 cytoplasmic domain (1 to 552 residues) expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2sc(-c3ccc(O)cc3)cc12)c1ccccc1		CHEMBL4177361	=	Inhibition	%	2.0	CHEMBL2973	Homo sapiens	INH	%	2.0
	18434194	CHEMBL4156132	Inhibition of recombinant human N-terminal GST-tagged ROCK2 cytoplasmic domain (1 to 552 residues) expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CCC(=O)Nc1ccc(-c2c[nH]c3ncnc(N[C@H](C)c4ccccc4)c23)cc1		CHEMBL4167749	=	Inhibition	%	6.0	CHEMBL2973	Homo sapiens	INH	%	6.0
	18434254	CHEMBL4156132	Inhibition of recombinant human N-terminal GST-tagged ROCK2 cytoplasmic domain (1 to 552 residues) expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CN(C)CCn1cc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL4159505	=	Inhibition	%	33.0	CHEMBL2973	Homo sapiens	INH	%	33.0
	18434326	CHEMBL4156132	Inhibition of recombinant human N-terminal GST-tagged ROCK2 cytoplasmic domain (1 to 552 residues) expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1		CHEMBL4175024	=	Inhibition	%	6.0	CHEMBL2973	Homo sapiens	INH	%	6.0
	18440432	CHEMBL4157256	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	18449848	CHEMBL4178087	Inhibition of human ROCK2 (2 to 543 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	112.0	CHEMBL2973	Homo sapiens	Activity	%	112.0
	18458414	CHEMBL4180097	Inhibition of ROCK2 (unknown origin) at 0.5 mM after 30 mins by immunoassay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Inhibition	%	32.33	CHEMBL2973	Homo sapiens	INH	%	32.33
	18458415	CHEMBL4180098	Inhibition of ROCK2 (unknown origin) at 1 mM after 30 mins by immunoassay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Inhibition	%	52.5	CHEMBL2973	Homo sapiens	INH	%	52.5
	18458811	CHEMBL4180097	Inhibition of ROCK2 (unknown origin) at 0.5 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(c2ccccn2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4213315	=	Inhibition	%	7.42	CHEMBL2973	Homo sapiens	INH	%	7.42
	18458812	CHEMBL4180097	Inhibition of ROCK2 (unknown origin) at 0.5 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(c2ncccn2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4218251	=	Inhibition	%	15.0	CHEMBL2973	Homo sapiens	INH	%	15.0
	18458813	CHEMBL4180097	Inhibition of ROCK2 (unknown origin) at 0.5 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(C(c2ccccc2)c2ccccc2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4204594	=	Inhibition	%	31.25	CHEMBL2973	Homo sapiens	INH	%	31.25
	18458814	CHEMBL4180097	Inhibition of ROCK2 (unknown origin) at 0.5 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(c2ccc([N+](=O)[O-])cc2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4208933	=	Inhibition	%	57.25	CHEMBL2973	Homo sapiens	INH	%	57.25
	18458815	CHEMBL4180097	Inhibition of ROCK2 (unknown origin) at 0.5 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(C(=O)c2ccco2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4218264	=	Inhibition	%	6.67	CHEMBL2973	Homo sapiens	INH	%	6.67
	18458816	CHEMBL4180097	Inhibition of ROCK2 (unknown origin) at 0.5 mM after 30 mins by immunoassay relative to control	B	COc1ccccc1N1CCN(CC(=O)Nc2nc3ccccc3[nH]2)CC1		CHEMBL4213328	=	Inhibition	%	25.25	CHEMBL2973	Homo sapiens	INH	%	25.25
	18458817	CHEMBL4180097	Inhibition of ROCK2 (unknown origin) at 0.5 mM after 30 mins by immunoassay relative to control	B	C[C@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL4208502	=	Inhibition	%	63.29	CHEMBL2973	Homo sapiens	INH	%	63.29
	18458818	CHEMBL4180098	Inhibition of ROCK2 (unknown origin) at 1 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(c2ccccn2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4213315	=	Inhibition	%	7.83	CHEMBL2973	Homo sapiens	INH	%	7.83
	18458819	CHEMBL4180098	Inhibition of ROCK2 (unknown origin) at 1 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(c2ncccn2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4218251	=	Inhibition	%	15.33	CHEMBL2973	Homo sapiens	INH	%	15.33
	18458820	CHEMBL4180098	Inhibition of ROCK2 (unknown origin) at 1 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(C(c2ccccc2)c2ccccc2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4204594	=	Inhibition	%	31.67	CHEMBL2973	Homo sapiens	INH	%	31.67
	18458821	CHEMBL4180098	Inhibition of ROCK2 (unknown origin) at 1 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(c2ccc([N+](=O)[O-])cc2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4208933	=	Inhibition	%	77.92	CHEMBL2973	Homo sapiens	INH	%	77.92
	18458822	CHEMBL4180098	Inhibition of ROCK2 (unknown origin) at 1 mM after 30 mins by immunoassay relative to control	B	O=C(CN1CCN(C(=O)c2ccco2)CC1)Nc1nc2ccccc2[nH]1		CHEMBL4218264	=	Inhibition	%	11.0	CHEMBL2973	Homo sapiens	INH	%	11.0
	18458823	CHEMBL4180098	Inhibition of ROCK2 (unknown origin) at 1 mM after 30 mins by immunoassay relative to control	B	COc1ccccc1N1CCN(CC(=O)Nc2nc3ccccc3[nH]2)CC1		CHEMBL4213328	=	Inhibition	%	29.63	CHEMBL2973	Homo sapiens	INH	%	29.63
	18458824	CHEMBL4180098	Inhibition of ROCK2 (unknown origin) at 1 mM after 30 mins by immunoassay relative to control	B	C[C@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL4208502	=	Inhibition	%	69.25	CHEMBL2973	Homo sapiens	INH	%	69.25
	18462195	CHEMBL4180882	Inhibition of recombinant human full length His6-tagged ROCK2 (2 to 543 residues) expressed in Sf21 insect cells assessed as residual activity at 1 uM after 30 mins in presence of [gamma-33P]ATP relative to control	B	CC(C)=CCC/C(C)=C/Cn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL4203120	=	Activity	%	91.0	CHEMBL2973	Homo sapiens	Activity	%	91.0
Not Active	18479306	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	COc1ccc(CC[N+](C)(CCO)C2CCCCC2)cc1OC.[I-]		CHEMBL4211183		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	18479307	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	COc1ccc(CCNC2CCCCC2O)cc1OC.Cl		CHEMBL4218558		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18479308	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	CCOc1ccc(CCN(CCO)C2CCCCC2O)cc1OCC.Cl		CHEMBL4206817		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	18479309	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	COc1cc2c(cc1OC)C(C)N(C1CCCCC1O)CC2.Cl		CHEMBL4207820		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	18479310	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	CCOc1cc2c(cc1OCC)CN(C1CCCCC1O)CC2.Cl		CHEMBL4218725		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	18479311	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	COc1cc2c(cc1OC)C(C1CCc3nc(N4CCOCC4)[nH]c(=O)c3C1)=NCC2.Cl.Cl		CHEMBL4213799		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	18479312	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	COc1cc2c(cc1OC)C1C(C)CN1CC2.Cl		CHEMBL4214302		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	18479313	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	C#CC[N+]12CCc3cc(OC)c(OC)cc3C1C(CO)C2.[Br-]		CHEMBL4209904		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	18479314	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	Br.COc1cc2c(cc1OC)C1C(CO)COC(=N)N1CC2		CHEMBL4205031		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	18479315	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	COc1cc2c(cc1OC)C(C(CO)CO)N(C1CCCC1)CC2		CHEMBL4214710		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18479316	CHEMBL4184667	Inhibition of ROCK2 (unknown origin) at 200 uM using MYPT1 as substrate after 30 mins by immunoassay	B	COc1cc2c(cc1OC)C(C(CO)CO)N(C(=S)Nc1ccccc1)CC2		CHEMBL4204539		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	18484388	CHEMBL4186035	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	18484872	CHEMBL4186035	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	78.0	CHEMBL2973	Homo sapiens	Activity	%	78.0
	18489562	CHEMBL4187303	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1		CHEMBL4207079	=	Activity	%	84.0	CHEMBL2973	Homo sapiens	Activity	%	84.0
	18507622	CHEMBL4191170	Inhibition of recombinant human ROCK2 (11 to 552 residues) at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	-2.0	CHEMBL2973	Homo sapiens	INH	%	-2.0
	18562097	CHEMBL4201784	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	uM	0.011
	18562098	CHEMBL4201784	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	COC(=O)C[C@H]1OC(C)=C2C(=O)c3c(ccc([C@H]4C[C@@H](N(C)C)[C@H](O)[C@@H](C)O4)c3O)C(=O)C2=C1O		CHEMBL4214797	=	IC50	nM	9000.0	CHEMBL2973	Homo sapiens	IC50	uM	9.0
	18562099	CHEMBL4201784	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	COC(=O)C[C@@H]1C[C@@]2(O)C(=O)c3ccc([C@H]4C[C@@H](N(C)C)[C@H](O)[C@@H](C)O4)c(O)c3C(=O)[C@]2(O)[C@@H](C)O1		CHEMBL4209877	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	uM	20.0
	18562100	CHEMBL4201784	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	COC(=O)C[C@H]1O[C@H](C)c2c(oc(=O)c3ccc([C@H]4C[C@@H](N(C)C)[C@H](O)[C@@H](C)O4)c(O)c3c2=O)[C@H]1O		CHEMBL4202607	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	uM	20.0
	18562101	CHEMBL4201784	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2c2oc(=O)c3ccc([C@H]4C[C@@H](N(C)C)[C@H](O)[C@@H](C)O4)c(O)c3c(=O)c21		CHEMBL4214283	>	IC50	nM	20000.0	CHEMBL2973	Homo sapiens	IC50	uM	20.0
	18568702	CHEMBL4220222	Inhibition of ROCK2 (unknown origin)	B	CN(C)[C@H]1C[C@@]23CC[C@@]4(O2)C(=CC[C@]2(C)[C@@H](c5ccc6ccncc6c5)CC[C@@H]42)C=C3[C@@H](O)[C@@H]1O		CHEMBL4080906	=	IC50	nM	220.0	CHEMBL2973	Homo sapiens	IC50	nM	220.0
	18570769	CHEMBL4220901	Inhibition of recombinant human ROCK2 at 10 uM in presence of ATP relative to control	B	CN(c1ncnc2[nH]ccc12)[C@@H]1CCN(C(=O)CC#N)C1		CHEMBL4224807	=	Inhibition	%	80.0	CHEMBL2973	Homo sapiens	INH	%	80.0
	18578826	CHEMBL4222466	Inhibition of ROCK2 (unknown origin)	B	CCN(CCO)Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1		CHEMBL4228240	>	IC50	nM	500.0	CHEMBL2973	Homo sapiens	IC50	nM	500.0
	18578827	CHEMBL4222466	Inhibition of ROCK2 (unknown origin)	B	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(Cc3ccccn3)ns2)n1		CHEMBL4227082	>	IC50	nM	500.0	CHEMBL2973	Homo sapiens	IC50	nM	500.0
	18578828	CHEMBL4222466	Inhibition of ROCK2 (unknown origin)	B	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C(NC(C)(C)C)c3ccccn3)ns2)n1		CHEMBL4225923	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	uM	1.0
	18653385	CHEMBL4230213	Inhibition of ROCK2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	18.0	CHEMBL2973	Homo sapiens	INH	%	18.0
	18653386	CHEMBL4230213	Inhibition of ROCK2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	4.0	CHEMBL2973	Homo sapiens	INH	%	4.0
	18655300	CHEMBL4230935	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	18663958	CHEMBL4232942	Inhibition of human ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	=	Activity	%	80.0	CHEMBL2973	Homo sapiens	Activity	%	80.0
	18664055	CHEMBL4233039	Binding affinity to human ROCK2 (M1 to T431 residues) expressed in mammalian expression system by KINOMEscan assay	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	>=	Kd	nM	5000.0	CHEMBL2973	Homo sapiens	Kd	uM	5.0
	18665524	CHEMBL4233400	Inhibition of ROCK2 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	nM	2.0
	18674878	CHEMBL4235428	Inhibition of ROCK2 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	<	Ki	nM	4.0	CHEMBL2973	Homo sapiens	Ki	nM	4.0
Not Determined	18674879	CHEMBL4235428	Inhibition of ROCK2 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242		Ki			CHEMBL2973	Homo sapiens	Ki		
	18674940	CHEMBL4235451	Inhibition of ROCK2 (unknown origin) at 2 uM relative to control	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525	=	Inhibition	%	99.0	CHEMBL2973	Homo sapiens	INH	%	99.0
	18706595	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	O=C1NCc2c1c1c3ccccc3[nH]c1c1[nH]c3ccc(O)cc3c21		CHEMBL4284524	=	IC50	nM	340.0	CHEMBL2973	Homo sapiens	IC50	uM	0.34
	18706596	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	O=C1NCc2c1c1c3cc(O)ccc3[nH]c1c1[nH]c3ccccc3c21		CHEMBL4294912	=	IC50	nM	5.7	CHEMBL2973	Homo sapiens	IC50	uM	0.0057
	18706597	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	COC1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccc(O)cc3c21		CHEMBL4284275	=	IC50	nM	910.0	CHEMBL2973	Homo sapiens	IC50	uM	0.91
	18706598	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	CC(=O)N[C@@H]1C[C@H](n2c3ccccc3c3c4c(c5c6cc(O)ccc6[nH]c5c32)CNC4=O)O[C@@H](C)[C@@H]1O		CHEMBL4279758	=	IC50	nM	1400.0	CHEMBL2973	Homo sapiens	IC50	uM	1.4
	18706599	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	CC(=O)N[C@@H]1C[C@H](n2c3ccc(O)cc3c3c4c(c5c6ccccc6[nH]c5c32)CNC4=O)O[C@@H](C)[C@@H]1O		CHEMBL4287662	=	IC50	nM	40.0	CHEMBL2973	Homo sapiens	IC50	uM	0.04
	18706600	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	C[C@@H]1O[C@@H](n2c3ccc(O)cc3c3c4c(c5c6ccccc6[nH]c5c32)CNC4=O)C[C@@H](N)[C@H]1O		CHEMBL4288105	=	IC50	nM	150.0	CHEMBL2973	Homo sapiens	IC50	uM	0.15
	18706601	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	CC(=O)N[C@H]1C[C@H]2O[C@@](C)([C@@H]1O)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4277459	=	IC50	nM	260.0	CHEMBL2973	Homo sapiens	IC50	uM	0.26
	18706602	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	C[C@@H]1O[C@@H]2C[C@](O)([C@H]1O)n1c3ccccc3c3c4c(c5c6cc(O)ccc6n2c5c31)C(=O)NC4		CHEMBL4291517	=	IC50	nM	970.0	CHEMBL2973	Homo sapiens	IC50	uM	0.97
	18706603	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	C[C@H]1O[C@@H]2C[C@](O)([C@H]1O)n1c3ccccc3c3c4c(c5c6cc(O)ccc6n2c5c31)C(=O)NC4		CHEMBL4280872	=	IC50	nM	340.0	CHEMBL2973	Homo sapiens	IC50	uM	0.34
	18706604	CHEMBL4256096	Inhibition of ROCK2 (unknown origin) by HTRF assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	7.8	CHEMBL2973	Homo sapiens	IC50	uM	0.0078
	18722686	CHEMBL4258491	Inhibition of human ROCK2 at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins in presence of [gamma-33P-ATP] by scintillation counting method relative to control	B	CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC12CC2		CHEMBL4279819	=	Inhibition	%	80.0	CHEMBL2973	Homo sapiens	INH	%	80.0
	18736436	CHEMBL4261161	Inhibition of ROCK2 (unknown origin) at 1 uM by ATP competition assay relative to control	B	c1cc(-c2cnco2)nc(-c2cnc(-c3cccc(-c4cccc(-c5ncc(-c6cccc(-c7cnco7)n6)o5)n4)n3)o2)c1		CHEMBL4284890	=	Inhibition	%	70.0	CHEMBL2973	Homo sapiens	INH	%	70.0
	18736437	CHEMBL4261162	Inhibition of ROCK2 (unknown origin) by ATP competition assay	B	c1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4284998	=	IC50	nM	29.0	CHEMBL2973	Homo sapiens	IC50	nM	29.0
	18736438	CHEMBL4261162	Inhibition of ROCK2 (unknown origin) by ATP competition assay	B	CN(C)CCOc1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4282551	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
	18736439	CHEMBL4261162	Inhibition of ROCK2 (unknown origin) by ATP competition assay	B	c1cc(-c2cnco2)nc(-c2cnc(-c3cccc(-c4cccc(-c5ncc(-c6cccc(-c7cnco7)n6)o5)n4)n3)o2)c1		CHEMBL4284890	=	IC50	nM	851.0	CHEMBL2973	Homo sapiens	IC50	nM	851.0
Active	18736519	CHEMBL4261167	Inhibition of ROCK2 in human HeLa cells assessed as reduction in MYPT1 phosphorylation at Thr853 at 2 uM after 3 hrs by immunofluorescence assay	B	c1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4284998		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18736520	CHEMBL4261167	Inhibition of ROCK2 in human HeLa cells assessed as reduction in MYPT1 phosphorylation at Thr853 at 2 uM after 3 hrs by immunofluorescence assay	B	c1cc(-c2cnco2)nc(-c2cnc(-c3cccc(-c4cccc(-c5ncc(-c6cccc(-c7cnco7)n6)o5)n4)n3)o2)c1		CHEMBL4284890		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18736521	CHEMBL4261168	Inhibition of ROCK2 in human HeLa cells assessed as reduction in MYPT1 phosphorylation at Thr853 at 5 uM after 3 hrs by immunofluorescence assay	B	CN(C)CCOc1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4282551		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18736522	CHEMBL4261169	Inhibition of ROCK2 in human HeLa cells assessed as reduction in cofilin phosphorylation at Ser3 at 2 uM after 3 hrs by immunofluorescence assay	B	c1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4284998		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18736523	CHEMBL4261169	Inhibition of ROCK2 in human HeLa cells assessed as reduction in cofilin phosphorylation at Ser3 at 2 uM after 3 hrs by immunofluorescence assay	B	c1cc(-c2cnco2)nc(-c2cnc(-c3cccc(-c4cccc(-c5ncc(-c6cccc(-c7cnco7)n6)o5)n4)n3)o2)c1		CHEMBL4284890		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18736524	CHEMBL4261170	Inhibition of ROCK2 in human HeLa cells assessed as reduction in cofilin phosphorylation at Ser3 at 5 uM after 3 hrs by immunofluorescence assay	B	CN(C)CCOc1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4282551		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18736525	CHEMBL4261171	Inhibition of ROCK2 in human HeLa cells assessed as reduction in cofilin phosphorylation at Ser3 at 2 uM after 3 hrs by Western blot analysis	B	c1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4284998		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18736526	CHEMBL4261171	Inhibition of ROCK2 in human HeLa cells assessed as reduction in cofilin phosphorylation at Ser3 at 2 uM after 3 hrs by Western blot analysis	B	c1cc(-c2cnco2)nc(-c2cnc(-c3cccc(-c4cccc(-c5ncc(-c6cccc(-c7cnco7)n6)o5)n4)n3)o2)c1		CHEMBL4284890		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	18736527	CHEMBL4261172	Inhibition of ROCK2 in human HeLa cells assessed as reduction in cofilin phosphorylation at Ser3 at 5 uM after 3 hrs by Western blot analysis	B	CN(C)CCOc1cc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)nc(-c2ncc(-c3ccc(-c4cnco4)cn3)o2)c1		CHEMBL4282551		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	18751227	CHEMBL4263936	Inhibition of ROCK2 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	9.0	CHEMBL2973	Homo sapiens	INH	%	9.0
	18752187	CHEMBL4264524	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	98.0	CHEMBL2973	Homo sapiens	Activity	%	98.0
	18761576	CHEMBL4266627	Inhibition of recombinant human N-terminal His6-tagged ROCK2 (11 to 552 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1		CHEMBL4279192	=	Inhibition	%	23.0	CHEMBL2973	Homo sapiens	INH	%	23.0
	18761847	CHEMBL4266627	Inhibition of recombinant human N-terminal His6-tagged ROCK2 (11 to 552 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1		CHEMBL4278882	=	Inhibition	%	-3.0	CHEMBL2973	Homo sapiens	INH	%	-3.0
	18762010	CHEMBL4266627	Inhibition of recombinant human N-terminal His6-tagged ROCK2 (11 to 552 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1		CHEMBL4290222	=	Inhibition	%	-2.0	CHEMBL2973	Homo sapiens	INH	%	-2.0
	18763088	CHEMBL4266885	Inhibition of ROCK2 (unknown origin) at 1 uM	B	CNC(=O)Nc1sc2c(C(C)C)cc(NS(=O)(=O)N(C)C)cc2c1C(N)=O		CHEMBL4290876	=	Inhibition	%	15.67	CHEMBL2973	Homo sapiens	INH	%	15.67
	18763123	CHEMBL4266920	Inhibition of ROCK2 (unknown origin) at 10 uM	B	CNC(=O)Nc1sc2c(C(C)C)cc(NS(=O)(=O)c3cccs3)cc2c1C(N)=O		CHEMBL4288081	=	Inhibition	%	11.82	CHEMBL2973	Homo sapiens	INH	%	11.82
	18764473	CHEMBL4267060	Inhibition of human ROCK2 at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4288103	<	Inhibition	%	70.0	CHEMBL2973	Homo sapiens	INH	%	70.0
	18764474	CHEMBL4267060	Inhibition of human ROCK2 at 100 nM	B	CN1CCC(c2nc(-c3cccc(S(C)(=O)=O)c3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4286880	<	Inhibition	%	70.0	CHEMBL2973	Homo sapiens	INH	%	70.0
	18764475	CHEMBL4267060	Inhibition of human ROCK2 at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)c(NS(C)(=O)=O)c3)c(-c3ccnc(NCC4CC4)n3)s2)CC1		CHEMBL4286841	<	Inhibition	%	70.0	CHEMBL2973	Homo sapiens	INH	%	70.0
	18782859	CHEMBL4270725	Inhibition of ROCK2 (unknown origin) assessed as residual enzyme activity at 1 uM relative to untreated control	B	Cc1cccc(-c2nn3c(c2-c2ccc(O)cc2)C(C)C(C)(C)C3)n1		CHEMBL4277021	>	Activity	%	80.0	CHEMBL2973	Homo sapiens	Activity	%	80.0
	18789033	CHEMBL4272383	Inhibition of ROCK2 (unknown origin)	B	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	=	IC50	nM	100.0	CHEMBL2973	Homo sapiens	IC50	nM	100.0
Not Active	18847269	CHEMBL4304951	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system at 1 uM by Kinomescan method	B	O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl		CHEMBL4517719		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	18858187	CHEMBL4308033	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
Not Active	18883528	CHEMBL4312763	Activity at human ROCK2 at 10 uM	B	CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F		CHEMBL4585668		Activity			CHEMBL2973	Homo sapiens	Activity		
	18892964	CHEMBL4314930	Inhibition of human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	105.0	CHEMBL2973	Homo sapiens	Activity	%	105.0
	18919530	CHEMBL4322886	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged ROCK2 (unknown origin) (1 to 553 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	23.0	CHEMBL2973	Homo sapiens	Kd	nM	23.0
	18919718	CHEMBL4322886	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged ROCK2 (unknown origin) (1 to 553 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	16.0	CHEMBL2973	Homo sapiens	Kd	nM	16.0
	18938275	CHEMBL4327864	Inhibition of human ROCK2 assessed as residual activity at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	99.84	CHEMBL2973	Homo sapiens	Activity	%	99.84
	18938276	CHEMBL4327864	Inhibition of human ROCK2 assessed as residual activity at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	95.52	CHEMBL2973	Homo sapiens	Activity	%	95.52
	18938709	CHEMBL4328228	Inhibition of human ROCK2 assessed as residual activity at 100 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL2973	Homo sapiens	Activity	%	65.0
	18939095	CHEMBL4328592	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.933	CHEMBL2973	Homo sapiens	IC50	10'-10M	9.33
Active	18939223	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	O=C(N[C@H](CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL4467869		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	18939224	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	=	IC50	nM	120.0	CHEMBL2973	Homo sapiens	IC50	uM	0.12
	18939225	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	=	IC50	nM	21.0	CHEMBL2973	Homo sapiens	IC50	uM	0.021
	18939226	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	CCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4454552	=	IC50	nM	110.0	CHEMBL2973	Homo sapiens	IC50	uM	0.11
	18939227	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4476761	=	IC50	nM	118.0	CHEMBL2973	Homo sapiens	IC50	uM	0.118
	18939228	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc(O)c1)c1ccc(-c2ccncc2)cc1		CHEMBL4536833	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	uM	0.003
	18939229	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc(OC(F)(F)F)c1)c1ccc(-c2ccncc2)cc1		CHEMBL4475535	=	IC50	nM	1300.0	CHEMBL2973	Homo sapiens	IC50	uM	1.3
	18939230	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1OC		CHEMBL4447521	=	IC50	nM	3800.0	CHEMBL2973	Homo sapiens	IC50	uM	3.8
	18939231	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc2c1OCCO2)c1ccc(-c2ccncc2)cc1		CHEMBL4522042	=	IC50	nM	37.0	CHEMBL2973	Homo sapiens	IC50	uM	0.037
	18939232	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc2c1OCCCO2)c1ccc(-c2ccncc2)cc1		CHEMBL4463301	=	IC50	nM	34.0	CHEMBL2973	Homo sapiens	IC50	uM	0.034
	18939233	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	CN(C)CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4436040	=	IC50	nM	87.0	CHEMBL2973	Homo sapiens	IC50	uM	0.087
	18939234	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	O=C(NCc1cccc(OCCN2CCOCC2)c1)c1ccc(-c2ccncc2)cc1		CHEMBL4570150	=	IC50	nM	250.0	CHEMBL2973	Homo sapiens	IC50	uM	0.25
	18939235	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4448806	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	uM	0.002
	18939236	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4575880	=	IC50	nM	2400.0	CHEMBL2973	Homo sapiens	IC50	uM	2.4
	18939237	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(N)c3)cc2)c1		CHEMBL4474946	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	uM	0.012
	18939238	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1		CHEMBL4459800	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	uM	0.014
	18939239	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(Cl)c3)cc2)c1		CHEMBL4451899	=	IC50	nM	140.0	CHEMBL2973	Homo sapiens	IC50	uM	0.14
	18939240	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(C)c3)cc2)c1		CHEMBL4438453	=	IC50	nM	96.0	CHEMBL2973	Homo sapiens	IC50	uM	0.096
	18939241	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cc(C)nc(C)c3)cc2)c1		CHEMBL4540054	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	18939242	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL4472858	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	uM	0.001
	18939243	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL4460511	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	uM	0.027
	18939244	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnnc3)cc2)c1		CHEMBL4584824	=	IC50	nM	700.0	CHEMBL2973	Homo sapiens	IC50	uM	0.7
	18939245	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	CCNc1cc(-c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc2)ccn1		CHEMBL4445356	=	IC50	nM	84.0	CHEMBL2973	Homo sapiens	IC50	uM	0.084
	18939246	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCC4CC4)c3)cc2)c1		CHEMBL4556370	=	IC50	nM	68.0	CHEMBL2973	Homo sapiens	IC50	uM	0.068
	18939247	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCC(C)(C)O)c3)cc2)c1		CHEMBL4568447	=	IC50	nM	390.0	CHEMBL2973	Homo sapiens	IC50	uM	0.39
	18939248	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCCO)c3)cc2)c1		CHEMBL4446212	=	IC50	nM	220.0	CHEMBL2973	Homo sapiens	IC50	uM	0.22
	18939249	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCCCO)c3)cc2)c1		CHEMBL4588929	=	IC50	nM	75.0	CHEMBL2973	Homo sapiens	IC50	uM	0.075
	18939250	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	O=C(N[C@H](CCN1CCCC1)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL4459077	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	uM	0.008
	18939251	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](CCN2CCCC2)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4583341	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	uM	0.003
	18939252	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](CCO)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4469316	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	uM	0.006
	18939253	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](CCN2CCOCC2)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1		CHEMBL4436197	=	IC50	nM	32.0	CHEMBL2973	Homo sapiens	IC50	uM	0.032
	18939254	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc([C@@H](CCN2CCCCC2)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1		CHEMBL4471862	=	IC50	nM	180.0	CHEMBL2973	Homo sapiens	IC50	uM	0.18
	18939255	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	O=C(N[C@H](CCN1CCCC1)c1cccc(F)c1)c1ccc(-c2ccnc(F)c2)cc1		CHEMBL4521871	=	IC50	nM	82.0	CHEMBL2973	Homo sapiens	IC50	uM	0.082
	18939256	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc([C@@H](CCO)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1		CHEMBL4590232	=	IC50	nM	350.0	CHEMBL2973	Homo sapiens	IC50	uM	0.35
	18939257	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc([C@@H](CCO)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL4577208	=	IC50	nM	140.0	CHEMBL2973	Homo sapiens	IC50	uM	0.14
	18939258	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	CCCOc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4469434	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	uM	0.015
	18939259	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2N2CCC(CN)CC2)c1		CHEMBL4434688	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	uM	0.001
	18939260	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2NCCN)c1		CHEMBL4572198	=	IC50	nM	21.0	CHEMBL2973	Homo sapiens	IC50	uM	0.021
	18939261	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL4553926	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	uM	0.012
	18939262	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCCN)c1		CHEMBL4555093	=	IC50	nM	21.0	CHEMBL2973	Homo sapiens	IC50	uM	0.021
	18939263	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2NCCCCN)c1		CHEMBL4585481	=	IC50	nM	72.0	CHEMBL2973	Homo sapiens	IC50	uM	0.072
	18939264	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CC[C@@H](CN)C2)c1		CHEMBL4550282	=	IC50	nM	320.0	CHEMBL2973	Homo sapiens	IC50	uM	0.32
	18939265	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CC[C@H](CN)C2)c1		CHEMBL4547725	=	IC50	nM	270.0	CHEMBL2973	Homo sapiens	IC50	uM	0.27
	18939266	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CCC[C@H](CN)C2)c1		CHEMBL4557041	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	uM	0.019
	18939267	CHEMBL4328667	Inhibition of GST-fused human recombinant ROCK2 (11 to 552 residues) expressed in Spodoptera frugiperda insect cells using STK S2 peptide substrate and 33P-ATP after 60 mins by HTRF assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CCC[C@@H](CN)C2)c1		CHEMBL4465725	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	uM	0.014
	18939460	CHEMBL4328710	Inhibition of ROCK2 (unknown origin) incubated for 2 hrs by AbbVie kinase panel assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL4448806	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	18953729	CHEMBL4331954	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccccc3F)c12		CHEMBL4449552	=	Inhibition	%	62.0	CHEMBL2973	Homo sapiens	INH	%	62.0
	18953789	CHEMBL4331954	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(NC3CCCCC3)c12		CHEMBL4440433	=	Inhibition	%	79.0	CHEMBL2973	Homo sapiens	INH	%	79.0
	18953868	CHEMBL4331954	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(OC3CCCCC3)c12		CHEMBL4524629	=	Inhibition	%	92.0	CHEMBL2973	Homo sapiens	INH	%	92.0
	18953960	CHEMBL4332013	Inhibition of ROCK2 (unknown origin) at 1 uM relative to control	B	CC(C)n1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cn1		CHEMBL4589022	=	Inhibition	%	28.0	CHEMBL2973	Homo sapiens	INH	%	28.0
	18954024	CHEMBL4332013	Inhibition of ROCK2 (unknown origin) at 1 uM relative to control	B	c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cc(N2CCOCC2)n1		CHEMBL4460272	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	18954091	CHEMBL4331954	Inhibition of ROCK2 (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccc4ncsc4c3)c12		CHEMBL4588446	=	Inhibition	%	86.0	CHEMBL2973	Homo sapiens	INH	%	86.0
	18958573	CHEMBL4333618	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	18964658	CHEMBL4335270	Inhibition of recombinant human ROCK2 (11 to 552 residues) assessed as residual activity at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	18964659	CHEMBL4335270	Inhibition of recombinant human ROCK2 (11 to 552 residues) assessed as residual activity at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	105.0	CHEMBL2973	Homo sapiens	Activity	%	105.0
	18972083	CHEMBL4337093	Inhibition of recombinant human ROCK2 (11 to 552 residues) assessed as residual activity at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 120 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	75.0	CHEMBL2973	Homo sapiens	Activity	%	75.0
	18995007	CHEMBL4342073	Inhibition of ROCK2 (unknown origin) using 2-biotin as substrate measured after 15 to 60 mins by HTRF assay	B	O=C(O)C(Cl)Cl.O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL4459126	=	IC50	nM	659.3	CHEMBL2973	Homo sapiens	IC50	nM	659.3
	18995008	CHEMBL4342073	Inhibition of ROCK2 (unknown origin) using 2-biotin as substrate measured after 15 to 60 mins by HTRF assay	B	Cl.Cl.O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL4435188	=	IC50	nM	508.8	CHEMBL2973	Homo sapiens	IC50	nM	508.8
	19021562	CHEMBL4347785	Inhibition of recombinant human ROCK2 at 20 nM using Ulight-RRRSLLE peptide as substrate measured after 15 mins by LANCE assay relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	-3.0	CHEMBL2973	Homo sapiens	INH	%	-3.0
	19021563	CHEMBL4347786	Inhibition of recombinant human ROCK2 at 200 nM using Ulight-RRRSLLE peptide as substrate measured after 15 mins by LANCE assay relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	-5.0	CHEMBL2973	Homo sapiens	INH	%	-5.0
	19030017	CHEMBL4349156	Inhibition of recombinant human N-terminal GST-tagged ROCK2 catalytic domain (1 to 552 residues) expressed in baculovirus expression system assessed as enzyme residual activity at 0.4 uM using fluorophore-labeled serine/threonine-13 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)CC1		CHEMBL4443805	=	Activity	%	96.3	CHEMBL2973	Homo sapiens	Activity	%	96.3
	19032212	CHEMBL4349805	Inhibition of recombinant human N-terminal GST/His6-tagged ROCK2 internal (P6 to S553) expressed in baculovirus infected Sf9 insect cells at 20 nM using phosphatidylserine as substrate incubated for 60 mins in presence of [33P]-ATP by scintillation counting method	B	Cn1cc(-c2n[nH]c3ccc(NCc4cc(F)ccc4S(C)(=O)=O)cc23)cn1		CHEMBL4555442	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	INH	%	5.0
Not Active	19040141	CHEMBL4352042	Inhibition of human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19041270	CHEMBL4352531	Inhibition of human ROCK2 at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	19059812	CHEMBL4358113	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	19072276	CHEMBL4361950	Inhibition of recombinant human GST-tagged ROCK2 (1 to 552 residues) using myelin basic protein as substrate incubated for 30 mins by ADP-Glo assay	B	COc1nc(N[C@H]2CC[C@H](N)CC2)c(F)cc1C(N)=O		CHEMBL4554795	=	IC50	nM	7.8	CHEMBL2973	Homo sapiens	IC50	nM	7.8
	19072283	CHEMBL4361944	Inhibition of human recombinant ROCK2 expressed in Baculovirus infected Sf21 cells assessed as inhibition of Ulight-RRRSLLE phosphorylation incubated for 15 mins by LANCE assay	B	CN(/N=C/c1ccccc1)S(=O)(=O)c1cccc2cnccc12		CHEMBL4471765	=	IC50	nM	3800.0	CHEMBL2973	Homo sapiens	IC50	uM	3.8
	19072285	CHEMBL4361942	Binding affinity to ROCK2 (unknown origin) incubated for 1 hr by qPCR analysis	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]ncc3c2c2c1CCC2		CHEMBL4461288	=	Kd	nM	1.2	CHEMBL2973	Homo sapiens	Kd	nM	1.2
	19072286	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	COc1c(B(O)O)cccc1-c1cc(-c2cc(F)cc(F)c2)c2c(ccc3[nH]ncc32)n1		CHEMBL4522022	=	Inhibition	%	10.0	CHEMBL2973	Homo sapiens	INH	%	10.0
	19072287	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	OB(O)c1ccc(-c2cc(-c3ccc(F)c(Cl)c3)c3c(ccc4[nH]ncc43)n2)cc1F		CHEMBL4435903	=	Inhibition	%	10.0	CHEMBL2973	Homo sapiens	INH	%	10.0
	19072288	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]ncc3c2c2c1CCC2		CHEMBL4461288	=	Inhibition	%	59.0	CHEMBL2973	Homo sapiens	INH	%	59.0
	19072289	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	COc1c(B(O)O)cccc1-c1cc(-c2ccc(F)c(Cl)c2)c2c(ccc3[nH]ncc32)n1		CHEMBL4449012	=	Inhibition	%	10.0	CHEMBL2973	Homo sapiens	INH	%	10.0
	19072290	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	c1nc2ccc3[nH]ncc3c2c2c1CCCC2		CHEMBL4445666	=	Inhibition	%	10.0	CHEMBL2973	Homo sapiens	INH	%	10.0
	19072291	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]nc(C)c3c2c2c1CCC2		CHEMBL4471129	=	Inhibition	%	32.0	CHEMBL2973	Homo sapiens	INH	%	32.0
	19072292	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]ncc3c2c2c1CCC2		CHEMBL4461288	>	Inhibition	%	90.0	CHEMBL2973	Homo sapiens	INH	%	90.0
	19072293	CHEMBL4361939	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 20 mins in presence of [gamma33P]ATP by filter binding method	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]ncc3c2c2c1CCC2		CHEMBL4461288	=	IC50	nM	0.51	CHEMBL2973	Homo sapiens	IC50	nM	0.51
	19072294	CHEMBL4361939	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 20 mins in presence of [gamma33P]ATP by filter binding method	B	Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1		CHEMBL4594250	=	IC50	nM	11.2	CHEMBL2973	Homo sapiens	IC50	nM	11.2
Not Active	19072299	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	COc1c(B(O)O)cccc1-c1cc(-c2cc(F)cc(F)c2)c2c(ccc3[nH]ncc32)n1		CHEMBL4522022		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	19072300	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	OB(O)c1ccc(-c2cc(-c3ccc(F)c(Cl)c3)c3c(ccc4[nH]ncc43)n2)cc1F		CHEMBL4435903		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072301	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	OB(O)c1ccc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)cc1		CHEMBL4444815		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072302	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	OB(O)c1ccc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)cc1F		CHEMBL4455667		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072303	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	OB(O)c1ccc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)cc1F		CHEMBL4455667		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072304	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	OB(O)c1cccc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)c1F		CHEMBL4461979		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072305	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	OB(O)c1cccc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)c1F		CHEMBL4461979		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072306	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	COc1ccc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)cc1B(O)O		CHEMBL4571201		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072307	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	OB(O)c1cccc(-c2nc3ccc4[nH]ncc4c3cc2-c2ccccc2)c1F		CHEMBL4518915		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	19072308	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	OB(O)c1cccc(-c2nc3ccc4[nH]ncc4c3cc2-c2ccccc2)c1F		CHEMBL4518915		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072309	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	OB(O)c1cccc(-c2nc3ccc4[nH]ncc4c3cc2-c2ccc(F)c(Cl)c2)c1F		CHEMBL4564175		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	19072310	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	OB(O)c1cccc(-c2nc3ccc4[nH]ncc4c3cc2-c2ccc(F)c(Cl)c2)c1F		CHEMBL4564175		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072311	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]ncc3c2cc1C		CHEMBL4559736		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072312	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]ncc3c2cc1-c1ccncc1		CHEMBL4526373		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072313	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	OB(O)c1ccc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)o1		CHEMBL4584740		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072314	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	OB(O)c1ccc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)o1		CHEMBL4584740		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072315	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	c1csc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)c1		CHEMBL4447299		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072316	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	OB(O)c1csc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)c1		CHEMBL4543111		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072317	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	OB(O)c1csc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)c1		CHEMBL4543111		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072318	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	c1cc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)cs1		CHEMBL4442151		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072319	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	Cc1n[nH]c2ccc3nc(-c4sccc4B(O)O)c4c(c3c12)CCC4		CHEMBL4436669		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072320	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	Cc1n[nH]c2ccc3nc(-c4sccc4B(O)O)c4c(c3c12)CCC4		CHEMBL4436669		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072321	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	COc1c(B(O)O)cccc1-c1nc2ccc3[nH]ncc3c2cc1-c1ccc(Cl)cc1		CHEMBL4435820		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072322	CHEMBL4361937	Inhibition of active ROCK2 (R11-11G) (unknown origin) at 100 nM using S6K as substrate incubated for 3 hrs by ADP-Glo kinase assay relative to control	B	OB(O)c1cccc(-c2nc3ccc4[nH]ncc4c3c3c2CCCC3)c1		CHEMBL4442130		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Active	19072323	CHEMBL4361938	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 50 nM incubated for 20 mins in presence of [gamma33P]ATP by filter binding method relative to control	B	OB(O)c1ccsc1-c1nc2ccc3[nH]ncc3c2c2c1CCC2		CHEMBL4582204		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	19090376	CHEMBL4365950	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	52.0	CHEMBL2973	Homo sapiens	Activity	%	52.0
	19092103	CHEMBL4366577	Inhibition of human ROCK2 at 100 nM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1	Outside typical range	CHEMBL4528675	=	Inhibition	%	-13.31	CHEMBL2973	Homo sapiens	INH	%	-13.31
	19144830	CHEMBL4377846	Inhibition of human ROCK2 (11 to 552 residues) at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	5.0	CHEMBL2973	Homo sapiens	INH	%	5.0
	19146967	CHEMBL4378825	Inhibition of human ROCK2 (11 to 552 residues) at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	16.0	CHEMBL2973	Homo sapiens	INH	%	16.0
	19147568	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)NC(=O)CC4)c2)cc1		CHEMBL4577999	=	IC50	nM	3141.0	CHEMBL2973	Homo sapiens	IC50	uM	3.141
	19147569	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)CCC(=O)N4)c2)cc1		CHEMBL4476081	=	IC50	nM	9974.0	CHEMBL2973	Homo sapiens	IC50	uM	9.974
	19147570	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1cccc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)c1		CHEMBL4585524	=	IC50	nM	5738.0	CHEMBL2973	Homo sapiens	IC50	uM	5.738
	19147571	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1cc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)ccc1C=O		CHEMBL4539818	=	IC50	nM	306.0	CHEMBL2973	Homo sapiens	IC50	uM	0.306
	19147572	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1ccc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)cc1OC		CHEMBL4514373	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	19147573	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1ccc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)cc1F		CHEMBL4460696	=	IC50	nM	652.0	CHEMBL2973	Homo sapiens	IC50	uM	0.652
	19147574	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(=O)c1ccc(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)cc1F		CHEMBL4447770	=	IC50	nM	98.0	CHEMBL2973	Homo sapiens	IC50	uM	0.098
	19147575	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)OCO4)c2)cc1		CHEMBL4569357	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	19147576	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)OCCO4)c2)cc1		CHEMBL4577880	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	19147577	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(c3)OCCC4=O)c2)cc1		CHEMBL4558371	=	IC50	nM	85.0	CHEMBL2973	Homo sapiens	IC50	uM	0.085
	19147578	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	uM	0.003
	19147579	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4occc(=O)c4c3)c2)cc1		CHEMBL4463505	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	19147580	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1coc2cc(OCC(=O)Nc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)ccc2c1=O		CHEMBL4568022	=	IC50	nM	2149.0	CHEMBL2973	Homo sapiens	IC50	uM	2.149
	19147581	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1c(OCC(=O)Nc2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)ccc2c(=O)ccoc12		CHEMBL4458703	=	IC50	nM	4163.0	CHEMBL2973	Homo sapiens	IC50	uM	4.163
	19147582	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(=O)Nc1cccc(NC(=O)COc2ccc3c(=O)ccoc3c2)c1		CHEMBL4473009	=	IC50	nM	136.0	CHEMBL2973	Homo sapiens	IC50	uM	0.136
	19147583	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CCCC(=O)Nc1cccc(NC(=O)COc2ccc3c(=O)ccoc3c2)c1		CHEMBL4452457	=	IC50	nM	176.0	CHEMBL2973	Homo sapiens	IC50	uM	0.176
	19147584	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccccc2)c1		CHEMBL4586795	=	IC50	nM	16.0	CHEMBL2973	Homo sapiens	IC50	uM	0.016
	19147585	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4459655	=	IC50	nM	22.0	CHEMBL2973	Homo sapiens	IC50	uM	0.022
	19147586	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CCc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4458667	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	uM	0.024
	19147587	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CCCc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4576394	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	uM	0.014
	19147588	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4556104	=	IC50	nM	34.0	CHEMBL2973	Homo sapiens	IC50	uM	0.034
	19147589	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc(F)cc2)c1		CHEMBL4586827	=	IC50	nM	54.0	CHEMBL2973	Homo sapiens	IC50	uM	0.054
	19147590	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc(Br)cc2)c1		CHEMBL4451407	=	IC50	nM	49.0	CHEMBL2973	Homo sapiens	IC50	uM	0.049
	19147591	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	N#Cc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4453948	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	uM	0.015
	19147592	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4446390	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	uM	0.007
	19147593	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CCOc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4476505	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	uM	0.009
	19147594	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc(OC(F)(F)F)cc2)c1		CHEMBL4555946	=	IC50	nM	77.0	CHEMBL2973	Homo sapiens	IC50	uM	0.077
	19147595	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc([N+](=O)[O-])cc2)c1		CHEMBL4467403	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	uM	0.015
	19147596	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	COC(=O)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4533805	=	IC50	nM	29.0	CHEMBL2973	Homo sapiens	IC50	uM	0.029
	19147597	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2cccc([N+](=O)[O-])c2)c1		CHEMBL4437283	=	IC50	nM	41.0	CHEMBL2973	Homo sapiens	IC50	uM	0.041
	19147598	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)ccc1C(F)(F)F		CHEMBL4519471	=	IC50	nM	43.0	CHEMBL2973	Homo sapiens	IC50	uM	0.043
	19147599	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(C)(C)c1cc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)no1		CHEMBL4451007	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	uM	0.005
	19147600	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1nc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cs1		CHEMBL4470778	=	IC50	nM	33.0	CHEMBL2973	Homo sapiens	IC50	uM	0.033
	19147601	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2cnc(C(F)(F)F)s2)c1		CHEMBL4445974	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	uM	0.01
	19147602	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)no1		CHEMBL4562184	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	uM	0.005
	19147603	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	NCc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4472964	=	IC50	nM	66.0	CHEMBL2973	Homo sapiens	IC50	uM	0.066
	19147604	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Nc1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4475912	=	IC50	nM	83.0	CHEMBL2973	Homo sapiens	IC50	uM	0.083
	19147605	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Nc1cccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)c1		CHEMBL4440876	=	IC50	nM	58.0	CHEMBL2973	Homo sapiens	IC50	uM	0.058
	19147606	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NC(=O)c2ccc(C(=O)O)cc2)c1		CHEMBL4529033	=	IC50	nM	2027.0	CHEMBL2973	Homo sapiens	IC50	uM	2.027
	19147607	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cn1ccc(S(=O)(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)n1		CHEMBL4514074	=	IC50	nM	1345.0	CHEMBL2973	Homo sapiens	IC50	uM	1.345
	19147608	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(S(=O)(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4474271	=	IC50	nM	263.0	CHEMBL2973	Homo sapiens	IC50	uM	0.263
	19147609	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CC(C)(C)c1ccc(S(=O)(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4467086	=	IC50	nM	899.0	CHEMBL2973	Homo sapiens	IC50	uM	0.899
	19147610	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2)c1		CHEMBL4444893	=	IC50	nM	6894.0	CHEMBL2973	Homo sapiens	IC50	uM	6.894
	19147611	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	O=C(COc1ccc2c(=O)ccoc2c1)Nc1cccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)c1		CHEMBL4474804	=	IC50	nM	1283.0	CHEMBL2973	Homo sapiens	IC50	uM	1.283
	19147612	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1ccc(NC(=O)COc2ccc3c(=O)ccoc3c2)cc1NC(=O)c1ccc(N(C)C)cc1		CHEMBL4551100	=	IC50	nM	169.0	CHEMBL2973	Homo sapiens	IC50	uM	0.169
	19147613	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1ccc(NC(=O)c2ccc(N(C)C)cc2)cc1NC(=O)COc1ccc2c(=O)ccoc2c1		CHEMBL4454066	=	IC50	nM	3526.0	CHEMBL2973	Homo sapiens	IC50	uM	3.526
	19147614	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1c(NC(=O)COc2ccc3c(=O)ccoc3c2)cccc1NC(=O)c1ccc(N(C)C)cc1		CHEMBL4587195	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	19147615	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(NC(=O)COc2ccc3c(=O)ccoc3c2)cc(NC(=O)c2ccc(N(C)C)cc2)c1		CHEMBL4588881	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	19147616	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cc(F)cc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4457201	=	IC50	nM	22.0	CHEMBL2973	Homo sapiens	IC50	uM	0.022
	19147617	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cc(Br)cc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4581933	=	IC50	nM	4557.0	CHEMBL2973	Homo sapiens	IC50	uM	4.557
	19147618	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cc(NC(=O)COc3ccc4c(=O)ccoc4c3)cc(C(F)(F)F)c2)cc1		CHEMBL4529129	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	19147619	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(NC(=O)COc2ccc3c(=O)ccoc3c2)cc(NC(=O)c2ccc(N(C)C)cc2)c1C		CHEMBL4452238	=	IC50	nM	374.0	CHEMBL2973	Homo sapiens	IC50	uM	0.374
	19147620	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2ccc(NC(=O)COc3ccc4c(=O)ccoc4c3)cc2)cc1		CHEMBL4526491	=	IC50	nM	302.0	CHEMBL2973	Homo sapiens	IC50	uM	0.302
	19147621	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	Cc1cc(NC(=O)COc2ccc3c(=O)ccoc3c2)ccc1NC(=O)c1ccc(N(C)C)cc1		CHEMBL4590957	=	IC50	nM	4206.0	CHEMBL2973	Homo sapiens	IC50	uM	4.206
	19147622	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2ccc(NC(=O)COc3ccc4c(=O)ccoc4c3)cc2C(F)(F)F)cc1		CHEMBL4475590	=	IC50	nM	7102.0	CHEMBL2973	Homo sapiens	IC50	uM	7.102
	19147623	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2ccc(CNC(=O)COc3ccc4c(=O)ccoc4c3)cc2)cc1		CHEMBL4444449	=	IC50	nM	999.0	CHEMBL2973	Homo sapiens	IC50	uM	0.999
	19147624	CHEMBL4379076	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKR as substrate incubated for 40 mins in presence of [gamma-33P]ATP and 10 uM ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NS(=O)(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4455163	=	IC50	nM	27.0	CHEMBL2973	Homo sapiens	IC50	uM	0.027
	19159640	CHEMBL4382744	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	96.0	CHEMBL2973	Homo sapiens	Activity	%	96.0
	19181133	CHEMBL4387344	Inhibition of recombinant human GST-tagged ROCK2 catalytic domain (1 to 552 residues) expressed in baculovirus expression system at 0.1 uM using serine/threonine-13 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	18.5	CHEMBL2973	Homo sapiens	INH	%	18.5
	19181358	CHEMBL4387344	Inhibition of recombinant human GST-tagged ROCK2 catalytic domain (1 to 552 residues) expressed in baculovirus expression system at 0.1 uM using serine/threonine-13 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	7.0	CHEMBL2973	Homo sapiens	INH	%	7.0
	19191367	CHEMBL4389463	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	49.0	CHEMBL2973	Homo sapiens	INH	%	49.0
	19192126	CHEMBL4389940	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	67.0	CHEMBL2973	Homo sapiens	INH	%	67.0
	19200382	CHEMBL4391566	Binding affinity to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	26.0	CHEMBL2973	Homo sapiens	Activity	%	26.0
	19266598	CHEMBL4405548	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	19276114	CHEMBL4408117	Inhibition of recombinant human ROCK2 (11 to 552 residues) at 1 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	54.0	CHEMBL2973	Homo sapiens	INH	%	54.0
	19298486	CHEMBL4413161	Binding affinity to wild-type partial length human ROCK2 (M1 to T431 residues) expressed in mammalian expression system by Kinomescan assay	B	CN(C)[C@H]1C[C@@]23CC[C@@]4(O2)C(=CC[C@]2(C)[C@@H](c5ccc6ccncc6c5)CC[C@@H]42)C=C3[C@@H](O)[C@@H]1O		CHEMBL4080906	=	Kd	nM	220.0	CHEMBL2973	Homo sapiens	Kd	nM	220.0
	19312971	CHEMBL4416526	Inhibition of recombinant human N-terminal His6-tagged ROCK2 (11 to 552 residues) expressed in baculovirus infected Sf21 insect cells at 10 uM using long S6 Kinase peptide as substrate relative to control	B	N#CC[C@H]1CC[C@H](n2c(=O)[nH]c3cnc(Nc4ccc[nH]c4=O)nc32)CC1		CHEMBL4463007	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
Not Active	19342046	CHEMBL4419723	Inhibition of constitutively active ROCK2 mutant (unknown origin) expressed in mouse NIH/3T3 cells assessed as reduction in 10% calf serum-induced actin stress fiber formation at 30 uM by rhodamine-phalloidin staining based assay	B	Cc1cccc(COc2cccc(/C=C3\C(=O)NN(c4ccccc4)C3=O)c2)c1		CHEMBL485210		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
Not Active	19342047	CHEMBL4419722	Inhibition of constitutively active ROCK2 mutant (unknown origin) expressed in mouse NIH/3T3 cells assessed as reduction in 10% calf serum-induced focal adhesion complex formation at 530 uM by anti-vinculin antibody staining based assay	B	Cc1cccc(COc2cccc(/C=C3\C(=O)NN(c4ccccc4)C3=O)c2)c1		CHEMBL485210		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	19371156	CHEMBL4424908	Inhibition of human N-terminal His6-tagged (11 to 552 residues) ROCK2 expressed in baculovirus infected Sf21 insect cells using Long S6 Kinase as substrate	A	COc1cc(C2CN(C(=O)c3cc(COC[C@@H](O)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4474690	>	IC50	nM	1000.0	CHEMBL2973	Homo sapiens	IC50	nM	1000.0
	19453007	CHEMBL4434257	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH substrate and ATP	B	COc1ccc2ncnc(NC3CC4(C3)CC(Oc3ncccc3C(N)=O)C4)c2c1		CHEMBL4579877	=	IC50	nM	62.0	CHEMBL2973	Homo sapiens	IC50	nM	62.0
	19453008	CHEMBL4434257	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH substrate and ATP	B	NC(=O)c1cccnc1OC1CC2(CC(Nc3nc4c(Cl)cccc4s3)C2)C1		CHEMBL4551951	=	IC50	nM	76.0	CHEMBL2973	Homo sapiens	IC50	nM	76.0
	19453009	CHEMBL4434257	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH substrate and ATP	B	NC(=O)c1cccnc1OC1CC2(CC(Nc3nc4cc(F)c(Br)cc4s3)C2)C1		CHEMBL4436001	=	IC50	nM	547.0	CHEMBL2973	Homo sapiens	IC50	nM	547.0
	19453010	CHEMBL4434257	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH substrate and ATP	B	COc1cnc(NC2CC3(C2)CC(Oc2ncccc2C(N)=O)C3)c2cc(Cl)ccc12		CHEMBL4440471	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	nM	15.0
	19453011	CHEMBL4434257	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH substrate and ATP	B	COc1ccc2c(NC3CC4(C3)CC(Oc3ncccc3C(N)=O)C4)nccc2c1		CHEMBL4580516	=	IC50	nM	17.0	CHEMBL2973	Homo sapiens	IC50	nM	17.0
	19453012	CHEMBL4434257	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH substrate and ATP	B	N#Cc1cnc(NC2CC3(C2)CC(Oc2ncccc2C(N)=O)C3)nc1		CHEMBL4460455	=	IC50	nM	1508.0	CHEMBL2973	Homo sapiens	IC50	nM	1508.0
	19476627	CHEMBL4479775	Inhibition of recombinant human N-terminal GST-tagged ROCK2 (1 to 552 residues) catalytic domain expressed in baculovirus expression system by Z'-LYTE assay	B	O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1		CHEMBL4569508	=	IC50	nM	430.0	CHEMBL2973	Homo sapiens	IC50	nM	430.0
	19476727	CHEMBL4479775	Inhibition of recombinant human N-terminal GST-tagged ROCK2 (1 to 552 residues) catalytic domain expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1		CHEMBL4550702	=	IC50	nM	560.0	CHEMBL2973	Homo sapiens	IC50	nM	560.0
	19476827	CHEMBL4479775	Inhibition of recombinant human N-terminal GST-tagged ROCK2 (1 to 552 residues) catalytic domain expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1		CHEMBL4568087	=	IC50	nM	52.0	CHEMBL2973	Homo sapiens	IC50	nM	52.0
	19476927	CHEMBL4479775	Inhibition of recombinant human N-terminal GST-tagged ROCK2 (1 to 552 residues) catalytic domain expressed in baculovirus expression system by Z'-LYTE assay	B	Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12		CHEMBL4552628	=	IC50	nM	1100.0	CHEMBL2973	Homo sapiens	IC50	nM	1100.0
	19488168	CHEMBL4481805	Inhibition of ROCK2 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3c[nH]nc3C)cc1OCCN(C)C)CO2		CHEMBL4570327	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
	19488169	CHEMBL4481805	Inhibition of ROCK2 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2		CHEMBL482336	=	IC50	nM	0.7	CHEMBL2973	Homo sapiens	IC50	nM	0.7
	19488188	CHEMBL4481805	Inhibition of ROCK2 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	B	CN(C)CCOc1cc(-c2ccncc2)ccc1NC(=O)C1COc2ccc(F)cc2C1		CHEMBL4483646	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	19488189	CHEMBL4481805	Inhibition of ROCK2 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	B	CN(C)CCOc1cc(-c2ccncc2)ccc1NC(=O)C1COc2ccc(Cl)cc2C1		CHEMBL4559633	=	IC50	nM	22.0	CHEMBL2973	Homo sapiens	IC50	nM	22.0
	19488190	CHEMBL4481805	Inhibition of ROCK2 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	B	CN(C)CCOc1cc(-c2ccncc2)ccc1NC(=O)C1COc2ccccc2C1		CHEMBL4521642	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	19488191	CHEMBL4481805	Inhibition of ROCK2 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	B	Cc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3ccncc3)cc1OCCN(C)C)CO2		CHEMBL4513652	=	IC50	nM	24.0	CHEMBL2973	Homo sapiens	IC50	nM	24.0
	19488192	CHEMBL4481805	Inhibition of ROCK2 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@@H](C(=O)Nc1ccc(-c3ccncc3)cc1OCCN(C)C)CO2		CHEMBL4547623	=	IC50	nM	172.0	CHEMBL2973	Homo sapiens	IC50	nM	172.0
	19488193	CHEMBL4481805	Inhibition of ROCK2 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	B	COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3ccncc3)cc1OCCN(C)C)CO2		CHEMBL4552537	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	19488194	CHEMBL4481805	Inhibition of ROCK2 (unknown origin) using STK2 as substrate measured after 4 hrs by HTRF assay	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3ccncc3)cc1OCCN(C)C)CO2		CHEMBL4588109	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	nM	9.0
	20600660	CHEMBL4603612	Inhibition of recombinant human GST-tagged ROCK2 catalytic domain expressed in baculovirus expression system using serine/threonine-13 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL2973	Homo sapiens	IC50	uM	100.0
	20601677	CHEMBL4603809	Inhibition of recombinant human N-terminal GST-tagged ROCK2 (1 to 552 residues) expressed in baculovirus expression system using Ser/Thr13 peptide as substrate at 0.6 uM incubated for 1 hr by Z'lyte assay relative to control	B	C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4646281	=	Inhibition	%	1.0	CHEMBL2973	Homo sapiens	INH	%	1.0
	20657238	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3cc(-c4ccc5[nH]ncc5c4)ccc3c2=O)c1		CHEMBL4641760	=	IC50	nM	88.0	CHEMBL2973	Homo sapiens	IC50	uM	0.088
	20657239	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2ncc3cc(-c4ccc5[nH]ncc5c4)ccc3c2=O)c1		CHEMBL4645772	=	IC50	nM	398.0	CHEMBL2973	Homo sapiens	IC50	uM	0.398
	20657240	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2ccc3cc(-c4ccc5[nH]ncc5c4)ccc3c2=O)c1		CHEMBL4639886	=	IC50	nM	107.0	CHEMBL2973	Homo sapiens	IC50	uM	0.107
	20657241	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(CN2CCc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4643620	=	IC50	nM	632.0	CHEMBL2973	Homo sapiens	IC50	uM	0.632
	20657242	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccc5[nH]ncc5c4)cc3c2=O)c1		CHEMBL4636499	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	uM	0.002
	20657243	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccncc4)cc3c2=O)c1		CHEMBL4643315	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	uM	0.006
	20657244	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4cccnc4)cc3c2=O)c1		CHEMBL4633510	=	IC50	nM	3475.0	CHEMBL2973	Homo sapiens	IC50	uM	3.475
	20657245	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccc(-c5ccncc5)cc4)cc3c2=O)c1		CHEMBL4635460	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	20657246	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(F)c4)cc3c2=O)c1		CHEMBL4649864	=	IC50	nM	83.0	CHEMBL2973	Homo sapiens	IC50	uM	0.083
	20657247	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(Cl)c4)cc3c2=O)c1		CHEMBL4646435	=	IC50	nM	501.0	CHEMBL2973	Homo sapiens	IC50	uM	0.501
	20657248	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(C)c4)cc3c2=O)c1		CHEMBL4644231	=	IC50	nM	42.0	CHEMBL2973	Homo sapiens	IC50	uM	0.042
	20657249	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(OC)c4)cc3c2=O)c1		CHEMBL4643565	=	IC50	nM	6915.0	CHEMBL2973	Homo sapiens	IC50	uM	6.915
	20657250	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc(N)c4)cc3c2=O)c1		CHEMBL4649403	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	uM	0.001
	20657251	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccc(N)nc4)cc3c2=O)c1		CHEMBL4634527	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	20657252	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4ccnc5[nH]ccc45)cc3c2=O)c1		CHEMBL4638815	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	uM	0.001
	20657253	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cccc(Cn2cnc3sc(-c4cccc5[nH]ccc45)cc3c2=O)c1		CHEMBL4639551	=	IC50	nM	583.0	CHEMBL2973	Homo sapiens	IC50	uM	0.583
	20657254	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	O=c1c2cc(-c3ccnc4[nH]ccc34)sc2ncn1Cc1cccc(F)c1		CHEMBL4645138	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	uM	0.001
	20657255	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	O=c1c2cc(-c3ccnc4[nH]ccc34)sc2ncn1Cc1cccc(C(F)(F)F)c1		CHEMBL4648713	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	uM	0.007
	20657256	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1ccc(Cn2cnc3sc(-c4ccnc5[nH]ccc45)cc3c2=O)cc1		CHEMBL4638636	=	IC50	nM	2.0	CHEMBL2973	Homo sapiens	IC50	uM	0.002
	20657257	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1ccc(Cn2cnc3sc(-c4ccnc5[nH]ccc45)cc3c2=O)cc1OC		CHEMBL4648698	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	uM	0.004
	20657258	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cc(Cn2cnc3sc(-c4ccnc5[nH]ccc45)cc3c2=O)cc(OC)c1		CHEMBL4634539	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	uM	0.004
	20657259	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	Nc1cc(-c2cc3c(=O)n(Cc4cccc(F)c4)cnc3s2)ccn1		CHEMBL4649693	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	uM	0.005
	20657260	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	Nc1cc(-c2cc3c(=O)n(Cc4cccc(C(F)(F)F)c4)cnc3s2)ccn1		CHEMBL4639553	=	IC50	nM	25.0	CHEMBL2973	Homo sapiens	IC50	uM	0.025
	20657261	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1ccc(Cn2cnc3sc(-c4ccnc(N)c4)cc3c2=O)cc1		CHEMBL4644637	=	IC50	nM	46.0	CHEMBL2973	Homo sapiens	IC50	uM	0.046
	20657262	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1ccc(Cn2cnc3sc(-c4ccnc(N)c4)cc3c2=O)cc1OC		CHEMBL4637847	=	IC50	nM	219.0	CHEMBL2973	Homo sapiens	IC50	uM	0.219
	20657263	CHEMBL4617455	Inhibition of recombinant human ROCK2 (11 to 552 residues) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation assay	B	COc1cc(Cn2cnc3sc(-c4ccnc(N)c4)cc3c2=O)cc(OC)c1		CHEMBL4649876	=	IC50	nM	58.0	CHEMBL2973	Homo sapiens	IC50	uM	0.058
	20669055	CHEMBL4620298	Inhibition of biotinylated ligand binding to wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system at 50 nM measured after 1 hr by kinomescan assay relative to control	B	CN(C)[C@@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]4CC=C(c5cccc6cnccc56)[C@@]4(C)CC[C@@H]32)C1		CHEMBL4637601	>	Inhibition	%	80.0	CHEMBL2973	Homo sapiens	INH	%	80.0
	20680344	CHEMBL4622709	Inhibition of ROCK2 (unknown origin) assessed as phosphorylation of MYPT1 using Tetramethylbenzidine as substrate in presence of ATP	B	CCC(O)CNCc1ccnc2ccc(OC)cc12		CHEMBL4634858	=	IC50	nM	8.02	CHEMBL2973	Homo sapiens	IC50	nM	8.02
	20680345	CHEMBL4622709	Inhibition of ROCK2 (unknown origin) assessed as phosphorylation of MYPT1 using Tetramethylbenzidine as substrate in presence of ATP	B	COCSC(C)CCSCCO		CHEMBL4635281	=	IC50	nM	8.4	CHEMBL2973	Homo sapiens	IC50	nM	8.4
	20680346	CHEMBL4622709	Inhibition of ROCK2 (unknown origin) assessed as phosphorylation of MYPT1 using Tetramethylbenzidine as substrate in presence of ATP	B	COC(=O)c1ccc(N(C)C(C(=O)c2ccccc2)c2ccccc2)cc1		CHEMBL4633684	=	IC50	nM	9.01	CHEMBL2973	Homo sapiens	IC50	nM	9.01
	20680347	CHEMBL4622709	Inhibition of ROCK2 (unknown origin) assessed as phosphorylation of MYPT1 using Tetramethylbenzidine as substrate in presence of ATP	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	IC50	nM	8.3	CHEMBL2973	Homo sapiens	IC50	nM	8.3
	20681610	CHEMBL4623291	Inhibition of ROCK2 (unknown origin)	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	nM	19.0
Active	20681778	CHEMBL4623327	Inhibition of ROCK2 (unknown origin) at 5 uM by radiometric kinase assay	B	NCC1CCN(c2nc(-c3ccncc3)nc3sc4c(c23)CCCC4)CC1		CHEMBL4637651		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	22392154	CHEMBL4667249	Inhibition of recombinant human N-terminal GST-tagged ROCK2 (1 to 552 residues) expressed in baculovirus expression system using Ser/Thr 13 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	-3.0	CHEMBL2973	Homo sapiens	INH	%	-3.0
	22396433	CHEMBL4668587	Inhibition of human ROCK2 expressed in baculovirus expression system by Kinase-Glo luminescent Assay	B	NC[C@@H](C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1		CHEMBL4753043	=	Ki	nM	0.2	CHEMBL2973	Homo sapiens	Ki	nM	0.2
	22396435	CHEMBL4668589	Inhibition of human ROCK2 by Kinase-Glo luminescent assay	B	Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1		CHEMBL4594250	=	Ki	nM	4.2	CHEMBL2973	Homo sapiens	Ki	nM	4.2
	22396436	CHEMBL4668590	Inhibition of ROCK2 (unknown origin) using histone as substrate incubated for 20 mins in presence of [gamma32P]-ATP by liquid scintillation counter method	B	CC(N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL3185765	=	IC50	nM	3.6	CHEMBL2973	Homo sapiens	IC50	nM	3.6
	22396437	CHEMBL4668591	Inhibition of N-terminal GST-fused human ROCK2 catalytic domain ( 1 to 553 residues) expressed in baculovirus expression system using Long S6 Kinase as substrate incubated for 90 mins by Kinase-Glo luminescent assay	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	19.0	CHEMBL2973	Homo sapiens	IC50	nM	19.0
	22396439	CHEMBL4668593	Inhibition of ROCK2 (unknown origin)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	320.0	CHEMBL2973	Homo sapiens	IC50	nM	320.0
	22401702	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@@H](N)CCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4749675	=	IC50	nM	11.0	CHEMBL2973	Homo sapiens	IC50	nM	11.0
	22401703	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](N)Cc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4783577	=	IC50	nM	8.0	CHEMBL2973	Homo sapiens	IC50	nM	8.0
	22401704	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](O)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL4784425	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	22401705	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2OC)c1		CHEMBL3907133	=	IC50	nM	1.1	CHEMBL2973	Homo sapiens	IC50	nM	1.1
	22401706	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(Cl)c2)c1		CHEMBL4109840	=	IC50	nM	0.7	CHEMBL2973	Homo sapiens	IC50	nM	0.7
	22401707	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@@H](c2ccccc2F)C(C)(C)O)ccc1-c1cn[nH]c1		CHEMBL4757844	=	IC50	nM	2.1	CHEMBL2973	Homo sapiens	IC50	nM	2.1
	22401708	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](C)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4746508	=	IC50	nM	1.6	CHEMBL2973	Homo sapiens	IC50	nM	1.6
	22401709	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3913336	=	IC50	nM	0.3	CHEMBL2973	Homo sapiens	IC50	nM	0.3
	22401710	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)Cc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL4756156	=	IC50	nM	3.3	CHEMBL2973	Homo sapiens	IC50	nM	3.3
	22401711	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](N)CCc2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4741358	=	IC50	nM	5.6	CHEMBL2973	Homo sapiens	IC50	nM	5.6
	22401712	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](N)c2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL4780269	=	IC50	nM	4.0	CHEMBL2973	Homo sapiens	IC50	nM	4.0
	22401713	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)cc2C)c1		CHEMBL4111347	=	IC50	nM	110.0	CHEMBL2973	Homo sapiens	IC50	nM	110.0
	22401714	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C#N)c2)c1		CHEMBL4740106	=	IC50	nM	6.7	CHEMBL2973	Homo sapiens	IC50	nM	6.7
	22401715	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	CCc1cc(C(=O)N[C@H](C)c2cccc(OC)c2)ccc1-c1cn[nH]c1		CHEMBL4791701	=	IC50	nM	0.4	CHEMBL2973	Homo sapiens	IC50	nM	0.4
	22401716	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](CO)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL3955445	=	IC50	nM	2.3	CHEMBL2973	Homo sapiens	IC50	nM	2.3
	22401717	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](C)c2ccccc2F)ccc1-c1cn[nH]c1		CHEMBL4753754	=	IC50	nM	1.3	CHEMBL2973	Homo sapiens	IC50	nM	1.3
	22401718	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1ccccc1CNC(=O)c1ccc(-c2cn[nH]c2)c(OC)c1		CHEMBL3951573	=	IC50	nM	66.0	CHEMBL2973	Homo sapiens	IC50	nM	66.0
	22401719	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)NCc2ccccc2Cl)ccc1-c1cn[nH]c1		CHEMBL3960736	=	IC50	nM	2.3	CHEMBL2973	Homo sapiens	IC50	nM	2.3
	22401720	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)Cc2ccccc2Cl)ccc1-c1cnco1		CHEMBL4799221	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	22401721	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(NC(=O)[C@H](N)Cc2ccc(Cl)c(Cl)c2)ccc1-c1cn[nH]c1		CHEMBL4764401	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	22401722	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2F)c1		CHEMBL4111518	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	22401723	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C(F)(F)F)c2)c1		CHEMBL4114533	=	IC50	nM	1.4	CHEMBL2973	Homo sapiens	IC50	nM	1.4
	22401724	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3cn[nH]c3)c(C)c2)c1		CHEMBL4111655	=	IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
	22401725	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](CO)c2c(F)cccc2F)ccc1-c1cn[nH]c1		CHEMBL4799704	=	IC50	nM	2.1	CHEMBL2973	Homo sapiens	IC50	nM	2.1
	22401726	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cc(C(=O)N[C@H](CN)c2ccccc2)ccc1-c1cn[nH]c1		CHEMBL4114628	=	IC50	nM	0.3	CHEMBL2973	Homo sapiens	IC50	nM	0.3
	22401727	CHEMBL4669819	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH peptide substrate by caliper assay	B	COc1cccc(CNC(=O)c2ccc(-c3cn[nH]c3)c(OC)c2)c1		CHEMBL3951271	=	IC50	nM	1.2	CHEMBL2973	Homo sapiens	IC50	nM	1.2
	22401804	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)COc2cncnc2-3)c1		CHEMBL4797403	=	IC50	nM	2.4	CHEMBL2973	Homo sapiens	IC50	nM	2.4
	22401805	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)c(=O)[nH]c2cnccc23)c1		CHEMBL4783882	=	IC50	nM	340.0	CHEMBL2973	Homo sapiens	IC50	nM	340.0
	22401806	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)[nH]c(=O)c2cnccc23)c1		CHEMBL4782709	=	IC50	nM	14.0	CHEMBL2973	Homo sapiens	IC50	nM	14.0
	22401807	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)COc2cnccc2-3)c1		CHEMBL4785041	=	IC50	nM	0.35	CHEMBL2973	Homo sapiens	IC50	nM	0.35
	22401808	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc(C(C)NC(=O)c2ccc3c(c2)OCc2cnccc2-3)n1		CHEMBL4749682	=	IC50	nM	6.2	CHEMBL2973	Homo sapiens	IC50	nM	6.2
	22401809	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)OCc2cnccc2-3)c1		CHEMBL3578250	=	IC50	nM	0.51	CHEMBL2973	Homo sapiens	IC50	nM	0.51
	22401810	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	C[C@@H](NC(=O)c1ccc2c(c1)OCc1cnccc1-2)c1ccccc1		CHEMBL4756660	=	IC50	nM	3.2	CHEMBL2973	Homo sapiens	IC50	nM	3.2
	22401811	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc(CNC(=O)c2ccc3c(c2)OCc2cnccc2-3)c1		CHEMBL4797055	=	IC50	nM	6.3	CHEMBL2973	Homo sapiens	IC50	nM	6.3
	22401812	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	O=C(NCc1ccccc1)c1ccc2c(c1)OCc1cnccc1-2		CHEMBL4748957	=	IC50	nM	29.0	CHEMBL2973	Homo sapiens	IC50	nM	29.0
	22401813	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	O=C(Cc1ccccc1)Nc1ccc2c(c1)OCc1cnccc1-2		CHEMBL4762662	=	IC50	nM	44.0	CHEMBL2973	Homo sapiens	IC50	nM	44.0
	22401814	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	N[C@@H](C(=O)Nc1ccc2c(c1)OCc1cnccc1-2)c1ccccc1		CHEMBL4748727	=	IC50	nM	9.4	CHEMBL2973	Homo sapiens	IC50	nM	9.4
	22401815	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	N[C@H](Cc1ccccc1)C(=O)Nc1ccc2c(c1)OCc1cnccc1-2		CHEMBL4746531	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
	22401816	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	N[C@@H](COc1ccc2c(c1)OCc1cnccc1-2)Cc1ccccc1		CHEMBL4743809	=	IC50	nM	54.0	CHEMBL2973	Homo sapiens	IC50	nM	54.0
	22401817	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)COc2cnc(N)cc2-3)c1		CHEMBL4778588	=	IC50	nM	16.0	CHEMBL2973	Homo sapiens	IC50	nM	16.0
	22401818	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)OC(C)c2cnccc2-3)c1		CHEMBL4778671	=	IC50	nM	4.7	CHEMBL2973	Homo sapiens	IC50	nM	4.7
	22401819	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)C(C)Oc2cnccc2-3)c1		CHEMBL4763198	=	IC50	nM	0.21	CHEMBL2973	Homo sapiens	IC50	nM	0.21
	22401820	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCC1Oc2cnccc2-c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc21		CHEMBL3578252	=	IC50	nM	0.56	CHEMBL2973	Homo sapiens	IC50	nM	0.56
	22401821	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCC1Oc2cnccc2-c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc21		CHEMBL3578252	=	IC50	nM	0.52	CHEMBL2973	Homo sapiens	IC50	nM	0.52
	22401822	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCC1Oc2cnccc2-c2ccc(C(=O)N[C@H](C)c3cccc(OC)c3)cc21		CHEMBL3578252	=	IC50	nM	0.18	CHEMBL2973	Homo sapiens	IC50	nM	0.18
	22401823	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	COc1cccc([C@@H](C)NC(=O)c2ccc3c(c2)C(C2CC2)Oc2cnccc2-3)c1		CHEMBL4749267	=	IC50	nM	0.72	CHEMBL2973	Homo sapiens	IC50	nM	0.72
	22401824	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CNC(=O)c1cccc(CNC(=O)c2ccc3c(c2)COc2cnccc2-3)c1		CHEMBL4746567	=	IC50	nM	1.3	CHEMBL2973	Homo sapiens	IC50	nM	1.3
	22401825	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCNC(=O)c1cccc(CNC(=O)c2ccc3c(c2)COc2cnccc2-3)c1		CHEMBL4790421	=	IC50	nM	0.8	CHEMBL2973	Homo sapiens	IC50	nM	0.8
	22401826	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CN1CC(NC(=O)c2cccc(CNC(=O)c3ccc4c(c3)COc3cnccc3-4)c2)C1		CHEMBL4749353	=	IC50	nM	0.85	CHEMBL2973	Homo sapiens	IC50	nM	0.85
	22401827	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCNC(=O)c1cccc(CNC(=O)c2ccc3c(c2)C(C)Oc2cnccc2-3)c1		CHEMBL4758151	=	IC50	nM	0.8	CHEMBL2973	Homo sapiens	IC50	nM	0.8
	22401828	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCNC(=O)c1cc(CNC(=O)c2ccc3c(c2)C(CC)Oc2cnccc2-3)ccc1F		CHEMBL4759713	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	nM	3.0
	22401829	CHEMBL4669834	Inhibition of ROCK2 (unknown origin) using FITC-AHA-AKRRRLSSLRA-OH as substrate by caliper assay	B	CCN1CCC[C@H]1CNC(=O)c1cccc(CNC(=O)c2ccc3c(c2)C(C)Oc2cnccc2-3)c1		CHEMBL4747999	=	IC50	nM	0.5	CHEMBL2973	Homo sapiens	IC50	nM	0.5
	22401856	CHEMBL4669836	Inhibition of ROCK2 (unknown origin)	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1.Cl.Cl		CHEMBL1605605	=	Ki	nM	300.0	CHEMBL2973	Homo sapiens	Ki	nM	300.0
	22401857	CHEMBL4669836	Inhibition of ROCK2 (unknown origin)	B	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	=	Ki	nM	105.0	CHEMBL2973	Homo sapiens	Ki	nM	105.0
	22401858	CHEMBL4669836	Inhibition of ROCK2 (unknown origin)	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	nM	20.0
	22401859	CHEMBL4669836	Inhibition of ROCK2 (unknown origin)	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	IC50	nM	220.0	CHEMBL2973	Homo sapiens	IC50	nM	220.0
	22401864	CHEMBL4669838	Inhibition of recombinant human GST-tagged ROCK2 catalytic domain expressed in baculovirus expression system by Kinase-Glo luminescent kinase assay	B	NC[C@@H](C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1		CHEMBL4753043	=	Ki	nM	0.2	CHEMBL2973	Homo sapiens	Ki	nM	0.2
	22401865	CHEMBL4669838	Inhibition of recombinant human GST-tagged ROCK2 catalytic domain expressed in baculovirus expression system by Kinase-Glo luminescent kinase assay	B	Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1.Cl.Cl		CHEMBL4796289	=	Ki	nM	1.0	CHEMBL2973	Homo sapiens	Ki	nM	1.0
	22423269	CHEMBL4674210	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	101.73	CHEMBL2973	Homo sapiens	Activity	%	101.73
	22423270	CHEMBL4674210	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	44.19	CHEMBL2973	Homo sapiens	Activity	%	44.19
	22816318	CHEMBL4714849	Inhibition of ROCK2 (unknown origin) using KRRRLSSLRA as substrate incubated for 75 mins in presence of ATP and DTT by Kinase-Glo luminescent assay	B	Cc1cncc2sc(NC(=O)C3CC3c3cc(C(=O)NCc4ncccn4)cs3)cc12		CHEMBL4743703	=	IC50	nM	5.0	CHEMBL2973	Homo sapiens	IC50	nM	5.0
	22816319	CHEMBL4714849	Inhibition of ROCK2 (unknown origin) using KRRRLSSLRA as substrate incubated for 75 mins in presence of ATP and DTT by Kinase-Glo luminescent assay	B	O=C(Nc1nc2ccncc2s1)[C@@H]1C[C@H]1c1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL4763003	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	22816320	CHEMBL4714849	Inhibition of ROCK2 (unknown origin) using KRRRLSSLRA as substrate incubated for 75 mins in presence of ATP and DTT by Kinase-Glo luminescent assay	B	O=C(Nc1ccc2cnccc2n1)[C@@H]1C[C@H]1c1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL4783299	=	IC50	nM	6.0	CHEMBL2973	Homo sapiens	IC50	nM	6.0
	22816321	CHEMBL4714849	Inhibition of ROCK2 (unknown origin) using KRRRLSSLRA as substrate incubated for 75 mins in presence of ATP and DTT by Kinase-Glo luminescent assay	B	O=C(Nc1ccc2cnccc2n1)C1CC1c1ccccc1		CHEMBL4776650	=	IC50	nM	7.0	CHEMBL2973	Homo sapiens	IC50	nM	7.0
	22816322	CHEMBL4714849	Inhibition of ROCK2 (unknown origin) using KRRRLSSLRA as substrate incubated for 75 mins in presence of ATP and DTT by Kinase-Glo luminescent assay	B	O=C(Nc1nc2ccncc2s1)C1CC1c1ccccc1		CHEMBL4749989	=	IC50	nM	12.0	CHEMBL2973	Homo sapiens	IC50	nM	12.0
	22816323	CHEMBL4714849	Inhibition of ROCK2 (unknown origin) using KRRRLSSLRA as substrate incubated for 75 mins in presence of ATP and DTT by Kinase-Glo luminescent assay	B	Cc1cncc2sc(NC(=O)[C@@H]3C[C@H]3c3ccccc3)cc12		CHEMBL4761315	=	IC50	nM	18.0	CHEMBL2973	Homo sapiens	IC50	nM	18.0
	22818130	CHEMBL4715353	Inhibition of recombinant human N-terminal GST-tagged ROCK2 (5 to 554 residues) expressed in baculovirus infected Spodoptera frugiperda insect cells at 2 uM using KRRRLASLR as substrate relative to control	B	C[C@@H](c1ccc2ncccc2c1)c1nnc2sc(-c3cnn(C)c3)nn12		CHEMBL4791034	<	Inhibition	%	50.0	CHEMBL2973	Homo sapiens	INH	%	50.0
	22820570	CHEMBL4716287	Inhibition of human ROCK2 assessed as residual activity at 1 uM relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	103.0	CHEMBL2973	Homo sapiens	Activity	%	103.0
	22820571	CHEMBL4716287	Inhibition of human ROCK2 assessed as residual activity at 1 uM relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	28.0	CHEMBL2973	Homo sapiens	Activity	%	28.0
	22843581	CHEMBL4720567	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.246	CHEMBL2973	Homo sapiens	IC50	10^-10M	2.46
	22843924	CHEMBL4720910	Inhibition of human ROCK2 assessed as residual activity using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	85.09	CHEMBL2973	Homo sapiens	Activity	%	85.09
	22844854	CHEMBL4721529	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	91.31	CHEMBL2973	Homo sapiens	Activity	%	91.31
	22853390	CHEMBL4724257	Effect on human recombinant N-terminal GST-tagged ROCK2 (5 to 554) expressed in baculovirus infected Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Activity	%	-23.0	CHEMBL2973	Homo sapiens	Activity	%	-23.0
	22853391	CHEMBL4724257	Effect on human recombinant N-terminal GST-tagged ROCK2 (5 to 554) expressed in baculovirus infected Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	=	Activity	%	-4.0	CHEMBL2973	Homo sapiens	Activity	%	-4.0
	22853392	CHEMBL4724257	Effect on human recombinant N-terminal GST-tagged ROCK2 (5 to 554) expressed in baculovirus infected Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	CN1CCN(CCCOc2ccc3ncnc(Nc4ccc(Oc5cccc(C(F)(F)F)c5)c(Cl)c4)c3c2)CC1		CHEMBL4749477	=	Activity	%	-12.0	CHEMBL2973	Homo sapiens	Activity	%	-12.0
	22853393	CHEMBL4724257	Effect on human recombinant N-terminal GST-tagged ROCK2 (5 to 554) expressed in baculovirus infected Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(Nc1ccc2ncnc(Nc3ccc(Oc4cccc(F)c4)c(Cl)c3)c2c1)c1ccc(CNCCO)cc1		CHEMBL4782561	=	Activity	%	-47.0	CHEMBL2973	Homo sapiens	Activity	%	-47.0
	22853394	CHEMBL4724257	Effect on human recombinant N-terminal GST-tagged ROCK2 (5 to 554) expressed in baculovirus infected Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	Cc1cccc(Oc2ccc(Nc3ncnc4ccc(NC(=O)CNCCO)cc34)cc2Cl)c1		CHEMBL4753194	=	Activity	%	2.0	CHEMBL2973	Homo sapiens	Activity	%	2.0
	22853395	CHEMBL4724257	Effect on human recombinant N-terminal GST-tagged ROCK2 (5 to 554) expressed in baculovirus infected Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c2c1		CHEMBL4777529	=	Activity	%	8.0	CHEMBL2973	Homo sapiens	Activity	%	8.0
	22853396	CHEMBL4724257	Effect on human recombinant N-terminal GST-tagged ROCK2 (5 to 554) expressed in baculovirus infected Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(Oc4cccc(F)c4)c(Cl)c3)c2c1		CHEMBL4757576	=	Activity	%	5.0	CHEMBL2973	Homo sapiens	Activity	%	5.0
	22853397	CHEMBL4724257	Effect on human recombinant N-terminal GST-tagged ROCK2 (5 to 554) expressed in baculovirus infected Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1		CHEMBL3637894	=	Activity	%	18.0	CHEMBL2973	Homo sapiens	Activity	%	18.0
	22853398	CHEMBL4724257	Effect on human recombinant N-terminal GST-tagged ROCK2 (5 to 554) expressed in baculovirus infected Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(CNCCO)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1		CHEMBL4783947	=	Activity	%	-15.0	CHEMBL2973	Homo sapiens	Activity	%	-15.0
Not Active	22889559	CHEMBL4729078	Inhibition of wild-type human partial length ROCK2 (M1 to T431 residues) expressed in mammalian expression system at 1 uM by Kinomescan method	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	22894549	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CN(C)C(=O)Cc1sc(NC(=O)C2COc3ccccc3O2)nc1-c1ccncc1		CHEMBL4784761	=	Inhibition	%	56.9	CHEMBL2973	Homo sapiens	INH	%	56.9
	22894550	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CN(C)C(=O)Cc1sc(NC(=O)c2ccncc2)nc1-c1ccncc1		CHEMBL4788089	=	Inhibition	%	38.1	CHEMBL2973	Homo sapiens	INH	%	38.1
	22894551	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CN(C)CCc1sc(NC(=O)C2COc3ccccc3O2)nc1-c1ccncc1		CHEMBL4778240	=	Inhibition	%	78.5	CHEMBL2973	Homo sapiens	INH	%	78.5
	22894552	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CN(C)CCc1sc(NC(=O)c2ccncc2)nc1-c1ccncc1		CHEMBL4746407	=	Inhibition	%	48.8	CHEMBL2973	Homo sapiens	INH	%	48.8
	22894553	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2ccncc2)c(CN2CCOCC2)s1)c1cccnc1		CHEMBL4749216	=	Inhibition	%	52.2	CHEMBL2973	Homo sapiens	INH	%	52.2
	22894554	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2ccncc2)c(CN2CCOCC2)s1)c1ccncc1		CHEMBL4797086	=	Inhibition	%	58.1	CHEMBL2973	Homo sapiens	INH	%	58.1
	22894555	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2ccncc2)c(CN2CCCC2)s1)c1ccncc1		CHEMBL4796246	=	Inhibition	%	47.6	CHEMBL2973	Homo sapiens	INH	%	47.6
	22894556	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2ccncc2)c(CN2CCCCC2)s1)c1ccncc1		CHEMBL4780253	=	Inhibition	%	48.2	CHEMBL2973	Homo sapiens	INH	%	48.2
	22894557	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CN(C)Cc1sc(NC(=O)c2ccncc2)nc1-c1cccnc1		CHEMBL4743854	=	Inhibition	%	35.3	CHEMBL2973	Homo sapiens	INH	%	35.3
	22894558	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2cccnc2)c(CN2CCOCC2)s1)c1ccncc1		CHEMBL4745315	=	Inhibition	%	51.1	CHEMBL2973	Homo sapiens	INH	%	51.1
	22894559	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2cccnc2)c(CN2CCOCC2)s1)c1cccnc1		CHEMBL4755156	=	Inhibition	%	41.1	CHEMBL2973	Homo sapiens	INH	%	41.1
	22894560	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CN1CCN(Cc2sc(NC(=O)c3cccnc3)nc2-c2cccnc2)CC1		CHEMBL4754858	=	Inhibition	%	32.1	CHEMBL2973	Homo sapiens	INH	%	32.1
	22894561	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CC(C)N(C)Cc1sc(NC(=O)c2cccnc2)nc1-c1cccnc1		CHEMBL4744551	=	Inhibition	%	38.1	CHEMBL2973	Homo sapiens	INH	%	38.1
	22894562	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CN(C)Cc1sc(NC(=O)c2cccnc2)nc1-c1cccnc1		CHEMBL4746027	=	Inhibition	%	33.9	CHEMBL2973	Homo sapiens	INH	%	33.9
	22894563	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2cccnc2)c(CN2CCCCC2)s1)c1cccnc1		CHEMBL4746349	=	Inhibition	%	28.5	CHEMBL2973	Homo sapiens	INH	%	28.5
	22894564	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2ccncc2)c(CN2CCOCC2)s1)C1COc2ccccc2O1		CHEMBL4781535	=	Inhibition	%	87.4	CHEMBL2973	Homo sapiens	INH	%	87.4
	22894565	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2cccnc2)c(CN2CCOCC2)s1)C1COc2ccccc2O1		CHEMBL4742283	=	Inhibition	%	63.8	CHEMBL2973	Homo sapiens	INH	%	63.8
	22894566	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2cccnc2)c(CN2CCCC2)s1)C1COc2ccccc2O1		CHEMBL4762307	=	Inhibition	%	61.3	CHEMBL2973	Homo sapiens	INH	%	61.3
	22894567	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CN(C)Cc1sc(NC(=O)C2COc3ccccc3O2)nc1-c1cccnc1		CHEMBL4761769	=	Inhibition	%	58.1	CHEMBL2973	Homo sapiens	INH	%	58.1
	22894568	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2ccncc2)c(N2CCOCC2)s1)C1COc2ccccc2O1		CHEMBL4784254	=	Inhibition	%	76.3	CHEMBL2973	Homo sapiens	INH	%	76.3
	22894569	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CN1CCN(c2sc(NC(=O)c3ccncc3)nc2-c2ccncc2)CC1		CHEMBL4743749	=	Inhibition	%	34.3	CHEMBL2973	Homo sapiens	INH	%	34.3
	22894570	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	CC(C)N(C)c1sc(NC(=O)c2ccncc2)nc1-c1ccncc1		CHEMBL4779907	=	Inhibition	%	32.1	CHEMBL2973	Homo sapiens	INH	%	32.1
	22894571	CHEMBL4730246	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate at 10 uM incubated for 30 mins in presence of ATP by ELISA relative to control	B	O=C(Nc1nc(-c2ccncc2)cs1)C1COc2ccccc2O1		CHEMBL510515	=	Inhibition	%	91.3	CHEMBL2973	Homo sapiens	INH	%	91.3
	22894572	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	CN(C)C(=O)Cc1sc(NC(=O)C2COc3ccccc3O2)nc1-c1ccncc1		CHEMBL4784761	=	IC50	nM	8830.0	CHEMBL2973	Homo sapiens	IC50	uM	8.83
	22894573	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	CN(C)CCc1sc(NC(=O)C2COc3ccccc3O2)nc1-c1ccncc1		CHEMBL4778240	=	IC50	nM	90.0	CHEMBL2973	Homo sapiens	IC50	uM	0.09
	22894574	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	O=C(Nc1nc(-c2ccncc2)c(CN2CCOCC2)s1)c1cccnc1		CHEMBL4749216	=	IC50	nM	9120.0	CHEMBL2973	Homo sapiens	IC50	uM	9.12
	22894575	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	O=C(Nc1nc(-c2ccncc2)c(CN2CCOCC2)s1)c1ccncc1		CHEMBL4797086	=	IC50	nM	8560.0	CHEMBL2973	Homo sapiens	IC50	uM	8.56
	22894576	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	O=C(Nc1nc(-c2ccncc2)c(CN2CCOCC2)s1)C1COc2ccccc2O1		CHEMBL4781535	=	IC50	nM	20.0	CHEMBL2973	Homo sapiens	IC50	uM	0.02
	22894577	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	O=C(Nc1nc(-c2cccnc2)c(CN2CCOCC2)s1)C1COc2ccccc2O1		CHEMBL4742283	=	IC50	nM	1730.0	CHEMBL2973	Homo sapiens	IC50	uM	1.73
	22894578	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	O=C(Nc1nc(-c2cccnc2)c(CN2CCCC2)s1)C1COc2ccccc2O1		CHEMBL4762307	=	IC50	nM	1560.0	CHEMBL2973	Homo sapiens	IC50	uM	1.56
	22894579	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	CN(C)Cc1sc(NC(=O)C2COc3ccccc3O2)nc1-c1cccnc1		CHEMBL4761769	=	IC50	nM	4960.0	CHEMBL2973	Homo sapiens	IC50	uM	4.96
	22894580	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	O=C(Nc1nc(-c2ccncc2)c(N2CCOCC2)s1)C1COc2ccccc2O1		CHEMBL4784254	=	IC50	nM	130.0	CHEMBL2973	Homo sapiens	IC50	uM	0.13
	22894581	CHEMBL4730247	Inhibition of ROCK2 (unknown origin) using C-terminus recombinant MBS (654-880 residues) as substrate incubated for 30 mins in presence of ATP by ELISA	B	O=C(Nc1nc(-c2ccncc2)cs1)C1COc2ccccc2O1		CHEMBL510515	=	IC50	nM	10.0	CHEMBL2973	Homo sapiens	IC50	uM	0.01
	22949414	CHEMBL4765796	Inhibition of human ROCK2 assessed as residual activity at 0.1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	94.0	CHEMBL2973	Homo sapiens	Activity	%	94.0
	22949415	CHEMBL4765796	Inhibition of human ROCK2 assessed as residual activity at 0.1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	79.0	CHEMBL2973	Homo sapiens	Activity	%	79.0
	22949416	CHEMBL4765796	Inhibition of human ROCK2 assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	92.0	CHEMBL2973	Homo sapiens	Activity	%	92.0
	22949417	CHEMBL4765796	Inhibition of human ROCK2 assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	101.0	CHEMBL2973	Homo sapiens	Activity	%	101.0
	22949418	CHEMBL4765796	Inhibition of human ROCK2 assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	99.0	CHEMBL2973	Homo sapiens	Activity	%	99.0
	22949419	CHEMBL4765796	Inhibition of human ROCK2 assessed as residual activity at 0.1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	76.0	CHEMBL2973	Homo sapiens	Activity	%	76.0
	22949420	CHEMBL4765797	Inhibition of human ROCK2 assessed as residual activity at 1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	79.0	CHEMBL2973	Homo sapiens	Activity	%	79.0
	22949421	CHEMBL4765797	Inhibition of human ROCK2 assessed as residual activity at 1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	69.0	CHEMBL2973	Homo sapiens	Activity	%	69.0
	22949422	CHEMBL4765797	Inhibition of human ROCK2 assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	89.0	CHEMBL2973	Homo sapiens	Activity	%	89.0
	22949423	CHEMBL4765797	Inhibition of human ROCK2 assessed as residual activity at 1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	61.0	CHEMBL2973	Homo sapiens	Activity	%	61.0
	22949424	CHEMBL4765797	Inhibition of human ROCK2 assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	87.0	CHEMBL2973	Homo sapiens	Activity	%	87.0
	22949425	CHEMBL4765797	Inhibition of human ROCK2 assessed as residual activity at 1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	55.0	CHEMBL2973	Homo sapiens	Activity	%	55.0
	22952984	CHEMBL4766921	Inhibition of recombinant human ROCK2 (11 to 552 residues) assessed as residual activity at 10 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate incubated for 120 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	89.0	CHEMBL2973	Homo sapiens	Activity	%	89.0
	23120995	CHEMBL4804485	Inhibition of ROCK2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4855542	=	IC50	nM	-11400.0	CHEMBL2973	Homo sapiens	IC50	uM	-11.4
	23120996	CHEMBL4804485	Inhibition of ROCK2 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	IC50	nM	20800.0	CHEMBL2973	Homo sapiens	IC50	uM	20.8
	23120997	CHEMBL4804485	Inhibition of ROCK2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4859660	=	IC50	nM	-55800.0	CHEMBL2973	Homo sapiens	IC50	uM	-55.8
	23122034	CHEMBL4804667	Inhibition of ROCK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	23122035	CHEMBL4804667	Inhibition of ROCK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	23122036	CHEMBL4804667	Inhibition of ROCK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	0.0	CHEMBL2973	Homo sapiens	INH	%	0.0
	23122797	CHEMBL4805148	Inhibition of human ROCK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	71.0	CHEMBL2973	Homo sapiens	Activity	%	71.0
	23123492	CHEMBL4805736	Inhibition of human ROCK2 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	49.0	CHEMBL2973	Homo sapiens	Activity	%	49.0
	23123947	CHEMBL4806191	Inhibition of DNA-tagged human ROCK2 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	77.0	CHEMBL2973	Homo sapiens	Activity	%	77.0
	23125074	CHEMBL4806753	Inhibition of human ROCK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL2973	Homo sapiens	Activity	%	100.0
	23125075	CHEMBL4806753	Inhibition of human ROCK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	80.0	CHEMBL2973	Homo sapiens	Activity	%	80.0
	23128533	CHEMBL4807986	Inhibition of ROCK2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL2973	Homo sapiens	Activity	%	75.0
	23128534	CHEMBL4807986	Inhibition of ROCK2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL2973	Homo sapiens	Activity	%	75.0
	23128535	CHEMBL4807986	Inhibition of ROCK2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL2973	Homo sapiens	Activity	%	75.0
	23277319	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4643620	=	IC50	nM	632.0	CHEMBL2973	Homo sapiens	IC50	uM	0.632
	23277320	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2COc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4864149	=	IC50	nM	434.0	CHEMBL2973	Homo sapiens	IC50	uM	0.434
	23277321	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCCc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4877788	=	IC50	nM	2115.0	CHEMBL2973	Homo sapiens	IC50	uM	2.115
	23277322	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4854297	=	IC50	nM	182.0	CHEMBL2973	Homo sapiens	IC50	uM	0.182
	23277323	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CC(C)(C)Oc3cc(-c4ccc5[nH]ncc5c4)ccc3C2=O)c1		CHEMBL4854400	=	IC50	nM	749.0	CHEMBL2973	Homo sapiens	IC50	uM	0.7490000000000001
	23277324	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccc5c(c4)OCO5)ccc3C2=O)c1		CHEMBL4847282	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	23277325	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4877688	=	IC50	nM	3.0	CHEMBL2973	Homo sapiens	IC50	uM	0.003
	23277326	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccnc(N)c4)ccc3C2=O)c1		CHEMBL4858407	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	uM	0.015
	23277327	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccc(N)nc4)ccc3C2=O)c1		CHEMBL4868359	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	23277328	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4cncnc4)ccc3C2=O)c1		CHEMBL4859095	>	IC50	nM	10000.0	CHEMBL2973	Homo sapiens	IC50	uM	10.0
	23277329	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4ccnc5[nH]ccc45)ccc3C2=O)c1		CHEMBL4865593	=	IC50	nM	15.0	CHEMBL2973	Homo sapiens	IC50	uM	0.015
	23277330	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3cc(-c4cnc5[nH]ccc5c4)ccc3C2=O)c1		CHEMBL4879278	=	IC50	nM	5535.0	CHEMBL2973	Homo sapiens	IC50	uM	5.535
	23277331	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cccc(CN2CCOc3ccc(-c4ccncc4)cc3C2=O)c1		CHEMBL4846889	=	IC50	nM	761.0	CHEMBL2973	Homo sapiens	IC50	uM	0.7609999999999999
	23277332	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	O=C1c2ccc(-c3ccncc3)cc2OCCN1Cc1cccc(C(F)(F)F)c1		CHEMBL4867403	=	IC50	nM	133.0	CHEMBL2973	Homo sapiens	IC50	uM	0.133
	23277333	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	O=C1c2ccc(-c3ccncc3)cc2OCCN1Cc1cccc(OC(F)(F)F)c1		CHEMBL4865566	=	IC50	nM	495.0	CHEMBL2973	Homo sapiens	IC50	uM	0.495
	23277334	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	N#Cc1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4857347	=	IC50	nM	50.0	CHEMBL2973	Homo sapiens	IC50	uM	0.05
	23277335	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COC(=O)c1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4876591	=	IC50	nM	9.0	CHEMBL2973	Homo sapiens	IC50	uM	0.009000000000000001
	23277336	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	O=Cc1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4874825	=	IC50	nM	29.0	CHEMBL2973	Homo sapiens	IC50	uM	0.028999999999999998
	23277337	CHEMBL4836444	Inhibition of wild type partial length human ROCK1 (M1 to T431 residues) expressed in Mammalian expression system by Euro-fins kinase profiler assay	B	COc1cc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)cc(OC)c1		CHEMBL4873381	=	IC50	nM	217.0	CHEMBL2973	Homo sapiens	IC50	uM	0.217
Active	23277359	CHEMBL4836448	Inhibition of ROCK2 (unknown origin) at 10 uM	B	COc1cccc(CN2CCOc3cc(-c4ccncc4)ccc3C2=O)c1		CHEMBL4877688		Inhibition	%		CHEMBL2973	Homo sapiens	INH		
	23279633	CHEMBL4836795	Inhibition of ROCK2 (unknown origin) assessed as residual activity at 500 nM	B	FC(F)(F)c1n[nH]cc1-c1nc2ccc3[nH]ncc3c2c2c1CCCC2		CHEMBL4593398	<	Activity	%	25.0	CHEMBL2973	Homo sapiens	Activity	%	25.0
Not Active	23317633	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	98.0	CHEMBL2973	Homo sapiens	% Control	%	98.0
Not Active	23318101	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23318767	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	94.0	CHEMBL2973	Homo sapiens	% Control	%	94.0
Not Active	23319251	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23319888	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	85.2	CHEMBL2973	Homo sapiens	% Control	%	85.2
Not Active	23320363	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23321041	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23321509	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	74.0	CHEMBL2973	Homo sapiens	% Control	%	74.0
Not Active	23322139	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	69.0	CHEMBL2973	Homo sapiens	% Control	%	69.0
Not Active	23322607	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	84.0	CHEMBL2973	Homo sapiens	% Control	%	84.0
Not Active	23323296	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	78.0	CHEMBL2973	Homo sapiens	% Control	%	78.0
Not Active	23323764	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	88.0	CHEMBL2973	Homo sapiens	% Control	%	88.0
Not Active	23324121	CHEMBL4880740	ROCK-II (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	-3.0	CHEMBL2973	Homo sapiens	% inhibition	%	-3.0
Not Active	23324618	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	91.9	CHEMBL2973	Homo sapiens	% Control	%	91.9
Not Active	23325253	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	80.0	CHEMBL2973	Homo sapiens	% Control	%	80.0
Not Active	23325721	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23326368	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	98.0	CHEMBL2973	Homo sapiens	% Control	%	98.0
Not Active	23326836	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23327536	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	95.0	CHEMBL2973	Homo sapiens	% Control	%	95.0
Not Active	23328004	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	93.0	CHEMBL2973	Homo sapiens	% Control	%	93.0
Not Active	23328591	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	99.0	CHEMBL2973	Homo sapiens	% Control	%	99.0
Not Active	23329059	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23329511	CHEMBL4881218	ROCK-II(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	91.0	CHEMBL2973	Homo sapiens	% residual kinase activity	%	91.0
Not Active	23330005	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23330473	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	91.0	CHEMBL2973	Homo sapiens	% Control	%	91.0
Not Active	23331229	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	98.0	CHEMBL2973	Homo sapiens	% Control	%	98.0
Not Active	23331697	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23332284	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	66.2	CHEMBL2973	Homo sapiens	% Control	%	66.2
Not Active	23332750	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	87.6	CHEMBL2973	Homo sapiens	% Control	%	87.6
Not Active	23333468	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	86.1	CHEMBL2973	Homo sapiens	% Control	%	86.1
Not Active	23334107	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	93.0	CHEMBL2973	Homo sapiens	% Control	%	93.0
Not Active	23334575	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23334952	CHEMBL4881574	ROCK-2 (h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		Inhibition	%	100.0	CHEMBL2973	Homo sapiens	% inhibition	%	100.0
	23334953	CHEMBL4881574	ROCK-2 (h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		IC50	nM	1.0	CHEMBL2973	Homo sapiens	IC50	nM	1.0
Active	23335167	CHEMBL4881481	Biochemical ROCK2 assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		IC50	nM	1.1	CHEMBL2973	Homo sapiens	IC50	nM	1.1
Not Active	23335169	CHEMBL4881481	Biochemical ROCK2 assay	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21	Non standard unit for type	CHEMBL4546802		IC50	µM	17.7	CHEMBL2973	Homo sapiens	IC50	µM	17.7
Active	23335554	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	0.9	CHEMBL2973	Homo sapiens	% Control	%	0.9
Not Active	23336022	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	83.0	CHEMBL2973	Homo sapiens	% Control	%	83.0
Not Active	23336649	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	90.0	CHEMBL2973	Homo sapiens	% Control	%	90.0
Not Active	23337117	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	86.0	CHEMBL2973	Homo sapiens	% Control	%	86.0
Not Active	23337760	CHEMBL4882131	ROCK2 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	102.0	CHEMBL2973	Homo sapiens	% Ctrl	%	102.0
Not Active	23338198	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23338666	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	89.0	CHEMBL2973	Homo sapiens	% Control	%	89.0
Not Active	23339278	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23339746	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	76.0	CHEMBL2973	Homo sapiens	% Control	%	76.0
Not Active	23340383	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	75.0	CHEMBL2973	Homo sapiens	% Control	%	75.0
Not Active	23340851	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23341508	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23341976	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	73.0	CHEMBL2973	Homo sapiens	% Control	%	73.0
Not Active	23342592	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23343060	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23343286	CHEMBL4882471	ROCK2 Invitrogen selectivity data (BI)	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Ctrl	%	56.0	CHEMBL2973	Homo sapiens	% Ctrl	%	56.0
Not Active	23343690	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	85.0	CHEMBL2973	Homo sapiens	% Control	%	85.0
Not Active	23344158	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	82.0	CHEMBL2973	Homo sapiens	% Control	%	82.0
Not Active	23344796	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	88.0	CHEMBL2973	Homo sapiens	% Control	%	88.0
Not Active	23345369	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	95.0	CHEMBL2973	Homo sapiens	% Control	%	95.0
Not Active	23345837	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23346414	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	85.9	CHEMBL2973	Homo sapiens	% Control	%	85.9
Not Active	23346882	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	85.3	CHEMBL2973	Homo sapiens	% Control	%	85.3
Not Active	23347090	CHEMBL4882617	Invitrogen kinase screen (ROCK2)	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1	Non standard unit for type	CHEMBL4538174		IC50	µM	1.4	CHEMBL2973	Homo sapiens	IC50	µM	1.4
Slightly Active	23347584	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	44.7	CHEMBL2973	Homo sapiens	% Control	%	44.7
Not Active	23347585	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174	=	Kd	nM	82.0	CHEMBL2973	Homo sapiens	Kd	nM	82.0
Not Active	23347974	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	88.4	CHEMBL2973	Homo sapiens	% Control	%	88.4
Not Active	23348553	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23349021	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23349608	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23350226	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23350694	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23351299	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23351767	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23352212	CHEMBL4882901	ROCK2 Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	10.19	CHEMBL2973	Homo sapiens	% Inhibition	%	10.1885
Not Active	23352791	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	89.0	CHEMBL2973	Homo sapiens	% Control	%	89.0
Not Active	23353259	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	97.0	CHEMBL2973	Homo sapiens	% Control	%	97.0
Not Active	23354141	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23354609	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	89.0	CHEMBL2973	Homo sapiens	% Control	%	89.0
Not Active	23355341	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	76.0	CHEMBL2973	Homo sapiens	% Control	%	76.0
Not Active	23355809	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	74.0	CHEMBL2973	Homo sapiens	% Control	%	74.0
Not Active	23356445	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	92.0	CHEMBL2973	Homo sapiens	% Control	%	92.0
Not Active	23356913	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23357522	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23358169	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23358637	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	90.0	CHEMBL2973	Homo sapiens	% Control	%	90.0
Not Active	23359223	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	69.1	CHEMBL2973	Homo sapiens	% Control	%	69.1
Not Active	23359821	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	94.0	CHEMBL2973	Homo sapiens	% Control	%	94.0
Not Active	23360289	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	90.0	CHEMBL2973	Homo sapiens	% Control	%	90.0
Not Active	23360874	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	85.0	CHEMBL2973	Homo sapiens	% Control	%	85.0
Not Active	23361342	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23361915	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	77.0	CHEMBL2973	Homo sapiens	% Control	%	77.0
Not Active	23362451	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	96.0	CHEMBL2973	Homo sapiens	% Control	%	96.0
Not Active	23362919	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	59.0	CHEMBL2973	Homo sapiens	% Control	%	59.0
Not Active	23364561	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23365029	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23365768	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23366311	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23366901	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23367369	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23367730	CHEMBL4884083	ROCK2 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	90.0	CHEMBL2973	Homo sapiens	% Residual activity with Skepinone-L	%	90.0
Not Active	23368247	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23368715	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	93.0	CHEMBL2973	Homo sapiens	% Control	%	93.0
Not Active	23369314	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23369782	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	91.0	CHEMBL2973	Homo sapiens	% Control	%	91.0
Not Active	23370225	CHEMBL4884467	ROCK-II(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	97.0	CHEMBL2973	Homo sapiens	% residual kinase activity	%	97.0
Not Active	23370750	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23371218	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	93.0	CHEMBL2973	Homo sapiens	% Control	%	93.0
Not Active	23372027	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23372495	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
	23372880	CHEMBL4884845	ROCK2(ROC2LGG1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL2973	Homo sapiens	pIC50		6.0
	23373289	CHEMBL4885136	ROCK2(ROC2LGG1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL2973	Homo sapiens	pIC50		6.0
	23373645	CHEMBL4885422	ROCK2(ROC2LGG1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL2973	Homo sapiens	pIC50		6.0
Not Active	23375090	CHEMBL4886078	ROCK2 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	6.0	CHEMBL2973	Homo sapiens	% Inhibition	%	6.0
Not Active	23375367	CHEMBL4886349	Rho-associated, coiled-coil containing protein kinase 2 Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	-3.0	CHEMBL2973	Homo sapiens	% inhibition	%	-3.0
Not Active	23375922	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23376390	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23376967	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	94.0	CHEMBL2973	Homo sapiens	% Control	%	94.0
Not Active	23377435	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	67.0	CHEMBL2973	Homo sapiens	% Control	%	67.0
Not Active	23378295	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	96.0	CHEMBL2973	Homo sapiens	% Control	%	96.0
Not Active	23378763	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	95.0	CHEMBL2973	Homo sapiens	% Control	%	95.0
Not Active	23379930	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	85.0	CHEMBL2973	Homo sapiens	% Control	%	85.0
Not Active	23380398	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	72.0	CHEMBL2973	Homo sapiens	% Control	%	72.0
Not Active	23381092	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23381740	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23382208	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23382832	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23383300	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	69.0	CHEMBL2973	Homo sapiens	% Control	%	69.0
Not Active	23383973	CHEMBL4887577	ROCK2 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	96.0	CHEMBL2973	Homo sapiens	% Ctrl	%	96.0
Slightly Active	23384067	CHEMBL4887665	ROCKII DUNDEE kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	40.1	CHEMBL2973	Homo sapiens	% Ctrl	%	40.1
Not Active	23384448	CHEMBL4888043	ROCK-II(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	-0.6	CHEMBL2973	Homo sapiens	% inhibition	%	-0.6
Not Active	23384707	CHEMBL4888233	ROCK2 SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	-3.0	CHEMBL2973	Homo sapiens	% Inhibition	%	-3.0
Not Active	23385215	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
Not Active	23385682	CHEMBL4879939	KinomeScan assay: inhibition of ROCK2	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL2973	Homo sapiens	% Control	%	100.0
